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Preface to ”Cyclic Nucleotide Signaling and the
Cardiovascular System”
Cyclic nucleotide signaling is one of the most important signaling pathways in the heart and
control vital functions such as excitation-contraction coupling, pacemaking, relaxation, and speed
of conduction [1]. Recent insights revealed that the different elements of this signaling pathway
interact and form protein complexes, which control the size and subcellular localization of cAMP
nanodomains and ensure the signal-specific activation of different effector proteins [2].
Adenylate cyclases (AC) produce cAMP and nine different membrane-bound isoforms exist in the
mammalian heart. This Special Issue starts with a review by Baldwin and Dessauer on the role of
AC isoforms in cardiac myocytes [3]. A single soluble AC isoform is present in cardiac myocytes and
the review by Pozdniakova and Ladilov discuss the functional importance of this isoform and the
different mechanisms of its activation in the heart and other tissues [4].
The compartmentation of cyclic nucleotide signaling is determined to a large extent by
phosphodiesterases (PDEs), of which there are 11 different families and approximately 50 different
isoforms. This enormous complexity is dealt with by several reviews in this issue. Movsesian and
colleagues give an overview of the functional role of PDE3 isoforms in the heart and therapeutic
opportunities to modulate their function [5]. The role of PDE4 isoforms in the heart are reviewed by
Fertig and Baillie [6], followed by a review article by Chen et al. on PDE1 isoforms and their roles
in pathological remodeling and cardiac dysfunction [7]. While PDEs are also important for cardiac
pacemaking, the individual functions of PDE3 and 4 isoforms are less clear. St. Clair et al. report on
their experiments to elucidate the impact of PDE3 and PFDE4 isoforms on the funny current (If) in
the murine sinoatrial node [8].
A kinase anchor proteins (AKAPs) are a large and diverse family of proteins which primarily
interact with protein kinase A (PKA) but are also responsible for the assembly of cAMP nanodomains
by binding PDEs, ACs, and other signaling proteins. Two reviews in this book discuss the various
AKAPS found in the heart [9] and the role of a specific AKAP, AKAP-LBC, in the adaptive response
to stress of the heart [10].
Four classes of cAMP effector proteins are known to date, including PKA, exchange protein
directly activated by cAMP (EPAC), cyclic nucleotide-gated (CNG) channels, and the Popeye
domain-containing (POPDC) genes. A review of the pulmonary and cardiac functions of EPAC by
Laudette et al. [11] is followed by a review of the newly discovered cAMP effector protein family
encoded by the POPDC genes [12].
The visualization of small molecules such as cAMP was a challenging problem until recently.
However, the development of sensors on the basis of cAMP-binding domains and the use of live-cell
imaging of Foerster resonance energy transfer (FRET) activity made it possible to detect cAMP
nanodomains. Schleicher and Zaccolo outline the current utilization of cAMP sensors to analyze
cAMP nanodomains and to detect stimulus-dependent differences in cAMP signal amplitude and
kinetics [13]. Pavlaki and Nikolaev describe the use of EPAC-derived FRET sensors to analyze
the cAMP-cGMP-mediated cross-talk, which is mediated by PDE2 and PDE3 [14]. Bhogal et al.
then review the currently available data on cAMP compartmentation in atrial and ventricular
myocytes [15].
Given the importance of cAMP for the heart, relatively little is known about the disease association
of proteins of the cAMP signaling pathway. In their article, Suryavanshi et al. review the available
ix
literature on knockout phenotypes in mice and mutations in genes encoding AKAP proteins [16].
Holland et al. discuss the importance of cyclic nucleotide kinases in cardiovascular inflammation
and growth [17]. Lehners et al. address the function of cGMP signaling in the control of vascular
smooth muscle cell plasticity [18].
Attempts to translate the accumulated knowledge into clinical practice will probably involve the
identification of small molecules or peptides that are able to activate or inhibit a particular protein
involved in cAMP signaling. Barker et al. report on their attempt to generate a novel class of
EPAC1-seective agonists, which might be able to block cardiovascular inflammation [19].
Many articles in this issue point out where we currently stand and what we do not know. Often,
technological advances generate novel insight but also spark the curious minds of a new generation
of researchers.
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Abstract: Cyclic adenosine monophosphate (cAMP), synthesized by adenylyl cyclase (AC), is a
universal second messenger that regulates various aspects of cardiac physiology from contraction
rate to the initiation of cardioprotective stress response pathways. Local pools of cAMP are maintained
by macromolecular complexes formed by A-kinase anchoring proteins (AKAPs). AKAPs facilitate
control by bringing together regulators of the cAMP pathway including G-protein-coupled receptors,
ACs, and downstream effectors of cAMP to finely tune signaling. This review will summarize
the distinct roles of AC isoforms in cardiac function and how interactions with AKAPs facilitate
AC function, highlighting newly appreciated roles for lesser abundant AC isoforms.
Keywords: adenylyl cyclase; A-kinase anchoring proteins; cyclic AMP; cardiomyocytes
1. Introduction
The heart continuously balances the interplay of various signaling mechanisms in order to
maintain homeostasis and respond to stress. One pathway that contributes to cardiac physiology and
stress is the cyclic adenosine monophosphate (cAMP) pathway. cAMP is a universal second messenger
that integrates input from G-protein-coupled receptors to coordinate subsequent intracellular signaling.
Synthesis of cAMP from adenosine triphosphate (ATP) is controlled by the enzyme adenylyl
cyclase (AC). In the heart, cAMP acts downstream on a variety of effectors including protein kinase
A (PKA), hyperpolarization-activated cyclic nucleotide-gated channels (HCN), exchange protein
directly activated by cAMP (EPAC), Popdc proteins, and a fraction of phosphodiesterases (PDEs).
PKA is the most well-known and studied cAMP effector. PKA phosphorylation of intracellular
targets coordinates a number of physiological outputs including contraction [1,2] and relaxation [3].
HCN channel regulation by cAMP maintains basal heart rate [4] while EPAC facilitates calcium
handling and cardiac hypertrophy [5]. PDEs degrade cAMP, further defining the temporal regulation
of the signal. The most recently discovered cAMP effector, Popdc, is important for heart rate dynamics
through regulation of the potassium channel TREK1 [6].
The AC family is composed of nine membrane-bound isoforms (AC 1–9) and one soluble
isoform (sAC). All of the isoforms can be found in the heart with the exception of AC8 [7,8].
Cardiac fibroblasts express AC 2–7 [9], while in adult cardiac myocytes AC5 and AC6 are considered
the major isoforms [10,11]. Lower levels of AC2, AC4, and AC9 are reported in myocytes [12,13].
2. Adenylyl Cyclases (ACs) and Their Role in Cardiac Function: Knockout Phenotypes
AC5 and AC6 are closely related isoforms that share similar regulatory mechanisms, including
inhibition by Gαi as the hallmark of this group; however, physiologically they appear to play distinct
roles in cardiac function [8,14]. Additional modes of regulation for AC5/6 are extensively reviewed
elsewhere [15]. AC5 and AC6 are differentially expressed in development, with age, and in a pressure
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overload model of cardiac hypertrophy where an increase in AC5 protein is observed in neonatal
heart and models of heart disease [16,17]. Another potential distinction between these two isoforms is
subcellular localization [18].
Several overexpression and deletion studies have focused on roles of these isoforms in cardiac function.
Two independent AC5-deletion (AC5−/−) mouse lines have been generated. Overall, deletion of AC5
decreases total cAMP activity in cardiac membranes and isolated myocytes (~35–40%) under basal and
stimulated (isoproterenol and forskolin) conditions [19,20]. The two studies reported varying results
for changes in cardiac function. Okumura et al. [19] observed a decrease in isoproterenol-stimulated left
ventricular (LV) ejection fraction (LVEF) but no alterations in basal cardiac function (with intravenous
isoproterenol). Conversely, Tang et al. [20] noted basal changes in the contractile function of perfused
isolated hearts in addition to a decreased sensitivity to β1-adrenergic receptor agonist. The most
notable finding of AC5−/− mice was the effect on parasympathetic regulation of cAMP. Inhibition of
cAMP production by Gi-coupled acetylcholine treatment is ablated and Ca2+-mediated inhibition is
significantly reduced upon AC5 deletion [19]. Physiologically, this corresponds to a reduction in LVEF
and heart rate in response to muscarinic agonists and an attenuation of baroreflexes [19,20]. Similarly,
AC6 deletion results in a significant reduction of cAMP production in stimulated LV homogenates or
cardiac myocytes (60–70%), with no changes to basal cAMP production [21]. AC6 deletion revealed a
number of unique contributions not observed in AC5−/− including impaired calcium handling, which
results in depressed LV function [21]. In addition, levels of AC6, but not AC5, limit β-adrenergic
receptor (βAR) signaling in heart [22,23].
In addition to cardiac contractility, AC5 and AC6 play important roles with regard to cardiac stress.
Deletion of AC5 is protective in a number of models of cardiac stress, including transverse aorta
constriction, chronic isoproterenol infusion, age-related cardiomyopathy, and high-fat diet, but not
overexpression of Gq [19,24–26]. While knockout of AC5 can be beneficial to heart, overexpression of
AC6 in heart infers protection in response to myocardial ischemia or dilated cardiomyopathy [27–29],
but not chronic pressure overload using transverse aorta constriction [30]. However, the protection
provided upon AC6 overexpression is independent of its catalytic activity as expression of catalytically
inactive AC6 is also cardioprotective [31], but requires proper localization via the N-terminus of
AC6 [32]. In fact, the expression of AC6 using adenoviral vectors for the treatment of heart disease
is currently in clinical trials [33]. Therefore, it is tempting to simplify the system and suggest that
AC5 is largely associated with stress responses while AC6 is necessary for calcium handling and
contractility. For these reasons, there has been considerable interest in AC5-selective inhibitors for the
treatment of heart disease. However, deletion of AC6 can also be protective from chronic pressure
overload in female but not male mice [34]; therefore, roles for AC isoforms may depend on the type of
heart disease model. AC inhibitors such as Ara-A (Vidarabine) do have benefits for the treatment of
myocardial ischemia when delivered after coronary artery reperfusion in mice [35]. However, Ara-A
and related AC inhibitors are not selective for AC5 over AC6, although they show considerable
selectivity over other AC isoforms [36,37]. Therefore, any benefits of Ara-A likely arise from inhibition
of both AC isoforms. However, this could prove risky as AC6 deletion increases mortality during
sustained catecholamine stress [38].
Surprisingly, no polymorphisms that give rise to cardiovascular disease are known to occur in
ACs [39]. However, mutations in AC5 are linked to familial dyskinesia with facial myokymia (FDFM),
a disease characterized by uncontrolled movement of limb and facial muscles [40,41]. These patients
may also have a predisposition to congestive heart failure [41]. Two FDFM mutations occur in a newly
appreciated region of AC5, a helical domain that is present immediately after the transmembrane
domain and precedes the catalytic cyclase domain (Figure 1). In other nucleotidyl cyclases, this domain
forms a tight hairpin to induce an active dimeric conformation of the catalytic domains [42]. Thus, the
helical domain may play a role in the stability of the catalytic core or direct regulation of activity.
Roles for additional AC isoforms in cardiac function have been largely overlooked. AC1 was
proposed to function as the calcium-stimulated AC in the sinoatrial node that modulates the I(f)
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pacemaker current [43,44]. However, AC1 knockout mice are not reported to have a heart rate defect
and RNA sequencing detects higher expression of AC1 in the right atrium versus the sinoatrial
node [45]. Roles for AC2 and/or AC4 are unknown. Currently, a knockout of AC4 is unavailable and
AC2 knockout mice display no cardiac phenotype, although RNA for AC2 is elevated in pediatric
dilated cardiomyopathy subjects [46]. Cardiac functions for AC9 are discussed below.
 
Figure 1. Topology of adenylyl cyclase (AC) isoforms. The structural topology of mammalian
membranous ACs consists of an N-terminal (NT) domain followed by a repeating set of transmembrane,
helical dimerization, and cytoplasmic domains. The two cytoplasmic domains (C1 and C2) make up
the catalytic core and the binding site for many regulatory proteins.
3. The AKAP Connection: Generating Specificity for AC Function
Tissue distribution and regulation provide one mode for how the AC isoforms contribute to
distinct physiological functions [8,15]. Another mode of signal specificity comes from the formation of
AC macromolecular complexes through the scaffolding family of A-kinase anchoring proteins (AKAPs).
AKAPs not only facilitate cellular localization of ACs but they also enhance temporal regulation of
cAMP signaling. A number of AKAPs exist in heart including AKAP15/18, AKAP79/150, Yotiao,
mAKAP, AKAP-Lbc, and Gravin [47] (Figure 2). In the heart, the spatial and temporal regulation by
AKAPs provide an important mechanism to facilitate stress response. The associations of ACs with
AKAPs facilitate regulation of PKA, downstream effectors, and ACs. This was shown in the dorsal
root ganglion where the activation of the transient receptor potential vanilloid 1 (TRPV1) channel by
forskolin or prostaglandin E2 is facilitated by AKAP79-AC5-PKA-TRPV1 complex formation and shifts
the response to lower concentrations of forskolin by ~100 fold. Disruption of this complex attenuates
sensitization of the channel, as anchoring of both PKA and AC5 were required to elicit the maximal
effect on TRPV1 current [48]. Anchoring of PKA and ACs to AKAPs can also regulate AC activity.
Association of AC5/6 with AKAP79/150 creates a negative feedback loop where cAMP production is
inhibited by PKA phosphorylation of AC5/6 [49]. Although this complex feedback mechanism was
defined in the nervous system, modulation of TRPV1 in heart is suggested to influence cardiovascular
response to disease and injury [50]. Fine tuning of the signal is important for modulating a number of
effectors contributing to physiological function.
AC localization is assessed primarily through functional roles of associated complex members
enriched at various cardiomyocytes substructures (Figure 2). Association of both AC5 and AC6 with
AKAP5 suggests localization at the t-tubule based upon functional association with calcium-induced
calcium release [51]. However, with respect to β adrenergic signaling, AC5 is enriched with β2ARin
t-tubules whereas AC6 localizes outside the t-tubule [18,52]. Disruption of cAMP compartmentalization
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is potentially an underlying mechanism of heart failure [52]. AC9 association with Yotiao and KCNQ1
suggests localization at intercalated discs, the sarcolemma, and t-tubules [53]. These AC–AKAP
complexes are discussed below.
Figure 2. Cardiac AC complexes. AC-associated A-kinase anchoring protein (AKAP) complexes localize
to distinct locations within the cardiomyocyte to facilitate physiological function. For each AKAP,
a subset of known binding partners and their interaction sites are represented. The model is based
upon functional localization of the AC complexes.
3.1. AKAP5
The AKAP5 family of orthologs are named for their size on SDS-PAGE and for different
species—for example, human AKAP79, mouse AKAP150, and bovine AKAP75. AKAP79/150 can
associate with AC 2, 3, 5, 6, 8, and 9 as evaluated in tissue culture models [49,54]. In heart, AKAP79
primarily interacts with AC5/6 [51]. The interaction site is located on the N-terminus of AC and in
the second and third polybasic domain on AKAP79 (aa 77–153). In cells, AKAP79-scaffolded PKA
phosphorylates AC5/6 to inhibit cAMP production [49,54]. This feedback loop allows for precisely
timed activation and inactivation of the cAMP signal. Although AKAP79-anchored AC5/6 is inhibited
by associated PKA, it is unclear how AKAP79 regulates AC2 activity in isolated plasma membranes.
Physiologically, AKAP79/150 has been studied in isolated cardiomyocytes from wild-type and
AKAP150 knockouts. Deletion of AKAP150 significantly reduced stimulated calcium transients
and calcium sparks in response to isoproterenol. Additionally, phosphorylation of the ryanodine
receptor (RyR) and phospholamban (PLN) was eliminated in cardiomyocytes from knockout mice.
It was further shown that AKAP150 forms a complex with AC5/6, PKA, protein phosphatase
type 2 (PP2B or calcineurin), Cav1.2, and caveolin 3 (CAV3). This complex is found on t-tubules,
while disruption of complex formation upon AKAP150 deletion alters CAV3 and AC6 localization [51].
AKAP150 has additional roles that are independent of AC and PKA. AKAP150 localizes protein
kinase C (PKC) and L-type calcium channels to the sub-sarcolemma in atrial myocytes enabling
regulation of calcium sparklets [55]. TRPV4 sparklets are also modulated by the AKAP150–PKC
complex in a distance-dependent manner; a distance less than 200 nM between the TRPV4 and
AKAP150–PKC is ideal for proper regulation [56]. AKAP150 is also implicated in β1AR recycling.
Knockdown or knockout of AKAP150 in isolated myocytes inhibits recycling of β1AR back to
the membrane after isoproterenol stimulation, but not internalization. Isolated AKAP150−/−
cardiomyocytes have an enhanced contraction rate in response to isoproterenol and an increased
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cell size at basal and stimulated conditions. Based on these results it was postulated that AKAP150 is
cardioprotective because the hypertrophy phenotype was enhanced in AKAP150−/− [57].
AKAP150 has been examined in a number of pathology models including myocardial infarction
and pressure overload. AKAP150−/− mice were subjected to transverse aortic constriction surgery
(TAC) to induce pressure overload; AKAP150 expression significantly decreased in conjunction
with a significant increase in hypertrophy, fibrosis, and cell death. Physiologically, deletion of
AKAP150 increased left ventricular end diastolic size and impaired fractional shortening after
TAC compared to sham animals. Physiological changes were mirrored by alterations in calcium
signaling, as AKAP150 creates a complex between the PLN, RyR, and the sarcoplasmic endoplasmic
reticulum calcium ATPase 2 (SERCA2). Phosphorylation of RyR and PLN in addition to calcium
transients were impaired in response to isoproterenol [58]. A model of myocardial infarction (MI)
was also examined in AKAP150−/− mice. Alteration in cardiac signaling that occurs after MI is well
documented. MI causes an increase in NFATc3 activation and associated Kv channel downregulation.
AKAP150−/− cardiomyocytes displayed impaired NFAT translocation in response to phenylephrine,
which was dependent on calcineurin activity, preventing downregulation of Kv channel currents [59].
Cardiovascular disease is a co-morbidity associated with diabetes [60]. Unlike the other models,
in a model of diabetes mellitus, knockdown of AKAP150 ameliorates glucotoxicity-induced diastolic
dysfunction in mice. In rat cardiomyocytes from diabetic animals or treated with high glucose,
AKAP150 expression is enhanced combined with increased active PKC at the plasma membrane.
This, in turn, promotes activation of NFκB and Nox [61], players in the reactive oxygen species
pathway that underlie diabetes-induced cardiovascular injury [60]. Thus, while AKAP150 may play a
cardioprotective role in some pathology models, this is not always the case.
3.2. mAKAP (AKAP6)
Anchored to the nuclear envelope, the cardiac splice variant of muscle AKAP (mAKAPβ)
interacts with AC5 to facilitate cardiac signaling [62,63]. mAKAP is localized to the nuclear envelope
through its interaction with nesprin [64] while much lower levels of mAKAP are found at the
sarcoplasmic reticulum (SR) [65]. While mAKAP is intracellularly located primarily at the nuclear
envelope and AC5 is membrane-bound, it is thought that localization of AC5 to the t-tubules
allows for this interaction due to the close proximity of the nucleus and t-tubules at sites within the
cardiomyocyte [66,67]. AC5 interacts with mAKAP through a unique binding site on the N-terminus
(245–340). Similar to AKAP79, PKA binding to the mAKAP complex creates a negative feedback loop
to inhibit AC5 activity [63].
A number of molecules implicated in hypertrophy are anchored by mAKAP, including protein
phosphatases 2A and 2B (PP2A/2B), PDE4D3, hypoxia-inducible factor 1α (HIF1α), phospholipase
Cε (PLCε), myocyte enhancer factor-2 (MEF2) [68], and p90 ribosomal S6 kinase 3 (RSK3) [69–73].
Other proteins are associated indirectly with mAKAP complexes, including EPAC1 and the ERK5 and
MEK5 mitogen-activated protein kinases via interactions with PDE4D3 [74]. The interaction of mAKAP
and the RyR at the SR promotes phosphorylation and enhances calcium release [75], while RyR located
within the nucleus promotes hypertrophy as discussed below.
A role for mAKAP in pathological hypertrophy was first described in mAKAP knockdown
myocytes [76] and subsequently shown in mAKAP knockout mice where knockout mice subjected to
TAC had reduced hypertrophy, cell death, and did not display TAC-inducible gene expression [77].
Further characterization of the mAKAP macromolecular complex highlights how multiple pathways
converge on mAKAP to integrate hypertrophic signaling. The cAMP pathway is integrated through
AC5–mAKAP–PDE4D3–EPAC binding to utilize and maintain local cAMP pools [63,69,71,74].
Activated calcineurin is recruited to the complex and is required for nuclear translocation of NFAT [78].
PLCε binds to a complex containing mAKAP, EPAC, protein kinase D (PKD), and RyR2 contributing
to PKD activity and nuclear calcium levels [72,79].
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3.3. Yotiao (AKAP9)
Yotiao is a 250 kDa splice variant of AKAP9 that is present in heart. Yotiao interacts with the alpha
subunit (KCNQ1) of the slowly activating delayed rectifier K+ current (IKs), a critical component for the
late phase repolarization of the cardiac action potential in humans [80]. IKs is made up of four alpha
subunits and accessory beta subunits, KCNE1. Beta-adrenergic control of IKs by PKA phosphorylation
of KCNQ1 increases channel current to shorten the action potential and maintain diastolic intervals
in response to an increase in heart rate. Mutations in KCNQ1 are associated with long QT syndrome
type 1 (LQT1), a potentially lethal hereditary arrhythmia. Not only do mutations in the KCNQ1 lead
to this disease, but mutations within Yotiao (LQT11) and KCNE1 (LQT5) can also give rise to LQT
syndrome [81,82]. A subset of these mutations in either Yotiao (S1570L) or KCNQ1 (G589D) disrupts
the KCNQ1–Yotiao interaction, resulting in altered regulation of the IKs channel [81].
Yotiao creates a macromolecular complex between KCNQ1 and important regulators of KCNQ1
phosphorylation. Yotiao scaffolds both positive (PKA) and negative regulators, protein phosphatase
1 (PP1) and phosphodiesterase 4DE3 (PDE4D3), of KCNQ1 phosphorylation [80,83–85]. Loss of
this scaffold decreases cAMP-dependent PKA phosphorylation of KCNQ1, eliminates the functional
response by IKs, and prolongs the action potential [85]. Yotiao is the key to maintaining a tightly
regulated feedback loop for IKs-dependent cardiac repolarization and heart rate. Although Yotiao
facilitates cardiac repolarization, it cannot overcome channel mutations that alter the capacity for
phosphorylation. For example, an A341V mutation in KCNQ1 acts as a dominant negative that reduces
basal channel activity and KCNQ1 phosphorylation with no alteration in Yotiao binding [86].
Of the AC isoforms that Yotiao scaffolds (AC 1, 2, 3, and 9) [87], AC9 is the only one present
in cardiomyocytes. Unlike the other AKAPs that interact with AC in heart, Yotiao does not scaffold
the major cardiac isoforms AC5/6. While Yotiao binds to the N-terminus of AC9, there appear to be
multiple sites of interaction of AC9 on Yotiao with the primary site located within the first 808 amino
acids and a second, weaker site that overlaps with the AC2 binding site on Yotiao (amino acids
808–956). The interaction of AC9 with Yotiao and KCNQ1 was shown by immunoprecipitation of the
complex from cells co-expressing all three proteins, a transgenic mouse line with cardiac expression of
KCNQ1–KCNE1, and from guinea pig hearts, which endogenously express the complex. Co-expression
of AC9 and Yotiao in CHO cells stably expressing KCNQ1–KCNE1 sensitize PKA phosphorylation of
KCNQ1 in response to isoproterenol compared to AC9 or Yotiao expression alone [13]. Yotiao inhibits
AC2 and AC3 activity but the mechanism of inhibition is unknown; no inhibition of AC9 activity
is observed [87]. Based on these results we would postulate that the AC9–Yotiao–PKA–KCNQ1
macromolecular complex generates a local pool of cAMP that is critical for cardiac repolarization
in humans.
4. Newly Appreciated ACs in Heart
4.1. AC9 Knockout Phenotype
An in-depth look at the role of AC9 in cardiomyocytes has long been overlooked. This is likely
due to the low level of expression of AC9 in cardiomyocytes, the fact that AC5/6 accounts for nearly
all of the total cAMP production [8], and observations from Antoni showing deletion of AC9 through
conventional targeting was embryonically lethal [88]. Interaction of AC9 with the Yotiao–IKs complex
sparked renewed interest in examining its role in cardiac physiology [13]. Meanwhile, the Mutant
Mouse Regional Resource Center, an NIH funded strain repository, generated a viable AC9 deletion
mouse utilizing a gene trapping cassette. Examination of this AC9 deletion strain resulted in two
distinct physiological phenotypes, bradycardia and diastolic dysfunction with preserved ejection
fraction; no structural abnormalities were observed in AC9−/− mice using echocardiograms [89].
In addition, Yotiao-anchored AC9 activity is present in the sinoatrial node, supporting a role for AC9
in heart rate. These findings, while intriguing, require further validation. Bradycardia measurements
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were made while under anesthesia, which has reported effects on heart rate; it will be of interest to see
whether the bradycardia phenotype is recapitulated in a conscious mouse model [90].
4.2. Complexes and Signaling Alterations in AC9−/− Heart
Deletion of either AC5 or AC6, the major cardiac AC isoforms, results in a significant reduction
in total cAMP activity, whereas deletion of AC9 is estimated to contribute to less than three percent
of total cardiac membrane AC activity (Gαs stimulated). To try and reveal the low AC9 activity in
cardiac membranes from WT and AC9−/− hearts, adenylyl cyclase activity was stimulated with Gαs
in the presence of the P-site inhibitor, SQ 22,536, which displays >100 fold selectivity for AC5/6 over
AC9 [36,89]. This estimate provides only an upper limit to which AC9 contributes to total AC activity
in heart. Although the global contribution of AC9 is negligible, it is required for maintaining local
cAMP levels in macromolecular complexes. AC9 can interact with two cardiac AKAPs: AKAP79/150
and Yotiao. Yotiao-associated AC activity, as determined by immunoprecipitation-adenylyl cyclase
assay [49,63,87], was completely abolished in AC9 knockout hearts, confirming AC9 as the only cardiac
isoform associated with Yotiao [87]. Conversely, local cAMP pools associated with AKAP150 were
unchanged in AC9−/−; AC5 and AC6 are the largest contributors to the AKAP79/150 local pool [51,54].
Similarly, AC9 deletion has a limited impact on global PKA signaling but is important for
targeted downstream signaling in local complexes. Although AC9 association with Yotiao sensitizes
IKs phosphorylation in cells [13], it could not be evaluated in the AC9−/− mouse as adult mice
do not express a functional IKs channel [80,89,91,92]. Nonetheless, AC9 deletion reduces basal
phosphorylation of the small heat shock protein 20 (Hsp20). Hsp20 and AC9 interact independently
of Yotiao as demonstrated by immunoprecipitation and proximity ligation assays. Disruption of this
complex by expression of a catalytically inactive AC9 in rat neonatal cardiomyocytes significantly
impaired isoproterenol stimulated phosphorylation of Hsp20 [89]. Taken together, this suggests that
cardioprotection is yet another role for AC9, by controlling baseline PKA-mediated phosphorylation
of Hsp20. Hsp20’s role in cardioprotection is well documented against a variety of insults: prolonged
beta-agonist induced hypertrophy, ischemia/reperfusion injury, and doxorubicin cardiotoxicity [93–95].
Although AC9 is a binding partner with Hsp20, it is likely that other ACs also bind Hsp20. Deletion of
AC9 reduced Hsp20-associated AC activity by only 30%, indicating that other AC(s) interact with
Hsp20 in heart [89].
The deletion of AC9 emphasizes the importance of localized cAMP signaling and complex
formation, as AC9 contributes to different aspects of cardiac physiology, despite its very low level of
activity in heart. AC9 association with the Yotiao–IKs complex contributes to cardiac repolarization in
humans, while an AC9–Hsp20 complex is potentially important for cardioprotection. Further support
for an AC9 cardioprotective role in heart comes from an observed upregulation of the micro RNA that
regulates AC9 expression (miR-142-3p) in patients with non-ischemic dilated cardiomyopathy and in
mouse models of hypertrophic cardiomyopathy [96–99]. Additional investigations into the role of AC9
regulation of Hsp20 phosphorylation are needed to understand how this complex functions under
stress and whether there are other proteins associated with this complex.
4.3. AC9 Regulation
Of the AC isoforms, AC9 is the most divergent in sequence and has been the least studied.
Expression analysis shows that AC9 is widely expressed in the central nervous system, heart,
and other tissues [100–103]. While the regulatory mechanisms of the other isoforms have been well
studied, studies of AC9 regulation have yielded conflicting results. Potential modes of AC9 regulation
include stimulation by Gαs, protein kinase C βII (PKCβII) [104], or calcium–calmodulin kinase II
(CaMKII) [105] and inhibition by Gαi/o [106], novel PKC isoforms [106], or calcium/calcineurin
(CaN) [101]. Determining the regulatory modalities for various AC isoforms is crucial for understanding
how the individual isoforms function physiologically. Ideally, the regulation of AC9 would be
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examined in biochemical and tissue culture models and then confirmed in cardiomyocytes; however,
due to the low levels of expression, examining AC9 regulation will prove difficult in this system.
4.3.1. G-Protein Regulation
Every membrane-bound AC isoform is stimulated by Gαs [8]. Compared to AC6, AC9 has a
right-shifted Gαs dose-response curve in Sf9 cells, showing a reduced sensitivity to Gαs (TA Baldwin,
unpublished observations). This would potentially impact signaling, where a decreased sensitivity to
Gαs would reduce downstream signaling outputs, making AC9 even more dependent on complex
formation to facilitate local pools of cAMP. Interestingly, all of the alterations in cardiac physiology
observed in AC9−/− mice were at basal levels, suggesting that AC9 may be more important for setting
the basal tone in cardiac signaling [89]. However, in cells AC9 requires Yotiao anchoring to sensitize
the phosphorylation of KCNQ1 in response to isoproterenol [13], emphasizing again the need for
complex-dependent signaling.
The original cloning and characterization of human AC9 examined Gαi/o regulation of AC9
in HEK293 cells but did not detect inhibition of AC9 by endogenously expressed somatostatin
receptors [101]. Subsequently, Gαi/o regulation of AC9 was reexamined in HEK293 cells upon transient
expression of the dopamine receptor (D2L); cells treated with a D2L selective agonist had a significant
reduction in AC activity. Thus, the researchers concluded that Gαi/o could inhibit AC9 [106]. It is
unclear whether the discrepancy between these two studies is due to the type of Gαi/o-coupled
receptor, receptor preference for Gαi versus Gαo, or background activity of endogenously
expressed AC6. Interestingly, AC9 does not contain the important residues that are required for Gαi
binding and inhibition of AC5 [107]. Further studies are needed to determine whether Gαi is a direct
regulator of AC9.
Gβγ is another common regulator of AC activity, inhibiting AC1, AC3, and AC8 or stimulating AC2,
AC4, and AC5–7 [8,15]. AC9 regulation by Gβγ had been postulated based on neutrophil chemotaxis
studies but never tested in cells [108]. Gβγ does not regulate basal or Gαs-stimulated AC9 activity
when assaying membranes from Sf9 cells overexpressing AC9 (TA Baldwin, unpublished observations).
Despite not having a direct regulatory role, Gβγ binds the N-terminus of AC9 [89,109].
4.3.2. Kinase and Phosphatase Regulation
Gq regulation of AC9 through CaMKII and PKC was examined in HEK293 cells expressing AC9
stably with transient transfection of either the muscarinic receptor M5 or the serotonin receptor 5HT2A.
Treatment of cells with the receptor agonists (M5, carbachol or 5HT2A, 5HT) potentiated AC9 activity
in the presence of isoproterenol; expression of the constitutively active Gαq mutant (Q209L) showed
similar results. Co-treatment with receptor agonists and the PKC inhibitor, bisindolylmaleimide,
further potentiated activity suggesting that PKC acted as an inhibitor of AC9 activity. The authors
also examined potentiation of AC9 activity by calcium/calmodulin (CaM) kinase (CaMK) through
the M5 receptor, by treating cells with carbachol in the presence of a CaM (W-7) or CaMKII
(KN-93) inhibitor; both inhibitors reduced AC9 activity. Thus, Gq potentiation of AC activity occurs
through activation of CaMKII. However, the authors could not determine whether AC9 is directly
phosphorylated by these kinases or whether regulation was via an indirect mechanism [105].
AC9 is also important for neutrophil chemotaxis through activation of AC9 by PKCβII.
Neutrophils express high levels of AC9 and have also been used to examine AC9 regulation.
Knockdown of AC9 in a neutrophil cell line was shown to inhibit chemotaxis in response to fMLP
caused by a decrease in cAMP in extending pseudopods [108]. This mechanism was further dissected
to show that PKCβII knockdown recapitulated the AC9 knockdown phenotype. It was proposed that
AC9 phosphorylation by PKCβII was the mechanism for increased cAMP in neutrophils leading to
chemotaxis [104].
AC9 was originally cloned from a mouse as a calcineurin-inhibited isoform [110]. In HEK293 cells
expressing mouse AC9, activity was inhibited by calcium in a concentration-dependent manner but
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was restored by increasing treatments with the calcineurin inhibitors FK506 or cyclosporin A [100,110].
Subsequent characterizations of human AC9 show conflicting results for calcineurin inhibition [101,102].
The discrepancy is suggested to occur due to differences in variants of AC9 mRNA. Overall, it is
unclear whether regulator differences reported for AC9 are due to different expression systems,
species differences, or interaction with cell-specific proteins (including AKAPs).
5. Conclusions
Multiple distinct AC complexes exist in heart and are important regulators of cardiac physiology.
While great strides have been made to understand the composition and roles of these complexes,
there are still many questions left to answer. Pharmacological targeting of AC isoforms has
been actively pursued but obtaining isoform specificity is difficult, especially for AC5 and AC6.
An alternative and widely considered approach is the targeting of specific protein–protein interactions
within the cardiac AC complexes. Targeting components of a complex could provide specificity,
unlike pan enzyme inhibitors, as these complexes frequently contain only a small percentage of
the total protein in the cell. This was the idea behind disrupting the AC5–mAKAP complex as
mAKAP-localized cAMP signaling is involved in cardiac hypertrophy [63]. While disruption of this
complex was proposed to have a beneficial effect on hypertrophy, the opposite effect was observed.
In cardiomyocytes, disruption of AC5–mAKAP binding leads to cellular hypertrophy through an
increase in cAMP levels. As previously discussed, AC5 binding to the mAKAP complex creates
multiple feedback loops to inhibit cAMP production. These data show how important the fine-tuning
of cAMP signaling is and emphasizes the need for extensive studies when designing AKAP complex
disruptors for therapeutic use. Finally, many ACs interact with up and or downstream effectors through
AKAP-facilitated interactions. However, there is still the possibility that other AC–AKAP complexes
have yet to be identified. Currently, an AKAP is not known to interact with the AC9–Hsp20 complex.
Moving forward, the possibility of AC complexes independent of AKAPs should also be considered.
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Abstract: Mounting evidence confirms the compartmentalized structure of evolutionarily conserved
3′–5′-cyclic adenosine monophosphate (cAMP) signaling, which allows for simultaneous participation
in a wide variety of physiological functions and ensures specificity, selectivity and signal strength.
One important player in cAMP signaling is soluble adenylyl cyclase (sAC). The intracellular
localization of sAC allows for the formation of unique intracellular cAMP microdomains that
control various physiological and pathological processes. This review is focused on the functional
role of sAC-produced cAMP. In particular, we examine the role of sAC-cAMP in different cellular
compartments, such as cytosol, nucleus and mitochondria.
Keywords: adcy10; cAMP; phosphodiesterase; compartmentalization
1. Introduction
Even though 3′–5′-cyclic adenosine monophosphate (cAMP) was discovered more than half
a century ago, it still remains an object of scientific interest. cAMP signaling plays an important
role in a wide variety of physiological processes: transcription regulation [1,2], metabolism [3,4],
cell migration [5,6], mitochondrial homeostasis [7–11] (reviewed in Reference [12]), as well as cell
proliferation [13] (reviewed in Reference [14]) and cell death [15] (reviewed in Reference [16]). The
importance of cAMP signaling is underlined by the fact that this pathway is evolutionarily conserved
and can be found in all species from microorganisms to mammals [17–19].
There are two main sources of cAMP in the cell: Transmembrane (tmAC) and intracellularly
localized soluble adenylyl cyclases (sAC). In mammalian cells, nine genes encode tmAC and one
gene encodes sAC. The structural organization of tmAC is common for all members of this subfamily
(9 tmAC) and the activity of tmAC is controlled by hormones and neurotransmitters [20,21]. Two
important properties characterize the principal difference between tmAC and sAC: First, Gs, Gi,
Gαi/o, Gßγ and Gq proteins regulate tmAC activity [22,23], whereas sAC activity is regulated by
bicarbonate [24]; second, tmAC’s localization is restricted to the plasma membrane, while sAC is
widely distributed within the cell and organelles [25]. The distinct spatial distribution of the two main
cAMP sources leads to the formation of multiple intracellular cAMP compartments, thereby enabling
the specificity and selectivity of cAMP signaling.
The specificity of cAMP signaling is further achieved through the restriction of cAMP diffusion
due to physical barriers, i.e., mitochondria [26], and phosphodiesterases (PDEs) [27–29]. Therefore,
with the exception of a rare internalization of tmAC [30], cAMP produced by tmAC under physiological
conditions is mainly localized close to the plasma membrane. In contrast, sAC builds cAMP pools
within various cellular compartments, e.g., cytosol, mitochondria, nucleus or the subplasmalemmal
compartment [31–33]. In this review, we focus on sAC-dependent cAMP signaling, with a particular
focus on its role in mitochondrial biology.
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2. Structure and Regulation of sAC Activity
2.1. Structure
Mammalian sAC shows structural and functional similarities with cyanobacterial sAC [24],
which argues for a bacterial origin of mammalian sAC that has been strongly conserved throughout
the process of evolution [34]. The structure of the sAC catalytic core has a typical Class III
pseudo-heterodimer arrangement of structurally similar C1 (residues 34–219) and C2 (residues 288–463)
domains positioned at the N-terminus and connected by a linker [35]. The C-terminal region of
sAC starts with a small motive, mediating auto-inhibitory effect [36], that most likely acts together
with the neighboring putative NTPase domain [37]. Additionally, the C-terminal region contains a
heme-binding domain that can bind nitric oxide (NO), carbon monoxide, and other potential gaseous
signaling molecules [38]. Active cyclase is a heterodimer of two catalytic domains [19]. sAC is encoded
by a single functional sAC gene in the human genome (ADCY10), comprising of 33 exons covering
approximately 104 kb of genomic DNA [39,40]. sAC mRNA undergoes extensive alternative splicing
which leads to smaller splice variants [41]. In mammalian cells the predominant isoform is a 50 kDa
truncated sAC (sACt) which is categorized as a splice variant of the full-length enzyme. sACt is
restricted to the N-terminal part of the full-length protein covering C1 and C2 [42]. sACt shows a
higher activity than the full-length enzyme, as the activity of the latter is suppressed by the small
auto-inhibitory module at the C-terminal [36]. More splice sAC variants have also been identified
in human somatic tissue. These isoforms predominantly consist of C2 domain and require a partner
protein to become active due to a missing or incomplete C1 domain [19,43].
2.2. Posttranslational Regulation of sAC
sAC is insensitive to heterotrimeric G-protein regulation due to a missing or modified Gsα and
Gßγ binding region, which is important for the activation of tmAC [44]. A recent study performed by
Hebert-Chatelain et al., however, challenged this paradigm of sAC insensitivity to G proteins. The
authors demonstrated that the activation of mitochondrial Gαi proteins through cannabinoid receptors
inhibits mitochondrial sAC [45]. However, the authors investigated the role of sAC applying the sAC
inhibitor KH7, which may have also led to sAC-independent effects on the mitochondria [9,46]. The
results could also be explained by an indirect downregulation of sAC activity.
sAC activity requires divalent metal cations in the catalytic active site of the enzyme in order to
coordinate the binding and cyclizing of ATP. sAC is most active in the presence of Mn2+, however
it is not clear whether the physiological intracellular Mn2+ concentration would support sAC
activity [47]. Mg2+ and Ca2+ concentrations within the expected intracellular range 1–10 mmol/L
for Mg2+ and 2–1200 nmol/L for Ca2+ make significant contributions to the regulation of sAC
activity [43]. Furthermore, sAC serves as an intracellular ATP sensor because its activity is dependent
on physiological changes in ATP concentrations. When the ATP level is reduced, sAC shows decreased
activity due to substrate limitation [48].
A unique property of sAC is its activation through bicarbonate binding, which makes sAC the only
protein with enzymatic activity regulated by bicarbonate. Bicarbonate directly binds to and activates
sAC in a pH-independent manner [24]. The EC50 for the bicarbonate stimulation of mammalian sAC
is within the 10–25 mmol/L range, which is appropriate for sensing physiological bicarbonate levels
of 2–25 mmol/L [24]. It is also worth mentioning that sAC activity increases synergistically in the
presence of bicarbonate and Ca2+ [43,49].
2.3. Pharmacological Regulation of sAC
sAC is involved in a wide variety of physiological processes, including metabolism, proliferation,
apoptosis, differentiation, migration development, ion transport, pH regulation and gene expression
(reviewed in [16,47]). It is also involved in different pathologies such as hyperproliferative skin
disease, hypercalciuria, type 2 diabetes glaucoma and prostate cancer [40,50–55]. Therefore, the
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pharmacological inhibition or activation of sAC may be considered for the treatment of the pathologies
and the maintenance of the physiological processes mentioned above. Although the search for potential
sAC activators remains unsuccessful, several inhibitors have been discovered. Catechol estrogens (CEs)
are physiologically occurring steroid derivatives that can inhibit mammalian AC enzymes. 2-hydroxy
estradiol (2-CE) and 4-hydroxy estradiol (4-CE) inhibit purified mammalian sAC (IC50 2–8 μmol/L)
as well as some purified tmAC isoforms with comparable potency [44,56]. CEs are postulated to be
non-competitive inhibitors of AC that bind to a pocket near the enzyme’s active site [57].
Another potent sAC inhibitor is (E)-2-(1H-Benzo[d]imidazol-2-ylthio)-N′-(5-bromo-2-
hydroxybenzylidene) propanehydrazide (KH7) (IC50~3 μmol/L) [58]. KH7 shows good membrane
permeability and has no significant effect on tmACs, GC or PDEs up to a concentration of
100 μmol/L [56]. KH7 has been used as a pharmacological tool in a large number of studies and
seems to be a promising compound for drug development. Unfortunately, KH7 exhibits an intrinsic
fluorescence and is therefore of limited use when studies involve fluorescence-based live cell cAMP
sensors, according to our own observations and research [9]. In addition, KH7 leads to mitochondrial
uncoupling in a sAC-independent manner [9,46]. Therefore, KH7 use should be restricted to short-term
assays and the results should be interpreted carefully.
Recently, LRE1—an improved sAC-specific inhibitor—has been identified [46]. LRE1 inhibits sAC
by occupying the bicarbonate binding site. LRE1 neither exhibits cell toxicity nor results in uncoupling
of isolated brain mitochondria [46]. In our experiments, we have not observed any interference
between LRE1 and fluorescence, which allows the compound to be used in live cell imaging.
3. Functional Role of sAC in Different Cellular Compartments
sAC-generated cAMP is involved in the regulation of multiple cellular functions as it is
generated locally within particular microdomains containing cAMP effectors (PKA, EPAC, cyclic
nucleotide-gated ion channels and Popeye domain-containing proteins [59–62]), scaffolding proteins
(A-kinase anchoring proteins, AKAPs) and a subset of PDEs, that degrade cAMP, and thus suppress
cAMP diffusion [28,29,63]. AKAPs form the complexes of cAMP and its downstream targets, and bind
these complexes to particular subcellular compartments [22]. Tight spatiotemporal regulation of cAMP
dynamics inside discrete signaling compartments provides specific responses to diverse stimuli at
certain locations and avoids unregulated cross-communication between microdomains.
Mammalian sAC is distributed over different compartments throughout the cell: the cytosol,
nucleus, plasma membrane and mitochondria [25,64–68]. Although numerous cellular functions have
been attributed to the activity of sAC, the functional significance of sAC in particular compartments
is still in need of clarification. Therefore, in this review, the functional significance of different sAC
domains will be described according to the sAC subcellular localization (Figure 1).
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Figure 1. Intracellular distribution of sAC-dependent cAMP pool. sAC, soluble adenylyl cyclase; PKA,
protein kinase A, EPAC, exchange protein directly activated by cAMP; CNGC, cyclic nucleotide gated
channels; PDE, phosphodiesterase.
3.1. Role of sAC-Dependent cAMP Signaling in Microtubules and Centrioles
It has been suggested that sAC both co-localizes with microtubules and centrioles, while also
playing a role in mitosis and cytokinesis [25]. During prophase, sAC is dispersed from the nucleus.
In metaphase and anaphase, it accumulates at the mitotic poles and spindle fibers. During cytokinesis,
sAC is localized in the midbody. In the centrioles, the main pathway that promotes the phosphorylation
cascade is PKA-dependent, whereas in the microtubules it is EPAC-dependent [25].
3.2. Role of Cytosolic/Nuclear sAC-Dependent cAMP Signaling
3.2.1. Proliferation and Cell Growth
Cytosolic sAC makes a significant contribution to the regulation of cell growth, particularly
in hyperplasia [16]. In prostate carcinoma tissue and cells (LNCaP, PC3), sAC was shown to
be overexpressed and the suppression of sAC activity significantly reduced the proliferation
rate [53]. A subsequent analysis of the underlying cellular mechanisms revealed the role of the
EPAC/Rap1/B-Raf axis in the sAC-dependent regulation of cell growth. Inhibiting sAC down
regulates cyclin B1 and cyclin-dependent kinase 1, which are the key proteins involved in the G2/M
transition. Thus, sAC suppression causes cell cycle arrest in the G2 phase [53]. In another tumor cell
line (PC12), nerve growth factor stimulation via sAC was shown to induce cAMP elevation, which,
in turn, promoted the activation of Rap1 [69]. This mechanism is considered to be implicated in the
process of brain-derived neurotrophic factor-mediated axonal guidance. A study performed in breast
cancer cells postulated that sAC in the EPAC-Rap1 dependent mechanism is involved in a metabolic
switch, thereby favoring the development of malignant progression [70].
sAC also plays a role in non-proliferative cell growth, i.e., hypertrophy. It is expressed in
embryonic neurons and generates cAMP in response to netrin-1, a member of the laminin-related
secreted proteins family, thus affecting axon outgrowth [71]. Moreover, retinal ganglion cell survival
and axon growth is regulated by Ca2+-dependent cAMP-PKA signaling [64]. Our recent study
revealed a novel role for sAC in cardiac hypertrophy induced by either β-adrenergic stimulation
or pressure overload [72]. B-Raf’s involvement in sAC-dependent hypertrophy was also demonstrated
in that study.
3.2.2. Motility
sAC plays a central role in sperm physiology [58,73]. During one of the first definable events
in capacitation, Ca2+ and bicarbonate enter into sperm and activate sAC to produce cAMP. This
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promotes an asymmetrical flagellar beat frequency and results in vigorous forward sperm motility [47].
In keeping with this role of sAC in sperm motility, male sAC knockout mice show an infertility
phenotype [74]. Though sAC’s role in cell motility was initially exclusively considered for sperm,
a recent report suggested that sAC is also involved in the regulation of leukocyte trans-endothelial
migration through the CD99 [75]. CD99 and sAC are co-localized in a signaling complex with ezrin and
PKA. The stimulation of CD99 promotes the sAC-PKA pathway that activates membrane trafficking
from the lateral border recycling compartment to sites of trans-endothelial migration, facilitating the
passage of leukocytes across the endothelium [75].
3.2.3. pH Homeostasis
sAC plays an important role in the regulation of pH homeostasis [76,77]. In epididymal clear
cells and in kidney intercalated cells, sAC-produced cAMP promotes the translocation of the vacuolar
proton pumping ATPase (V-ATPase) to the acid-secreting surface in a PKA-dependent manner [78,79].
The apical translocation of V-ATPase, associated with the protein activation, plays an important role in
the regulation of pH homeostasis and extracellular acidification/alkalinization. The maintenance of
acid/base balance is important for the regulation of acids in the body. V-ATPase dysfunction is one of
the factor that leads to renal distal tubular acidosis, the formation of kidney stones and proteinuria [80].
Recently, sAC’s control of the endosomal-lysosomal acidification has been shown to function
in a PKA-dependent manner. The absence of sAC disrupts V-ATPase localization at the lysosomal
membrane which is rescued by treatment with membrane-permeable cAMP [81]. It is interesting
to note that a disturbance in lysosomal acidification through sAC knockout leads to an impaired
autophagic degradative system.
3.2.4. Transcriptional Regulation
An increasing number of reports argue for the essential role of sAC in regulating the transcriptional
activity of the cell. Indeed, sAC has been identified as a unique source of cAMP in the nucleus
that in PKA-dependent manner regulates CREB activity [68]. sAC, in a PKA-dependent manner, is
especially involved in corticotropin-releasing hormone-mediated CREB phosphorylation and c-fos
(endogenous CREB target) induction in hippocampal neuronal cells [82]. A recent study demonstrated
that sAC contributes to the regulation of CREB-mediated Na+/K+-ATPase expression in the vascular
endothelium and is an important regulator of endothelial stiffness [83,84]. Besides promoting
CREB activity, sAC also regulates several other transcription factors. For example, sAC supports
hypercapnia-accelerated adipogenesis via the activation of pro-adipogenic transcription factors, such
as CREB, CCAAT/enhancer binding protein ß and proliferator-activated receptor γ [85]. Similarly,
sAC-PKA-dependent phosphorylation, and thus the activation of transcription factor 4, is required for
brain development [86].
3.2.5. CFTR Regulation
The Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) is a chloride channel,
primarily localized in the apical membrane of secretory epithelial cells. Mutations in the CFTR lead to
the development of cystic fibrosis [87]. In cultured human airway epithelial cells, it has been found that
sAC, activated by bicarbonate, modulates CFTR function in a PKA-dependent manner. The inhibition
of sAC attenuated bicarbonate-stimulated CFTR activity [88]. Further studies have demonstrated
that CFTR is involved in bicarbonate entry into granulosa cells, which further promotes the nuclear
cAMP-PKA-CREB axis [89]. CFTR is involved in triggering sperm capacitation, as CFTR promotes
bicarbonate secretion by the endometrium [90] which, in turn, activates sAC in sperm, increases cAMP
production, and then activates PKA and the cyclic nucleotide gate cation channels [91,92]. Moreover,
CFTR via the sAC-cAMP-PKA pathway has been shown to promote embryo development through the
suppression of p53-dependent development arrest [93]. Taken together, the CFTR-sAC axis seems to
play an important role in reproductive processes [94].
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3.2.6. Na+/K+-ATPas Endocytosis
In alveolar epithelial cells, a high CO2 concentration promotes the sAC-cAMP axis, which in
turn induces a PKA-dependent phosphorylation of α-adducin, a component of the actin cytoskeleton,
resulting in Na+/K+-ATPase endocytosis [95]. In the vascular endothelium, the role that the sAC-cAMP
axis plays in Na+/K+-ATPase regulation has been demonstrated, as the inhibition of sAC (KH7 and
interfering RNA) significantly decreases the mRNA and protein levels of Na+/K+-ATPase [84]. A recent
study confirmed that the sAC-dependent regulation of Na+/K+-ATPase in the vascular endothelium
plays an important role in endothelial stiffness [83].
3.2.7. Endothelial Permeability
The importance of the intracellular distribution of cAMP for endothelial barrier function has been
demonstrated, because the stimulation of plasma membrane and cytosolic cAMP pools exerts the
opposite effects [96,97].
A recent study suggested that sAC has a protective effect on endothelial barrier function
under inflammatory and hypoxic conditions [98]. In this study, the bicarbonate-mediated activation
of sAC elevated cellular cAMP levels was followed by PKA and EPAC activation, which led to
the inhibition of RhoA/Rock signaling and the translocation of VE-cadherin at cell–cell junctions.
Moreover, sAC activation abrogated thrombin and hypoxia/reoxygenation-induced endothelial cells
hyperpermeability. Pharmacological inhibition or knockdown of sAC worsened the thrombin-induced
endothelial hyperpermeability suggesting that basal sAC activity is required for the maintenance of
the endothelial barrier function under inflammatory conditions.
3.3. Role of Mitochondrial sAC-Dependent cAMP Signaling
3.3.1. Extra-Mitochondrial sAC
According to the current view on mitochondrial cAMP signaling, two main cores that contain
distinct cAMP signaling pathways—the extra-mitochondrial sAC (outer mitochondrial membrane
(OMM)) and intra-mitochondrial (the mitochondrial matrix)—can be distinguished [99]. The specificity
of cAMP in OMM is mainly achieved through PKA tethering to OMM by several AKAPs, which allows
multiple processes to be carried out, including mitochondrial protein import, autophagy, mitophagy,
mitochondrial fission and fusion, and apoptosis [99]. Our recent study defined the role that sAC plays
in regulating mitochondrial biogenesis and mitophagy [100].
It has been demonstrated that the cytosolic pool of cAMP generated by sAC is also involved in
controlling mitochondrial apoptosis. Under stress conditions, the translocation of cytosolic sAC to the
mitochondria leads to a selective activation of PKA, followed by phosphorylation and binding of the
pro-apoptotic protein Bax to mitochondria and the release of cytochrome c in coronary endothelial
cells, cardiomyocytes and aortic smooth muscle cells [15,101,102]. Furthermore, the overexpression of
cytosolic sAC, but not intra-mitochondrial sAC, promotes the activation of the mitochondrial pathway
of apoptosis under oxysterol treatment [102].
3.3.2. Intra-Mitochondrial sAC
An increasing amount of evidence suggests that intra-mitochondrial cAMP/PKA signaling is
present in mammals [8,45,103] and yeast [104]. Although transmembrane adenylyl cyclase was initially
assumed to be a source of mitochondrial cAMP [105], a recent study [9] reconsidered this paradigm
and demonstrated that cytosolic cAMP cannot permeate the inner mitochondrial membrane and a
mitochondria-localized cAMP source, i.e., sAC, is required [99]. In a recent study [106] we confirmed
the previously published findings [9] that activating plasmalemmal adenylyl cyclase with forskolin
leads to a rapid elevation of cytosolic cAMP, but does not affect cAMP concentration in mitochondria.
It is worth noting that we [106], as well as other authors [9,107,108], have all observed a rapid increase
in intra-mitochondrial cAMP under sAC stimulation with bicarbonate.
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Bicarbonate and Ca2+ stimulation of mitochondrial sAC may couple the activity of the TCA
cycle—the main source of CO2/bicarbonate in the cell—and alterations in the intra-mitochondrial
Ca2+ concentration to the OXPHOS activity [9]. Indeed, the seminal studies of Acin-Perez et al.
demonstrated that cAMP produced in the mitochondrial matrix promotes cytochrome c oxidase activity
via a PKA-dependent phosphorylation of cytochrome c oxidase subunit IV [8,109]. Knockout of sAC in
fibroblasts causes a decline in OXPHOS activity that is compensated with elevated OXPHOS expression,
whereas restoring sAC expression in the mitochondrial matrix rescues OXPHOS activity [110]. Similar
results (regulation of OXPHOS activity via cAMP-PKA axis) were obtained in yeast, where the
inhibition of sAC caused a decline in respiration and OXPHOS activity [104]. Furthermore, in a study
on human fibroblasts, the inhibition of sAC depressed complex I activity was rescued by adding a
membrane-permeable cAMP analog [111].
The role of intra-mitochondrial sAC in the regulation of memory processing was recently
demonstrated [45]. The authors suggested that the activation of mitochondrial localized type-1
cannabinoid receptors (mtCB1) decreases mitochondrial cAMP, complex I activity, mitochondrial
respiration and cellular ATP content in hippocampal cell culture. In their study bicarbonate stimulation
fully reversed the effect of mtCB1-receptor activation and eliminated the cannabinoid-induced
reduction in respiration. The study also confirmed that the modulation of brain mitochondrial
respiration occurs through the PKA-dependent phosphorylation of complex I subunit NDUFS2 [45].
In addition to the post-translational regulation of OXPHOS activity via PKA-dependent
phosphorylation, [8] it has also been suggested that sAC has an effect on the turnover of OXPHOS
proteins. Indeed, intra-mitochondrial cAMP prevents the digestion of nuclear-encoded subunits
of complex I by mitochondrial proteases and supports its NADH-ubiquinone oxidoreductase
activity [111].
Aside from the above-mentioned studies, several other reports have demonstrated the presence of
functional PKA in the mitochondrial matrix [112,113]. In a notable study that applied a PKA-sensing
system with a robust dynamic range, Agnes et al. [113] characterized the compartmentalized location
of PKA activity as being in bovine heart mitochondria. The experimentally determined PKA activity
ratio—79:8:13 in mitochondrial matrix/intermembrane space/outer membrane respectively—provided
evidence that the major PKA activity is located in the mitochondrial matrix. In agreement with
that study, Sardanelli et al. [112], applying densitometric immunoblot analysis and activity assays,
concluded that the majority (~90%) of mitochondrial PKA is localized in the inner mitochondrial
compartment. Nevertheless, this issue of PKA localization is still a matter of debate [114]. Indeed,
applying FRET-based analysis of PKA activity Lefkimmiatis et al. found no evidence of PKA
activity in the mitochondrial matrix [115]. In addition, it was demonstrated that calcium-induced
cardiac mitochondrial respiration is PKA independent [116]. This obvious discrepancy may be
due to differences in the methods used in the analysis of PKA activity or cell models (reviewed
in Valsecchi et al. [114]). In fact, the absence of PKA activity in Lefkimmiatis’s study may be due to the
use of predominantly glycolytic cell lines, i.e., HeLa and HEK cells. In addition, in many studies PKA
activity was examined through treatment with H89, which is an unspecific PKA inhibitor and may
lead to numerous side effects.
Though PKA has long been considered the most active kinase in the matrix and the main effector
of intra-mitochondrial cAMP [12], another cAMP downstream target involved in the regulation of
mitochondrial function—EPAC—has also been described [117]. The mitochondrial sAC-cAMP-EPAC
pathway regulates coupling efficiency and the structural organization of F0F1ATP synthase in
mammalian mitochondria [118]. In a recent study, Wang et al. [107] demonstrated a down-regulation
of sAC in an animal model of heart failure, which was accompanied by a reduced resistance
to Ca2+ overload in cardiac mitochondria. The authors underlined the inhibitory effect of the
sAC/cAMP/Epac1 axis on the Ca2+ overload-induced opening of mitochondrial permeability pore
transition [107]. In contrast, a study by Fazal et al. [119] postulated that activation of the mitochondrial
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sAC-cAMP-EPAC axis stimulates the mitochondrial Ca2+ entry, the opening of mitochondrial
permeability pore transition and cell death.
3.3.3. Intra-Mitochondrial PDE2
In addition to the sAC, PDEs also contribute to the intra-mitochondrial cAMP level. PDE2A has
been found to be a predominant intra-mitochondrial isoform [103]. This PDE is activated by cGMP that
enables a negative cGMP-cAMP cross-talk [103,120]. A study performed with mitochondria isolated
from mouse brains suggested that PDE2A, and the PDE2A2 isoform in particular, is localized in the
mitochondrial matrix—due to the mitochondrial targeted sequence at N terminus of PDE2A2—where
it regulates the activity of the mitochondrial respiratory chain [103]. Applying the super-resolution
stimulated emission depletion microscopy in neonatal rat ventricular myocytes, Monterisi et al.
revealed the localization of PDE2A outside of the mitochondrial matrix, particularly at the outer
or inner mitochondrial membrane, where it regulates mitochondrial morphology, mitochondrial
membrane potential and cell death via sAC-independent mechanisms [121]. Further investigation is
required to clarify the localization and activity of PDE2 in mitochondria.
Since the PDE2 is activated by cGMP, it is tempting to speculate that an activation of NO signaling
may lead to the activation of mitochondrial PDE2. In fact, our new report demonstrated a decline in
mitochondrial cAMP concentration after NO signaling activation, either by NO donor or estradiol,
in a PDE2- and sGC-dependent manner [106]. It is worth nothing that the localization of sGC in
mitochondria was confirmed by western blot analysis. The reduction of mitochondrial cAMP level was
accompanied by a decline in mitochondrial COX activity in a PDE2-dependent manner [106]. These
data are in agreement with a previous report that demonstrated that the inhibition of PDE2A with
BAY60-7550 increases oxygen consumption and ATP production in isolated mitochondria [103].
To prove whether the beneficial effect of PDE2 inhibition may be translated to cardiac pathology,
adult rat cardiomyocytes were challenged metabolically with cyanide followed by a recovery phase.
Inhibition of PDE2A with BAY60-7550 significantly improved cell viability [122]. In alignment
with these results, a recent report suggested that PDE2 inhibition has a protective effect in a brain
ischemia/reperfusion model, although it was delayed rather than acute effects of reperfusion that
were analyzed [123]. Similarly, an inhibition of matrix localized PDE2A with BAY60-7550 reduced the
uncoupled respiration rate and increased cytochrome c oxidase activity in septic mice [124].
3.4. Importance of sAC in the Cardiovascular System
The role of cAMP in the regulation of numerous physiological and pathological processes in the
heart is well known [125–127]. Nevertheless, knowledge about the role of sAC in the cardiovascular
system is limited. A seminal study by Sayner et al. [97] showed sAC’s regulation of endothelial barrier
function. We have also demonstrated that sAC plays a role in cardiovascular apoptosis [15,101].
The importance of sAC in cardiac pathology, like heart failure, has recently been suggested by
Wang et al. [107]. The authors revealed a dramatic downregulation of sAC in mitochondrial fraction
isolated from rat hearts at the late phase of cardiomyopathy and linked it to the reduced Ca2+ resistance
of mitochondria. Our recent study presented further evidence of the importance of sAC in cardiac
hypotrophy induced by isoprenaline (isolated cardiomyocytes) or pressure overload (sAC-knockout
mice) [72].
4. Conclusions
cAMP signaling plays a fundamental role in controlling numerous cellular functions. The system
is complex and has a well-organized spatiotemporal structure. Different mechanisms are involved
in the compartmentalized structure of cAMP within the cell, including phosphodiesterases, tmAC-
and sAC-dependent cAMP sources. The discovery of sAC as an alternative, intracellular source of
cAMP significantly expands our knowledge of the spatial compartmentalization of cAMP signaling.
The multifunctional role of sAC in the regulation of mitochondrial function and transcriptional activity
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in the cells, together with other functions described in this review, shows how important this cyclase
is for cellular and organismal homeostasis and health. In this light, an in-depth understanding of
sAC biology may contribute significantly to the prevention, prediction and treatment of several
pathologies. The appearance of recent data describing the role of sAC in cardiovascular physiology [9]
and pathology [11,15,72,102,107,119,124] is not surprising, especially considering the fundamental role
that cAMP signaling plays in the regulation of heart function.
Author Contributions: S.P. and Y.L. wrote the manuscript.
Acknowledgments: This study was supported by DZHK (German Centre for Cardiovascular Research) partner
site Berlin (Project DZHK TP BER 3.2 HF).
Conflicts of Interest: The authors declare no conflict of interest.
Abbreviations
cAMP 3′–5′-cyclic adenosine monophosphate
sAC soluble adenylyl cyclase
tmAC transmembrane adenylyl cyclase
PDEs phosphodiesterases
PKA protein kinase A
EPAC exchange protein directly activated by cAMP
CREB cAMP-response element binding protein
CE Catechol estrogens
GC guanylyl cyclase
AKAP A-kinase anchoring proteins
CFTR cystic fibrosis transmembrane conductance regulator
V-ATPase vacuolar H+-ATPase
IMS intra-mitochondrial space
OMM outer mitochondrial membrane




1. Wu, Z.; Huang, X.; Feng, Y.; Handschin, C.; Feng, Y.; Gullicksen, P.S.; Bare, O.; Labow, M.; Spiegelman, B.;
Stevenson, S.C. Transducer of regulated CREB-binding proteins (TORCs) induce PGC-1α transcription and
mitochondrial biogenesis in muscle cells. Proc. Natl. Acad. Sci. USA 2006, 103, 14379–14384. [CrossRef]
[PubMed]
2. Chowanadisai, W.; Bauerly, K.A.; Tchaparian, E.; Wong, A.; Cortopassi, G.A.; Rucker, R.B.
Pyrroloquinoline quinone stimulates mitochondrial biogenesis through cAMP response element-binding
protein phosphorylation and increased PGC-1α expression. J. Biol. Chem. 2010, 285, 142–152. [CrossRef]
[PubMed]
3. Catterall, W.A. Regulation of cardiac calcium channels in the fight-or-flight response. Curr. Mol. Pharmacol.
2015, 8, 12–21. [CrossRef] [PubMed]
4. Kashina, A.S.; Semenova, I.V.; Ivanov, P.A.; Potekhina, E.S.; Zaliapin, I.; Rodionov, V.I. Protein kinase A,
which regulates intracellular transport, forms complexes with molecular motors on organelles. Curr. Biol.
2004, 14, 1877–1881. [CrossRef] [PubMed]
5. Burdyga, A.; Conant, A.; Haynes, L.; Zhang, J.; Jalink, K.; Sutton, R.; Neoptolemos, J.; Costello, E.;
Tepikin, A. cAMP inhibits migration, ruffling and paxillin accumulation in focal adhesions of pancreatic
ductal adenocarcinoma cells: Effects of PKA and EPAC. Biochim. Biophys. Acta 2013, 1833, 2664–2672.
[CrossRef] [PubMed]
6. Zimmerman, N.P.; Roy, I.; Hauser, A.D.; Wilson, J.M.; Williams, C.L.; Dwinell, M.B. Cyclic AMP regulates
the migration and invasion potential of human pancreatic cancer cells. Mol. Carcinog. 2015, 54, 203–215.
[CrossRef] [PubMed]
24
J. Cardiovasc. Dev. Dis. 2018, 5, 29
7. Acin-Perez, R.; Salazar, E.; Brosel, S.; Yang, H.; Schon, E.A.; Manfredi, G. Modulation of mitochondrial protein
phosphorylation by soluble adenylyl cyclase ameliorates cytochrome oxidase defects. EMBO Mol. Med. 2009,
1, 392–406. [CrossRef] [PubMed]
8. Acin-Perez, R.; Salazar, E.; Kamenetsky, M.; Buck, J.; Levin, L.R.; Manfredi, G. Cyclic AMP produced inside
mitochondria regulates oxidative phosphorylation. Cell Metab. 2009, 9, 265–276. [CrossRef] [PubMed]
9. Di Benedetto, G.; Scalzotto, E.; Mongillo, M.; Pozzan, T. Mitochondrial Ca2+ uptake induces cyclic AMP
generation in the matrix and modulates organelle ATP levels. Cell Metab. 2013, 17, 965–975. [CrossRef]
[PubMed]
10. Valsecchi, F.; Ramos-Espiritu, L.S.; Buck, J.; Levin, L.R.; Manfredi, G. cAMP and mitochondria. Physiology
2013, 28, 199–209. [CrossRef] [PubMed]
11. Signorile, A.; Santeramo, A.; Tamma, G.; Pellegrino, T.; D’Oria, S.; Lattanzio, P.; De Rasmo, D. Mitochondrial
cAMP prevents apoptosis modulating Sirt3 protein level and OPA1 processing in cardiac myoblast cells.
Biochim. Biophys. Acta 2017, 1864, 355–366. [CrossRef] [PubMed]
12. Zhang, F.; Zhang, L.; Qi, Y.; Xu, H. Mitochondrial cAMP signaling. Cell. Mol. Life Sci. 2016, 73, 4577–4590.
[CrossRef] [PubMed]
13. Bacallao, K.; Monje, P.V. Opposing roles of PKA and EPAC in the cAMP-dependent regulation of schwann
cell proliferation and differentiation [corrected]. PLoS ONE 2013, 8, e82354. [CrossRef] [PubMed]
14. Stork, P.J.; Schmitt, J.M. Crosstalk between cAMP and MAP kinase signaling in the regulation of cell
proliferation. Trends Cell Biol. 2002, 12, 258–266. [CrossRef]
15. Appukuttan, A.; Kasseckert, S.A.; Micoogullari, M.; Flacke, J.P.; Kumar, S.; Woste, A.; Abdallah, Y.; Pott, L.;
Reusch, H.P.; Ladilov, Y. Type 10 adenylyl cyclase mediates mitochondrial bax translocation and apoptosis
of adult rat cardiomyocytes under simulated ischaemia/reperfusion. Cardiovasc. Res. 2012, 93, 340–349.
[CrossRef] [PubMed]
16. Ladilov, Y.; Appukuttan, A. Role of soluble adenylyl cyclase in cell death and growth. Biochim. Biophys. Acta
2014, 1842, 2646–2655. [CrossRef] [PubMed]
17. Ohmori, M.; Okamoto, S. Photoresponsive cAMP signal transduction in cyanobacteria. Photochem.
Photobiol. Sci. 2004, 3, 503–511. [CrossRef] [PubMed]
18. Knapp, G.S.; McDonough, K.A. Cyclic amp signaling in mycobacteria. In Molecular Genetics of Mycobacteria,
2nd ed.; American Society of Microbiology: Washington, DC, USA, 2014; pp. 281–295.
19. Kamenetsky, M.; Middelhaufe, S.; Bank, E.M.; Levin, L.R.; Buck, J.; Steegborn, C. Molecular details of cAMP
generation in mammalian cells: A tale of two systems. J. Mol. Biol. 2006, 362, 623–639. [CrossRef] [PubMed]
20. Federman, A.D.; Conklin, B.R.; Schrader, K.A.; Reed, R.R.; Bourne, H.R. Hormonal stimulation of adenylyl
cyclase through Gi-protein βγ subunits. Nature 1992, 356, 159–161. [CrossRef] [PubMed]
21. Dessauer, C.W.; Watts, V.J.; Ostrom, R.S.; Conti, M.; Dove, S.; Seifert, R. International union of basic and
clinical pharmacology. Ci. Structures and small molecule modulators of mammalian adenylyl cyclases.
Pharmacol. Rev. 2017, 69, 93–139. [CrossRef] [PubMed]
22. Baldwin, T.A.; Dessauer, C.W. Function of adenylyl cyclase in heart: The AKAP connection. J. Cardiovasc.
Dev. Dis. 2018, 5, 2. [CrossRef] [PubMed]
23. Ostrom, R.S.; Naugle, J.E.; Hase, M.; Gregorian, C.; Swaney, J.S.; Insel, P.A.; Brunton, L.L.; Meszaros, J.G.
Angiotensin ii enhances adenylyl cyclase signaling via Ca2+/calmodulin. Gq-Gs cross-talk regulates collagen
production in cardiac fibroblasts. J. Biol. Chem. 2003, 278, 24461–24468. [CrossRef] [PubMed]
24. Chen, Y.; Cann, M.J.; Litvin, T.N.; Iourgenko, V.; Sinclair, M.L.; Levin, L.R.; Buck, J. Soluble adenylyl cyclase
as an evolutionarily conserved bicarbonate sensor. Science 2000, 289, 625–628. [CrossRef] [PubMed]
25. Zippin, J.H.; Chen, Y.; Nahirney, P.; Kamenetsky, M.; Wuttke, M.S.; Fischman, D.A.; Levin, L.R.; Buck, J.
Compartmentalization of bicarbonate-sensitive adenylyl cyclase in distinct signaling microdomains. FASEB J.
2003, 17, 82–84. [CrossRef] [PubMed]
26. Richards, M.; Lomas, O.; Jalink, K.; Ford, K.L.; Vaughan-Jones, R.D.; Lefkimmiatis, K.; Swietach, P.
Intracellular tortuosity underlies slow cAMP diffusion in adult ventricular myocytes. Cardiovasc. Res.
2016, 110, 395–407. [CrossRef] [PubMed]
27. Mika, D.; Leroy, J.; Vandecasteele, G.; Fischmeister, R. Pdes create local domains of cAMP signaling. J. Mol.
Cell. Cardiol. 2012, 52, 323–329. [CrossRef] [PubMed]
28. Agarwal, S.R.; Clancy, C.E.; Harvey, R.D. Mechanisms restricting diffusion of intracellular cAMP. Sci. Rep.
2016, 6, 19577. [CrossRef] [PubMed]
25
J. Cardiovasc. Dev. Dis. 2018, 5, 29
29. Fischmeister, R.; Castro, L.R.; Abi-Gerges, A.; Rochais, F.; Jurevicius, J.; Leroy, J.; Vandecasteele, G.
Compartmentation of cyclic nucleotide signaling in the heart: The role of cyclic nucleotide phosphodiesterases.
Circ. Res. 2006, 99, 816–828. [CrossRef] [PubMed]
30. Godbole, A.; Lyga, S.; Lohse, M.J.; Calebiro, D. Internalized tsh receptors en route to the tgn induce local
Gs-protein signaling and gene transcription. Nat. Commun. 2017, 8, 443. [CrossRef] [PubMed]
31. Calebiro, D.; Maiellaro, I. CAMP signaling microdomains and their observation by optical methods.
Front. Cell. Neurosci. 2014, 8, 350. [CrossRef] [PubMed]
32. Musheshe, N.; Schmidt, M.; Zaccolo, M. cAMP: From long-range second messenger to nanodomain signalling.
Trends Pharmacol. Sci. 2017, 39, 209–222. [CrossRef] [PubMed]
33. Lefkimmiatis, K.; Zaccolo, M. cAMP signaling in subcellular compartments. Pharmacol. Ther. 2014, 143,
295–304. [CrossRef] [PubMed]
34. Kobayashi, M.; Buck, J.; Levin, L.R. Conservation of functional domain structure in bicarbonate-regulated
“soluble” adenylyl cyclases in bacteria and eukaryotes. Dev. Genes Evol. 2004, 214, 503–509. [CrossRef]
[PubMed]
35. Kleinboelting, S.; Diaz, A.; Moniot, S.; van den Heuvel, J.; Weyand, M.; Levin, L.R.; Buck, J.; Steegborn, C.
Crystal structures of human soluble adenylyl cyclase reveal mechanisms of catalysis and of its activation
through bicarbonate. Proc. Natl. Acad. Sci. USA 2014, 111, 3727–3732. [CrossRef] [PubMed]
36. Chaloupka, J.A.; Bullock, S.A.; Iourgenko, V.; Levin, L.R.; Buck, J. Autoinhibitory regulation of soluble
adenylyl cyclase. Mol. Reprod. Dev. 2006, 73, 361–368. [CrossRef] [PubMed]
37. Leipe, D.D.; Koonin, E.V.; Aravind, L. Stand, a class of p-loop ntpases including animal and plant regulators
of programmed cell death: Multiple, complex domain architectures, unusual phyletic patterns, and evolution
by horizontal gene transfer. J. Mol. Biol. 2004, 343, 1–28. [CrossRef] [PubMed]
38. Middelhaufe, S.; Leipelt, M.; Levin, L.R.; Buck, J.; Steegborn, C. Identification of a haem domain in human
soluble adenylate cyclase. Biosci. Rep. 2012, 32, 491–499. [CrossRef] [PubMed]
39. Farrell, J.; Ramos, L.; Tresguerres, M.; Kamenetsky, M.; Levin, L.R.; Buck, J. Somatic ‘soluble’ adenylyl cyclase
isoforms are unaffected in Sacytm1lex/Sacytm1lex ‘knockout’ mice. PLoS ONE 2008, 3, e3251. [CrossRef]
[PubMed]
40. Reed, B.Y.; Gitomer, W.L.; Heller, H.J.; Hsu, M.C.; Lemke, M.; Padalino, P.; Pak, C.Y. Identification and
characterization of a gene with base substitutions associated with the absorptive hypercalciuria phenotype
and low spinal bone density. J. Clin. Endocrinol. Metab. 2002, 87, 1476–1485. [CrossRef] [PubMed]
41. Chen, X.; Baumlin, N.; Buck, J.; Levin, L.R.; Fregien, N.; Salathe, M. A soluble adenylyl cyclase form targets
to axonemes and rescues beat regulation in soluble adenylyl cyclase knockout mice. Am. J. Respir. Cell
Mol. Biol. 2014, 51, 750–760. [CrossRef] [PubMed]
42. Buck, J.; Sinclair, M.L.; Schapal, L.; Cann, M.J.; Levin, L.R. Cytosolic adenylyl cyclase defines a unique
signaling molecule in mammals. Proc. Natl. Acad. Sci. USA 1999, 96, 79–84. [CrossRef] [PubMed]
43. Geng, W.; Wang, Z.; Zhang, J.; Reed, B.Y.; Pak, C.Y.; Moe, O.W. Cloning and characterization of the human
soluble adenylyl cyclase. Am. J. Physiol. Cell Physiol. 2005, 288, C1305–C1316. [CrossRef] [PubMed]
44. Steegborn, C. Structure, mechanism, and regulation of soluble adenylyl cyclases—Similarities and differences
to transmembrane adenylyl cyclases. Biochim. Biophys. Acta 2014, 1842, 2535–2547. [CrossRef] [PubMed]
45. Hebert-Chatelain, E.; Desprez, T.; Serrat, R.; Bellocchio, L.; Soria-Gomez, E.; Busquets-Garcia, A.; Pagano
Zottola, A.C.; Delamarre, A.; Cannich, A.; Vincent, P.; et al. A cannabinoid link between mitochondria and
memory. Nature 2016, 539, 555–559. [CrossRef] [PubMed]
46. Ramos-Espiritu, L.; Kleinboelting, S.; Navarrete, F.A.; Alvau, A.; Visconti, P.E.; Valsecchi, F.; Starkov, A.;
Manfredi, G.; Buck, H.; Adura, C.; et al. Discovery of LRE1 as a specific and allosteric inhibitor of soluble
adenylyl cyclase. Nat. Chem. Biol. 2016, 12, 838–844. [CrossRef] [PubMed]
47. Tresguerres, M.; Levin, L.R.; Buck, J. Intracellular cAMP signaling by soluble adenylyl cyclase. Kidney Int.
2011, 79, 1277–1288. [CrossRef] [PubMed]
48. Zippin, J.H.; Chen, Y.; Straub, S.G.; Hess, K.C.; Diaz, A.; Lee, D.; Tso, P.; Holz, G.G.; Sharp, G.W.;
Levin, L.R.; et al. CO2/HCO3−- and calcium-regulated soluble adenylyl cyclase as a physiological ATP
sensor. J. Biol. Chem. 2013, 288, 33283–33291. [CrossRef] [PubMed]
49. Litvin, T.N.; Kamenetsky, M.; Zarifyan, A.; Buck, J.; Levin, L.R. Kinetic properties of “soluble” adenylyl
cyclase. Synergism between calcium and bicarbonate. J. Biol. Chem. 2003, 278, 15922–15926. [CrossRef]
[PubMed]
26
J. Cardiovasc. Dev. Dis. 2018, 5, 29
50. Magro, C.M.; Yang, S.E.; Zippin, J.H.; Zembowicz, A. Expression of soluble adenylyl cyclase in lentigo
maligna: Use of immunohistochemistry with anti-soluble adenylyl cyclase antibody (R21) in diagnosis
of lentigo maligna and assessment of margins. Arch. Pathol. Lab. Med. 2012, 136, 1558–1564. [CrossRef]
[PubMed]
51. Magro, C.M.; Crowson, A.N.; Desman, G.; Zippin, J.H. Soluble adenylyl cyclase antibody profile as a
diagnostic adjunct in the assessment of pigmented lesions. Arch. Dermatol. 2012, 148, 335–344. [CrossRef]
[PubMed]
52. Ramos, L.S.; Zippin, J.H.; Kamenetsky, M.; Buck, J.; Levin, L.R. Glucose and GLP-1 stimulate cAMP
production via distinct adenylyl cyclases in INS-1E insulinoma cells. J. Gen. Physiol. 2008, 132, 329–338.
[CrossRef] [PubMed]
53. Flacke, J.P.; Flacke, H.; Appukuttan, A.; Palisaar, R.J.; Noldus, J.; Robinson, B.D.; Reusch, H.P.; Zippin, J.H.;
Ladilov, Y. Type 10 soluble adenylyl cyclase is overexpressed in prostate carcinoma and controls proliferation
of prostate cancer cells. J. Biol. Chem. 2013, 288, 3126–3135. [CrossRef] [PubMed]
54. Pierre, S.; Eschenhagen, T.; Geisslinger, G.; Scholich, K. Capturing adenylyl cyclases as potential drug targets.
Nat. Rev. Drug Discov. 2009, 8, 321–335. [CrossRef] [PubMed]
55. Lee, Y.S.; Tresguerres, M.; Hess, K.; Marmorstein, L.Y.; Levin, L.R.; Buck, J.; Marmorstein, A.D. Regulation of
anterior chamber drainage by bicarbonate-sensitive soluble adenylyl cyclase in the ciliary body. J. Biol. Chem.
2011, 286, 41353–41358. [CrossRef] [PubMed]
56. Bitterman, J.L.; Ramos-Espiritu, L.; Diaz, A.; Levin, L.R.; Buck, J. Pharmacological distinction between
soluble and transmembrane adenylyl cyclases. J. Pharmacol. Exp. Ther. 2013, 347, 589–598. [CrossRef]
[PubMed]
57. Steegborn, C.; Litvin, T.N.; Hess, K.C.; Capper, A.B.; Taussig, R.; Buck, J.; Levin, L.R.; Wu, H. A novel
mechanism for adenylyl cyclase inhibition from the crystal structure of its complex with catechol estrogen.
J. Biol. Chem. 2005, 280, 31754–31759. [CrossRef] [PubMed]
58. Hess, K.C.; Jones, B.H.; Marquez, B.; Chen, Y.; Ord, T.S.; Kamenetsky, M.; Miyamoto, C.; Zippin, J.H.;
Kopf, G.S.; Suarez, S.S.; et al. The “soluble” adenylyl cyclase in sperm mediates multiple signaling events
required for fertilization. Dev. Cell 2005, 9, 249–259. [CrossRef] [PubMed]
59. Kaupp, U.B.; Seifert, R. Cyclic nucleotide-gated ion channels. Physiol. Rev. 2002, 82, 769–824. [CrossRef]
[PubMed]
60. Froese, A.; Breher, S.S.; Waldeyer, C.; Schindler, R.F.; Nikolaev, V.O.; Rinne, S.; Wischmeyer, E.; Schlueter, J.;
Becher, J.; Simrick, S.; et al. Popeye domain containing proteins are essential for stress-mediated modulation
of cardiac pacemaking in mice. J. Clin. Investig. 2012, 122, 1119–1130. [CrossRef] [PubMed]
61. Simrick, S.; Schindler, R.F.; Poon, K.L.; Brand, T. Popeye domain-containing proteins and stress-mediated
modulation of cardiac pacemaking. Trends Cardiovasc. Med. 2013, 23, 257–263. [CrossRef] [PubMed]
62. Schmidt, M.; Dekker, F.J.; Maarsingh, H. Exchange protein directly activated by cAMP (EPAC): A
multidomain cAMP mediator in the regulation of diverse biological functions. Pharmacol. Rev. 2013,
65, 670–709. [CrossRef] [PubMed]
63. Lomas, O.; Zaccolo, M. Phosphodiesterases maintain signaling fidelity via compartmentalization of cyclic
nucleotides. Physiology 2014, 29, 141–149. [CrossRef] [PubMed]
64. Corredor, R.G.; Trakhtenberg, E.F.; Pita-Thomas, W.; Jin, X.; Hu, Y.; Goldberg, J.L. Soluble adenylyl cyclase
activity is necessary for retinal ganglion cell survival and axon growth. J. Neurosci. 2012, 32, 7734–7744.
[CrossRef] [PubMed]
65. Han, H.; Stessin, A.; Roberts, J.; Hess, K.; Gautam, N.; Kamenetsky, M.; Lou, O.; Hyde, E.; Nathan, N.;
Muller, W.A.; et al. Calcium-sensing soluble adenylyl cyclase mediates tnf signal transduction in human
neutrophils. J. Exp. Med. 2005, 202, 353–361. [CrossRef] [PubMed]
66. Stowe, D.F.; Gadicherla, A.K.; Zhou, Y.; Aldakkak, M.; Cheng, Q.; Kwok, W.M.; Jiang, M.T.; Heisner, J.S.;
Yang, M.; Camara, A.K. Protection against cardiac injury by small Ca2+-sensitive K+ channels identified in
guinea pig cardiac inner mitochondrial membrane. Biochim. Biophys. Acta 2013, 1828, 427–442. [CrossRef]
[PubMed]
67. Monterisi, S.; Zaccolo, M. Components of the mitochondrial cAMP signalosome. Biochem. Soc. Trans. 2017,
45, 269–274. [CrossRef] [PubMed]
27
J. Cardiovasc. Dev. Dis. 2018, 5, 29
68. Zippin, J.H.; Farrell, J.; Huron, D.; Kamenetsky, M.; Hess, K.C.; Fischman, D.A.; Levin, L.R.; Buck, J.
Bicarbonate-responsive “soluble” adenylyl cyclase defines a nuclear cAMP microdomain. J. Cell Biol. 2004,
164, 527–534. [CrossRef] [PubMed]
69. Stessin, A.M.; Zippin, J.H.; Kamenetsky, M.; Hess, K.C.; Buck, J.; Levin, L.R. Soluble adenylyl cyclase
mediates nerve growth factor-induced activation of Rap1. J. Biol. Chem. 2006, 281, 17253–17258. [CrossRef]
[PubMed]
70. Onodera, Y.; Nam, J.M.; Bissell, M.J. Increased sugar uptake promotes oncogenesis via EPAC/Rap1 and
o-glcnac pathways. J. Clin. Investig. 2014, 124, 367–384. [CrossRef] [PubMed]
71. Wu, K.Y.; Zippin, J.H.; Huron, D.R.; Kamenetsky, M.; Hengst, U.; Buck, J.; Levin, L.R.; Jaffrey, S.R. Soluble
adenylyl cyclase is required for netrin-1 signaling in nerve growth cones. Nat. Neurosci. 2006, 9, 1257–1264.
[CrossRef] [PubMed]
72. Schirmer, I.; Bualeong, T.; Budde, H.; Cimiotti, D.; Appukuttan, A.; Klein, N.; Steinwascher, P.; Reusch, P.;
Mugge, A.; Meyer, R.; et al. Soluble adenylyl cyclase: A novel player in cardiac hypertrophy induced by
isoprenaline or pressure overload. PLoS ONE 2018, 13, e0192322. [CrossRef] [PubMed]
73. Buffone, M.G.; Wertheimer, E.V.; Visconti, P.E.; Krapf, D. Central role of soluble adenylyl cyclase and cAMP
in sperm physiology. Biochim. Biophys. Acta 2014, 1842, 2610–2620. [CrossRef] [PubMed]
74. Esposito, G.; Jaiswal, B.S.; Xie, F.; Krajnc-Franken, M.A.; Robben, T.J.; Strik, A.M.; Kuil, C.; Philipsen, R.L.;
van Duin, M.; Conti, M.; et al. Mice deficient for soluble adenylyl cyclase are infertile because of a severe
sperm-motility defect. Proc. Natl. Acad. Sci. USA 2004, 101, 2993–2998. [CrossRef] [PubMed]
75. Watson, R.L.; Buck, J.; Levin, L.R.; Winger, R.C.; Wang, J.; Arase, H.; Muller, W.A. Endothelial cd99 signals
through soluble adenylyl cyclase and PKA to regulate leukocyte transendothelial migration. J. Exp. Med.
2015, 212, 1021–1041. [CrossRef] [PubMed]
76. Chang, J.C.; Oude-Elferink, R.P. Role of the bicarbonate-responsive soluble adenylyl cyclase in pH sensing
and metabolic regulation. Front. Physiol. 2014, 5, 42. [CrossRef] [PubMed]
77. Brown, D.; Bouley, R.; Paunescu, T.G.; Breton, S.; Lu, H.A. New insights into the dynamic regulation of
water and acid-base balance by renal epithelial cells. Am. J. Physiol. Cell Physiol. 2012, 302, C1421–C1433.
[CrossRef] [PubMed]
78. Pastor-Soler, N.M.; Hallows, K.R.; Smolak, C.; Gong, F.; Brown, D.; Breton, S. Alkaline ph- and cAMP-induced
v-ATPase membrane accumulation is mediated by protein kinase a in epididymal clear cells. Am. J. Physiol.
Cell Physiol. 2008, 294, C488–C494. [CrossRef] [PubMed]
79. Gong, F.; Alzamora, R.; Smolak, C.; Li, H.; Naveed, S.; Neumann, D.; Hallows, K.R.; Pastor-Soler, N.M.
Vacuolar h+-atpase apical accumulation in kidney intercalated cells is regulated by PKA and AMP-activated
protein kinase. Am. J. Physiol.-Renal Physiol. 2010, 298, F1162–F1169. [CrossRef] [PubMed]
80. Breton, S.; Brown, D. Regulation of luminal acidification by the v-atpase. Physiology 2013, 28, 318–329.
[CrossRef] [PubMed]
81. Rahman, N.; Ramos-Espiritu, L.; Milner, T.A.; Buck, J.; Levin, L.R. Soluble adenylyl cyclase is essential for
proper lysosomal acidification. J. Gen. Physiol. 2016, 148, 325–339. [CrossRef] [PubMed]
82. Inda, C.; Bonfiglio, J.J.; Dos Santos Claro, P.A.; Senin, S.A.; Armando, N.G.; Deussing, J.M.; Silberstein, S.
cAMP-dependent cell differentiation triggered by activated crhr1 in hippocampal neuronal cells. Sci. Rep.
2017, 7, 1944. [CrossRef] [PubMed]
83. Mewes, M.; Nedele, J.; Schelleckes, K.; Bondareva, O.; Lenders, M.; Kusche-Vihrog, K.; Schnittler, H.J.;
Brand, S.M.; Schmitz, B.; Brand, E. Salt-induced Na+/K+-atpase-alpha/beta expression involves soluble
adenylyl cyclase in endothelial cells. Pflugers Arch. Eur. J. Physiol. 2017, 469, 1401–1412. [CrossRef] [PubMed]
84. Schmitz, B.; Nedele, J.; Guske, K.; Maase, M.; Lenders, M.; Schelleckes, M.; Kusche-Vihrog, K.; Brand, S.M.;
Brand, E. Soluble adenylyl cyclase in vascular endothelium: Gene expression control of epithelial sodium
channel-alpha, Na+/K+-ATPase-α/β, and mineralocorticoid receptor. Hypertension 2014, 63, 753–761.
[CrossRef] [PubMed]
85. Kikuchi, R.; Tsuji, T.; Watanabe, O.; Yamaguchi, K.; Furukawa, K.; Nakamura, H.; Aoshiba, K. Hypercapnia
accelerates adipogenesis: A novel role of high CO2 in exacerbating obesity. Am. J. Respir. Cell Mol. Biol. 2017,
57, 570–580. [CrossRef] [PubMed]
86. Sepp, M.; Vihma, H.; Nurm, K.; Urb, M.; Page, S.C.; Roots, K.; Hark, A.; Maher, B.J.; Pruunsild, P.; Timmusk, T.
The intellectual disability and schizophrenia associated transcription factor tcf4 is regulated by neuronal
activity and protein kinase a. J. Neurosci. 2017, 37, 10516–10527. [CrossRef] [PubMed]
28
J. Cardiovasc. Dev. Dis. 2018, 5, 29
87. Lim, S.H.; Legere, E.A.; Snider, J.; Stagljar, I. Recent progress in cftr interactome mapping and its importance
for cystic fibrosis. Front. Pharmacol. 2017, 8, 997. [CrossRef] [PubMed]
88. Wang, Y.; Lam, C.S.; Wu, F.; Wang, W.; Duan, Y.; Huang, P. Regulation of cftr channels by HCO3—Sensitive
soluble adenylyl cyclase in human airway epithelial cells. Am. J. Physiol. Cell Physiol. 2005, 289, C1145–C1151.
[CrossRef] [PubMed]
89. Chen, H.; Guo, J.H.; Lu, Y.C.; Ding, G.L.; Yu, M.K.; Tsang, L.L.; Fok, K.L.; Liu, X.M.; Zhang, X.H.; Chung, Y.W.;
et al. Impaired cftr-dependent amplification of fsh-stimulated estrogen production in cystic fibrosis and pcos.
J. Clin. Endocrinol. Metab. 2012, 97, 923–932. [CrossRef] [PubMed]
90. Wang, X.F.; Zhou, C.X.; Shi, Q.X.; Yuan, Y.Y.; Yu, M.K.; Ajonuma, L.C.; Ho, L.S.; Lo, P.S.; Tsang, L.L.;
Liu, Y.; et al. Involvement of cftr in uterine bicarbonate secretion and the fertilizing capacity of sperm.
Nat. Cell Biol. 2003, 5, 902–906. [CrossRef] [PubMed]
91. Xu, W.M.; Shi, Q.X.; Chen, W.Y.; Zhou, C.X.; Ni, Y.; Rowlands, D.K.; Yi Liu, G.; Zhu, H.; Ma, Z.G.; Wang, X.F.;
et al. Cystic fibrosis transmembrane conductance regulator is vital to sperm fertilizing capacity and male
fertility. Proc. Natl. Acad. Sci. USA 2007, 104, 9816–9821. [CrossRef] [PubMed]
92. Chen, W.Y.; Xu, W.M.; Chen, Z.H.; Ni, Y.; Yuan, Y.Y.; Zhou, S.C.; Zhou, W.W.; Tsang, L.L.; Chung, Y.W.;
Hoglund, P.; et al. Cl- is required for HCO3− entry necessary for sperm capacitation in guinea pig:
Involvement of a Cl-/HCO3− exchanger (slc26a3) and cftr. Biol. Reprod. 2009, 80, 115–123. [CrossRef]
[PubMed]
93. Lu, Y.C.; Chen, H.; Fok, K.L.; Tsang, L.L.; Yu, M.K.; Zhang, X.H.; Chen, J.; Jiang, X.; Chung, Y.W.;
Ma, A.C.; et al. Cftr mediates bicarbonate-dependent activation of mir-125b in preimplantation embryo
development. Cell Res. 2012, 22, 1453–1466. [CrossRef] [PubMed]
94. Chen, H.; Chan, H.C. Amplification of fsh signalling by cftr and nuclear soluble adenylyl cyclase in the
ovary. Clin. Exp. Pharmacol. Physiol. 2017, 44 (Suppl. S1), 78–85. [CrossRef] [PubMed]
95. Lecuona, E.; Sun, H.; Chen, J.; Trejo, H.E.; Baker, M.A.; Sznajder, J.I. Protein kinase a-ialpha regulates
na,k-atpase endocytosis in alveolar epithelial cells exposed to high CO2 concentrations. Am. J. Respir. Cell
Mol. Biol. 2013, 48, 626–634. [CrossRef] [PubMed]
96. Sayner, S.L.; Frank, D.W.; King, J.; Chen, H.; VandeWaa, J.; Stevens, T. Paradoxical cAMP-induced lung
endothelial hyperpermeability revealed by pseudomonas aeruginosa exoy. Circ. Res. 2004, 95, 196–203.
[CrossRef] [PubMed]
97. Sayner, S.L.; Alexeyev, M.; Dessauer, C.W.; Stevens, T. Soluble adenylyl cyclase reveals the significance of
cAMP compartmentation on pulmonary microvascular endothelial cell barrier. Circ. Res. 2006, 98, 675–681.
[CrossRef] [PubMed]
98. Das, A.; Härtel, F.; Ihle, K.; Ladilov, Y.; Noll, T. Role of soluble adenylyl cyclase on barrier function of human
umbilical vein endothelial monolayers: P21–13. Acta Physiol. 2016, 216, 216.
99. Di Benedetto, G.; Gerbino, A.; Lefkimmiatis, K. Shaping mitochondrial dynamics: The role of cAMP
signalling. Biochem. Biophys. Res. Commun. 2017, 500, 65–74. [CrossRef] [PubMed]
100. Jayarajan, V.; Appukuttan, A.; Reusch, P.; Ladilov, Y.; Regitz-Zagrosek, V. Soluble adenylyl cyclase controls
AMPK activity, mitochondrial function and biogensis and may play a role in estradiol-dependent protection
against oxidative stress. In Proceedings of the 42nd FEBS Congress on Molecules to Cells and back, Jerusalim,
Israel, 10–14 September 2017.
101. Kumar, S.; Kostin, S.; Flacke, J.P.; Reusch, H.P.; Ladilov, Y. Soluble adenylyl cyclase controls
mitochondria-dependent apoptosis in coronary endothelial cells. J. Biol. Chem. 2009, 284, 14760–14768.
[CrossRef] [PubMed]
102. Appukuttan, A.; Kasseckert, S.A.; Kumar, S.; Reusch, H.P.; Ladilov, Y. Oxysterol-induced apoptosis of smooth
muscle cells is under the control of a soluble adenylyl cyclase. Cardiovasc. Res. 2013, 99, 734–742. [CrossRef]
[PubMed]
103. Acin-Perez, R.; Russwurm, M.; Gunnewig, K.; Gertz, M.; Zoidl, G.; Ramos, L.; Buck, J.; Levin, L.R.; Rassow, J.;
Manfredi, G.; et al. A phosphodiesterase 2a isoform localized to mitochondria regulates respiration.
J. Biol. Chem. 2011, 286, 30423–30432. [CrossRef] [PubMed]
104. Hess, K.C.; Liu, J.; Manfredi, G.; Muhlschlegel, F.A.; Buck, J.; Levin, L.R.; Barrientos, A. A mitochondrial
CO2-adenylyl cyclase-cAMP signalosome controls yeast normoxic cytochrome c oxidase activity. FASEB J.
2014, 28, 4369–4380. [CrossRef] [PubMed]
29
J. Cardiovasc. Dev. Dis. 2018, 5, 29
105. DiPilato, L.M.; Cheng, X.; Zhang, J. Fluorescent indicators of cAMP and EPAC activation reveal differential
dynamics of cAMP signaling within discrete subcellular compartments. Proc. Natl. Acad. Sci. USA 2004, 101,
16513–16518. [CrossRef] [PubMed]
106. Pozdniakova, S.; Guitart-Mampel, M.; Garrabou, G.; Di Benedetto, G.; Ladilov, Y.; Regitz-Zagrosek, V.
17ß-estradiol reduces mitochondrial cAMP content and cytochrome oxidase activity in a phosphodiesterase
2-dependent manner. In Proceedings of the 42nd FEBS Congress on Molecules to Cells and back, Jerusalim,
Israel, 10–14 September 2017.
107. Wang, Z.; Liu, D.; Varin, A.; Nicolas, V.; Courilleau, D.; Mateo, P.; Caubere, C.; Rouet, P.; Gomez, A.M.;
Vandecasteele, G.; et al. A cardiac mitochondrial cAMP signaling pathway regulates calcium accumulation,
permeability transition and cell death. Cell Death Dis. 2016, 7, e2198. [CrossRef] [PubMed]
108. Mukherjee, S.; Jansen, V.; Jikeli, J.F.; Hamzeh, H.; Alvarez, L.; Dombrowski, M.; Balbach, M.; Strunker, T.;
Seifert, R.; Kaupp, U.B.; et al. A novel biosensor to study cAMP dynamics in cilia and flagella. eLife 2016, 5,
e14052. [CrossRef] [PubMed]
109. Acin-Perez, R.; Gatti, D.L.; Bai, Y.; Manfredi, G. Protein phosphorylation and prevention of cytochrome
oxidase inhibition by atp: Coupled mechanisms of energy metabolism regulation. Cell Metab. 2011, 13,
712–719. [CrossRef] [PubMed]
110. Valsecchi, F.; Konrad, C.; D’Aurelio, M.; Ramos-Espiritu, L.S.; Stepanova, A.; Burstein, S.R.; Galkin, A.;
Magrane, J.; Starkov, A.; Buck, J.; et al. Distinct intracellular sac-cAMP domains regulate er Ca2+ signaling
and oxphos function. J. Cell Sci. 2017, 130, 3713–3727. [CrossRef]
111. De Rasmo, D.; Signorile, A.; Santeramo, A.; Larizza, M.; Lattanzio, P.; Capitanio, G.; Papa, S.
Intramitochondrial adenylyl cyclase controls the turnover of nuclear-encoded subunits and activity of
mammalian complex i of the respiratory chain. Biochim. Biophys. Acta 2015, 1853, 183–191. [CrossRef]
[PubMed]
112. Sardanelli, A.M.; Signorile, A.; Nuzzi, R.; Rasmo, D.D.; Technikova-Dobrova, Z.; Drahota, Z.; Occhiello, A.;
Pica, A.; Papa, S. Occurrence of a-kinase anchor protein and associated cAMP-dependent protein kinase in
the inner compartment of mammalian mitochondria. FEBS Lett. 2006, 580, 5690–5696. [CrossRef] [PubMed]
113. Agnes, R.S.; Jernigan, F.; Shell, J.R.; Sharma, V.; Lawrence, D.S. Suborganelle sensing of mitochondrial
cAMP-dependent protein kinase activity. J. Am. Chem. Soc. 2010, 132, 6075–6080. [CrossRef] [PubMed]
114. Valsecchi, F.; Konrad, C.; Manfredi, G. Role of soluble adenylyl cyclase in mitochondria. Biochim. Biophys. Acta
2014, 1842, 2555–2560. [CrossRef] [PubMed]
115. Lefkimmiatis, K.; Leronni, D.; Hofer, A.M. The inner and outer compartments of mitochondria are sites of
distinct cAMP/PKA signaling dynamics. J. Cell Biol. 2013, 202, 453–462. [CrossRef] [PubMed]
116. Covian, R.; French, S.; Kusnetz, H.; Balaban, R.S. Stimulation of oxidative phosphorylation by calcium
in cardiac mitochondria is not influenced by cAMP and PKA activity. Biochim. Biophys. Acta 2014, 1837,
1913–1921. [CrossRef] [PubMed]
117. Laudette, M.; Zuo, H.; Lezoualc’h, F.; Schmidt, M. EPAC function and cAMP scaffolds in the heart and lung.
J. Cardiovasc. Dev. Dis. 2018, 5, 9. [CrossRef] [PubMed]
118. De Rasmo, D.; Micelli, L.; Santeramo, A.; Signorile, A.; Lattanzio, P.; Papa, S. CAMP regulates the
functional activity, coupling efficiency and structural organization of mammalian fof1 atp synthase.
Biochim. Biophys. Acta 2016, 1857, 350–358. [CrossRef] [PubMed]
119. Fazal, L.; Laudette, M.; Paula-Gomes, S.; Pons, S.; Conte, C.; Tortosa, F.; Sicard, P.; Sainte-Marie, Y.;
Bisserier, M.; Lairez, O.; et al. Multifunctional mitochondrial EPAC1 controls myocardial cell death. Circ. Res.
2017, 120, 645–657. [CrossRef] [PubMed]
120. Pavlaki, N.; Nikolaev, V.O. Imaging of pde2- and pde3-mediated cgmp-to-cAMP cross-talk in cardiomyocytes.
J. Cardiovasc. Dev. Dis. 2018, 5, 4. [CrossRef] [PubMed]
121. Monterisi, S.; Lobo, M.J.; Livie, C.; Castle, J.C.; Weinberger, M.; Baillie, G.; Surdo, N.C.; Musheshe, N.;
Stangherlin, A.; Gottlieb, E.; et al. Pde2a2 regulates mitochondria morphology and apoptotic cell death via
local modulation of cAMP/PKA signalling. eLife 2017, 6, e21374. [CrossRef] [PubMed]
122. Rinaldi, L.; Pozdniakova, S.; Jayarajan, V.; Troidl, C.; Abdallah, Y.; Muhammad, A.; Ladilov, Y. Role of Soluble
adenylyl cyclase in reperfusion-induced injury of cardiac cells. Clin. Res. Cardiol. 2018. [CrossRef]
30
J. Cardiovasc. Dev. Dis. 2018, 5, 29
123. Soares, L.M.; Meyer, E.; Milani, H.; Steinbusch, H.W.; Prickaerts, J.; de Oliveira, R.M. The phosphodiesterase
type 2 inhibitor bay 60-7550 reverses functional impairments induced by brain ischemia by decreasing
hippocampal neurodegeneration and enhancing hippocampal neuronal plasticity. Eur. J. Neurosci. 2017, 45,
510–520. [CrossRef] [PubMed]
124. Neviere, R.; Delguste, F.; Durand, A.; Inamo, J.; Boulanger, E.; Preau, S. Abnormal mitochondrial cAMP/PKA
signaling is involved in sepsis-induced mitochondrial and myocardial dysfunction. Int. J. Mol. Sci. 2016,
17, 2075. [CrossRef] [PubMed]
125. Lezoualc’h, F.; Fazal, L.; Laudette, M.; Conte, C. Cyclic amp sensor EPAC proteins and their role in
cardiovascular function and disease. Circ. Res. 2016, 118, 881–897. [CrossRef] [PubMed]
126. Khaliulin, I.; Bond, M.; James, A.F.; Dyar, Z.; Amini, R.; Johnson, J.L.; Suleiman, M.S. Functional
and cardioprotective effects of simultaneous and individual activation of protein kinase a and EPAC.
Br. J. Pharmacol. 2017, 174, 438–453. [CrossRef] [PubMed]
127. Zoccarato, A.; Surdo, N.C.; Aronsen, J.M.; Fields, L.A.; Mancuso, L.; Dodoni, G.; Stangherlin, A.; Livie, C.;
Jiang, H.; Sin, Y.Y.; et al. Cardiac hypertrophy is inhibited by a local pool of cAMP regulated by
phosphodiesterase 2. Circ. Res. 2015, 117, 707–719. [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution






Functions of PDE3 Isoforms in Cardiac Muscle
Matthew Movsesian 1,*, Faiyaz Ahmad 2,† and Emilio Hirsch 3 ID
1 Department of Internal Medicine/Division of Cardiovascular Medicine, University of Utah,
Salt Lake City, UT 841132, USA
2 Vascular Biology and Hypertension Branch, Division of Cardiovascular Sciences, National Heart, Lung and
Blood Institute, Bethesda, MD 20892, USA; ahmadf@nhlbi.nih.gov
3 Department of Molecular Biotechnology and Health Sciences, Center for Molecular Biotechnology,
University of Turin, 10126 Turin, Italy; emilio.hirsch@unito.it
* Correspondence: matthew.movsesian@hsc.utah.edu; Tel.: +1-801-582-1565
† Beginning 18 February 2018: Sidra Medical Research Center, Doha, Qatar.
Received: 9 January 2018; Accepted: 1 February 2018; Published: 6 February 2018
Abstract: Isoforms in the PDE3 family of cyclic nucleotide phosphodiesterases have important roles in
cyclic nucleotide-mediated signalling in cardiac myocytes. These enzymes are targeted by inhibitors
used to increase contractility in patients with heart failure, with a combination of beneficial and
adverse effects on clinical outcomes. This review covers relevant aspects of the molecular biology of
the isoforms that have been identified in cardiac myocytes; the roles of these enzymes in modulating
cAMP-mediated signalling and the processes mediated thereby; and the potential for targeting these
enzymes to improve the profile of clinical responses.
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1. Introduction
Cyclic nucleotide phosphodiesterases regulate intracellular signalling by hydrolysing cAMP
and/or cGMP. Enzymes in the PDE3 family of phosphodiesterases are dual-specificity enzymes
with high affinities for both cAMP and cGMP but much higher turnover rates for cAMP [1–3].
In cardiac muscle, these enzymes have been studied principally in the context of their role in regulating
cAMP-mediated signalling, and this is the focus of our review.
Several isoforms of PDE3 are expressed in cardiac myocytes, and PDE3 inhibitors are used
therapeutically to potentiate cAMP-mediated signalling in patients with heart failure. In the short
term, these agents have the desired action of increasing myocardial contractility, but their long-term
administration has been shown in several clinical trials to increase cardiovascular mortality [4–10].
This frustrating combination of beneficial and adverse effects of PDE3 inhibition presents a challenge
that remains to be solved. Here we review the function of PDE3 isoforms in cardiac muscle and raise
possibilities for targeting these isoforms so as to achieve more satisfying clinical outcomes.
2. The PDE3 Family of Cyclic Nucleotide Phosphodiesterases
Cyclic nucleotide phosphodiesterases comprise a superfamily of enzymes. As of now, more
than 50 mammalian isoforms have been described and classified into eleven gene families (PDE1
through PDE11) defined on the basis of sensitivity to pharmacologic inhibitors, kinetic activity,
and regulatory mechanisms [11]. PDE1, 2, 3, 10, and 11 hydrolyse both cAMP and cGMP; PDE4,
PDE7, and PDE8 selectively hydrolyse cAMP; and PDE5, PDE6, and PDE9 selectively hydrolyse
cGMP [11–13]. The N-terminal regulatory regions of phosphodiesterases contain sequences involved
in post-translational modifications and protein–protein interactions that target the enzymes to specific
functional compartments. Transcription start sites and alternative splicing lead to the generation of
multiple different isoforms of the same family.
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Enzymes in the PDE3 family are transcribed from two genes, PDE3A and PDE3B [14,15]. In the
case of PDE3A, three isoforms (some prefer the term ‘variants’) are generated by transcription from
alternative starts sites in the gene, yielding two mRNAs, as well as translation from alternative start
sites in the smaller mRNA (Figure 1) [16]. As a result of these N-terminal ‘deletions’, the amino-acid
sequences of these three isoforms differ only with respect to the lengths of their N-terminal sequences.
PDE3A1 (length: 996 amino acids; MW: 109,980), which is transcribed from an upstream start site and
translated from the second AUG in the PDE3A open reading frame—a possibly misleading term in
this case, as no isoform translated from the first AUG has been described—has an N-terminal sequence
containing hydrophobic loops that insert into intracellular membranes [17,18], as well as three sites
of phosphorylation that regulate protein–protein interactions [19–21]. PDE3A2 (length: 842 amino
acids; MW: 93,600) is transcribed from a downstream site in exon 1 and translated from the fourth
AUG in the PDE3A open reading frame; it lacks the most N-terminal phosphorylation site and the
transmembrane hydrophobic loops of PDE3A1. PDE3A3 (length: 659 amino acids; MW: 73,720) is
translated from the same mRNA as PDE3A2 and lacks all of the hydrophobic loops and the upstream
phosphorylation sites. These three isoforms are essentially indistinguishable with respect to their
basal catalytic activity and their sensitivity to catalytic site inhibitors [22]. At this time, only one
isoform of PDE3B (length: 1112 amino acids; MW: 124,333) has been described [15]. Like PDE3A1, its
N-terminal sequence contains hydrophobic loops (six for PDE3B, as compared to four for PDE3A1) and
phosphorylation sites, and its C-terminal sequence contains its catalytic region [23,24]. The sequence
of the catalytic region of PDE3B is >80% identical to that of PDE3A (both contain a 44-amino-acid
insert absent from other phosphodiesterase families), and its catalytic activity and inhibitor sensitivity
are similar to those of PDE3A; the remainder of the PDE3B sequence is 20–30% identical to that of
PDE3A [3].
Figure 1. Structure and subcellular localisation of the PDE3 genes and their variants. Length in amino
acids (aa) is provided at the top of the two PDE3 isoforms. PDE3A1 is translated from the second
AUG codon of the open-reading frame found in the PDE3 mRNA. While the longest variant of PDE3A,
PDE3A1, is mainly localised to the sarcoplasmic reticulum, PDE3A2 and PDE3A3 are found both in
membranes and cytoplasm. PDE3B is mainly localised to plasma membrane invaginations known as T
tubules. Coloured diamonds indicate phosphorylation sites. Selected PDE3-interacting proteins are
listed where the precise binding sequences are known. Membrane-associated N-terminal hydrophobic
regions 1 and 2 (NHR1 and 2) are depicted as loops. The catalytic domain, highly conserved between
PDE3A and PDE3B, is indicated as a striped oval that includes the 44-amino-acid insert characteristic
of PDE3 isoforms.
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3. Intracellular Localisation of PDE3A and PDE3B in Cardiac Myocytes and Their
Protein-Protein Interactions
Cyclic nucleotide-mediated signalling is highly compartmentalised in cardiac myocytes, and the
roles of individual phosphodiesterases in regulating cAMP- and cGMP-mediated signalling depend
upon their intracellular localisation. While PDE3A and PDE3B are both expressed in cardiac myocytes
(PDE3A more abundantly [25]), their intracellular distributions are distinct, with PDE3A localised
mainly to the sarcoplasmic reticulum and PDE3B to T tubules in proximity to mitochondria [26]
(Figure 1). PDE3 activity is also associated with nuclear membranes in cardiac myocytes [27], though
the specific isoforms have not been delineated. Furthermore, in subcellular preparations from cardiac
muscle, PDE3A1 is recovered solely in microsomal fractions, while PDE3A2 and PDE3A3 are recovered
in cytosolic as well as microsomal fractions [16]. This corresponds to studies in cells transfected with
PDE3A1- and PDE3B-derived constructs that show that the N-terminal hydrophobic loops in these
isoforms direct the insertion of these proteins into lipid membranes [17,18].
3.1. PDE3A
The precise intracellular localisation of PDE3 isoforms depends upon their interactions with anchoring,
scaffold, and adaptor proteins that recruit the enzyme to multiprotein signalling complexes [28–33].
Localised A-kinase anchoring proteins (AKAPs) tether protein kinase A (PKA) and other signalling
proteins—adenylyl cyclases, phosphatases, Epacs, PDEs and other effector molecules—to ‘signalosomes’
that allow selective phosphorylation of individual PKA substrates [31–34].
PDE3 has long been known to be associated with the sarcoplasmic reticulum of cardiac
myocytes [35,36]. Confocal microscopy studies more recently demonstrated co-localisation of PDE3A
with SERCA2, AKAP18, phospholamban, and desmin in the Z-bands of cardiac myocytes [37,38].
PDE3A was found to be a constituent of a multiprotein complex in the sarcoplasmic reticulum
containing AKAP18, phospholamban, and SERCA2 [38,39]. Addition of cAMP to microsomes from
human heart results in the phosphorylation of phospholamban by endogenous PKA; this leads
to a dissociation of phospholamban from SERCA2 and an increase in SERCA2 activity, and this
effect is potentiated by PDE3 inhibition [38] (Figure 2). Although PDE3 and PDE4 have both
been found to co-immunoprecipitate with AKAP-based signalosomes from human and mouse
myocardium and modulate effects of cAMP on L-type Ca2+ channels, ryanodine-sensitive Ca2+
channels, and SERCA2 [40–43], only PDE3 inhibition potentiates the PKA-mediated phosphorylation
of phospholamban and the consequent stimulation of SERCA2 activity [37]. The role of PDE3A in
modulating these effects is the likely explanation for the inotropic actions of PDE3 inhibition.
Furthermore, while PDE3 isoforms regulate the phosphorylation of other proteins through the
cAMP/PKA pathway, they are themselves substrates for protein kinases that modulate their catalytic
activity and protein–protein interactions [19,21,44–47]. The incorporation of PDE3A into the SERCA2
complex is an example. In co-immunoprecipitation experiments, phosphorylation of endogenous
PDE3A by PKA increases its interactions with SERCA2, caveolin-3, PKA regulatory subunit (PKARII),
PP2A, and AKAP18 [38]. Studies with recombinant proteins showed that phosphorylation of PDE3A
by PKA increased its co-immunoprecipitation with SERCA2a and AKAP18, suggesting that PDE3A
interacts directly with both proteins in a phosphorylation-dependent manner [38]. Deletion of the
N-terminal region of PDE3A1/PDE3A2 blocked PKA-induced phosphorylation of PDE3A and its
interaction with recombinant SERCA2. Of particular interest is the sequence RRRRSSS (amino acids
288–294 of the open reading frame, which are found only in PDE3A1), which provides three serines that
can be phosphorylated in vitro by different kinases under different conditions [19]. The introduction
of serine-to-alanine substitutions at S292-4 identified this sequence as the principal site responsible for
regulating the interactions of PDE3A1 with SERCA2 (Figure 1).
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Figure 2. Control of SERCA2 activity by PDE3A. Left panel: Under resting conditions, phospholamban
(PLN) binds to SERCA2, whose activity it inhibits, as well as AKAP18δ on the cytoplasmic surface of the
sarcoplasmic reticulum (double black line). Upon β-adrenergic receptor-stimulated cAMP production,
PKA associated with AKAP18δ is activated and phosphorylates PLN (upper dotted line) and PDE3A1
(lower dotted line). This leads to the condition shown in the right panel, where phosphorylated PLN
detaches from SERCA2 and loses its inhibitory action. As a consequence, SERCA2-dependent Ca2+
uptake into the lumen of the sarcoplasmic reticulum is stimulated (encircled by the double black line).
At the same time, phosphorylated PDE3A1 binds to SERCA2 and increases its cAMP-hydrolytic activity,
which limits the extent to which β-adrenergic receptor-mediated signalling amplifies intracellular
Ca2+ cycling.
The absence of the S292-4 site from PDE3A2 and PDE3A3 establishes a PDE3A1-specific
mechanism for recruitment of PDE3A to the SERCA2 complex. The protein–protein interactions
of PDE3 isoforms are distinct in other ways as well, as has been described for the
phosphorylation-dependent interactions of PDE3A1, PDE3A2, and PDE3B with 14-3-3 [20,21,48–50].
The common sequence of PDE3A1 and PDE3A2 includes two 14-3-3-binding sites: S428, a PKC
site; and S312, a PKA/PKB (alternatively referred to Akt) site that resembles S318, a 14-3-3-binding
site in PDE3B [48,49] (Figure 1). In vitro, PDE3A1 is preferentially phosphorylated by PKA at S312,
whereas PDE3A2 is preferentially phosphorylated by PKC at S428; in preparations from human hearts,
PDE3A1 is phosphorylated primarily at S312, while PDE3A2 is phosphorylated primarily at S428 [50].
Furthermore, in transfected HEK293 cells, the phosphorylation-dependent interactomes of PDE3A1
and PDE3A2 are distinct [50]: PDE3A1 interacts with the 5-HT4(b) receptor, for example, while PDE3A2,
PDE3A3, and PDE3B do not [51]. These unique protein–protein interactions may provide opportunities
for isoform-specific targeting of the protein–protein interactions of individual isoforms.
In cardiac myocytes, PDE3A is also part of a multiprotein complex containing the unconventional
AKAP PI3Kγ [52]. While PI3Kγ directly binds the RII subunit of the PKA holoenzyme, how
PDE3A contacts the complex is still unclear, though a likely intermediate is the PI3Kγ interactor
p84/p87 [53]. Within this complex, PKA exerts a negative feedback regulation by phosphorylating
and activating the different associated PDE isoforms, including PDE3A [39]. In line with the role
of PDE3A (and PDE4A/B) in controlling SERCA2, loss of the scaffold function of PI3Kγ leads
to cAMP elevation and PKA-mediated hyperphosphorylation of phospholamban and L-type Ca2+
channels [39,54] (Figure 3, left panel). In hearts lacking PI3Kγ and subjected to pressure overload, this
effect causes cAMP elevation, contractile dysfunction, and increased mortality due to lethal arrhythmic
events such as sustained ventricular tachycardia [39] (Figure 3, right panel). Interestingly, this
abnormally increased cAMP accumulation appears to be selectively associated with signalling through
β-adrenergic receptors localised to T tubules [55]. This would suggest that the PI3Kγ PKA/PDE
complex is part of an ‘insulating’ system that blocks ‘leakage’ of cAMP from this compartment to
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the sarcoplasmic reticulum [39]. In heart failure, the expression of various elements of the PI3Kγ
PKA/PDE3A-containing complex change their stoichiometric ratios, with reduced expression of
p84/87 and coincident increased expression of PI3Kγ. This causes a dysfunctional cAMP regulation
potentially contributing to the increase in ventricular arrhythmias associated with heart failure [52].
Figure 3. Regulation of PDE3 and PDE4 by the AKAP function of PI3Kγ. Left panel: Regulation
of PI3Kγ and phosphodiesterase activity in healthy conditions. Upon stimulation of β-adrenergic
receptors, cAMP production is promoted but simultaneously constrained by the activation of a negative
feedback loop involving the scaffold function of PI3Kγ that directly binds the PKA holoenzyme
containing the RII regulatory subunit as well as PDE3s and PDE4s. PKA activation leads to the
phosphorylation of these phosphodiesterases and the consequent increase in their activity that, in
turn, reduces cAMP levels. At the same time, PKA phosphorylates and inhibits PI3Kγ, thus blocking
the classical PI3K pathway signalling. Right panel: In the absence of PI3Kγ, PKA is displaced from
PDE3 and PDE4 enzymes and is unable to efficiently stimulate their activity. As a consequence, cAMP
levels rise and cAMP diffuses to compartments that β-adrenergic receptor-mediated signalling does
not usually affect.
3.2. PDE3B
In contrast to PDE3A, PDE3B is mainly located in caveolin-3-rich areas of the plasma membrane
and, in cardiac myocytes, in the T tubules (Figure 1). This indicates that the two PDE3 genes are
specifically involved in the regulation of spatially and functionally distinct pools of cAMP. In line with
this view, while PDE3A is involved in the regulation of contractility, PDE3B appears more connected
to the regulation of metabolism. PDE3B is also known to have a role in the liver, pancreatic β cells, and
in the brown and white adipose tissue where it is involved in the control of the anti-lipolytic effect of
insulin, generally in contrast to β-adrenergic signalling [56,57]. In the heart, the specific inactivation of
PDE3A causes alterations in basal cardiac contractility, while genetic ablation of PDE3B has no major
impact on contractility but protects the myocardium from ischemic damage [26,37]. Interestingly, the
protective effect of PDE3 inhibitors in ischemic heart preconditioning had been known for several
years, but the precise nature of the PDE3 isoform only emerged with studies in knockout mice that
excluded a role of PDE3A. The specific localisation of PDE3B in T tubules, and particularly both
in dyads and in close proximity to mitochondria, suggests that this particular phosphodiesterase
plays a role in modulating energy metabolism. Elevation in cAMP concentration in this location
might mediate cardioprotective signals that improve mitochondrial function and energy supply
during ischaemia/reperfusion, where mitochondrial Ca2+ overload and consequent mitochondrial
permeability transition (MPT) pore opening, oxidative stress, and apoptosis contribute to injury [58].
In hearts lacking PDE3B, mitochondria are enriched in Bcl-2, produce lower amounts of reactive oxygen
species, and show more numerous contacts with T tubules. In response to ischaemia, mitochondria
from PDE3B-deficient cardiac myocytes are more resistant to Ca2+-induced opening of the MPT pore,
36
J. Cardiovasc. Dev. Dis. 2018, 5, 10
and associate with caveolin-3-enriched membrane subfractions containing cardioprotective proteins.
The recruitment of these cardioprotective proteins to these subfractions is PKA-dependent, and can be
reproduced in wild-type mice by PDE3 inhibition [26].
The nature of the localization signal that keeps PDE3B in such spatially and functionally
distinct cellular subdomains remains unknown. Various reports indicate that PDE3B can be
recruited to different multiprotein complexes with distinct properties. In adipocytes, for example,
treatment with insulin increases the phosphorylation of PDE3B associated with internal membranes,
promoting its interactions with IRS-1 (insulin receptor substrate-1), IRS-2, PI3K p85 (p85-subunit of
phosphoinositide 3-kinase), PKB (protein kinase B), HSP-90 (heat-shock protein 90), 14-3-3, and a
50 kD protein [46,47,56,59,60]. Conversely, treatment with β3-adrenergic receptor agonists increases
the phosphorylation of PDE3B associated with caveolin-1 in caveolae, promoting interactions with
β3-adrenergic receptors, PKA-RII (PKA regulatory subunit), and hormone-sensitive lipase [46,61].
Whether these associations also occur in cardiac myocytes is not yet clear. PDE3B has been reported
to weakly associate in a complex containing the unconventional AKAP PI3Kγ, especially with
overexpression in HEK293 cells [53,62]. Nonetheless, the significant effects on contractility and
rhythm detected in mice lacking PI3Kγ indicate that the determinant of the cardiac phenotype is the
ability of PI3Kγ to form more stable complexes with other phosphodiesterases, including PDE3A and
PDE4A/B [39].
Of note, however, is that PDE3B can be phosphorylated not only by PKA but also by PKB, the
main effector of the PI3K pathway. Although the weak interaction between PI3Kγ and PDE3B reported
in the heart awaits further experimental confirmation, severe reduction of the G protein-coupled
receptor-driven PI3K pathway by the concomitant loss of PI3Kγ and PI3Kβ has been shown to lead
to reduced PDE3B phosphorylation and activity in neurons [63]. Nonetheless, whereas the specific
association of PI3Kγ with β-adrenergic signalling in T tubules supports at least a spatial co-localisation
of both PI3K and PDE3B [39,53], experiments in knockout mice indicate that PI3Kγ and PDE3B might
be part of different functional complexes. On the other hand, the association of PI3Kγ with PKA
triggers a negative feedback loop where PKA phosphorylates and inhibits PI3Kγ itself. Interestingly,
loss of PDE3B in the heart leads to an unexpectedly strong elevation of cAMP [26], which likely remains
spatially confined due to the normal activity of the other phosphodiesterases. Whether this elevated
cAMP and PKA activity influences PI3Kγ catalytic activity and, indirectly, the PKB signalling axis is
yet to be determined. As enhanced PI3Kγ signalling is involved in the downregulation of β-adrenergic
receptor density on the cell surface and, generally, in cardiac myocyte decompensation under stress,
PDE3B inhibition could reduce a detrimental signal [64]. Inhibitors specifically distinguishing PDE3B
from PDE3A are not currently available, but specific targeting of PDE3B may be therapeutically useful
for ischaemia/reperfusion injury.
4. Inotropic Actions of PDE3A Inhibition
As discussed above, PDE3A is part of a multiprotein complex in the sarcoplasmic reticulum
through which phospholamban phosphorylation and SERCA2 activity are regulated, and PDE3
inhibition potentiates the stimulatory effects of cAMP on SERCA2 activity in microsomes from cardiac
muscle. These effects would be expected to increase contractility by increasing the amplitude of
intracellular Ca2+ transients. Experiments in mice with selective ablation of PDE3A and PDE3B
indicate that inotropic responses to PDE3 inhibition are attributable specifically to inhibition of PDE3A.
Phospholamban phosphorylation, SERCA2 activity, intracellular Ca2+ cycling, and contractility are
increased—and inotropic responses to PDE3 inhibition are eliminated—in Pde3a−/− mice; none of
these effects are observed in Pde3b−/− mice [37]. Furthermore, myocardial contractility in mice is
reduced when PDE3A1 is overexpressed [65]. Total intracellular cAMP levels are higher in Pde3b−/−
mice than in Pde3a−/− mice [26], indicating that this is not simply a ‘mass effect’ reflecting the higher
abundance of PDE3A relative to PDE3B in cardiac myocytes but is instead due to the specific functional
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consequences of the intracellular localisation of these isoforms. (A unique role of PDE3B in mitigating
reperfusion injury, discussed below, is further evidence along these lines [26].)
5. Pro-Apoptotic Actions of PDE3A Inhibition
PDE3 inhibition in rats and Pde3a ablation in mice lead to increases in the phosphorylation
of cAMP response element-binding protein (CREB) and consequent increases in the expression
of inducible cAMP early repressors (ICER’s), promoting apoptosis [66,67]. Inhibition of PDE3,
and especially of PDE3A, by milrinone might involve a phospho-CREB-induced increase in the
expression of ICER, with consequent apoptosis and myocardial pathological remodelling. Conversely,
there is evidence that increased PDE3A activity, achieved by overexpression in mice, reduces
ICER expression, increases Bcl-2 expression, and protects cardiac myocytes against apoptosis [65].
In fact, specific overexpression of myocardial PDE3A1 in transgenic mice confers protection during
ischaemia/reperfusion by decreasing cAMP signalling and phosphorylation of CREB, resulting in
decreased expression of ICER and reduced apoptosis [65]. PDE3 activity is associated with nuclear
membranes in cardiac myocytes [27], and it is possible that the activity localised to this region is
responsible for these pro-apoptotic changes in gene expression.
6. Pro-Hypertrophic Actions of PDE3A Inhibition
PDE3 inhibition has pro-hypertrophic actions in neonatal rat ventricular myocytes [68].
These effects are essentially reproduced by expression of a dominant-negative form of PDE3A2 induced
by a single amino acid substitution in the C-terminal region that renders the protein catalytically
inactive but otherwise intact [68]. This dominant-negative construct presumably functions as a
competitive inhibitor of the localising protein–protein interactions of the native protein to disrupt
its intracellular targeting; this is further evidence that the intracellular targeting of PDE3 isoforms
is as important as their catalytic activity. The antihypertrophic effect is especially interesting in
view of the description of a set of genetically unrelated missense mutations within a five-amino-acid
sequence in PDE3A that increase catalytic activity and lead to a syndrome of brachydactyly and
hypertension [69,70]. The hypertension is likely attributable to increased cGMP hydrolysis in vascular
smooth muscle; the resulting decrease in intracellular cGMP content would lead to a combination of
vasoconstriction and vessel wall hyperplasia. Despite the severe hypertension, however, patients with
this syndrome have strikingly low levels of cardiac hypertrophy [71]. This suggests that an increase in
PDE3A activity in cardiac myocytes may in fact be antihypertrophic, consistent with the benefits of
PDE3A1 overexpression with respect to pathologic remodelling in animal models discussed above [65].
7. Clinical Experience with PDE3 Inhibition in the Treatment of Heart Disease
With respect to cardiac disease, PDE3 has been of interest principally as a target for increasing
contractility in patients with heart failure, a condition in which decreases in β-adrenergic receptor
density and increases in Gαi and β-adrenergic receptor kinase activity in cardiac myocytes attenuate
cAMP generation lead to decreases in cAMP content, protein phosphorylation and the amplitude of
intracellular Ca2+ transients [72–81]. Inhibiting PDE3 has the effect of compensating to some extent for
these changes by blocking cAMP hydrolysis and potentiating cAMP-mediated signalling, leading to
an increase in myocardial contractility [82–88].
This short-term benefit, unfortunately, is outweighed by an increase in mortality from sudden
cardiac death of ~3% per year when these drugs are administered chronically [4–10]. The explanation
for this increase is unclear (though it seems restricted to patients in whom PDE3 inhibition is
used to treat contractile failure; no increase in mortality has been seen when the PDE3 inhibitor
cilostazol has been used to treat intermittent claudication [89]). Overexpression of SERCA2 in animal
models of ischaemia/reperfusion and chronic heart failure is anti-arrhythmic [90,91]. On the other
hand, an increase in the phosphorylation of L-type and ryanodine-sensitive Ca2+ channels may
be pro-arrhythmic [40–43]. It seems more probable, however, based on the fact that short-term
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administration of these agents is well tolerated, that mechanisms other than direct pro-arrhythmic
actions are involved, and that the pro-apoptotic and pro-hypertrophic effects of PDE3 inhibition
described above induce pathologic changes in the myocardium that increase the proclivity toward
malignant arrhythmias.
8. Selective Targeting of PDE3 Isoforms
The fact that PDE3A and PDE3B have different roles in cardiac myocytes, with PDE3A
controlling the pathways responsible for inotropic effects, raises the possibility that targeting PDE3A
selectively—or, perhaps even better, selectively targeting one of its three known variants—might
improve contractility without increasing sudden cardiac death (as noted above, PDE3A1 is restricted in
its distribution to intracellular membranes, so that its inhibition may be less likely to elicit pro-apoptotic
and pro-arrhythmic actions [16]). The catalytic activities, substrate affinities, and inhibitor sensitivities
of PDE3A1, PDE3A2, and PDE3A3 are identical, making it impossible to selectively target the active
sites of individual PDE3A variants [22]. The similarity of the PDE3B active site to the PDE3A active
site suggested that selectivity between these two proteins would also prove challenging. Recently,
however, investigators described a compound with a tenfold higher affinity for PDE3A relative to
PDE3B [92], so this supposition needs to be reconsidered. It is not obvious how targeting all PDE3A
isoforms without targeting PDE3B would confer a therapeutic advantage, however. To our knowledge,
no compound with a significantly higher affinity for PDE3B relative to PDE3A has been reported.
Another possibility is that of targeting individual isoforms not through their active sites but
through the protein–protein interactions by which they are localised intracellularly. As noted above,
PDE3A1 and PDE3A2 are recruited, by phosphorylation within their N-terminal sequences, to a
SERCA2/phospholamban/AKAP/PKA complex in the sarcoplasmic reticulum [37,93]. As a result of
this recruitment, PDE3 inhibition has a particularly pronounced effect in potentiating phospholamban
phosphorylation and increasing SERCA2 activity, leading to an increase in SERCA2 activity and
intracellular Ca2+ [38]. Experiments using recombinant proteins have demonstrated direct interactions
of PDE3A1 and PDE3A2 with both SERCA2 and AKAP18, and have shown that the interaction of
PDE3A1 with SERCA2 is dependent upon its phosphorylation at serine 293, a site within its unique
N-terminal extension (Figure 1) [38]. These findings indicate that the protein–protein interactions
of the PDE3A isoforms responsible for inotropic responses are highly individualised, opening an
avenue to isoform-selective targeting with a high degree of precision. In fact, this approach to
isoform-selective targeting—displacing PDE3A from specific multiprotein complexes—has the added
benefit of compartment selectivity, which is likely its most important advantage. Conventional PDE3
inhibitors target the enzyme regardless of its intracellular location; this can raise cAMP content globally
within the cell, resulting in a combination of pro-apoptotic, pro-hypertrophic, and inotropic [66–68].
Blocking the protein–protein interactions that integrate PDE3A into SERCA2 complexes could lead
to a selective increase in cAMP content in the vicinity of phospholamban and SERCA2 so as to
amplify intracellular Ca2+ cycling and increase contractility without the deleterious pro-arrhythmic,
pro-apoptotic, and pro-hypertrophic consequences (Figure 4).
On the other hand, the protein–protein interactions that localise PDE3B intracellularly may be
targets through which the cardioprotective effects of PDE3B ablation can be elicited without the
adverse pro-hypertrophic and pro-arrhythmic consequences of PDE3A inhibition. The feasibility of
this approach has been demonstrated in experiments using peptides that block the protein–protein
interactions of cyclic nucleotide phosphodiesterases. In one example, peptide-array scanning identified
a cell-permeant peptide based on a sequence in the N-terminus of PDE3B through which it is
incorporated into an Epac1/PI3Kγ complex in vascular endothelial cells. This peptide has been
shown to block the integration of PDE3B into this complex, increasing the activation of Epac1 by cAMP
and promoting intracellular tubule formation, cell adhesion, and cell spreading [94].
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Figure 4. Targeting PDE3A through protein–protein interactions. Conventional PDE3 inhibition
activates cAMP-mediated signalling in multiple intracellular compartments, leading possibly to a
combination of beneficial and adverse effects. Blocking the protein–protein interactions through which
PDE3A is integrated into the SERCA2 complex may stimulate intracellular Ca2+ cycling without the
adverse effects.
9. Conclusions
Several isoforms in the PDE3 family are expressed in cardiac myocytes, where they have important
roles regulating signalling pathways involved in inotropic, pro-apoptotic, and pro-hypertrophic
responses. Inhibition of myocardial PDE3 activity is an established therapeutic strategy for increasing
contractility in patients with heart failure, but an increase in sudden cardiac death in patients treated
chronically with existing PDE3 inhibitors has limited the benefits. Targeting individual PDE3A
isoforms in specific intracellular targets could potentially yield inotropic responses without this
adverse effect, while targeting PDE3B could have beneficial actions in ischaemia/reperfusion injury.
Recent discoveries open the possibility of selectively inhibiting PDE3A or PDE3B at their catalytic
sites or, probably more interestingly, of targeting their unique protein–protein interactions to yield
compartment-specific effects on intracellular signalling. Time will tell.
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cAMP Cyclic adenosine monophosphate
IRS Insulin-receptor substrate
NHR N-terminal hydrophobic region
PLN Phospholamban
PKA cAMP-dependent protein kinase
PKA-RII cAMP-dependent protein kinase regulatory subunit II
PKB (AKT) Protein kinase B
PKC Protein kinase C
PI3Kγ Phosphoinositide 3-kinase γ
PIP3 Phosphatidylinositol (3,4,5)-triphosphate
p110γ Phosphoinositide 3-kinase γ (PI3Kγ) catalytic subunit
p87 PI3Kγ regulatory subunit (also known as p87PIKAP p87-PI3K adapter protein)
SERCA2 Sarcoplasmic/endoplasmic reticulum calcium ATPase-2
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Abstract: cAMP is the archetypal and ubiquitous second messenger utilised for the fine control of
many cardiovascular cell signalling systems. The ability of cAMP to elicit cell surface receptor-
specific responses relies on its compartmentalisation by cAMP hydrolysing enzymes known
as phosphodiesterases. One family of these enzymes, PDE4, is particularly important in the
cardiovascular system, where it has been extensively studied and shown to orchestrate complex,
localised signalling that underpins many crucial functions of the heart. In the cardiac myocyte,
cAMP activates PKA, which phosphorylates a small subset of mostly sarcoplasmic substrate proteins
that drive β-adrenergic enhancement of cardiac function. The phosphorylation of these substrates,
many of which are involved in cardiac excitation-contraction coupling, has been shown to be
tightly regulated by highly localised pools of individual PDE4 isoforms. The spatial and temporal
regulation of cardiac signalling is made possible by the formation of macromolecular “signalosomes”,
which often include a cAMP effector, such as PKA, its substrate, PDE4 and an anchoring protein such
as an AKAP. Studies described in the present review highlight the importance of this relationship
for individual cardiac PKA substrates and we provide an overview of how this signalling paradigm
is coordinated to promote efficient adrenergic enhancement of cardiac function. The role of PDE4
also extends to the vascular endothelium, where it regulates vascular permeability and barrier
function. In this distinct location, PDE4 interacts with adherens junctions to regulate their stability.
These highly specific, non-redundant roles for PDE4 isoforms have far reaching therapeutic potential.
PDE inhibitors in the clinic have been plagued with problems due to the active site-directed nature of
the compounds which concomitantly attenuate PDE activity in all highly localised “signalosomes”.
Keywords: phosphodiesterase 4; cardiac myocyte; vascular endothelium
1. Introduction
Cyclic 3′,5′-adenosine monophosphate (cAMP) was the first second messenger molecule to be
discovered, and has been researched tirelessly in the context of numerous physiological systems.
Much of the current understanding of cAMP signalling, however, has come from studying its function
in the cardiovascular system, where it has major roles in the heart and vessels [1]. In the heart, cAMP
influences a multitude of processes from contractility and hypertrophy of myocytes to apoptosis and
cell survival [2]. In the vasculature, effects on smooth muscle cell contraction and relaxation, as well as
endothelial cell permeability has been attributed to cAMP signalling processes [3]. Additionally, cAMP
can modify cell proliferation, migration, differentiation, and response to stress [4–7]. cAMP produces
these vast cellular effects by activating four types of effector proteins: protein kinase A (PKA),
exchange protein directly activated by cAMP (EPAC), cyclic nucleotide activated ion channels (CNGC),
and popeye domain containing proteins (POPDC). The present review will focus on the effects of
PKA and EPAC. PKA functions to phosphorylate substrate proteins, while EPAC activates the RAS
superfamily of enzymes [8]. The present review will focus on the ways in which phosphodiesterase
4 (PDE4) enzymes modify cAMP’s ability to produce these varied physiological effects within the
cardiovascular system.
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2. cAMP Signalling and Compartmentalisation
The small, highly diffusible molecule, cAMP can be produced by both membrane-bound adenylyl
cyclase (mAC) and soluble adenylyl cyclase (sAC) in response to various stimuli, such as the activation
of various Gs-coupled receptors, which activates mAC [9]. Its properties suggest that it would quickly
diffuse throughout the cell, simultaneously activating all effector proteins almost instantly. In striking
contrast, it was shown by Larry Brunton and colleagues in the early 1980s that cAMP can cause
multiple discrete receptor specific responses in the same cells [10,11]. To explain this phenomenon,
it was quickly postulated, and eventually proven, that compartmentalisation of cAMP signalling
underpins receptor specific responses by restricting the number and identity of PKA substrates that
get phosphorylated in response to each specific receptor ligation [12,13]. Such fine control of one
ubiquitous second messenger that acts to activate only discrete pools of PKA is made possible by the
subcellular localisation of proteins that degrade cAMP. This function is attributed to a super-family
of enzymes called phosphodiesterases (PDEs). PDEs are the only known route to the hydrolysis of
cAMP and this function empowers these enzymes to act as “sinks”, reducing cAMP concentration in
localised areas preventing the inappropriate phosphorylation of PKA substrates under basal conditions.
Following receptor activation, however, this situation can be altered to allow cAMP concentrations
to exceed the activation threshold of PKA enzymes tethered to discretely positioned “signalosomes”.
This situation occurs only when the cAMP concentration in the vicinity of the relevant “signalosomes”
is high enough to swamp the PDE component, promoting downstream physiological effects [14].
The integration of PDE4 isoforms into specific “signalosomes” within the heart and the function of
these protein complexes will be the subject of this review.
3. PDEs and PDE4-Ology
PDEs are a large super-family of enzymes, which are the products of 11 different gene families,
grouped according to their structure, function, and affinity for cAMP and cGMP. Structurally, all PDEs
have conserved carboxy-terminal catalytic cores while their amino-terminal regions differ among
families, subfamilies, and specific isoforms. The N-terminal regions have a number of functional
roles. These include the targeting to specific subcellular locations and to signalosomes, and the
modulation of responses to signals from regulatory molecules or post-translational modifications [1,15].
cAMP-specific PDE4s make up the largest family with over 20 isoforms encoded by four genes (A, B,
C, and D). Each isoform has a unique N-terminal region, made up of an N-terminal targeting domain
(TD). Additionally, the N-terminal region contains upstream conserved regions 1 and 2 (UCR1 and
UCR2), which are linked to each other and to the catalytic domain by linker region 1 and 2 (LR1 and
LR2) respectively [16]. Based on the presence and size of UCR1 and UCR2, PDE4 isoforms can be
categorised into long, short, super-short, and dead-short isoforms (Figure 1); long isoforms have both
UCR1 and 2, short isoforms have only UCR2, super-short have a truncated UCR2, and dead-short
isoforms lack both UCR domains and have a truncated catalytic domain [17].
Figure 1. Diversity of domain organisation of PDE4 isoforms TD, transduction domain; LR1/2, linker
region 1/2; UCR1/2, upstream conserved region 1/2.
48
J. Cardiovasc. Dev. Dis. 2018, 5, 8
UCR1 and 2 have a number of roles, including the regulation of functional outcomes following
PDE4 phosphorylation by protein kinase A (PKA) or extracellular signal-regulated kinase (ERK).
The presence or absence of these domains means that phosphorylation can have different, and even
opposite, functional effects in different isoforms [18–20].
The catalytic domain of PDE4 has been extensively studied, and X-ray crystal structures have
demonstrated the deep hydrophobic pocket made of numerous helices which makes up the active site
for the hydrolysis of cAMP [15,21]. The structure of this domain has been integral for the design of
family-specific inhibitors, which have been widely used both clinically and experimentally [22,23].
As previously mentioned, the subcellular localisation of PDEs is integral to their function in
shaping cAMP gradients and responses. This localisation is often directed by the N-terminal targeting
domains, which are highly varied among PDE4 isoforms [24,25], though targeting can also be driven
by other regions including the newly identified multi-functional docking domain positioned at
the C-terminal end of the catalytic unit [26]. Unique subsets of PDE4 specific interactions allow
single isoforms to have multiple non-redundant roles in different tissues, cells and even different
micro-domains within the same cell [27]. The disruption of this location dependent function of small
pools of highly active PDE4s has been considered as a novel way to circumvent side-effects observed
following the systemic inhibition of global PDE4 activity using site-directed PDE4 inhibitors [28].
4. Technological Approaches to Defining Roles for PDE4 Isoforms
Isoform specific roles of PDEs have been identified within the realm of the cardiovascular system
and historically, as new technologies have been invented, these have been used to identify specific
interactions and functions of PDE4. Often, the first and easiest approach utilised is pharmacological,
and employs family-specific inhibitors. However, this strategy gives little information on individual
isoforms and can often engender “bulk” cAMP effects due to simultaneous inhibition of all
PDE4 enzymes in all locations. Other more targeted approaches include siRNA knockdown and
overexpression of dominant-negative PDEs. Both of these allow diminution of the influence of
one isoform by either genetic silencing or displacement of endogenous, functional PDEs [29–31].
Often these approaches are sufficient to pinpoint specific cellular functions for single isoforms; however,
if one isoform has multiple roles in the same cell, an incomplete understanding of the complexity of
PDE4 action can be lost.
The identification of specific protein-protein interactions within PDE signalosomes has been
integral to understanding PDE4 function. Peptide array technology has proved to be an accurate way
to screen for such interactions and to predict the regions and specific amino acids which are essential
for holding signalling complexes together [32–34]. Another advantage of this technique is that it allows
the informed design of cell-permeable disruptor peptides, which can interrupt these signalosome
interactions. Disruptor peptides provide by far the most specific form of inhibition as only a specific
localised pool of the PDE4 isoform of choice is displaced, leaving any other cellular effects of that
isoform untouched [28,35].
The development of fluorescent probes which can monitor cAMP dynamics in real time have led
to vast advancements in the field. Briefly, these probes contain two fluorescent moieties, a donor and
an acceptor, and a cAMP binding domain. When cAMP binds, a conformational change is induced,
altering the fluorescent energy transfer between the donor and acceptor, known as fluorescence
resonance energy transfer (FRET). The detection of the two emissions allows real time changes in
cAMP concentration to be measured [36].
Many of the studies described in the present report employ a combination of these techniques to
create robust evidence for the specific roles of PDE4 isoforms in the cardiovascular system.
5. PDE4 in the Heart
Much of the understanding of cAMP compartmentalisation and the role of PDEs comes from
extensive studies of the signalling pathway in cardiac myocytes. Generally speaking, four PDE families
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have been identified as having notable roles in cAMP signalling in the heart: PDE1, PDE2, PDE3,
and PDE4 [37]. Despite the identification of localised expression of PDE4 in cardiac myocytes, inhibition
of this family was shown to have very limited effects on cardiovascular parameters, such as basal
blood pressure, heart rate, and contractility. This can be explained by the fact that PDE4 is a major
player not at basal cAMP levels, but during β-adrenergic stimulation, when intracellular [cAMP] is
raised. Additionally, it has been shown that redundancy of the PDE network can lead to compensatory
effects, in which other families with the same hydrolytic activity attenuate the effects of PDE4 loss of
function [38].
In the cardiac myocyte, sympathetic activation leads to β-adrenergic signalling, a major part of
the fight or flight response. Briefly, when the receptor is activated, its associated Gs-protein causes the
activation of AC, which catalyses the production of cAMP from ATP. cAMP in turn activates various
effector proteins; of major importance for this signalling paradigm is PKA, which phosphorylates a
number of substrates important for cardiac excitation-contraction coupling, and EPAC, which is of
particular importance in the vasculature. These phosphorylation effects lead to positive inotropic and
lusitropic effects, increasing the function of the heart for increased circulatory demands [39].
Interestingly, the phosphorylation of these substrate proteins by PKA is tightly regulated by PDE4
enzymes, which associate directly within signalosomes, modifying the signalling in tight compartments.
In this way, it is not global signalling which is affected by PDE4, but local, compartmentalised
signalling. This concept, developed in the 1980s by Hayes et al. using biochemical means was
proven unequivocally using advanced imaging techniques [12]. Optical probes that acted as cAMP
FRET reporters, allowed visualisation of the formation of cAMP gradients following submaximal
β-adrenergic stimulation. When used in combination with PDE inhibitors, it became apparent that the
loss of cAMP hydrolysis within cellular microdomains abrogated the spatial and temporal control of
cAMP dynamics that is required to channel receptor-specific physiological outcomes [13,40].
PDE4 and cardiac disease have a complicated relationship [41]. On one hand, PDE inhibition has
been shown to enhance cAMP signalling, resulting in increased cardiomyocyte function. In contrast,
chronic inhibition of PDEs results in increased mortality, often due to cardiac side effects [41,42].
Finally, PDE4 activity is decreased in heart failure, potentially contributing to disease progression due
to faulty regulation of the sympathetic induction of phosphorylation of cardiac excitation-contraction
coupling proteins [43,44].
The role of PDE4 in the cardiac myocyte cannot be described in full without delving into the
discrete roles of specific isoforms within their discrete subcellular compartments. The next sections of
this review will focus on these unique functions. A schematic summary of cardiac PDE signalosomes
is shown in Figure 2.
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Figure 2. Cardiac PDE signalosomes. PDE4 family members have been shown to integrate
into macromolecular complexes with numerous cardiac proteins, many of which are involved in
excitation-contraction coupling and calcium handling. PDE4D5 interacts with β-arrestin, regulating
receptor desensitisation. PDE4B regulates both the LTCC and RyR, which controls the process of
calcium induced calcium release. PDE4D interacts with SERCA, regulating the reuptake of calcium
into the SR. PDE4D3 interacts with IKs, modulating basal channel function. Finally, PKE4D5 regulates
the cardioprotective effects of HSP20. AC, adenylyl cyclase; AKAP, A-kinase anchoring protein; ATP,
adenosine triphosphate; β-AR, β-adrenoceptor; β-Arr, β-arrestin; ERK, extracellular signal regulated
kinases; Gi; inhibitory G-protein; Gs, stimulatory G-protein; HSP20, heat shock protein 20; IKS,
cardiac IKS potassium channel; LTCC, L-type calcium channel; P, phosphorylation; PKA, protein
kinase A PLN, phosphopamban, RyR, ryanodine receptor SERCA, sarcoplasmic reticulum calcium
ATPase [35,43,45–49].
5.1. PDE4D5’s Role in β-Adrenoceptor Desensitisation
One of the best understood functions of PDE4 in the cardiovascular system is the role of PDE4D5
in the regulation of β2-adrenergic signalling in the cardiac myocyte. When the β2-adrenoceptor is
stimulated, its coupled Gs protein stimulates AC, which produces cAMP to activate localised PKA.
Desensitisation of adrenergic signalling occurs when a negative-feedback loop is created when the
receptor itself is phosphorylated by PKA. This phosphorylation switches the receptor’s signalling to an
inhibitory G protein, Gi, which inhibits AC as well as activating other pathways, such as ERK1/2 [50].
Additionally, the phosphorylation of the receptor by G-protein coupled receptor kinases (GRKs)
causes the recruitment of β-arrestin, which further desensitises the receptor by sterically hindering
access to the G-protein [51]. However, when it was observed that the recruitment of β-arrestin also
increased local cAMP degradation, it became clear that PDE translocation was a crucial function of
β-arrestin [52]. In 2003, Baillie and colleagues used pharmacological inhibition and overexpression of
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dominant negative mutants to show that PDE4D5 is recruited to the β2-adrenoceptor by β-arrestin.
In neonatal rat ventricular myocytes (NRVM), both rolipram (a PDE4 inhibitor) and dominant negative
PDE4D5 increased the PKA phosphorylation of the receptor, and the activation of ERK1/2, which is
consistent with phenotypic switching of the receptor [53]. In a similar study, siRNA was used to
knockdown pan-PDE4D, which caused similar effects, namely, increased PKA phosphorylation of the
receptor and ERK activation. The same effects were achieved by the specific knockdown of PDE4D5
and this was the first time a function had been ascribed to an individual PDE4 isoform [29].
Interestingly, PDE4D5 is not the only isoform which has been shown to interact with β-arrestin.
In fact, all PDE4 isoforms have this ability due to the presence of the binding site in the conserved
catalytic region [52]. The presence of an additional β-arrestin binding site on PDE4D5’s unique
N-terminal binding domain could confer the specificity of its functioning as it is the “chosen-one” for
β-arrestin translocation [46]. Additionally, other pools of PDE4 which are expressed in the cell could
be preferentially sequestered in a different cellular location with different binding partners.
The direct interaction of the PDE with β-arrestin, however, is not sufficient to explain these
observations. The localisation of a pool of PKA to the β2-adrenergic receptor has been shown to
depend on the scaffolding protein, AKAP79 [29]. This allows the tethered PDE to regulate the activity
of this discrete pool of PKA. This determines the phosphorylation status and, thereby, the phenotypic
switching of the receptor.
5.2. PDE4D5 Regulates Cardioprotection by HSP20
Another example in which PDE4 has been shown to regulate the phosphorylation of a crucial
cardiac signalling protein is in the case of the small heat shock protein 20 (HSP20, HSPB6). HSP20 is
part of a diverse, ubiquitously expressed family of small chaperone proteins, whose expression patterns
are regulated by cellular stressors [54]. HSP20 has been shown to have a protective role in cardiac
myocytes, but only in its phosphorylated state [55–57]. In fact, when HSP20 is phosphorylated by PKA
at Ser16, it protects the cell by switching off harmful signalling (NF-kB) and switching on protective
signalling (Akt/PKB), inhibiting necrosis and apoptosis, and stabilising the cell’s cytoskeleton [58–61].
These protective mechanisms have been studied in the context of a variety of cardiac indications,
including ischaemia/reperfusion, chronic β-adrenergic stimulation, and heart failure [61–63].
The importance of phosphorylation has been shown in a variety of mutant studies, in which
a non-phosphorylated mutant (S16A) lost its protective effects in I/R injury, and constitutively
phosphorylated mutant (S16D) effectively protected cells from apoptosis [55,56].
The importance of PKA phosphorylation for HSP20’s cardioprotective abilities led researchers
to investigate the role of PDEs in this signalling pathway [35]. Initial experiments showed that
pharmacological inhibition of PDE4 augmented the isoprenaline-induced increase in phosphorylated
HSP20, confirming the functional role of PDE4. Real time monitoring of cAMP levels using FRET
technology gave more insight into PDE4’s role in this pathway. Comparing the response of a cAMP
FRET probe tethered to HSP20 with an untethered, cytosolic probe showed that PDE4 inhibition caused
a greater increase in cAMP in the vicinity of HSP20. This result highlights once again that the location
of small active pools of PDE4 is key to the enzyme’s control of specific events in cardiac myocytes.
The next step was to determine whether there was a direct interaction. Co-immunoprecipitation
studies were used in conjunction with peptide array experiments to show that HSP20 directly interacts
with the conserved catalytic region of PDE4D isoforms. The identification of the amino acids important
for the docking of HSP20 to PDE4D allowed the design and manufacturing of a cell permeable
peptide (peptide 906) which dismantles the interaction. Treatment of NRVM with this peptide not only
resulted in an increased phosphorylation of HSP20, but also an attenuation of hypertrophic response
to sustained β-adrenergic stimulation [64]. The peptide was also subsequently used in a rodent model
of heart disease with great effect [65].
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5.3. PDE4D3’s Regulation of RyR Phosphorylation
In the clinic, the use of PDE inhibitors has been plagued with cardiac problems, including
increased susceptibility to arrhythmia and heart failure. The underlying mechanisms were unknown
until Lehnart and colleagues performed an elegant study using PDE4D deficient mice [43]. It was
observed that these animals developed a dilated cardiomyopathy which had many characteristics
consistent with human chronic heart failure as well as exercise induced ventricular arrhythmias (VT).
Upon observation at the cellular level, it was shown that despite normal global cAMP signalling in
the PDE4D−/− mice, there was a marked increase in localised cAMP at the cardiomyocyte Z line.
This observation coupled with the evidence of previous studies showing that the ryanodine receptor
(RyR) is hyperphosphorylated by PKA at Ser2808 in heart failure led the researchers to study the role
of PDE4’s regulation of RyR phosphorylation in their model [66–69]. Indeed, the PDE4D−/− mice
showed both hyperphosphorylation of the RyR as well as diminished levels of calstabin-2 (FKBP12.6),
which functions to stabilise RyR and reduce calcium leak from the sarcoplasmic reticulum [70,71].
These changes led to multiple phenotypic observations. In terms of RyR function, the channels had a
“leaky” phenotype, similar to that which has been shown in heart failure and exercise induced sudden
cardiac death [66,70].
The individual isoform of PDE which associates with RyR to regulate these effects was identified
as PDE4D3. This is consistent with PDE4D3 being one of the three PDE4D isoforms expressed in the
heart; however, studies completed in rat hearts should be extrapolated with caution due to potential
differences in expression patterns of human hearts [72]. The elimination of PDE4D3 in complex with
RyR was shown to be highly relevant physiologically as PDE4D3 levels in the complex are also reduced
in human heart failure samples. This provided an interesting explanation for the hyperphosphorylation
of RyR by PKA despite globally decreased cAMP signalling in failing human cardiac myocytes, as had
been previously observed [73].
As the final piece of the puzzle, the group sought to confirm the role of hyperphosphorylated
RyR as a causative factor for the observed phenotypes. The PDE4D−/− mice were crossed with mice
harbouring a mutation which did not allow PKA phosphorylation of the RyR (S2808A). These mice
were protected against both exercise induced sudden cardiac death and myocardial infarction (MI)
induced sudden cardiac death, confirming the role of the PDE4D3, PKA, RyR signalosome in the
observed phenotypes.
The similarities of the phenotypes observed in PDE4D−/− mice with human cardiac disease
provide a compelling argument for the role of aberrant signalling relating to maladjustment of the
PDE complement within cardiac “signalosomes” in cardiomyopathy. Additionally, the identification of
PDE4D3 in complex with the RyR pinpointed another unique function for an individual PDE4 isoform.
5.4. PDE4D3 Regulates Basal IKs Activity
The electrical activity of cardiac myocytes is another function where PDE4 has an active
input. The slowly activating potassium channel (IKs) is a major repolarising current in the cardiac
action potential. IKs exists as a macromolecular complex which comprises KCNQ1 α-subunits
and KCNE1 β-subunits which interact with a variety of proteins that regulate the channel’s
function [74,75]. These include AC9, AKAP-9, PKA, and protein phosphatase-1 [76,77]. As with many
other cAMP signalling models in the cardiac myocyte, it was clear that a PDE may be involved
in this signalosome, thereby regulating PKA phosphorylation of the α-subunits. In a primarily
biochemical study, immunoprecipitation techniques identified that PDE4D3 is spatially confined
within this macromolecular complex via a direct interaction with AKAP-9 [49]. Functional experiments
in ventricular myocytes using pharmacological inhibitors showed that the PDE4 was able to fine tune
the functioning of the channel at basal conditions, probably due to a basally active AC in the vicinity.
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5.5. PDE4B Has a Dominant Role in LTCC Regulation
The L-type calcium channel (LTCC) is yet another cardiac excitation-contraction coupling protein
whose function is modified by a PDE4 isoform. This protein functions to allow calcium influx through
the cardiac myocyte membrane, which triggers the release of calcium from intracellular stores by
the RyR, in a process known as calcium-induced calcium release (CICR) [39]. Under conditions of
β-adrenergic stimulation, PKA phosphorylates the pore forming subunits of the LTCC, which increases
channel activity [78,79]. In combination with RyR phosphorylation, CICR is increased, leading to a
positive inotropic effect [39].
Although both PDE4B and PDE4D were both shown to tether to the LTCC signalosome, a study
using subfamily specific knockout mice showed that PDE4B exhibits the dominant functional role in the
regulation of LTCC phosphorylation and the protection against arrhythmia [47]. Firstly, experiments
in wild type mice showed that PDE4 inhibition had no effect on basal calcium current through the
LTCC (ICa,L) but markedly increased ICa,L under conditions of β-adrenergic stimulation. Consistently,
in both PDE4B−/− and PDE4D−/− mice, ICa,L was increased, leading to increased calcium transients
and increased contractility. The disease relevance of this research was shown using in vivo pacing
in the knockout animals, which resulted in ventricular tachycardia (VT) in PDE4B−/− mice but not
in PDE4D−/− mice. This study displayed the dominant functional role of PDE4B in the regulation
of phosphorylation of LTCC, which consequently regulates the entry of calcium into the cell and the
initiation of CICR.
The role of PDE4B in the protection against arrhythmia is consistent with the observation of
decreased PDE4B activity in cardiac hypertrophy [44]. The combination of these two findings could
represent at least a partial explanation of the incidence of arrhythmia and sudden cardiac death
associated with heart failure.
5.6. PDE4D and PDE3A Regulate PLN Phosphorylation and SERCA Function
The regulation of sarcoplasmic reticular calcium ATPase (SERCA) function relies on both PDE3
and PDE4 isoforms, unlike in other cardiac PDE signalosomes.
SERCA is a calcium channel on the sarcoplasmic reticular membrane which functions to sequester
calcium in its intracellular store. Phospholamban (PLN) inhibits its activity, tightly regulating channel
function. PLN can be phosphorylated by PKA, which reduces its inhibitory influence, leading to
increased SERCA activity and enhanced sarcoplasmic reticulum (SR) calcium load and contractility [80].
Both PDE4D and PDE3A have been shown to integrate into a signalosome containing SERCA,
PLN, PKA and other structural and regulatory proteins, thereby regulating PLN phosphorylation and
exhibiting a regulation of basal contractile function [48,81]. In separate studies, members of both PDE
subfamilies were detected in SERCA immunoprecipitates, showing that these PDEs integrate into the
SERCA/PLN signalosome. Knockout of PDE3A in rodents resulted in increased phosphorylation
of PLN associated with increased SERCA activity, SR calcium load, and increased contractility,
suggesting a major role for this isoform in the SERCA microdomain. However, similar studies in
PDE4D knockout rodents produced strikingly similar results, from increased PLN phosphorylation
to increased contractility. Taken together, it is apparent that both PDE3A and PDE4D are important
modulators of cAMP signalling at the SERCA microdomain as both seem to have comparable effects.
Further studies will be necessary to dissect any unique, non-compensated roles of these PDE isoforms
on SERCA function.
As evidenced by the examples above, highly localised pools of PDEs and in particular PDE4
have influence on many steps of the cardiac excitation-contraction coupling process. Although the
identity of the PDE4 isoforms differ in the distinct locations, the underlying concept of dormant
signalosomes being activated following the inhibition, displacement, silencing or overwhelming of a
spatially restricted PDE4 cohort prevails. Clearly, the initial concept pioneered by Hayes et al. and
subsequently validated using optical cAMP probes has also been upheld in diseases that occur as a
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result of the malformation of highly tuned cAMP gradients underpinned by loss of localised PDE4
machinery [12].
6. Vascular cAMP Signalling and PDEs
Although cardiac myocytes have taken centre stage in terms of PDE4 research, this group of
enzymes also has major roles in the wider cardiovascular system, regulating many characteristics of the
vasculature. cAMP signalling is particularly important in the signalling systems of vascular endothelial
cells (VECs) where increases in cAMP concentration results in reduced vascular permeability.
The literature is clear that PDEs are integral to the fine control of such processes [82]. In conditions
of low cGMP, PDE4 is the major regulator of PKA and EPAC activation, both of which influence
permeability. In addition to PDE4, PDE2 and PDE3 activity also impinge on VEC permeability,
but their influence is changed by increases in cGMP, which activates PDE2 and inhibits PDE3, allowing
fine tuning of regulation [82,83]. As in cardiac myocytes, localised signalosomes have been identified
as crucial in the maintenance of signalling specificity. The components of compartmentalised signalling
complexes in this location include various AC subtypes, PDE2, PDE3, and PDE4 isoforms, and AKAPs.
An important study by Maurice and colleagues identified the unique, non-compensated role of PDE4D
in the regulation of vascular permeability, confirming the notion of compartmentalised signalling in
VECs [3,83].
PDE4D’s Role in the Regulation of Vascular Permeability
VEC permeability is largely mediated through adherens junctions (AJ), structures comprised
of vascular endothelial cell cadherins (VECAD) which interact with those of neighbouring cells and
assemble a complex containing catenins and actinins to the cytoskeleton [84,85]. When VECs are
stimulated by agents that increase cAMP, the activation of PKA and EPAC results in the stabilisation of
AJs, decreasing cell permeability [83]. Pharmacological inhibition and siRNA-mediated knockdown
identified PDE4D and EPAC1 as the mediators of cAMP-dependent changes in permeability [3].
Interestingly, the use of pharmacological inhibition of PDE4 and knockdown of PDE4D yielded
conflicting results. As expected, PDE4 inhibition decreased cell permeability; however, in stark contrast,
knockdown of PDE4D increased cell permeability. This was explained by a dual role of PDE4D in this
cellular compartment. Not only does the PDE regulate EPAC1 activation by hydrolysing cAMP, but
it also acts as the tether, localising EPAC1 to the VECAD structures. The identification of PDE4D’s
function as a scaffold identified a novel role for the family of enzymes. Maurice et al. also employed a
disruptor peptide to determine the function of the interaction between EPAC1 and PDE4D. Treatment
with this peptide reduced VEC permeability to a similar degree as global PDE4 inhibition (Figure 3).
The specific disruption of the PDE4D-EPAC1 interaction proved to be a novel method to alter VEC
permeability and barrier function.
 
Figure 3. PDE regulation of Vascular Endothelial Permeability. PDE4D has been shown to regulate the
permeability of the vascular endothelium through interactions with components of AJs. Treatment
with PDE inhibitors or a specific disruptor of the PDE4D/EPAC1 interaction results in increased cAMP
and stabilization of AJs, ultimately causing reduced permeability and increased barrier function [3].
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7. Future Directions and Outlook
As described in the present review, the study of PDE4 in the cardiovascular system is centered
on the discovery of isoform specific roles within signalosomes. Compartmentalisation of distinct
PDE4 isoforms underpin their function and allow low cellular concentrations of the enzyme to have a
pivotal role in many areas of cardiac signaling. Future development of new technologies, such as the
expansion of novel, highly targeted FRET probes, will allow the effects of PDEs on cAMP signalling
to be observed in novel ways that were not previously possible [86]. In conjunction with PDE4 gene
therapy, PDE4 activators and novel animal models where inducible dominant negative PD4 constructs
are expressed, our understanding of the currently accepted roles of PDEs will be increased, and novel
roles at additional microdomains will inevitably be uncovered. This information will undoubtedly
drive novel therapeutic endeavors to target this versatile enzyme family for the good of humankind.
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Abstract: Pathological cardiac hypertrophy and dysfunction is a response to various stress
stimuli and can result in reduced cardiac output and heart failure. Cyclic nucleotide signaling
regulates several cardiac functions including contractility, remodeling, and fibrosis. Cyclic nucleotide
phosphodiesterases (PDEs), by catalyzing the hydrolysis of cyclic nucleotides, are critical in the
homeostasis of intracellular cyclic nucleotide signaling and hold great therapeutic potential as drug
targets. Recent studies have revealed that the inhibition of the PDE family member PDE1 plays
a protective role in pathological cardiac remodeling and dysfunction by the modulation of distinct
cyclic nucleotide signaling pathways. This review summarizes recent key findings regarding the roles
of PDE1 in the cardiac system that can lead to a better understanding of its therapeutic potential.
Keywords: phosphodiesterases (PDEs); PDE1; cyclic nucleotide; cardiac hypertrophy;
cardiac dysfunction
1. Introduction
Heart failure, the inability of the heart to provide sufficient blood to the body, is a leading cause
of death in the United States. Heart failure is associated with significant myocardial deterioration,
including pathological hypertrophy, fibrosis, and cell death, as well as contractile dysfunction and
ventricular arrhythmia [1]. Therefore, identifying novel molecular targets involved in pathological
cardiac remodeling and dysfunction is crucial. Cyclic nucleotide signaling is important in numerous
biological functions and pathological processes in the cardiovascular system, ranging from short-term
muscle contraction/relaxation to long-term cell growth/survival and structural remodeling [2].
Phosphodiesterases (PDEs), by catalyzing the hydrolysis of cyclic nucleotides, play important roles in
the regulation of intracellular cyclic nucleotide amplitude, duration, and compartmentalization [3].
Alterations in PDE expression and activity are responsible for disruptions in cyclic nucleotide
homeostasis, contributing to disease progression [3]. In this review, we give an overview of the
role and therapeutic potential of PDE1 regulation in pathological cardiac remodeling and dysfunction.
2. Pathological Cardiac Remodeling and Heart Failure
The heart is comprised of both cardiac myocytes and non-myocytes, including fibroblasts,
endothelial cells, mast cells, and smooth muscle cells, as well as extracellular matrix [4]. In response
to pathological conditions such as hypertension, neurohumoral activation, obesity, valvular heart
disease, myocardial injury, and genetic mutations, the heart can undergo pathological remodeling,
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which features an increase in myocyte size, increased levels of myocyte death, and extracellular
matrix protein deposition [5]. Cardiac hypertrophy is an adaptive response to increased workload and
initially helps to maintain an almost normal function [1]. However, with prolonged stress, the heart
can undergo irreversible decompensation, which is associated with a complex array of unfavorable
events [1]. These pathological events include myocyte elongation and myocyte loss, which leads
to chamber dilation and the thinning of the ventricular walls [1,6]. In addition, chronic stress
stimulates cardiac fibroblast activation, characterized by a phenotypic changes to alpha-smooth muscle
actin (α-SMA)-positive myofibroblasts [7]. Activated fibroblasts gain functions in cell proliferation,
migration, and extracellular matrix (ECM) production, which leads to cardiac fibrosis, a hallmark of
pathological cardiac remodeling [7,8]. Moreover, cardiac myocyte death is associated with various
types of cardiac disease [9]. Apoptosis, necrosis, and autophagy are the three major types of cell death
found in the heart, which induce cardiac arrhythmia, trigger cardiac remodeling, and ultimately lead
to cardiac dysfunction [10]. Therefore, limiting cardiac myocyte loss by attenuating cell death has
critical implications for the treatment of heart failure.
Numerous signaling pathways and molecular mechanisms have been implicated in cardiac
hypertrophy [11]. For example, calcium (Ca2+)-dependent signaling molecules such as Ca2+/calmodulin-
dependent serine/threonine phosphatase, calcineurin, and the Ca2+/calmodulin- dependent kinase II
(CaMKII) play well-known roles in pathological cardiac remodeling [12]. Calcineurin has been implicated
in mediating pathological hypertrophy in conjunction with the transcription factor nuclear factor of
activated T cells (NFAT) [1,12]. Upon dephosphorylation by calcineurin in the cytosol, NFAT is imported
into the nucleus and thus serves to induce a hypertrophic response [1]. The inhibition of calcineurin
alleviates cardiac myocyte hypertrophy induced by Ang II or α-adrenergic agonist stimulation
in vitro, and by pressure overload and isoproterenol (ISO) treatment in vivo [13]. The expression
and phosphorylation of CaMKII can also be induced by an upregulation of intracellular Ca2+
levels in the cardiac myocyte [14]. In cardiac hypertrophy, CaMKII exerts its molecular effects
by binding to and phosphorylating target proteins such as class II histone deacetylases (HDACs).
Upon phosphorylation by CaMKII, several class II HDACs regulate the derepression of myocyte
enhancer factor 2 (MEF2)-dependent genes through the nuclear export of HDACs, which contributes
critically to hypertrophic signaling in the heart [15].
3. Cyclic Nucleotide Signaling and PDEs in the Heart
3.1. Cyclic 3′,5′ Adenosine Monophosphate (cAMP) Signaling
Cyclic AMP was first isolated and characterized by Sutherland and Rall over a half-century
ago [16,17]. A large family of enzymes known as the adenylyl cyclases (ACs) catalyze the synthesis
of cAMP from adenosine triphosphate (ATP) in response to a variety of extracellular signals such as
hormones, growth factors, and neurotransmitters [18,19]. To date, 10 ACs, including nine membrane
ACs and one soluble AC, have been identified [20,21]. Membrane ACs are regulated by G-protein
coupled receptors (GPCRs), whereas soluble ACs are regulated by bicarbonate and Ca2+ [20–22].
This increase in cAMP leads to the activation of several downstream effector molecules including
protein kinase A (PKA), an exchange factor directly activated by cAMP (EPAC), and cyclic nucleotide
gated channels (CNGs) [18]. The development of Förster resonance energy transfer (FRET)-based
techniques that enable the measurement of cAMP concentrations at the single cell level have
demonstrated that cAMP levels are not uniform throughout the entire cell, which may indicate
that it regulates different biological functions [23,24].
In the cardiac myocyte, catecholamines stimulate the β-adrenergic receptors (β-ARs), leading to
cAMP-mediated activation of PKA signaling, which then is able to phosphorylate L-type Ca2+ channels
(LTCC) and ryanodine receptors (RYRs) to induce intracellular Ca2+ increases, thus stimulating
myocyte contractility [25–28]. Furthermore, the PKA-mediated phosphorylation of phospholamban
(PLB) leads to enhanced Ca2+ re-uptake through the sarcoplasmic/endoplasmic reticulum calcium
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ATPase 2 (SERCA2) in the sarcoplasmic reticulum (SR) adjacent to the T-tubule, leading to faster
myofilament relaxation [29]. β-AR mediated cAMP signaling can be either detrimental or beneficial
to the heart. Acute stimulation of β1-AR/cAMP has beneficial effects on cardiac contractile function,
whereas chronic stimulation results in myocyte hypertrophy, apoptosis, and cardiac fibrosis, finally
leading to heart failure [30]. Interestingly, it has been found that the activation of cAMP/PKA signaling
by stimulating the adenosine A2 receptor (A2R) is cardiac-protective: for example, A2R activation
alleviated transverse aortic constriction (TAC)-induced cardiac dysfunction [31]. These studies indicate
that different cAMP signaling modules regulate distinct and even opposing effects in cardiac myocytes.
3.2. Cyclic 3′,5′ Guanosine Monophosphate (cGMP) Signaling
Cyclic GMP is generated from GTP by two families of guanylyl cyclases (GCs), with seven
particulate GCs (pGCs) activated by natriuretic peptides (NPs) and three soluble GCs (sGCs) activated
by nitric oxide (NO) or carbon monoxide (CO) [32,33]. cGMP regulates three major types of effector
molecules: cGMP dependent protein kinases (PKG), cGMP-regulated PDEs, and cGMP-gated cation
channels [34]. Similar to cAMP, cGMP is highly compartmentalized in the cell, and elicits distinct
downstream biological effects [35,36]. There appear to be multiple protective cGMP signaling modules
in the heart [37–40]. For example, a study by Frantz and colleagues found that mice with a cardiac
myocyte-specific PKGI knockout (KO) developed significant cardiac dysfunction and cardiomyopathy
in both Ang II- and TAC-induced cardiac hypertrophic models, with decreased expression of SERCA2
and PLB and altered Ca2+ homeostasis [37]. PDE5 inhibition has been shown to attenuate cardiac
hypertrophy by targeting NO-sGC-derived cGMP [38,40–43]. PDE9 inhibition also protects against
cardiac hypertrophy by targeting NP-pGC-derived cGMP [44]. Similarly, we have also found that
PDE1A inhibition attenuates cardiac myocyte hypertrophy in a cGMP-dependent manner [45].
3.3. Different PDE Isozymes in the Heart
The degradation of cyclic nucleotides is catalyzed by PDEs. The PDE superfamily is comprised of
11 structurally related but functionally distinct gene families, PDE1–PDE11, with differences in their
cellular functions, structures, catalytic properties, and mechanisms of regulation [3]. All PDEs share
a conserved carboxyl-terminal catalytic core of approximately 270 amino acids, with a shared sequence
identity of 25–50% between family members [46]. However, the regulatory characteristics of PDEs are
determined by their unique amino-terminal regions, which contain elements known to be involved
in enzyme phosphorylation, dimerization, auto-inhibition, ligand binding, and protein-protein
interaction. These regions thus allow distinct localization and heterogeneity in cyclic nucleotide
signaling and enable diverse functions of various PDEs [3,46,47].
Research has clearly established that the degradation of cyclic nucleotides by PDEs is regulated
differently under physiological and pathological conditions. In particular, the expression and activity
of several PDEs are altered in various types of cardiovascular disease [40,44,45,48,49]. Up to now,
at least seven PDE family members have been found in the heart, including PDE1–PDE9 [44,48,50–54].
Among these, PDE4 and PDE8 specifically hydrolyze cAMP, PDE5 and PDE9 specifically hydrolyze
cGMP, while PDE1, 2, and 3 can hydrolyze both cAMP and cGMP [3]. Thus, a thorough understanding
of the roles of specific PDE isoforms in cardiac pathology and physiology is critical. This review mainly
focuses on the roles of two isoforms of PDE1 in the heart (PDE1A and PDE1C).
4. PDE1 and Pathological Cardiac Remodeling and Dysfunction
4.1. PDE1
The PDE1 family was one of the first classes of PDEs to be identified [55]. All PDE1 family
members are regulated by the binding of Ca2+/CaM, which is the reason that PDE1 is also referred
to as Ca2+/CaM-stimulated PDE [56]. Thus, the Ca2+-dependent activation of PDE1 isozymes plays
a critical role in the crosstalk between Ca2+ and cyclic nucleotide signaling [57]. The PDE1 family
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members are encoded by three distinct genes, PDE1A, 1B, and 1C, and alternative splicing of these genes
gives rise to a number of functionally distinct isozymes, which allows for differential cell/subcellular
expression and Ca2+ sensitivity, leading to the finely tuned regulation of cyclic nucleotide signaling [45].
Like other PDEs, PDE1 variants consist of a conserved C-terminal catalytic domain with diverse
N-terminal regulatory domains. The N-terminus of all PDE1s contains two CaM binding domains
with an inhibitory sequence in between them. It has been suggested that the binding of Ca2+/CaM
therefore relieves the inhibition of PDE1 activity [58]. As a consequence, the catalytic activity of PDE1
can be stimulated more than 10-fold upon the binding of Ca2+/CaM [56,59]. Each PDE1 isoform is able
to catalyze the hydrolysis of both cAMP and cGMP, but with different substrate affinities. PDE1As
hydrolyze cGMP (Km ≈ 5 μM) with greater affinity than cAMP (Km ≈ 112 μM) in vitro [59]. PDE1B
enzymes also prefer cGMP (Km ≈ 2.4 μM) to cAMP (Km ≈ 24 μM) [49]. However, PDE1Cs hydrolyze
cAMP and cGMP with a similarly high affinity (Km ≈ 1 μM) [49,56].
Given the well-established role of Ca2+ signaling in pathological cardiac remodeling and the
potential role of PDE1 as a mediator for Ca2+ to antagonize cyclic nucleotide signaling, understanding
the role of PDE1 in cardiac diseases is of great interest. PDE1 expression is highly regulated with
differential isozyme localization to specific tissues and cell types [50,58,60,61]. PDE1A expression
is relatively low in the normal heart but is upregulated in the diseased heart, which is consistent
among humans, rats, and mice [62]. PDE1C expression varies with species: it is high in human,
modest in mouse, and low in rat normal heart [45,62,63]. PDE1B expression is barely detectable in the
heart [62,63]. In human myocardium, PDE1C has been shown to be localized along the M- and Z-lines
of cardiac myocytes in a striated pattern [62]. Taken together, these observations indicate that there
are substantial species-specific differences in PDE1 expression in the heart. With the development
of PDE1-selective inhibitors and the genetically engineered PDE1 KO mice, the roles of PDE1 in
cardiac cells and cardiac disease models have been recently explored in vitro and in vivo. Here we
review the expression and regulation of different PDE1 isoforms in pathological cardiac remodeling
and dysfunction.
4.2. Role of PDE1A in Cardiac Myocyte Hypertrophy and Fibroblast Activation
PDE1A expression has been found to be significantly upregulated in diseased hearts of various
etiologies, such as in mouse hearts with dysfunction induced by chronic ISO infusion, myocardial
infarction (MI), and TAC, in rat heart treated with chronic Ang II infusion, as well as in human
failing hearts with both dilated and ischemic cardiomyopathy [36,45]. PDE1A induction in diseased
hearts appears to occur in both cardiac myocytes as well as in activated cardiac fibroblasts in fibrotic
areas [36]. PDE1A upregulation has been also observed in cultured neonatal rat ventricular myocytes
(NRVMs) and adult rat ventricular myocytes (ARVMs) given hypertrophic stimuli such as ISO or
Ang II [45]. To determine the specific contribution of PDE1A to the regulation of cardiac hypertrophy,
Miller et al. utilized the pan PDE1-selective inhibitor IC86340 and PDE1A-specific shRNA to block
PDE1A function in rat cardiac myocytes where PDE1C expression is limited [45]. They found that
PDE1 inhibition by IC86340 and PDE1A downregulation by shRNA prevent the hypertrophic response
induced by phenylephrine (PE) treatment in both NRVMs and ARVMs. PE causes a reduction
in cGMP levels in cardiac myocytes, which can be abolished by the PDE1 inhibitor IC86340 or
PDE1A shRNA [45]. This suggests that PDE1A plays a critical role in the PE-induced suppression
of cGMP signaling in cardiac myocytes, likely through the Ca2+-dependent activation of PDE1A.
Consistently, PDE1A suppression of cardiac hypertrophy also occurs in a PKG-dependent manner [45].
These studies indicate that the inhibition of PDE1A alleviates cardiac myocyte hypertrophy by blocking
a PE-induced decrease in intracellular cGMP and PKG activity [45]. However, the detailed underlying
molecular mechanism by which PDE1A-mediated cGMP/PKG signaling regulates cardiac myocyte
hypertrophy remains unknown. PDE5A inhibition also suppressed cardiac myocyte hypertrophy
in a cGMP/PKG-dependent manner [38]. However, the mechanisms by which PDE1A and PDE5A
mediate the regulation of cardiac myocyte hypertrophy appear to be different. This is supported by
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the fact that treatment with the PDE5 inhibitor sildenafil together with the PDE1 inhibitor IC86340 or
PDE1A shRNA elicited additive effects on antagonizing myocyte hypertrophy, suggesting that two
different pathways are involved [45].
In addition to cardiac myocytes, PDE1A is also significantly induced in activated cardiac
fibroblasts (α-SMA positive myofibroblasts) within fibrotic areas of rodent and human failing
hearts [36]. In vitro, PDE1A can be upregulated in rat cardiac fibroblasts by treatment with pro-fibrotic
stimuli such as Ang II and transforming growth factor β (TGF-β) [36]. In addition, the PDE1
family contributes 70% of total cGMP-hydrolyzing PDE activity under Ang II stimulation, suggesting
a major role for PDE1 in Ang II-activated fibroblasts [36]. The role of PDE1A in cardiac fibroblast
activation (phenotype changing to myofibroblasts) was investigated in primary cultured rat cardiac
fibroblasts [36]. Both IC86340 and PDE1A shRNA treatment reduced Ang II- or TGF-β-induced
myofibroblast activation and ECM synthesis [36]. PDE1A-mediated myofibroblast transformation
and ECM synthesis are dependent on the suppression of both cAMP/Epac1/Rap1 signaling as
well as cGMP/PKG signaling [36], which is in line with the dual substrate specificity of PDE1A.
FRET-based approaches further showed that IC86340 induces a rapid but transient elevation
of cGMP, and preferentially stimulated nuclear and perinuclear cAMP production in activated
fibroblasts [36]. The roles of PDE1A-mediated regulation of cAMP/Epac1 and cGMP/PKG in cardiac
fibroblasts are consistent with previous findings that the activation of Epac1 [64–66] or cGMP/PKG
signaling [38,67,68] exerts anti-fibrotic effect in cardiac fibroblasts.
Recently, Wang et al. generated two different lines of global PDE1A null mice by using the
transcription activator-like effector nucleases (TALEN) approach, one containing a frame deletion of
15bp within the catalytic active site of mPDE1A and the other exhibiting a frame shift insertion, for the
purpose of studying polycystic kidney disease (ADPKD) [69]. It has been shown that both null lines
of mice developed a mild renal cystic disease phenotype on a wild-type background and accelerated
the development of phenotype in an ADPKD mouse model (a pkd2 gene mutant background) at ages
≤16 weeks [69]. Additionally, these PDE1A null mice had lower aortic blood pressure and increased
left ventricular ejection fraction [69]. However, whether PDE1A deficiency affects stress-induced
pathological cardiac remodeling and dysfunction is still not clear.
4.3. Role of PDE1C in Pathological Cardiac Remodeling and Dysfunction
PDE1C represents one of the major PDE activities in the normal human heart [62]. Its role in
cardiac remodeling and dysfunction was recently evaluated by Knight et al. using a global PDE1C
knockout (PDE1C-KO) mouse strain. In their study, it was found that PDE1C expression is upregulated
in both mouse and human failing hearts [49], which is consistent with a recent RNA-sequencing study
of human failing heart samples reporting an increase of PDE1C expression in both ischemic heart
disease and dilated cardiomyopathy [49,70]. Unlike PDE1A, PDE1C is only expressed in cardiac
myocytes and is undetectable in cardiac fibroblasts or myofibroblasts [49]. Interestingly, TAC-induced
cardiac remodeling and dysfunction observed in PDE1C wild-type (PDE1C-WT) mice was significantly
alleviated in PDE1C-KO mice, as indicated by reduced chamber dilation, myocardial hypertrophy,
cardiac myocyte apoptosis, and interstitial fibrosis, as well as attenuated loss of fractional shortening
and ejection fraction [49]. This indicates a detrimental role for PDE1C in the development of heart
failure induced by chronic pressure overload.
In isolated cardiac cells, PDE1C deficiency abolished Ang II-, PE-, or ISO-induced cardiac myocyte
hypertrophy [49]. Ang II- and ISO-induced cell death were also blocked in PDE1C-KO myocytes.
In addition, IC86340 attenuated cell death and apoptosis in WT myocytes but had no further effect in
PDE1C-KO myocytes, indicating that the protective effect of IC86340 on myocyte death is primarily
through PDE1C [49]. The anti-hypertrophic and anti-apoptotic effects of PDE1C deficiency and/or
inhibition were mediated in a cAMP/PKA-dependent manner, and the PI3K/AKT signaling pathway
appears to be important for this protective effect [49]. However, the detailed molecular mechanisms by
which PDE1C regulates cAMP-mediated cardiac-protective signaling pathways deserve to be further
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investigated. PDE1C expression was barely detectable in WT cardiac fibroblasts or WT myofibroblasts
(stimulated with TGF-β) [49]. However, TAC-induced cardiac interstitial fibrosis was attenuated in
PDE1C-KO hearts [49]. This raises the hypothesis that myocyte PDE1C regulates fibroblast function
through a paracrine-dependent mechanism. Indeed, conditioned medium collected from PDE1C-KO
but not PDE1C-WT cardiomyocytes was found to attenuate TGF-β-induced fibroblast activation,
suggesting that PDE1C inhibition or deficiency inhibits fibroblast activation through secreted factor(s)
from myocytes [49]. However, the secreted factor(s) that mediate this crosstalk between cardiac
myocytes and fibroblasts remain unknown.
4.4. PDE1 and Other PDEs: Similarities, Differences, and Potential Interactions
Although PDE1A is able to regulate cGMP levels and cGMP-dependent signaling in cardiac
myocytes [45], the specific source(s) of cGMP modulated by PDE1A in cardiac myocytes remains
unknown. In vascular SMCs, PDE1A appears to be able to regulate cGMP derived from atrial natriuretic
peptide (ANP) stimulation [71]. Several other PDEs have previously been shown to regulate cGMP
signaling in cardiomyocytes. For example, PDE5A likely regulates NO-derived cGMP [38] and plays
a critical role in mediating various types of cardiac diseases including ischemia/reperfusion (I/R)
injury [72,73], doxorubicin cardiotoxicity [74], ischemic and diabetic cardiomyopathy [75], and cardiac
hypertrophy [38,76]. PDE5 is expressed at low levels and localized to sarcomeric Z-bands within cardiac
myocytes [53]. A recent study found that PDE9, another cGMP-specific PDE, upregulated expression
in both mouse and human hypertrophic hearts [44]. The inhibition and genetic deletion of PDE9
was shown to protect the heart against TAC-induced cardiac remodeling and pre-established heart
disease [44]. PDE9 couples to NP-derived cGMP [44]. Moreover, PDE2, which preferentially localizes
in the membrane fraction of cardiac myocytes, is also critical for cGMP catabolism in cardiac myocytes
in response to particulate GC activation [35]. Evidence to date suggests that PDE1C primarily regulates
cAMP signaling in cardiac myocytes [49]. PDE1C inhibition/deficiency protects cardiac myocyte
from death in a PKA-dependent manner [49]. Also, PDE1C is responsible for the Ang II-mediated
suppression of myocyte cAMP levels [49]. These observations suggest that PDE1C antagonizes
a protective cAMP signaling pathway in cardiac myocytes. Indeed, our unpublished observations
suggest that PDE1C negatively regulates cardiac protective A2R-cAMP signaling. In contrast, previous
studies have shown that PDE3A inhibition potentiates a detrimental cAMP signaling pathway that
promotes cardiac myocyte death [48,77–79]. However, PDE4 inhibition has a limited effect on cardiac
myocyte death/survival despite the drastic elevation of cAMP upon PDE4 inhibition [48].
Taken together, these findings suggest that in cardiac myocytes there are multiple different,
even functionally opposing cyclic nucleotide signaling pathways that are modulated by distinct PDE
isozymes. The functional diversity of individual PDEs could be achieved through multiple mechanisms:
the association of PDEs with discrete “pools” of cyclic nucleotides, targeted to spatially separated
compartments, and complexed with distinct sets of signaling molecules. In addition, the variable
enzymatic and regulatory properties make individual PDEs function in different biological conditions,
such as basal vs. stimulated, physiological vs. pathological cellular environments, etc. PDE1-mediated
functions are associated with intracellular Ca2+ levels because PDE1 needs Ca2+ to be activated.
For example, previous studies have shown that PDE1A is responsible for PE-induced cGMP reduction,
while PDE1C is important for Ang II-induced cAMP reduction in cardiac myocytes [45,49]. Moreover,
a recent study using FRET approaches further supported the role of Ca2+ in the PDE1-mediated
regulated cAMP response in cardiac myocytes [80]. Specifically, it has been shown that PDE1 inhibition
is able to elicit significant cAMP elevation under stimulation by forskolin but not ISO, under a paced
but not basal state, or mimicked by pretreating resting cells with Ca2+ elevating agents [80]. It will
be of great interest to understand the integratory roles of these different cyclic nucleotide signaling
pathways modulated by distinct PDEs in regulating cardiac myocyte functions. Targeting multiple
PDEs in combination may represent a compelling strategy. Indeed, a number of recent studies have
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shown synergistic effects on cyclic nucleotide level and subsequent biological functions resulting from
the inhibition of combinations of PDEs [81,82].
5. Therapeutic Potential of PDE1 Inhibition in Pathological Cardiac Remodeling
To evaluate the pharmacological effects of PDE1 inhibition in pathological cardiac remodeling
in vivo, the systemic application of IC86340 was evaluated in an ISO-induced mouse hypertrophy and
fibrosis model [36,45]. It was found that mice receiving daily IC86340 treatment at the doses of 3 and
6 mg/kg per day elicited a small (10 to 20 mmHg) reduction of blood pressure (BP) with no significant
changes in heart rate. The effect on BP reduction is consistent with that of other PDE1 inhibitors such
as Lu AF41228/Lu AF58027 and vinpocetine, which have been shown to cause vasodilation and/or
lower BP in rodents [71,83]. The effects of PDE1 inhibitors on blood pressure regulation are likely
mediated exclusively by PDE1A, but not PDE1C, as PDE1A is expressed in the medial vascular smooth
muscle cells (SMCs) responsible for vascular contractile function [84–86]. The role of PDE1A in the
regulation of blood pressure has been more directly supported by the recent findings from two lines
of PDE1A null mice that showed reduced aortic blood pressure [69]. Additionally, the association
of PDE1A single nucleotide polymorphisms (SNPs) with diastolic blood pressure has been revealed
by human genetic studies [87,88]. In addition to the effect of IC86340 on BP, there is no correlation
between BP and ISO-induced remodeling [89]. In the mouse heart, IC86340 treatment (3 mg/kg per
day) attenuated ISO infusion-mediated increases in cardiac hypertrophy, as assessed by increased heart
size, heart weight/body weight ratio, and heart weight/tibia length ratio [45]. In addition, enlarged
cardiac myocyte cross-sectional area and elevated ANP gene expression were also significantly reduced
by IC86340 treatment [45]. Moreover, cardiac fibrosis, as indicated by α-SMC-positive myofibroblasts
and collagen deposition, were significantly reduced by IC86340 [36]. These results support a critical
role for PDE1 activation in ISO-induced cardiac hypertrophy in vivo. The effects of IC86340 or other
PDE1-selective inhibitors deserve to be evaluated in different models of cardiovascular disease in
the future.
Vinpocetine is also widely used as a PDE1 inhibitor. It is a derivative of the alkaloid vincamine and
has, for several decades now, been used clinically in many countries for the treatment of cerebrovascular
disorders such as stroke and dementia [90–92]. In addition to being a PDE1 inhibitor, vinpocetine
can act as a blocker for voltage-dependent Na+ channels as well as act as an inhibitor for IkB kinase
(IKK), serving as a critical mediator of inflammatory signaling [93]. The excellent safety profile
of vinpocetine has attracted significant interest for exploring the potential therapeutic effects of
vinpocetine treatment in various other disease models. Indeed, emerging experimental evidence
has shown the beneficial effects of vinpocetine in various inflammatory and cardiovascular disease
models. For example, vinpocetine treatment partially restored the sensitivity of the vasculature to
nitroglycerin (NTG) in a rat model of NTG tolerance [71]. In addition, vinpocetine significantly
attenuated mouse carotid artery wall thickening and neointimal formation induced by ligation injury,
and markedly suppressed the spontaneous remodeling of human saphenous vein explants in an ex
vivo culture model [94]. High-fat diet-induced atherosclerosis in ApoE-deficient mice was also
significantly suppressed by vinpocetine [95,96]. Moreover, the inhibition of PDE1 by vinpocetine
has been suggested to play a protective role in cardiac hypertrophy and fibrosis [97]. It has been
found that vinpocetine significantly alleviates chronic Ang II-induced cardiac hypertrophy and fibrosis
in vivo [97]. Consistently, in isolated cardiac myocytes, vinpocetine attenuates Ang II-induced myocyte
hypertrophy in a dose-dependent manner [97]. In addition, vinpocetine blocks TGF-β-induced
fibroblast activation [97]. Interestingly, when PDE1 activity is blocked by IC86340, vinpocetine exerts
no additional effects on cardiac myocyte hypertrophy and fibroblast activation, likely demonstrating
that its protective effects are effective largely through PDE1 inhibition [97]. Taken together, these data
indicate that vinpocetine is a drug with multiple pharmacological targets and multiple therapeutic
effects [93]. In addition to its direct protective effects on cardiac cells, other biological effects of
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vinpocetine may also act together in an indirect beneficial manner for preventing cardiac diseases,
including vasodilation, anti-inflammation, and anti-vascular occlusive remodeling [93,94,98–100].
6. Conclusions and Perspective
Experimental evidence has suggested that both PDE1A and PDE1C are important in regulating
cardiac structural remodeling and function (Figure 1). However, their regulation, function,
and mechanistic actions in the heart appear to be distinct. PDE1A is expressed and functions in
both cardiac myocytes and fibroblasts, particularly in response to stimulation with hypertrophic and
fibrotic stimuli [36,45]. However, PDE1C is expressed in cardiac myocytes but not fibroblasts [49].
PDE1A and PDE1C both regulate cardiac myocyte hypertrophy induced by pathological stimuli
such as Ang II, but via distinct signaling pathways: PDE1A acts through cGMP/PKG while
PDE1C acts through cAMP/PKA [45,49]. The differential functions and mechanisms of PDE1A
and PDE1C in cardiac hypertrophy stimulated with other growth factors or particularly in response to
physiological hypertrophy also deserve to be further investigated. Interestingly, the protective effect
of pan PDE1 inhibition on cardiac myocyte death is primarily dependent on PDE1C inhibition [49].
PDE1C deficiency but not PDE1A deficiency blocked myocyte death induced by different death stimuli
(our unpublished observations). These results suggest that PDE1C but not PDE1A plays a major
role in regulating cardiac myocyte death, at least in isolated cardiac myocytes in vitro. In cardiac
fibroblasts, PDE1A directly regulates fibroblast activation and ECM production [36]. However, PDE1C
appears to regulate fibroblast function through the myocyte-PDE1C-mediated regulation of unknown
secreted factor(s) via a paracrine mechanism [49]. Most knowledge of PDE1A in cardiac myocytes
and fibroblasts is derived from experimental observations in cultured primary cells [36,45,49]. Future
validation in animal models in vivo is necessary. Taken together, PDE1A and PDE1C regulate distinct
cyclic nucleotide signaling pathways and play different roles in the heart. Future development of
cardiac cell-specific PDE1A or 1C knockout mice, or genetically modified mice with selectively altered
PDE1A or PDE1C, should be helpful in elucidating a more detailed characterization of the role of PDE1
isoforms in cardiac remodeling and dysfunction.
Although both PDE1A and PDE1C exhibit direct biological effects in cardiac myocytes and/or
fibroblasts, the two major cell types in the heart, the expression of PDE1 isozymes in other cardiac
cell types or in other organs may also indirectly influence cardiac structural remodeling and
function [36,45,49]. These tissues/organs include but are not limited to the vasculature, brain, kidney,
and lung. PDE1A and 1C have very different expression profiles in many tissues of the human
body [63]. PDE1A null mice have been shown to have a mild renal cystic disease and a urine
concentrating defect [69]. Moreover, a recent study defined a significant level of expression of PDE1A in
sinoatrial nodal tissue, which may be important in regulating sinoatrial nodal pacemaker function [101].
Therefore, when studying cardiac function using global PDE1A knockout mice or systemically applying
pan PDE1 inhibitors, the potential effects on heart rate, contractility, BP reduction, and kidney function
should be taken into consideration.
To date, all PDE1 inhibitors are pan inhibitors, lacking the ability to distinguish between different
PDE1 isozymes. The future development of PDE1 isozyme-selective inhibitors is important for
achieving specific pharmacological effects. Taken together, basic research studies in isolated cardiac
cells and in experimental cardiac disease models provide strong evidence for roles of PDE1A and
PDE1C in pathological cardiac remodeling and dysfunction, suggesting that PDE1A and PDE1C might
represent potential novel and promising therapeutic targets.
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Figure 1. Schematic diagram showing the potential role of PDE1A and PDE1C in regulating pathological
cardiac remodeling including cardiac hypertrophy and fibrosis. In cardiac myocytes, PDE1A-dependent
regulation of cGMP/PKG signaling alleviates myocyte hypertrophy, PDE1C-dependent regulation of
cAMP/PKA signaling suppresses both myocyte hypertrophy and apoptosis. In cardiac fibroblasts,
PDE1A-dependent dual regulation of cAMP-Epac1-Rap1 and cGMP-PKG signaling decreases fibroblast
activation and ECM synthesis, whereas PDE1C may regulate cardiac fibrosis through paracrine signaling
between cardiac myocytes and fibroblasts.
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Abstract: Cardiac pacemaking, at rest and during the sympathetic fight-or-flight response, depends
on cAMP (3′,5′-cyclic adenosine monophosphate) signaling in sinoatrial node myocytes (SAMs).
The cardiac “funny current” (If) is among the cAMP-sensitive effectors that drive pacemaking in
SAMs. If is produced by hyperpolarization-activated, cyclic nucleotide-sensitive (HCN) channels.
Voltage-dependent gating of HCN channels is potentiated by cAMP, which acts either by binding
directly to the channels or by activating the cAMP-dependent protein kinase (PKA), which
phosphorylates them. PKA activity is required for signaling between β adrenergic receptors (βARs)
and HCN channels in SAMs but the mechanism that constrains cAMP signaling to a PKA-dependent
pathway is unknown. Phosphodiesterases (PDEs) hydrolyze cAMP and form cAMP signaling
domains in other types of cardiomyocytes. Here we examine the role of PDEs in regulation of If in
SAMs. If was recorded in whole-cell voltage-clamp experiments from acutely-isolated mouse SAMs
in the absence or presence of PDE and PKA inhibitors, and before and after βAR stimulation. General
PDE inhibition caused a PKA-independent depolarizing shift in the midpoint activation voltage
(V1/2) of If at rest and removed the requirement for PKA in βAR-to-HCN signaling. PDE4 inhibition
produced a similar PKA-independent depolarizing shift in the V1/2 of If at rest, but did not remove
the requirement for PKA in βAR-to-HCN signaling. PDE3 inhibition produced PKA-dependent
changes in If both at rest and in response to βAR stimulation. Our results suggest that PDE3 and
PDE4 isoforms create distinct cAMP signaling domains that differentially constrain access of cAMP to
HCN channels and establish the requirement for PKA in signaling between βARs and HCN channels
in SAMs.
Keywords: sinoatrial node; HCN channel; funny current (If); cardiac pacemaking; cardiomyocyte;
cell compartmentalization; phosphodiesterases; cyclic AMP (cAMP); ion channel; patch clamp
1. Introduction
Cardiac pacemaking, at rest and during the sympathetic fight-or-flight response, depends on
cAMP signaling in sinoatrial node myocytes (SAMs). SAMs are highly-specialized cells that drive
pacemaking by firing spontaneous action potentials (APs). Spontaneous APs in SAMs result from a
spontaneous depolarization during diastole that drives the membrane potential to its threshold
to initiate the subsequent AP. The diastolic depolarization in SAMs arises as a function of the
coordinated activity of a unique complement of ion channels that work in concert with intracellular Ca2+
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signaling [1–4]. 3′,5′-cyclic adenosine monophosphate (cAMP) is a critical regulator of pacemaking in
SAMs. The resting cytoplasmic concentration of cAMP is thought to be higher in SAMs than in other
cardiac myocytes [5] and sympathetic nervous system stimulation increases heart rate by activating β
adrenergic receptors (βARs) and further increasing cAMP in SAMs.
The “funny current” (If) is a hallmark of SAMs and is among the many cAMP-sensitive effectors
that contribute to spontaneous pacemaker activity in SAMs. If is produced by hyperpolarization-
activated, cyclic nucleotide-sensitive (HCN) ion channels. HCN4 is the predominant HCN channel
isoform in the sinoatrial node of all mammals; it is expressed at high levels in SAMs and is used
as a marker of the sinoatrial node [6–9]. If is activated by membrane hyperpolarization and is a
mixed cationic conductance with a reversal potential of approximately −30 mV in physiological
solutions [10,11]. Thus, If is inward at diastolic potentials, and it is thought to contribute to the diastolic
depolarization phase of the sinoatrial AP. In accordance with a critical role for If in pacemaking,
mutations in HCN4 channels cause sinoatrial node dysfunction in human patients and animal
models [12–14] and HCN channel blockers decrease the heart rate [15,16].
cAMP potentiates voltage-dependent gating of HCN4 channels either by binding directly to a
conserved cyclic nucleotide binding domain in the proximal C-terminus [17,18] or by protein kinase
A (PKA)-mediated phosphorylation of the distal C-terminus [11]. In either case, cAMP causes a
depolarizing shift in the midpoint activation voltage (V1/2). We previously showed that PKA activity
is necessary for cAMP-dependent signaling between βARs and HCN channels in SAMs; inhibition
of PKA with an inhibitory peptide, PKI, significantly reduced the shift in V1/2 produced by βAR
stimulation [11]. However, we have also shown that HCN channels in SAMs can be activated by
cAMP even in the absence of PKA activity [19], presumably by binding directly to the channels. Thus,
the requirement for PKA in βAR-to-HCN4 channel signaling in SAMs could arise as a function of
compartmentalization or restricted diffusion of cAMP [19].
Although cAMP is a small, soluble molecule, it does not behave as a freely-diffusing molecule
in many types of cells [20–27]. cAMP concentration in cells is determined by a balance between
production by adenylyl cyclases and degradation by cyclic nucleotide phosphodiesterases (PDEs)
PDEs have been shown to form functional diffusion barriers in other types of cardiac myocytes [28–32].
PDEs are organized into 11 families, of which the PDE3 and PDE4 families are the most abundant
in the mouse sinoatrial node [33]. Functional studies using subtype-specific inhibitors have shown
that the PDE3 and PDE4 families regulate the beating rate of mouse right atrial preparations [34],
as well as the AP firing rate and Ca2+ currents in isolated mouse SAMs [33]. PDE4 is specific for cAMP,
although it has a relatively low affinity (2–8 μM). In contrast, PDE3 can hydrolyze both cAMP and
cGMP, but has a high affinity for cAMP (10–100 nM). Hydrolysis of cAMP by PDE3 is inhibited by
cGMP due to a ~10-fold slower maximum reaction rate for cGMP [35,36].
In this study we tested the hypothesis that PDEs contribute to regulation of If in SAMs by creating
functional cAMP signaling domains. Indeed, we found that the PDE3 and PDE4 isoforms play distinct
roles in regulation of If, such that PDE4s control access of cAMP to HCN channels at rest, while PDE3s
interact functionally with PKA to constrain signaling between βARs and HCN channels in SAMs.
2. Materials and Methods
2.1. Ethical Approval
This study was carried out in accordance with the US Animal Welfare Act and the National
Research Council’s Guide for the Care and Use of Laboratory Animals and was conducted according to a
protocol that was approved by the University of Colorado-Anschutz Medical Campus Institutional
Animal Care and Use Committee (protocol number 84814(06)1E). Six- to eight-week old male C57BL/6J
mice were obtained from Jackson Laboratories (Bar Harbor, ME, USA; Cat. #000664). Animals were
anesthetized by isofluorane inhalation and euthanized under anesthesia by cervical dislocation.
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2.2. Sinoatrial Myocyte Isolation
Sinoatrial myocytes were isolated as we have previously described [11,19,37–42]. Briefly, hearts
were removed into heparinized (10 U/mL) Tyrodes solution at 35 ◦C (in mM: 140 NaCl, 5.4 KCl,
1.2 KH2PO4, 1.8 MgCl2, 1 CaCl2, 5 HEPES, and 5.55 glucose, with pH adjusted to 7.4 with NaOH).
The sinoatrial node, as defined by the borders of the crista terminalis, the interatrial septum, and
the inferior and superior vena cavae, was excised and digested in an enzyme cocktail consisting of
collagenase type II (Worthington Biochemical, NJ, USA), protease type XIV (Sigma Aldrich, St. Louis,
MO, USA), and elastase (Worthington Biochemical, Lakewood, NJ, USA) for 25–30 min at 35 ◦C in a
modified Tyrodes solution (in mM: 140 NaCl, 5.4 KCl, 1.2 KH2PO4, 5 HEPES, 18.5 glucose, 0.066 CaCl2,
50 taurine, and 1 mg/mL BSA; pH adjusted to 6.9 with NaOH). Tissue was transferred to a modified
KB solution (in mM: 100 potassium glutamate, 10 potassium aspartate, 25 KCl, 10 KH2PO4, 2 MgSO4,
20 taurine, 5 creatine, 0.5 EGTA, 20 glucose, 5 HEPES, and 0.1% BSA; pH adjusted to 7.2 with KOH) at
35 ◦C, and cells were dissociated by trituration with a fire-polished glass pipet for ~10 min. Ca2+ was
gradually reintroduced, and dissociated cells were maintained at room temperature for up to 8 h prior
to electrophysiological recordings.
2.3. Sinoatrial Myocyte Electrophysiology
For electrophysiology, an aliquot of the sinoatrial node myocyte suspension was transferred
to a glass-bottomed recording chamber on the stage of an inverted microscope. Individual SAMs
were identified by spontaneous contractions, characteristic morphology [11,19,37–42], capacitance
<45 pS, and the presence of If. Borosilicate glass pipettes had resistances of 1–3 MΩ when filled with
an intracellular solution containing (in mM): 135 potassium aspartate, 6.6 sodium phosphocreatine,
1 MgCl2, 1 CaCl2, 10 HEPES, 10 EGTA, 4 Mg-ATP; pH adjusted to 7.2 with KOH. SAMs were constantly
perfused (1–2 mL/min) with Tyrodes solution containing 1 mM BaCl2 to block K+ currents. A 1 mM
stock solution of isoproterenol hydrochloride (ISO; Calbiochem/EMD Millipore, Billerica, MA, USA)
in 1 mM ascorbic acid was stored as frozen aliquots, which were thawed on the day of experimentation
and added to the perfusing Tyrodes solution to a final concentration of 1 μM as indicated.
Whole cell voltage clamp recordings were performed >2 min after achieving the whole cell
recording configuration, to allow for intracellular perfusion with the pipette solution. To determine
the voltage dependence of If, families of currents were elicited by 3 s hyperpolarizing voltage steps
ranging from −60 mV up to −170 mV in 10 mV increments from a holding potential of −35 mV,
as previously described [11,19,37–42]. Although steady state activation of If is not attained within 3 s
for more depolarized potentials owing to the very slow kinetics of activation of If, the protocol is an
experimentally-feasible means to approximate and compare the voltage-dependence of activation of
If in the presence of different inhibitors (see [11]). Conductance (G) was calculated from the inward
currents as:
G = I/(Vm − Vr) (1)
where I is the time-dependent component of If, Vm is the applied membrane voltage (corrected for a
+14 mV junction potential error, calculated using JPCalc [43]), and Vr is the reversal potential for If
under these experimental conditions (−30 mV; [10,11]). Conductances were plotted as a function of
voltage, and isochronal midpoint activation voltages (V1/2) were determined for each cell by fitting
with a Boltzmann function:






where Vmin and Vmax are the voltages corresponding to the minimum and maximum currents,
Zd is the charge valence, R is the gas constant, T is temperature, and F is the Faraday constant.
The conductance-voltage relationship was determined for each individual cell included in the study
and all individual GVs reached saturation. Averaged GV relationships are extrapolated to −170 for all
conditions to facilitate comparisons. All experiments were conducted at room temperature in order to
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access the full range of activation midpoints for If (approximately −110 to −130 mV). Three cells were
considered outliers and were excluded from the datasets because their midpoint activation voltages
were greater than two standard deviations from the mean.
The isoproterenol- (ISO-) dependent shift in voltage dependence (ΔV1/2-ISO) was determined
from paired recordings in individual cells before and after wash-on of 1 μM ISO in the absence or
presence of PDE inhibitors. Current elicited by 1 s test pulses to −120 mV every 5–10 s was monitored
during the ISO wash-on. The second GV protocol was begun when the increased current due to the
ISO-dependent shift in V1/2 reached steady state (within 1–2 min). PDE inhibitors were present in
the extracellular solution as follows: total PDE inhibition with 100 μM 3-isobutyl-1-methylxanthine
(IBMX; Tocris Bioscience, Bristol, UK), PDE4 inhibition with 10 μM rolipram (roli; Tocris Bioscience) or
PDE3 inhibition with 10 or 50 μM milrinone (milr; Tocris Bioscience). The PKA inhibitory peptide 6-22
amide (PKI; Tocris Bioscience) was added to the intracellular (patch pipette) solution as noted at a final
concentration of 10 μM. The adenylyl cyclase inhibitor MDL-12,330A (MDL) was applied at a final
concentration of 10 μM in the bath solution.
2.4. Statistical Analysis
Data are presented as mean ± SEM. Statistical significance was evaluated by paired or unpaired
two-tailed t tests or one-way ANOVAs with post-hoc tests as indicated. A p value of <0.05 was
considered to be statistically significant.
3. Results
3.1. Phosphodiesterases Restrict Access of cAMP to HCN Channels at Rest
To evaluate the overall effects of PDEs on If in mouse SAMs, we applied the general,
non-subtype-selective PDE inhibitor, 3-isobutyl-1-methylxanthine (IBMX; 100 μM in the extracellular
solution) to acutely isolated SAMs in whole-cell voltage-clamp experiments. We found that IBMX
shifted the midpoint activation voltage (V1/2) of If by ~15 mV to more depolarized potentials
(Figure 1A,C; Table 1), consistent with an increase in cAMP concentration in the vicinity of the
HCN channels. Thus PDEs limit access of basal cAMP to HCN channels at rest.
Since we previously found that PKA activity is required for the cAMP-dependent activation of
If by βARs in SAMs [11], we next asked whether PKA is also required for the cAMP liberated by
IBMX to activate If. To this end, we evaluated the effects of IBMX on If in SAMs in which PKA was
inhibited by the pseudosubstrate inhibitory peptide, PKI 6-22 amide (PKI; 10 μM in the patch pipette).
We found that IBMX had essentially identical effects in the presence or absence of PKI; the V1/2 of If
did not differ in IBMX versus IBMX plus PKI (Figure 1C). Thus, in contrast to the cAMP generated
upon βAR stimulation, the basal cAMP released upon PDE inhibition can activate HCN channels in
SAMs independent of PKA activity.
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Figure 1. General PDE inhibition activates If in SAMs at rest via a PKA-independent mechanism.
(A,B) Average (±SEM) normalized conductance-voltage plots for If in control (black), IBMX (100 μM in
extracellular solution; red), PKI (10 μM in patch pipette; grey), or IBMX plus PKI (dark red). Numbers in
parentheses in the legends indicate the number of cells in each dataset. Insets show representative If
current families. Red traces show currents elicited by voltage steps to −120 mV to illustrate shifts in
voltage dependence. Scale bars, 200 pA, 500 ms; and (C) average (±SEM) V1/2 for If for the indicated
conditions. Asterisks indicate p < 0.05 versus control; one-way ANOVA with Holm-Sidak post-test.
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Table 1. Midpoint activation voltages for If in mouse sinoatrial myocytes. V1/2 values for If were
determined in the absence or presence of PDE inhibitors (IBMX 100 μM, rolipram 10 μM, milrinone
10 μM, or 50 μM as indicated) in the extracellular solution with and without the PKA inhibitory peptide,
PKI (10 μM) in the pipette solution. For each cell, V1/2 values were determined before or after wash-on
of 1 μM isoproterenol in the extracellular solution; ΔV1/2(ISO) is the average ISO-induced shift in V1/2.
Data for cAMP (1 mM in the patch pipette) and MDL-12,330A (10 μM in the extracellular solution) are









p Value Control vs. ISO
(Paired t-Test)
CONTROL −129.7 ± 1.9 −119.6 ± 1.5 10.1 ± 1.2 17 0.000000237
+PKI −127.7 ± 3.8 −123.6 ± 3.5 4.1 ± 0.7 9 0.00188
IBMX −114.9 ± 2.2 −110.1 ± 2.8 4.8 ± 1.9 10 0.0328
+PKI −117.7 ± 2.7 −110.6 ± 2.7 7.1 ± 1.1 10 0.000128
ROLIPRAM −117.4 ± 1.6 −113.4 ± 2.2 4.0 ± 1.1 9 0.00712
+PKI −118.9 ± 3.0 −118.8 ± 2.8 0.1 ± 1.9 7 0.967
MILRINONE (10 μM) −124.0 ± 4.3 −121.1 ± 4.7 2.9 ± 1.7 8 0.123
+PKI −119.3 ± 4.7 −112.5 ± 4.8 6.8 ± 2.4 10 0.0206
MILRINONE (50 μM) −124.1 ± 1.9 −122.2 ± 2.0 1.8 ± 1.0 10 0.104
+PKI −116.8 ± 1.3 −110.9 ± 1.8 5.9 ± 1.2 11 0.000648
MDL-12,330A −131.1 ± 1.9 −132.0 ± 2.2 −0.9 ± 1.1 7 0.469
1 mM cAMP −112.0 ± 1.6 - - 10 -
3 mM cAMP −114.1 ± 1.9 - - 7 -
3.2. Different Effects of PDE4 and PDE3 on If under Basal Conditions
PDE4 activity is thought to regulate sinoatrial node pacemaker activity in a number of species,
based on experiments using rolipram, a PDE4 family inhibitor [33,34,44,45]. To determine the role of
PDE4 in basal regulation of If in mouse SAMs, we evaluated the effects of rolipram (10 μM in the bath
solution) on the V1/2 of If. We found that rolipram caused a significant depolarizing shift in V1/2 which
was indistinguishable from the shift produced by IBMX (Figure 2A,C; Table 1). As in the case of IBMX,
the rolipram-liberated cAMP did not require PKA activity in order to activate HCN channels, since the
V1/2 values did not differ in rolipram alone compared to rolipram plus PKI (Figure 2C; Table 1).
The PDE3 family is also thought to affect sinoatrial node function; inhibition of PDE3 increases
basal pacemaker activity in isolated SAMs and atrial preparations from mice [33,34]. In contrast to
IBMX or rolipram, we found that the PDE3 family inhibitor, milrinone (10 or 50 μM) produced only a
modest, statistically insignificant, depolarizing shift in the V1/2 of If in SAMs when applied by itself
(Figure 3A,C; Table 1). However, when milrinone was applied in the presence of PKI, it produced a
significant depolarizing shift in V1/2 of If, which was similar in magnitude to the shifts produced by
IBMX or rolipram (Figure 3; Table 1).
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Figure 2. PDE4 inhibition activates If in SAMs at rest via a PKA-independent mechanism. (A,B) Average
(±SEM) normalized conductance-voltage plots for If in control (black), rolipram (10 μM in the
extracellular solution; green), PKI (10 μM in the patch pipette; grey), or PKI plus rolipram (dark green).
Numbers in parentheses in the legends indicate the number of cells in each dataset. Insets show
representative If current families. Red traces elicited by voltage steps to −120 mV illustrate shifts in the
voltage dependence. Scale bars, 100 pA, 500 ms. for control, 500 pA, 500 ms for PKI; and (C) shows the
average (±SEM) V1/2 for If for indicated conditions. Asterisks indicate p < 0.05 versus control; one-way
ANOVA with Holm-Sidak post-test.
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Figure 3. Effects of PDE3 inhibition on If at rest. (A,B) Average (±SEM) normalized conductance-
voltage plots for If in control (black), milrinone (50 μM in the extracellular solution; blue), PKI (10 μM
in the patch pipette; grey), or milrinone plus PKI (dark blue). Numbers in parentheses in the legends
indicate the number of cells in each dataset. Insets show representative If current families. Red traces
elicited by voltage steps to −120 mV illustrate shifts in the voltage dependence. Scale bars, 100 pA,
500 ms for control, 500 pA, 500 ms for PKI; and (C) shows the average (±SEM) V1/2 for If for indicated
conditions. Asterisk indicates p < 0.05 versus control; one-way ANOVA with Holm-Sidak post-test.
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3.3. PDEs Establish the Requirement for PKA Activity in Signaling between βARs and HCN Channels
in SAMs
To evaluate the role of PDEs in establishing the requirement for PKA in βAR-to-HCN channel
signaling in SAMs, we assayed the shift in V1/2 in individual cells in response to the wash-on of the
βAR agonist, isoproterenol (ΔV1/2-ISO). ΔV1/2-ISO shifts were determined in the absence or presence
of PDE inhibitors and PKI. In control Tyrode’s solution, the wash-on of ISO produced a ~10 mV
depolarizing shift in the V1/2 of If (Figure 4A). In the presence of PKI in the patch pipette (but the
absence of any PDE inhibitors), ISO still produced a significant shift in V1/2 in paired recordings
from individual cells, but the magnitude of this shift was significantly reduced compared to control
(Figure 4A; Table 1). In cells treated with IBMX, ISO produced a significant ~5 mV depolarizing shift
in V1/2, in addition to the ~15 mV shift already caused by IBMX (Figure 4B; Table 1). We attribute the
reduced ΔV1/2-ISO in IBMX versus control (Figure 4B versus Figure 4A) to a ceiling effect, because
the absolute value of the V1/2 in IBMX plus ISO (approximately −110 mV) did not differ from that
produced by a saturating concentration of cAMP introduced via the patch pipette (approximately
−112 mV; Table 1). Whereas PKI significantly decreased the ΔV1/2-ISO under control conditions
(Figure 4A), it did not reduce ΔV1/2-ISO when PDEs were inhibited by IBMX (Figure 4B). Thus,
PDEs contribute to the formation of the PKA-dependent signaling pathway between βARs and HCN
channels in SAMs, apparently by restricting the ability of βAR-stimulated cAMP to access the channels.
The contributions of the PDE4 and PDE3 families to the PKA-dependent βAR-to-HCN channel
signaling pathway were evaluated using rolipram or milrinone. In cells treated with rolipram, ISO
produced a significant depolarizing shift in the V1/2 of If (Figure 4C; Table 1). As in the case of IBMX,
this ISO-dependent shift was reduced in magnitude compared to the shift in control conditions, and
again, the reduction is attributed to a ceiling effect because the V1/2 for rolipram plus ISO did not differ
from that of saturating cAMP (Table 1). However, in contrast to the situation of general PDE block
with IBMX, block of PDE4s with rolipram did not relieve the requirement for PKA in βAR-to-HCN
channel signaling in SAMs. In fact, PKI completely abolished the ability of ISO to shift the V1/2 in the
presence of rolipram (p = 0.967 versus a hypothetical mean shift of 0; Figure 4C; Table 1). Thus, PDE4
does not appear to contribute to the PKA dependent βAR-to-HCN signaling pathway.
While the ability of ISO to shift the V1/2 was nearly eliminated by the PDE3 inhibitor milrinone
when it was applied alone (p = 0.104 versus a hypothetical mean shift of 0; Figure 4D; Table 1),
simultaneous inhibition of both PDE3 and PKA, with milrinone plus PKI, restored the ability of ISO
to shift in V1/2 of If (Figure 4D; Table 1) consistent with a role for PDE3 in the formation of the PKA
dependent βAR-to-HCN signaling pathway and, again, indicative of an interaction between PKA and
PDE3 in the regulation of If in SAMs.
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Figure 4. Effects of PDE inhibition on the ability of ISO to shift the voltage-dependence of If. The shift
in V1/2 of If in response to ISO (ΔV1/2-ISO) was determined for individual cells by measuring V1/2
values before and after wash-on of ISO in (A) control Tyrode’s extracellular solution (black) or Tyrode’s
solution with PKI (10 μM) in the patch pipette (grey); (B) IBMX (100 μM in the extracellular solution;
red) or IBMX with PKI in the pipette (dark red); (C) rolipram (10 μM in the extracellular solution; light
green) or rolipram with PKI in the pipette (dark green); and (D) milrinone (50 μM; blue) or milrinone
with PKI in the pipette (dark blue). Dashed lines indicate the ΔV1/2-ISO shift in control conditions
for comparison. Asterisks indicate p < 0.05 compared to the corresponding condition without PKI;
t-tests. Double daggers indicate a significant shift in response to ISO (p < 0.05 versus a hypothetical
shift of 0 mV; one-sample t-tests). Insets represent the hyperpolarization-activated currents elicited by
single voltage steps to near the midpoint activation voltage for each condition from individual cells
before (black) and after (red) wash-on of ISO in the absence (left) or presence (right) of PKI. Scale bars:
Tyrode’s, 200 pA; PKI, 200 pA; IBMX, 50 pA; IMBX + PKI, 100 pA; rolipram, 100 pA; rolipram + PKI,
200 pA; milrinone, 100 pA; milrinone + PKI, 200 pA. All time scale bars, 500 ms.
4. Discussion
In this study we examined the role of phosphodiesterases in cAMP-dependent regulation of If
in acutely-isolated sinoatrial node myocytes from mice. We found that the PDE3 and PDE4 isoforms
contribute to formation of at least two functional cAMP signaling domains that control If in SAMs.
The PDE4 family restricts access of cAMP to HCN channels under basal conditions, but does not
appear to play a role in the formation of the PKA-dependent βAR-to-HCN channel signaling pathway.
Meanwhile, the PDE3 family interacts functionally with PKA to regulate If at rest and contributes to
the formation of the PKA-dependent pathway between βARs and HCN channels in SAMs.
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Our interpretation of the results assumes that the pharmacological agents we used are relatively
selective and that the degree of block achieved is fairly complete. While we cannot exclude the
possibility of some off-target block, our results using PKI, IBMX, rolipram, and milrinone cannot be
explained by isoform cross-reactivity amongst the blockers. For example, although high concentrations
of the PDE3 blocker milrinone (>10 μM) can also inhibit PDE4, lower concentrations are thought to be
specific for PDE3 [33,35,46]. We tested the effects of 10 μM milrinone on If, and observed a minimal
response (Table 1). To ensure that we had reached a maximal effective concentration in mouse SAMs,
and to compare our results to other studies [45], we also evaluated the effects of 50 μM milrinone.
We found no difference in the response of If to 10 or 50 μM milrinone (Table 1 [11]). Moreover, the
effects of milrinone were qualitatively different from the effects of either the general PDE inhibitor,
IBMX, or the PDE4 inhibitor, rolipram. Thus, we conclude that (1) PDE3, alone, has minimal effects on
If (although it interacts functionally with PKA, see below), and (2) the effects of milrinone on If in our
experiments did not reflect appreciable block of PDE4.
A key finding of our study is that the shifts in the basal V1/2 of If produced by IBMX or rolipram
were similar in the presence and absence of the PKA inhibitory peptide, PKI. The shifts produced by
PDE inhibition alone (without PKA inhibition) could reflect combined effects of direct cAMP binding
and PKA phosphorylation, whereas those in the presence of PKI presumably result from a direct effect
of cAMP alone. We interpret the similar effects in the presence and absence of PKI as an indication that
the cAMP liberated upon total PDE inhibition or PDE4 inhibition activates If without a requirement
for PKA activity. However, this interpretation assumes that PKI blocks a substantial fraction of the
PKA activity near HCN channels in SAMs. We feel that this assumption is justified based on our
finding that PKI significantly reduced the shift in V1/2 in response to ISO under the same conditions
(Figure 4A; Table 1; [11]). A more direct assessment of PKA activity (e.g., PKA assays in sinoatrial
node homogenates) would be difficult to interpret because data from tissue extracts is a poor proxy for
PKA activity within temporally- and spatially-restricted cAMP signaling domains in SAMs.
The results of the present study extend our previous observations that, although PKA activity is
required for βAR signaling to HCN channels in SAMs [11], it is still possible for cAMP to activate If in
SAMs even in the absence of PKA activity [19]. Taken together, the previous and new data suggest
a working model in which members of the PDE4 family form a functional “barrier” that isolates
HCN channels from the high basal cAMP in SAMs. Disruption of this barrier with either rolipram
or IBMX permits cAMP to access HCN channels, where it activates them via a PKA-independent
mechanism (presumably via direct binding to the cyclic nucleotide binding domain of the channels).
In our model, PDE3 family members are proposed to form a distinct functional barrier that prevents the
cAMP generated upon βAR stimulation from reaching HCN channels directly, thereby constraining
βAR signaling to HCN channels to a PKA-dependent pathway. Additional work will be required to
determine whether these barriers represent distinct cAMP compartments in SAMs and whether the
PKA-dependent activation of If by βAR stimulation results from phosphorylation of HCN channels by
PKA, or if it occurs as a result of an indirect mechanism, such as control of cAMP production—e.g.,
by Ca2+-activated adenylyl cyclases [47]—with the resulting cAMP then potentiating If by binding
directly to HCN channels.
Our observations of differing effects when PDE3 and PKA were inhibited together, instead of
individually, indicates a complex functional interaction between PDE3 and PKA in the regulation
of If in SAMs. The data preclude a simple model in which PDE3 simply acts to restrict the cAMP
source that controls PKA regulation of If. Instead, there must be co-regulation between PDE3 and PKA.
Possible nodes of cross-talk between PDE3 and PKA include the activation of PDE3 by PKA and the
inhibition of PDE3 hydrolysis of cAMP by cGMP [35,36]. In the first scenario, inhibition of PKA with
PKI would also inhibit PDE3, thereby increasing cAMP, and allowing it to act by binding directly to
HCN channels. Consistent with this notion, we found that milrinone, alone, had no significant effect
on the V1/2 of If, but produced a significant depolarizing shift when it was applied in the presence of
PKI (Figure 3, Table 1). Meanwhile, a role for cGMP is suggested by the observation of high levels of
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soluble guanylyl cyclase and cGMP in the sinoatrial node [48]. Indeed, cGMP-mediated inhibition
of PDE3 has been suggested to increase cAMP concentration and accelerate AP firing rate in mouse
sinoatrial nodes [49]. cGMP-mediated inhibition of PDE3 has also been shown to modulate cAMP
levels in subcellular compartments involved in βAR signaling in ventricular myocytes [50].
Our data complement results of previous studies in which PDEs have been shown to regulate
pacemaker activity of the sinoatrial node. Our observations of depolarizing shifts in the voltage
dependence of If in response to PDE inhibition are in agreement with the notions that the resting cAMP
concentration is relatively high in SAMs and that it is limited by constitutive PDE activity [5,33,45,47].
The role of PDE4 in limiting the basal cAMP concentration in the vicinity of HCN channels in our
study is in agreement with the observations of Hua et al. [33], who found that inhibition of PDE4 with
rolipram (10 μM) increased AP firing rate and ICa,L in isolated mouse SAMs to a greater extent than
did PDE3 inhibition with milrinone (10 μM). Our data suggest that If works along with ICa,L to mediate
the increase in AP firing rate in response to PDE4 inhibition. Galindo-Tovar and Kaumann [34] used
rolipram (1 μM) along with the PDE3 inhibitor cilostamide (300 nM) to show that both PDE3 and
PDE4 contribute to control of basal firing rate in isolated mouse right atria via actions on a cAMP
compartment that is distinct from that mediated by βARs. These data are in good agreement with
our observations of multiple functional cAMP signaling domains formed by PDEs in SAMs and of
PDE4-dependent regulation of If under basal conditions. However, they also suggest that additional
PDE3-dependent mechanisms may also contribute to pacemaker activity in the mouse sinoatrial node.
Interestingly, βAR-induced tachycardia across many species is resistant to PDE inhibition, suggesting
that cAMP signaling between βARs and relevant effectors for the fight-or-flight increase in heart
rate is not controlled by PDEs [51,52]. Hence, βAR regulation of If appears to serve primarily as a
frequency adaptation mechanism rather than a primary driver of the sympathetic heart rate response.
Vinogradova et al. [45] used milrinone (50 μM) to suggest that PDE3 may be the dominant isoform
controlling basal firing rate in rabbit SAMs. However, we did not observe a difference between 10 μM
and 50 μM milrinone in mouse SAMs, and saw effects of milrinone only in combination with PKA
inhibition. Taken together, these data suggest that there may be species-dependent differences in the
roles of different PDE isoforms in regulation of sinoatrial node activity.
5. Conclusions
In summary, our results indicate that the PDE3 and PDE4 isoforms create functionally-distinct
cAMP signaling domains in mouse SAMs that regulate If at rest and in response to βAR stimulation.
Specifically, the PDE4 family restricts access of cAMP to HCN4 channels under basal conditions,
and the PDE3 family contributes to the formation of a preferred PKA-dependent pathway between
βARs and HCN channels. Given that If is a critical factor in sinoatrial node pacemaker activity, it is
likely that these mechanisms contribute to the regulation of heart rate.
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Abstract: A-kinase anchoring proteins (AKAPs) and cyclic nucleotide phosphodiesterases (PDEs)
are essential enzymes in the cyclic adenosine 3′-5′ monophosphate (cAMP) signaling cascade. They
establish local cAMP pools by controlling the intensity, duration and compartmentalization of cyclic
nucleotide-dependent signaling. Various members of the AKAP and PDE families are expressed in
the cardiovascular system and direct important processes maintaining homeostatic functioning of
the heart and vasculature, e.g., the endothelial barrier function and excitation-contraction coupling.
Dysregulation of AKAP and PDE function is associated with pathophysiological conditions in
the cardiovascular system including heart failure, hypertension and atherosclerosis. A number
of diseases, including autosomal dominant hypertension with brachydactyly (HTNB) and type I
long-QT syndrome (LQT1), result from mutations in genes encoding for distinct members of the
two classes of enzymes. This review provides an overview over the AKAPs and PDEs relevant for
cAMP compartmentalization in the heart and vasculature and discusses their pathophysiological
role as well as highlights the potential benefits of targeting these proteins and their protein-protein
interactions for the treatment of cardiovascular diseases.
Keywords: cAMP; compartmentalization; A-kinase anchoring proteins (AKAP); cyclic nucleotide
phosphodiesterases (PDE); PDE inhibitors
1. Introduction
Cardiovascular diseases (CVD) represent the leading cause of death worldwide and hypertension
is the main risk factor for such conditions [1]. Treatments targeting the causes of cardiovascular
diseases such as hypertension or heart failure are rare [2].
The second messenger cyclic adenosine 3′-5′ monophosphate (cAMP) is ubiquitous and functions
as a signal transducer of many extracellular cues [3]. It regulates a variety of biological processes
that are essential for, among others, proper cardiac function and it is involved in disease [4,5]. cAMP
exerts its effects via activation of downstream effector proteins, i.e., cAMP-dependent protein kinase A
(PKA), exchange proteins activated by cAMP (Epac) and cyclic nucleotide-gated ion channels (CNG),
hyperpolarization-activated cyclic nucleotide-gated channels (HCN) and the recently identified Popeye
domain containing (POPDC) proteins [6–8].
The plethora of extracellular signals, the limited number of intracellular cAMP effectors and
the requirement of a specific biological response to each of the external signals imply a tight control
of the intracellular signaling. This is achieved through signaling in defined cellular compartments.
Local cAMP pools are established by the interplay of essentially four processes within the cell, namely
cAMP synthesis, its diffusion, formation of multi-protein signaling complexes and cAMP degradation.
In the heart, stimulation of β-adrenoceptors (β-ARs) triggers the activation the α-subunits of the
stimulatory G proteins (Gs), which in turn stimulate adenylyl cyclases (ACs) to convert ATP to
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cAMP [9]. The formation of multi-protein signaling complexes in the cAMP signaling pathway is
orchestrated by the family of A-kinase anchoring proteins (AKAPs), which act as scaffolds and engage
in direct protein-protein interactions, including with PKA, and target them to defined subcellular
compartments [10–15]. AKAPs play essential roles both in the heart and vascular physiology by
coordinating complexes involved in the regulation of various processes including endothelial-barrier
function [16,17] cardiac contraction and relaxation [18–21] and action potential duration [22,23]. AKAPs
apparently play a role in several pathophysiological conditions in the cardiovascular system, e.g.,
in the heart their dysregulation is associated with heart failure [24,25].
Termination of cAMP signaling is predominantly achieved by hydrolysis of the phosphodiester
bond within the second messenger, a reaction catalyzed by cyclic nucleotide phosphodiesterases
(PDEs) [26]. Various PDE families regulate different aspects of cardiac and vascular muscle
functions [27], such as the endothelial barrier function [28,29], the Ca2+ handling and thus
contractility [30] and the basal pacemaking activity [31]. PDEs are also involved in the pathological
cardiac remodeling and dysfunction [4,32–35].
The aim of this review is to provide an overview over the AKAPs and PDEs that are relevant
in the compartmentalization of cAMP signaling in the cardiovascular system, to discuss their role
in physiology and pathophysiology and the potential of these proteins and their protein-protein
interactions as pharmacological targets in cardiovascular diseases.
2. A-kinase Anchoring Proteins (AKAPs)
AKAPs are a family of over 40 different scaffolding proteins and are key players in the
spatio-temporal control of cAMP-dependent signaling by targeting PKA and additional signaling
proteins including ACs, PDEs, further protein kinases and phosphatases to specific subcellular
compartments [11,36–38]. PKA is the major downstream effector of cAMP. It is a serine/threonine
kinase with broad specificity that controls many cellular processes, e.g., metabolism, cell growth,
cell division and cardiac myocyte contraction [39]. It is a heterotetramer that consists of two catalytic
subunits (Cα, Cβ or Cγ) kept in an inactive state by two regulatory RI (RIα or RIβ) or RII (RIIα or
RIIβ) subunits that are organized as homodimers in the holoenzyme [40]. Upon cAMP binding to
the R subunits, the C subunits are released and thus activated and subsequently phosphorylate local
substrates [39]. This view was recently confirmed by quantitative mass spectrometric analyses [41].
However, PKA holoenzyme can also be active, as indicated by early biochemical experiments [42,43].
This notion was supported by recent fluorescence resonance energy transfer (FRET) imaging-based
experiments, which suggested that physiological cAMP levels promote only minimal dissociation of
the C subunits from the holoenzyme, thereby limiting the range of PKA action to the substrates in
the immediate proximity [44]. Thus, it appears that both PKA holoenzyme and/or the dissociated C
subunits can be active.
The structural feature that all AKAPs share is their ability to bind PKA via their A-kinase binding
domains (AKBs), a structurally conserved amphipathic helix of 14–18 amino acids that docks into the
hydrophobic groove formed by the N-terminal dimerization/docking (D/D) domains upon R subunits’
dimerization (Figure 1) [45–48]. Despite the fact that most AKAPs bind to PKA-RII subunits [37,49],
there are the so-called dual specific AKAPs [50] that can bind both RI and RII subunits as well as
AKAPs that specifically bind RI subunits (e.g., sphingosine kinase interacting protein (SKIP) and
small membrane (sm) AKAP) [51–53]. Recently, hydrophilic anchor points have been identified within
and outside the amphipathic helix forming the AKB that are involved in determining the affinity of
the binding between an AKAP and the D/D domain. These observations suggest that targeting the
amino acids that act as anchor points could lower the binding affinity or even prevent the interaction,
making them candidates for pharmacological targeting. Moreover, targeting the anchor points makes
the development of selective inhibitors of specific AKAP-PKA interactions feasible [48]. Selective
inhibitory agents would be valuable tools for the investigation of cellular functions of individual
AKAP-PKA interactions and could be starting points for drug development efforts.
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Figure 1. Schematic representation of A-kinase anchoring proteins (AKAP)-protein kinase A (PKA)
interactions displayed at two different angles. The amphipathic AKB helix of AKAPs docks into the
hydrophobic groove formed by the dimers of the N-terminal D/D domains of regulatory subunits of
PKA. AKB A-kinase-binding domain; D/D dimerization and docking domain.
2.1. AKAP Subcellular Localization
Targeting of AKAPs to specific subcellular compartments is essential for a coordinated
cAMP-dependent signaling response, including accurate PKA-catalyzed substrate phosphorylation [54].
AKAPs can be directed to various cellular compartments, including the plasma membrane (PM,
e.g., AKAP18α, AKAP18β, AKAP79 [55–57]), the sarcoplasmic reticulum (SR, e.g., AKAP18δ [20]),
the cytosol (e.g., SKIP, GSKIP [51,58–61]), the cytoskeleton (e.g., gravin, ezrin [62]), the mitochondria
(e.g., D-AKAP1 [63]) and the nucleus (e.g., pericentrin and AKAP350 [64,65]).
2.2. AKAPs in the Cardiovascular System
Several AKAPs are expressed in the cardiovascular system (Table 1). They regulate a variety
of processes and are key proteins in maintaining the homeostatic functioning of the heart and
vasculature [66]. For instance, gravin and AKAP220 are involved in maintaining the vascular
integrity [16,17]. Homeostasis of the vascular tone is achieved through tight control of the balance
between contraction and relaxation of vascular smooth muscle cells (VSMC), processes in which
AKAP79 is involved [67,68]. Ca2+ handling and thus cardiac myocyte contractility is regulated by
several macromolecular protein complexes whose platforms are AKAPs, e.g., AKAP18α, γ and δ,
mAKAPβ [19–21,69]. The AKAP Yotiao is the key player in cardiac myocyte repolarization that follows
contraction [22]. Several AKAPs are involved in stress response-induced cardiac myocyte hypertrophy,
including AKAP-Lbc and mAKAPβ [70,71]. AKAP79 and gravin are important for the recycling of
β1-ARs and β2-ARs, respectively [72,73].
Table 1. Overview of AKAPs expressed in the heart and vasculature and of the cardiovascular processes
that they regulate.
Common Name Gene Name Alternative Name Regulated Cardiovascular Process
D-AKAP1 AKAP1 AKAP121/AKAP149/AKAP84 Cardiac stress response
D-AKAP2 AKAP10 - Cardiac repolarization




AKAP7 - Excitation-contraction coupling
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AKAP220 AKAP11 - Endothelial barrier function
AKAP-Lbc AKAP13 Brx-1/Proto-Lbc/ Ht31 Cardiac stress response
mAKAPβ AKAP6 AKAP100 Excitation-contraction coupling;Cardiac stress response
AKAP Yotiao AKAP9 GC-NAP Cardiac repolarization
Gravin AKAP12 AKAP250 Endothelial barrier function;
β-AR desensitization/resensitization cycle
SKIP SPHKAP - Cardiac stress response
2.2.1. AKAPs Regulating the Endothelial Barrier Function
The vascular endothelium lining the intima of blood vessels consists of a layer of endothelial cells
tightly adherent to each other through cell-cell junctions. A healthy endothelium plays an essential
role in the proper functioning of the vascular system. It regulates macromolecular permeability
and anti-inflammatory, anti-thrombotic and anti-hypertrophic responses. Inflammatory conditions
trigger pathological changes in the vascular system that lead to endothelial dysfunction, a state in
which pathologically activated endothelial cells lose their barrier properties and initiate expression
of pro-inflammatory adhesion molecules on their surface [74]. This results in increased vascular
permeability allowing the infiltration of various molecules such as lipoproteins into the sub-endothelial
space, and of circulating immune cells (e.g., monocytes). Ultimately, this leads to severe pathological
conditions including atherosclerosis, allergy and sepsis [75,76].
AKAP-mediated PKA compartmentalization is essential for the maintenance of proper endothelial
barrier function [16,17,77]. The vascular endothelium integrity is mainly dependent on tight junctions
(TJs), important in sealing space between adjacent cells, and on adherens junctions, which assure
direct contacts with the actin cytoskeleton of neighboring cells, thus providing mechanical strength.
AKAP220 associates with PKA, β-catenin and the endothelial adherens junctions protein VE-cadherin,
tethering PKA in close proximity to the cell-cell junctions [16]. Gravin (also known as AKAP12
or AKAP250) promotes vascular integrity by regulating the actin cytoskeleton via p21-activated
kinase family proteins 2 (PAK2), an actin cytoskeletal regulator and afadin (AF6), a linker of the actin
cytoskeleton with intercellular adhesion molecules [17]. Rac1 is a member of the Rho family of small
GTPases, which upon activation strengthens the adherens junctions and the cortical actin skeleton,
thereby preserving the endothelial barrier [78]. Simultaneous depletion of gravin and AKAP220
inhibited cAMP-mediated Rac1 activation, underlining the importance of these AKAPs in preventing
endothelial dysfunction [16].
One other member of the AKAP family is involved in maintaining vascular integrity, the long
isoform of AKAP9. Following Epac1 activation, AKAP9 contributes to microtubule growth regulation
and is essential for preserving the endothelial barrier [79].
2.2.2. AKAPs Regulating the Vascular Tone
Homeostasis of the vascular tone is maintained by a tight balance between dilation and
constriction of blood vessel endothelium; the main regulator is the renin-angiotensin-aldosterone
system (RAAS). The main effector molecule of this system is angiotensin II (AngII), which exerts most
of its effects via angiotensin type I receptors (AT1R). For instance, arterial smooth muscle contraction is
induced by AngII-dependent stimulation of AT1R, localized at the sarcolemma, and subsequent
activation of phospholipase C (PLC), which catalyzes the hydrolysis of phosphatidylinositol
4,5-bisphosphate (PIP2) to diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). DAG activates
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protein kinase C (PKC), which in turn phosphorylates L-type Ca2+ (CaV1.2) channels, thereby
increasing their open probability and increasing Ca2+ entry into the cytosol [75].
In arterial smooth muscle cells, the activity of a specific subpopulation of CaV1.2 channels is
regulated by AKAP79 (AKAP5/AKAP75/AKAP150)-dependent targeting of PKCα to the sarcolemma,
which facilitates phosphorylation of the channels and increases their open probablility [80]. By affecting
the opening probability of specific CaV1.2 channels, the AKAP79 complex regulates the so-called
“CaV1.2 sparklets”, which refers to local elevations of intracellular Ca2+ pools that directly induce
contraction of the VSMCs. The sparklets increase the vascular tone [67]. In addition, AKAP79
facilitates and most probably stabilizes the coupling of small clusters of adjacent CaV1.2 channels,
which can then open synchronously and generate large CaV1.2 sparklets, thus increasing the contractile
force [81,82]. Prolonged CaV1.2 channel activity and thus persistent CaV1.2 sparklets could lead to
vascular dysfunction and eventually contribute to AngII-induced hypertension [80].
Transient receptor potential vanilloid 4 (TRPV4) channels are Ca2+ permeant channels that
unlike the CaV1.2 channels, promote relaxation upon activation. Both CaV1.2- and TRPV4-mediated
Ca2+ influxes activate adjacent ryanodine receptors (RyR), leading to release of Ca2+ from the SR
into the cytosol in the form of Ca2+ sparks. While the CaV1.2-mediated Ca2+ influx increases
contraction, the local TRPV4-generated Ca2+ sparks activate the large-conductance, Ca2+-activated
K+ (BK) channels, which promote membrane hyperpolarization and closure of the CaV1.2 channels,
ultimately resulting in relaxation [83,84]. In the arterial smooth muscle cells, AngII increased TRPV4
activity via PKC, which is tethered to the sarcolemma in close proximity of the channel by AKAP79,
thus opposing the CaV1.2 channel-induced vasoconstriction [68].
In conclusion, AKAP79 plays an essential role in the control of arterial vascular tone by regulating
two opposing processes, contraction and relaxation of arterial myocytes.
2.2.3. AKAPs Controlling Excitation-Contraction Coupling
The cycling of Ca2+ between the cytosol and the SR is at the basis of cardiac contraction and
relaxation. Key players in these processes are L-type Ca2+ CaV1.2 channels, RyR2, SR Ca2+ ATPase 2
(SERCA2) and the Na+/Ca2+ exchanger. More specifically, upon sarcolemma depolarization, CaV1.2
channels located at the T tubules open allowing Ca2+ influx into the cardiac myocyte. This causes
Ca2+-induced Ca2+ release from the SR into the cytosol through RyR2 located at the SR. The Ca2+, upon
interaction with troponin T located on the thin myofibers, promotes contraction. Relaxation occurs via
SERCA2-mediated Ca2+ re-uptake into the SR and through Ca2+ transport out of the cell by Na+/Ca2+
exchangers [85]. SERCA2 is activated upon the phosphorylation and subsequent dissociation of
phospholamban (PLN), a SR phosphoprotein [20,86,87].
β-ARs introduce a further layer into the regulation of cardiac myocyte contractility.
Their stimulation induces PKA-dependent phosphorylation of several proteins involved in Ca2+
handling, e.g., the CaV1.2 channels, RyR2 and PLN. These phosphorylations are facilitated by
distinct AKAPs.
AKAP18α is a membrane-associated scaffolding protein and is the smallest AKAP7 gene
transcript, comprising 81 amino acids. AKAP18α promotes cardiac contractility by mediating the
PKA-dependent phosphorylation of CaV1.2 channels at Serine 1928 (Ser1928) on its α subunit and at
multiple sites on its β subunit, which enhances the open probability of the channel and increases the
Ca2+ current [69,88]. The activity of a subset of CaV1.2 channels associated with caveolin-3 (Cav3) is
regulated by PKA phosphorylation of the specific channel subpopulation mediated by an AKAP79
(AKAP5/AKAP75/AKAP150)-based macromolecular complex consisting of β-AR, PKA, AC5/6 and
protein phosphatase calcineurin (PP2B) [89]. The muscle selective AKAP, mAKAPβ (a short version
of mAKAP) associates with RyR2 at the SR and thereby facilitates the PKA phosphorylation of the
channel, leading to enhanced opening of the channel and subsequent enhanced Ca2+ release from
the SR into the cytosol [19]. In addition, mAKAPβ interacts with the Na+/Ca2+ exchanger 1 at the
sarcolemma and promotes the PKA-dependent activation of the exchanger, resulting in increased Ca2+
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efflux [90,91]. AKAP18δ (rat heart) and AKAP18γ (human heart) facilitate the PKA phosphorylation
of PLN and promote its dissociation from SERCA2 and hence activation of the ATPase, thus enhancing
the re-uptake of Ca2+ into the SR [20,21,92].
2.2.4. AKAPs Regulating Cardiac Repolarization
The cardiac repolarization phase is initiated by the slow heart potassium current (IKs) moving
outwards through the IKs potassium channel, a macromolecular complex consisting of a pore-forming
α subunit (KCNQ1) and a regulatory β subunit (KCNE1) along other intracellular proteins [93].
The AKAP Yotiao, the smallest transcript of the AKAP9 gene, is essential for cardiac repolarization
since it mediates the PKA-dependent phosphorylation of KCNQ1 and therefore regulates the activity
of the IKs potassium channel [22]. Mutations in the KCNQ1 subunit or Yotiao increase the duration of
the action potential and lead to type I long-QT syndrome (LQT1), a channelopathy that can elicit fatal
arrhythmia [94]. Another AKAP that contributes to the regulation of cardiac action potentials is the dual
specific D-AKAP2 (AKAP10). A single-nucleotide polymorphism (SNP) in its PKA binding domain
causes a decrease in the PR interval in the electrocardiogram, which in turn can cause arrhythmias and
sudden cardiac death [54,95–97].
2.2.5. AKAPs Involved in Cardiac Stress Response
Cardiac hypertrophy is a stress-induced adaptation to maintain normal heart function [23,25].
At the cellular level, it is characterized by the upregulation of specific genes that promote the
non-mitotic growth of cardiac myocytes [98]. AKAP-Lbc encodes in addition to its AKAP function
for a guanine nucleotide exchange factor (GEF) that directly binds and activates the GTP-binding
protein RhoA [99–102]. The interaction is involved in both cardiac development [103] and pathological
cardiac myocyte hypertrophy [70]. α1-AR stimulation enhances the RhoGEF activity of AKAP-Lbc,
which in turn activates RhoA, contributing to a pathological increase in the hypertrophic response [70].
PKA-mediated phosphorylation at Ser1565 of AKAP-Lbc leads to the recruitment of 14-3-3 proteins,
which inhibit the Rho-GEF activity of the anchoring protein [104]. Also, an AKAP-Lbc-dependent
signalosome mediates the activation and cytosolic release of activated protein kinase D (PKD),
which has been shown to promote cardiac hypertrophy by facilitating the nuclear export of histone
deacetylase 5 (HDAC5) [105,106].
Another AKAP that plays a central role in modulating stress signal-induced hypertrophic
pathways is mAKAPβ. It coordinates a variety of cAMP-responsive enzymes. This anchoring protein is
targeted to the nuclear envelope of cardiac myocytes via an interaction with nesprin-1α [107]. At the SR
it can integrate and transduce a variety of hypertrophic signals [71]. For instance, mAKAPβ-mediated
PKA phosphorylation and subsequent activation of RyR2 located at the nuclear envelope promotes
the activation and nuclear translocation of the pro-hypertrophic transcription factor nuclear factor
of activated T cells (NFAT) [108]. In addition, a mAKAPβ-based signalosome consisting of PKA,
PDE4D3, Epac1, ERK5 and PP2A promotes ERK5-induced cardiomyocyte hypertrophy [71,109].
Cardiac remodeling can also be regulated by hypoxia, a process in which a mAKAP-based protein
complex consisting of hypoxia-inducible factor 1α (HIF-1α), prolyl hydroxylase domain protein (PHD),
the von Hippel-Lindau protein (pVHL) and the E3 ligase designated seven in absentia homolog 2
(Siah2) plays a role. More specifically, when oxygen levels are reduced, mAKAP promotes the
degradation of PHD and thereby facilitates an increase in HIF-1α levels, which regulates transcription
of genes that promote cell survival [110].
Other AKAPs that are thought to be involved in the cardiac stress response are D-AKAP1 and
SKIP [111,112]. D-AKAP1 is a scaffolding protein of the outer mitochondrial membrane, which is
protective against cardiac hypertrophy since its overexpression leads to cardiac myocyte cell size
reduction and inhibition of the β-AR agonist isoproterenol-induced hypertrophy [111]. Moreover,
D-AKAP1 expression maintains the mitochondrial structure and function in the heart and reduces
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the infarct size, cardiac remodeling and mortality under conditions of ischemia, i.e., after myocardial
infarction [113].
SKIP plays an important role in the generation of the cardioprotective and anti-apoptotic
lysophospholipid sphingosine-1-phosphate (S1P) produced upon myocardial ischemia-reperfusion
injury [112]. It is involved in the regulation of sphingosine kinase type 1 (SPHK1), which upon
activation phosphorylates sphingosine to form S1P [114].
2.2.6. AKAPs Involved in the β-ARs Desensitization/Resensitization Cycle
Upon activation, β-ARs are phosphorylated and subsequently bind β-arrestin, which prevents
further ligand binding leading to receptor desensitization. The phosphorylated β-ARs are
internalized and reach the early endosomes where they undergo resensitization after PP2A-mediated
dephosphorylation. Upon resensitization, the non-phosphorylated receptors are recycled to the plasma
membrane where they can bind further ligands. Therefore, β-AR desensitization and resensitization
are essential processes in maintaining the proper functioning of the receptor [115].
Gravin and AKAP79 are important in the desensitization/resensitization cycle [72,73].
A gravin-based complex consisting of PKA, PKC, PP2B, β-arrestin and G protein-linked receptor
kinase 2 (GRK2) is essential for the desensitization and resensitization of the β2-ARs, with which
it interacts at their C-terminal tail [72]. AKAP79 mediates the PKA-dependent phosphorylation
of the β1-ARs by also binding to the C terminus of the receptor, leading to their recycling and
resensitization [73].
2.3. Aberrant cAMP Compartmentalization Can be Visualized
Dysregulation of local cAMP signaling is associated with cardiovascular diseases, e.g.,
maladaptive cardiac remodeling and heart failure [116,117]. FRET-based imaging using genetically
encoded sensors (cAMP-binding and PKA activity reporters) is utilized to visualize local
cAMP signaling components and real-time changes in cAMP levels with high spatio-temporal
resolution [118–121]. Such sensors can be targeted to various subcellular locations including in
cardiac myocytes in close proximity of sarcolemmal ion channels and SR proteins involved in Ca2+
handling, e.g., RyR2 and SERCA2a [122–125]. In addition, the FRET-based reporters can be used for
cAMP imaging in intact cardiac tissue as well as in ex vivo and in vivo hearts [126]. For monitoring
activities of signaling molecules in their cognate microdomains, FRET approaches have also been
combined with other techniques such as scanning ion-conductance microscopy (SICM), a non-optical
method that allows the imaging of both cell membrane morphology and functional parameters at
resolutions in the nanometer range [127–130].
3. Cyclic Nucleotide Phosphodiesterases (PDEs)
Hydrolysis by PDEs is the main route for lowering of intracellular levels of cAMP and cGMP
and is essential for the spatio-temporal regulation of cyclic nucleotide-dependent signaling [26].
The PDE superfamily consists of 21 genes that give rise to more than 100 proteins due to differential
transcription initiation sites and alternative splicing. PDEs are classified into 11 families (PDE1–PDE11).
They differ in their primary structures, substrate specificities, mechanisms of regulation and kinetic
properties [131]. Some PDE families selectively hydrolyze cAMP or cGMP, while others, the so-called
dual specific PDEs, catalyze the hydrolysis of both second messengers (Figure 2) [132].
PDEs display a common general structure consisting of three components: a family-specific
N-terminal regulatory domain, a conserved catalytic domain (25–52 % homology) and a C-terminal
domain that can be either phosphorylated by the mitogen-activated protein kinase (MAPK) or
prenylated [131,133–135]. The regulatory domains contain various structural features involved in the
regulation (i.e., sites for covalent modifications, e.g., phosphorylation), binding of regulatory molecules
(e.g., Ca2+-binding protein calmodulin), localization (targeting domains and protein-protein interaction
motifs, e.g., AKAP-binding motifs) and dimerization (e.g., GAF domains) of the enzymes [131,136,137].
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The catalytic domains feature in the active site a Zn2+ binding motif and an additional divalent metal
binding site that is most probably occupied by Mg2+, but could also correspond to Mn2+ and Co2+ [138].
Figure 2. Substrate specificity of individual phosphodiesterase (PDE) families.
3.1. PDE Subcellular Localization
The subcellular localization of PDEs is key in achieving compartmentalized cyclic nucleotide
signaling and, therefore, in the generation of specific physiological responses [136]. PDEs are located at
various intracellular locations, e.g., the cytosol (e.g., PDE3A3 and PDE5 [139,140]), plasma membrane
(e.g., PDE2A, PDE3A1, PDE6α, PDE6β [139,141,142]), the Golgi–centrosome (e.g., PDE7A1 [143]) and
nuclear regions (e.g., PDE9A1, PDE9A16, PDE9A17 [144]).
3.2. PDEs in the Cardiovascular System
Members from most PDE families are expressed in the cardiovascular system and regulate
a variety of processes essential for the proper functioning of the heart and vasculature (Table 2).
The PDE families 2, 3, 4 and 5, for example, regulate the endothelial barrier function and are,
therefore, of utmost importance in maintaining vascular integrity [28,145,146]. Several members
of the PDE families 2, 3, 4, 5 and 8 are involved in the control of cardiac contractility [30,120,147–150].
In addition, the basal pace-making activity of the sinoatrial (SA) node of the heart is regulated by
two PDE families, namely PDE3 and PDE4 [151]. In addition, various PDE family members, PDE1A,
PDE3A, PDE4B, PDE4D, PDE5 and PDE9A, are implicated in the cardiac stress response, which
triggers pathological cardiac remodeling and ultimately cardiac dysfunction (e.g., heart failure and
arrhythmias) [34,152–156].
Table 2. Overview of the PDE families expressed in the cardiovascular system and the corresponding
cardiovascular processes that they regulate.
PDE Family PDE Gene Substrate Specificity Regulated Cardiovascular Process
PDE1
PDE1A
cAMP, cGMP Cardiac stress responsePDE1B
PDE1C
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PDE9 PDE9A cGMP Cardiac stress response
3.2.1. PDE3A and Autosomal Dominant Hypertension with Brachydactyly (HTNB)
PDE3A along with PDE3B belongs to the PDE3 family, also known as the cGMP-inhibited cAMP
PDE family, which is able to hydrolyze both cAMP and cGMP in a competitive manner. PDE3A
is highly expressed and plays important roles in VSMCs, cardiac myocytes, platelets and oocytes,
whereas PDE3B is mainly expressed in adipose and soft tissue. Upon alternative splicing, three
PDE3A isoforms are generated, namely PDE3A1 (136 kDa), PDE3A2 (118 kDa) and PDE3A3 (94 kDa)
(Figure 3A). They are located in different cellular compartments. PDE3A1 is the main isoform found
in human cardiac myocytes and is predominantly located at membranes. It contains two N-terminal
hydrophobic regions (NHR), of which the first one consists of four transmembrane domains. PDE3A2,
which lacks the first but contains the second NHR can be both membrane-associated and cytosolic and
is the main variant found in VSMCs. PDE3A3 is found only in the cytosol, since it lacks both previously
mentioned hydrophobic regions. All three isoforms possess the same catalytic region and present high
similarities regarding their catalytic activity and inhibitor sensitivity (Figure 3A) [157,158].
Mutations in genes encoding for distinct PDE family members can have detrimental effects
and cause specific human diseases. One such example is represented by the Mendelian syndrome
Autosomal-dominant hypertension with brachydactyly type E (HTNB), caused by missense mutations
in the gene encoding for PDE3A [159]. The syndrome is characterized by an age-dependent
progressive hypertension, brachydactyly type E and blood vessel hyperplasia [159]. If untreated,
blood pressure increases by 50 mm Hg and patients die from stroke before age 50 years. Surprisingly,
hypertension-associated end organ damage such as cardiac hypertrophy, kidney damage or
hypertensive retinopathy is low [160,161].
Eight mutations in PDE3A were discovered in eight unrelated families from Turkey, France,
the United States, South Africa, Canada, Netherlands and Japan. All these mutations were missense,
gain of function mutations and found in close proximity to each other. The identified mutations
cause amino acid substitutions in a region between amino acids 445 and 449 and increases of
PKA-mediated phosphorylation of serine residues 428 and 438 of PDE3A1 and PDE3A2. The region
is not present in PDE3A3 (Figure 3A) [159]. The substitutions lead to increased cAMP affinity and
hydrolytic activity of the enzymes (Figure 3B). In addition, the hyperactive enzyme is erroneously
localized in microsomal fractions from HeLa cells, suggesting that aberrant compartmentalization is
detrimental in the cardiovascular system [159,161]. VSMCs from patients expressing the hyperactive
version of the enzyme with the T445N substitution display higher proliferation rates, explaining the
vascular phenotype.
In the human heart, PKA-mediated phosphorylation of PDE3A1 induces its recruitment to
an AKAP18-based signalosome in the heart that controls the Ca2+ reuptake into the SR and thereby
participates in the control of cardiac relaxation [21]. An extended overview over functions of PDE3 in
the heart was provided in recent reviews (e.g., [162,163]).
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Figure 3. Schematic representation of the PDE3A gene, PDE3A protein isoforms and the
hyperphosphorylation caused by the identified mutations. (A) Eight mutations have been identified
in families from the countries indicated by the flags. The mutations cluster within a region of the
gene encoding amino acids 445 and 449. The mutations cause hyperphosphorylations of Ser428 and
Ser438. The N-terminal hydrophobic region (NHR) 1 of PDE3A1 comprises four transmembrane
domains, while NHR2 contains no typical transmembrane region but a cluster of hydrophobic amino
acids. PDE3A2 contains only NHR2 and PDE3A3 lacks all N-terminal hydrophobic regions (for details
see text). (B) The hyperphosphorylation increases cyclic adenosine 3′-5′ monophosphate (cAMP)
hydrolysis, causing low cAMP levels.
3.3. PDE Inhibitors
Due to their essential physiological and pathological roles in cyclic nucleotide signaling, PDEs are
considered pharmacological targets for a variety of cardiovascular diseases, including atherosclerosis,
hypertension, heart failure and intermittent claudication [26,164–166]. Several inhibitors of PDE3,
4 and 5 are approved as drugs, some of which are used for the treatment of cardiovascular diseases.
3.3.1. PDE3
The PDE3 inhibitor cilostazol is an antiplatelet agent with vasodilatory and antiproliferative
properties. It has been widely studied in a number of cardiovascular diseases including coronary
and peripheral artery diseases and cerebrovascular disease [167]. Cilostazol is administered for the
treatment of peripheral arterial circulatory disorders and also used as an antiplatelet agent in patients
that underwent carotid artery stenting [168,169]. In addition, it is also approved for the treatment
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of intermittent claudication-induced symptoms [170–172]. Cilostazol appears to be a promising
therapeutic agent for secondary prevention of stroke and was shown to improve right ventricular
systolic function as well as to decrease pulmonary artery pressure [167,173]. PDE3 inhibitors inhibit
neointima formation in a rat balloon double-injury model displaying neither cytotoxicity nor effects on
VSMC migration, and thus are considered targets in preventing acute re-occlusion after angioplasties,
e.g., percutaneous transluminal coronary angioplasty (PTCA) [174].
Milrinone is another PDE3 inhibitor. It has inotropic and vasodilatory properties, and is
widely used in patients with end-stage heart failure in order to temporarily improve cardiac
contractility (positive inotropic effect) and decrease vascular resistance. Taking into account
that long-term administration of milrinone can induce apoptosis of cardiac myocytes, cardiac
arrhythmias, hypotension and increases cardiovascular mortality, it is only used in a selected
group of patients [170,175–177]. A potential explanation for the long-term PDE3 inhibitor
therapy-induced mortality could be the fact that PDE3A inhibition induces cardiac myocyte apoptosis
via a PDE3A-inducible cAMP early repressor (ICER) feedback loop. More specifically, PDE3A
inhibition leads to PKA activation and ICER protein stabilization, which, in turn, promotes cardiac
myocyte apoptosis. Therefore, therapeutic strategies that would diminish PDE3A activity without
affecting the PDE3A-ICER feedback loop could promote the beneficial effects while by-passing the
side effects [152,162]. Current research aims at determining the effects of milrinone on pulmonary
hypertension and right ventricular failure, where it is believed to be particularly helpful [176].
3.3.2. PDE4
The PDE4 family is encoded by four genes, PDE4A, PDE4B, PDE4C and PDE4D [178] and was
shown to be involved in the excitation-contraction coupling regulation, especially in rodents. It has
been recently suggested that PDE4 inhibitors could be beneficial in treating sepsis in infants with
cardio-renal syndrome (CRS) since they are effective in improving cardiac function in a rat model
suffering from sepsis-induced acute cardiac dysfunction and kidney injury [179]. In addition, PDE4
depletion stabilized the endothelial barrier by reducing the atrial natriuretic peptide (ANP)-induced
vascular permeability and, therefore, was efficient in maintaining the plasma volume [180]. Despite the
fact that PDE4A, PDE4B and PDE4D are expressed in the human and rodent heart, with PDE4D being
the predominant isoform found in the human heart [181], there is no approval for a PDE4 inhibitor
for the treatment of cardiovascular diseases. A highly selective PDE4 inhibitor, roflumilast, has been
approved in various countries for the treatment of chronic obstructive pulmonary disease (COPD),
a chronic inflammatory lung disease characterized by heavily breathing due to obstructive airflow
from the lungs as well as a decline of lung function over time [182–184]. Another inhibitor, apremilast
is employed for the treatment of psoriasis [185].
3.3.3. PDE5
PDE5A is the sole gene coding for the PDE5 family, which plays an essential role in the
cardiovascular system. PDE5 expression is low in the healthy cardiac tissue, whereas it is upregulated
in the diseased heart [155,186]. PDE5 inhibition counteracts cardiac remodeling and fibrosis of
isolated cardiac fibroblasts via repression of transforming growth factor (TGF)-β1-induced Smad
signaling [187]. PDE5 depletion inhibits left ventricular remodeling induced by hypertrophic and
pro-fibrotic stimuli [188]. Reduction in PDE5 expression was beneficial for chronic heart failure
patients by enhancing the endothelium-dependent, flow-mediated vasodilation [189]. In addition,
high PDE5 expression was identified in the hypertrophic human right ventricle and its inhibition
enhanced contractility, particularly important for pulmonary hypertension [186]. PDE5 inhibitors
such as sildenafil, vardenafil and tadalafil are approved for the treatment of erectile dysfunction
and pulmonary hypertension but are not yet approved for the treatment of other cardiovascular
diseases [26]. Nevertheless, recent studies suggest potential therapeutic benefits for PDE5 inhibitors,
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i.e., sildenafil and tadalafil in the treatment of myocardial infarction, ischemia/reperfusion injury,
endothelial dysfunction, cardiac hypertrophy and heart failure [190,191].
3.3.4. Potential for PDE1, PDE2, PDE8 and PDE9 Inhibitors
PDE1, PDE2, PDE8 and PDE9 inhibition is considered a therapeutic opportunity for the treatment
of cardiovascular diseases but inhibitors are not approved.
The PDE1 family is encoded by three distinct genes, PDE1A, PDE1B and PDE1C, and is the
only PDE family activated by calcium/calmodulin (Ca2+/CaM) binding [192,193]. Due to their
potential to dilate coronary arteries, inhibition of PDE1 enzymes may be beneficial for the treatment
of coronary artery disease (CAD) and angina pectoris [194]. Nuclear PDE1A is important for the
proliferation of VSMCs and, therefore, could contribute to neointima formation in diseases, e.g.,
atherosclerosis and restenosis [195]. Thus, diminishing its expression could decrease pathological
neointima development. In addition, inhibition of the PDE1 family might improve cardiopathy and
pulmonary arterial hypertension since it decreases the structural remodeling process underlying these
two conditions [196].
PDE2A is the only gene coding for the PDE2 family and plays a central role in the cardiac CaV1.2
current regulation. The expression is up-regulated in human failing hearts [197,198]. Inhibition of PDE2
had a positive inotropic effect in dogs and mice, whereas its overexpression decreased the heart rate
in mice. Interestingly, in a heart-specific PDE2-transgenic mouse model, increased PDE2 abundance
prevents ventricular arrhythmias by inhibiting Ca2+ leak from the SR and helps in maintaining the
contractile function of the heart after myocardial infarction [199]. On the contrary, a recent study
in patients that had experienced an acute myocardial infarction (AMI) suggests that inhibition of
endothelial PDE2A could have a beneficial effect and improve the clinical outcome. Hypoxia and
pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α) promote PDE2A activation, which
results in diminished submembrane cAMP levels and endothelial barrier disruption. This facilitates
the extravasation of activated neutrophils and leads to inflammation in the early post-myocardial
infarction phase [29].
The PDE8 family comprises two members, PDE8A and PDE8B and regulates excitation-contraction
coupling in ventricular myocytes. More specifically, it has been suggested that PDE8A controls at
least one cAMP pool involved in the cardiac myocyte-dependent Ca2+ cycling regulation. It was also
observed that PDE8A deletion caused both increased RyR2 leak as well as enhanced Ca2+ refilling of
the SR [150].
The PDE9 family is encoded by a single gene, PDE9A, and consists of more than 20 different splice
variants. PDE9A expression was identified in human and rodent hearts, where its expression increased
upon hypertrophy and heart failure development [156,200]. PDE9A depletion had a protective effect
for the heart against pathological remodeling caused by pressure overload and it reversed a previously
established heart disease without requiring the activity of NO synthase [156].
4. Concluding Remarks
Compartmentalized cyclic nucleotide signaling is found at the basis of precision of cellular
signaling and its dysregulation is associated with various pathological conditions including several
cardiovascular diseases. Local pools of cAMP are established by the interplay of cAMP synthesis,
diffusion, degradation as well as positioning of the relevant signaling proteins. AKAPs and
PDEs are essential players in these processes since they orchestrate the formation of multi-protein
signaling complexes and terminate local cAMP signaling, respectively. This interplay ensures the
spatio-temporal regulation of cyclic nucleotide-dependent signaling. Despite the fact that both
molecules are key elements in the cAMP signaling pathway, very little is known with respect to
their direct interaction or their interplay in the cardiovascular system. However, a few PDE-containing
AKAP complexes have been identified; examples are the SERCA2/AKAP18 signalosome, which
incorporates PDE3A1 upon its phosphorylation and is important for cardiac contractility, and the
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PDE4D3 containing mAKAPβ-based signalosome involved in cardiomyocyte hypertrophy regulation
([21,71,109]). Alterations in AKAP expression and their protein-protein interactions are associated with
various cardiovascular diseases [12,24]. Hence the development of pharmacological agents targeting
such dysregulated signaling components for evaluating their relevance as pharmacological targets
is needed. First examples show that targeting AKAPs and their protein-protein interactions with
small molecules is possible. For instance, an AKAP-PKA interaction inhibitor, FMP-API-1 [201]
was identified. Recently, a novel small molecule, Scaff10-8, was developed, which inhibits the
interaction of AKAP-Lbc and RhoA and prevents the AKAP-Lbc-mediated RhoA activation, an event
pathologically activated in models of cardiac hypertrophy [102]. Further molecules directed against the
AKAP-Lbc-RhoA interface have recently been identified and may serve to guide to further preclinical
drug development efforts [202,203].
Approved inhibitors of PDEs target the catalytic activities of PDEs. However, the catalytic
domains of the various members of individual families are identical and inhibition of one inhibits all.
This lack of selectivity presumably explains PDE inhibitor therapy-associated side effects, which are
frequent and dramatic over long-term administration [158]. PDE isoform-selective inhibition may be
achieved through disruption of specific protein-protein interactions. and therefore the displacement of
particular PDE isoforms from their subcellular compartments [204].
In conclusion, targeting proteins directing compartmentalized cAMP signaling, in particular
AKAPs and PDEs, not only serves to understanding their role in heart and vascular physiology
and pathophysiology but also has therapeutic potential for the treatment of a wide range of
cardiovascular diseases.
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Abstract: Heart failure is a lethal disease that can develop after myocardial infarction, hypertension,
or anticancer therapy. In the damaged heart, loss of function is mainly due to cardiomyocyte death
and associated cardiac remodeling and fibrosis. In this context, A-kinase anchoring proteins (AKAPs)
constitute a family of scaffolding proteins that facilitate the spatiotemporal activation of the cyclic
adenosine monophosphate (AMP)-dependent protein kinase (PKA) and other transduction enzymes
involved in cardiac remodeling. AKAP-Lbc, a cardiac enriched anchoring protein, has been shown
to act as a key coordinator of the activity of signaling pathways involved in cardiac protection and
remodeling. This review will summarize and discuss recent advances highlighting the role of the
AKAP-Lbc signalosome in orchestrating adaptive responses in the stressed heart.
Keywords: A-kinase anchoring protein (AKAP); protein kinase A; cyclic AMP; cardiomyocyte;
cardiac protection; signal transduction
1. Introduction
The heart responds to various stresses and insults such as increased blood pressure, myocardial
infarction, and exposure to drugs and toxicants by undergoing a remodeling process that leads to
heart failure, a lethal condition in which the cardiac output cannot satisfy the oxygen needs of the
body [1–3]. Cardiac remodeling can be associated with an initial adaptive phase where ventricular
cardiomyocytes undergo compensatory hypertrophy to maintain cardiac function [4,5]. However, in
the long term, hypertrophy predisposes to adverse ventricular events associated with cardiomyocyte
death, fibrosis, and progressive cardiac dysfunction [3,6,7]. Heart failure has an annual incidence
of 1% in the population over 65 and a five-year survival rate after diagnosis lower than 50% [4].
This underscores the urgent need of identifying new therapies for this syndrome. In this respect,
defining key protective signaling pathways favoring survival of cardiomyocyte subjected to stress could
provide new opportunities to prevent cardiac remodeling and dysfunction under pathophysiological
situations associated with heart injury or insults.
A-kinase anchoring proteins (AKAPs) are molecular scaffolds that act as signal organizers. They
ensure coordination of multiple signaling pathways at discrete microdomains of cardiomyocytes
and cardiac fibroblasts by locally recruiting the cAMP-dependent protein kinase (PKA) as well as
other signaling enzymes [8–11]. Anchoring of PKA is mediated by conserved domains constituted by
amphipathic helices of about 20 amino acids [12,13], whereas targeting of AKAP-based signaling
complexes to distinct subcellular sites is achieved through specialized protein- or lipid-binding
domains located on the anchoring proteins [10]. Among the multitude of signaling molecules recruited
by AKAPs one can find kinases, phosphodiesterases (PDEs), adenylyl cyclases (ACs), phosphatases,
and GTPases [14–20]. In this respect, the assembly of signaling enzymes displaying opposing action
(i.e., kinases and phosphatases) allows bidirectional regulation of transduction events, whereas the
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clustering of activators and downstream targets (i.e., ACs and PKA substrates) promotes signal
potentiation [18].
So far, about 17 AKAPs have been identified in cardiac tissues [21–23] and shown to regulate
various homeostatic, adaptive as well as pathophysiological functions including heart rhythm and
action potential propagation, calcium cycling and cardiac contraction, cardiac remodeling and heart
failure, as well as cardiac protection [5,24–26]. This suggests that modulating the ability of AKAP
complexes to locally coordinate the activity of signaling molecules might have major impact on the
function of the stressed and/or diseased heart and could be exploited to promote protection and
maintain cardiac function. In particular, AKAP-Lbc (AKAP13), a heart-enriched anchoring protein [17],
has been shown to organize diverse signaling pathways favoring protection against a cardiac stresses
including pressure overload, as well as drugs and toxicants [27–29]. The current minireview article will
focus on the role of this multifunctional anchoring protein in favoring adaptive and survival responses
in the injured heart. In recent years, additional AKAPs have been show to confer cardiomyocyte
protection either in vitro or in vivo including D-AKAP-1 (AKAP1), AKAP79/150 (AKAP5) mAKAP
(AKAP6) and AKAP12. For more information about the cardioprotective role of these AKAP-based
signaling complexes we refer the reader to other recent publications [30–36].
2. The Role of the cAMP/PKA Pathways in Cardiac Protection
Studies undertaken during the last 20 years indicate that activation of the cAMP/PKA signaling
pathway can protect cardiomyocytes against cell death and damage induced by ischemia/reperfusion,
anthracycline treatment, hyperglycemic stress, and pressure overload. Early experiments performed
using isolated rats hearts demonstrated that cardiac cAMP levels and PKA activity are increased during
ischemic preconditioning and that suppression of cAMP signaling attenuates myocardial protection
against sustained ischemia [37,38]. Several additional studies later showed that preconditioning
of mouse, rat or rabbit hearts with various Gs-coupled receptor agonists including isoproterenol
(ISO) [39], glucagon-like peptide 1 (GLP-1) [40], adrenomedullin [41], corticotropin releasing factor [42],
and adiponectin [43], confers protection against subsequent ischemia and reduces infarct size in a
PKA-dependent manner. Similarly, PKA has also been shown to mediate the protective effects of the
GLP-1 receptor agonist exendin-4 against hyperglycemia-induced cardiomyocyte apoptosis [44], of the
antidiabetic drug metformin against anthracycline cardiotoxicity [45], and of adrenomedullin 2 against
pressure-overload induced cardiac remodeling [46].
These protective effects rely on the ability of PKA to regulate multiple effector proteins and
responses in cardiomyocytes. On the one hand, protection against ischemia/reperfusion has been
shown to rely on the ability of PKA to (1) inhibit calpain-dependent proteolysis and degradation of
structural proteins in cardiomyocytes [38]; (2) increase the opening of the mitochondrial Ca2+-activated
K+ (mitoK(Ca)) channels and improve the efficiency of mitochondrial energy production [41];
(3) promote phosphorylation and enhance the cardioprotective effects of the small heat-shock protein
HSP20 [47,48]; (4) reduce inhibitor of Kappa B (IκB) phosphorylation and nuclear factor Kappa B (NF-κB)
activation [43]; (5) reduce nicotinamide adenine dinucleotide phosphate (NADPH) oxidase overexpression
and superoxide overproduction [43]; and (6) improve calcium handling through phospholamban (PLB)
phosphorylation and sarcoplasmic reticulum Ca2+ ATPase 2 (SERCA2) activation [49].
On the other hand, protection against pathological cardiac remodeling requires PKA
mediated-regulation of histone deacetylases (HDACs) 4 and 5 [50,51]. These two signaling molecules
control the activity of transcription factors, such as the myocyte enhancer factor 2 (MEF2), crucially
involved in the regulation of gene programs associated with cardiac remodeling [52]. PKA induces
HDAC4 proteolysis and the formation of an N-terminal HDAC cleavage product that inhibits
the activity of MEF2 [50]. Moreover, the kinase also phosphorylates HDAC5, which, in turn,
prevents its nuclear export, leading to the inhibition of MEF2-dependent transcription and fetal
gene expression [51]. However, since these later findings where obtained using primary cultures of
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cardiomyocytes as a model system, investigation should be pursued to determine whether regulation
of HDAC function by PKA has anti-remodeling effects in hearts subjected to various forms of stress.
Interestingly, PKA reduces detrimental cardiac remodeling not only by protecting cardiomyocytes
from dysfunction and death but also by inhibiting cardiac fibrosis. In this respect, it has been
recently shown that activation of PKA signaling by prostaglandin E2 receptor 4 (EP4) agonists
significantly prevented progression of myocardial fibrosis in response to pressure overload [53].
Experiments performed using isolated cardiac fibroblasts subsequently indicated that PKA activation
suppresses collagen overproduction induced by the profibrotic agonist transforming growth factor
β1 (TGF-β1) [53]. This suggests that PKA might attenuate the formation interstitial cardiac fibrosis,
and consequent heart dysfunction through the reduction of excessive extracellular matrix deposition.
The studies described above were carried out using activators or inhibitors that impact cardiac PKA
signaling in a global manner and do not allow the precise identification of specific PKA functions in the
heart. To circumvent this problem, several studies now adopt more targeted approaches and investigate
the function of individual AKAP-PKA signaling complexes in specific cardiac cellular populations.
3. AKAP-Lbc Signaling and Cardiac Protection
AKAP-Lbc (AKAP13) is a cardiac enriched anchoring protein [17], which functions as a scaffold
for multiple signaling enzymes as well as a guanine nucleotide exchange factor (GEF) that selectively
activates the small molecular weight GTPases RhoA and RhoC [17,23,54]. The exchange of GDP for GTP
and the binding to Rho-GTPases is ensured by tandem Dbl-homology (DH) and plekstrin-homology
(PH) domains located in the middle of the anchoring protein [17,54,55]. This central catalytic core is
surrounded by N-terminal and C-terminal sequences, which provide anchoring sites for signaling
molecules [23], and inhibit the basal Rho-GEF activity of AKAP-Lbc in the absence of stimulatory
signals [17]. Deletion of these key regulatory regions, which has been shown to occur in chronic myeloid
leukemia (CML) patients as the consequence of a chromosomal translocation between chromosomes 15
and 7, significantly increases the basal Rho-GEF activity and promotes oncogenic transformation [55,56].
The Rho-GEF activity of AKAP-Lbc is enhanced by G-protein-coupled receptors (GPCRs) linked
to the heterotrimeric G protein G12 such as α1-adrenergic receptors (α1-ARs) [57]. In this respect, it has
been shown that the α subunit of G12 (Gα12) can directly activate AKAP-Lbc by binding to a docking
site located in its C-terminus. This interaction is proposed to suppress autoinhibitory intramolecular
bonds between C-terminal regulatory sequences and the GEF region of the anchoring protein [58].
Initial in vitro studies performed in primary cultures of rat neonatal cardiomyocytes (NVMs)
indicated that AKAP-Lbc acts as a mediator of the hypertrophic effects induced by α1-AR and
endothelin 1 receptor (ET1-R) agonists [57,59]. These findings served as base for subsequent in vivo
investigations showing that the anchoring protein mediates early adaptive growth responses that
allow the heart to functionally compensate biomechanical or neurohumoral stresses [27,28]. Finally,
in recent years, it became evident that AKAP-Lbc also coordinates and regulates signaling molecules
such as the mitogen activated protein kinase (MAPK) p38α [27,60], protein kinase D1 (PKD1) [28,59],
and the heat shock protein 20 (HSP20) [61], that promote adaptive and/or cytoprotective responses in
cardiomyocytes. The following sections will discuss how coordination of distinct signaling pathways
by the AKAP-Lbc signaling complex contributes to cardiomyocyte adaptation and protection against
to various stressors and toxicants.
3.1. AKAP-Lbc Mediates Protection against Pressure Overload-Induced Cardiac Dysfunction
Left ventricular pressure overload can be triggered by chronically elevated systemic blood
pressure or obstructions of the outflow tract such as aortic valve stenosis. It initially leads to cardiac
hypertrophy, which eventually may become maladaptive and predispose to heart failure. It is estimated
that chronic hypertension doubles the risk of developing heart failure [4]. Experimentally, pressure
overload can be induced in the mouse by transverse aortic constriction (TAC). Cardiac AKAP-Lbc
is significantly upregulated in mice subjected to TAC as well as in patients with hypertrophic
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cardiomyopathy [27,28,59]. It assembles a macromolecular signaling complex coordinating the
activity of transduction enzymes such as p38α and PKD1 that have a direct impact on compensatory
hypertrophy and maintenance of cardiac function during the early phase of cardiac remodeling.
3.1.1. The Role of AKAP-Lbc-Mediated Regulation of p38α
The role of p38α in cardiac adaptation to stress has been subject of discussion over the last decade.
Initial investigations suggested that chronic (constitutive) activation or inhibition of cardiac p38α
does not affect hypertrophy [62–66]. However, subsequent studies overturned this view by showing
that inducible activation of p38α signaling in adult hearts promotes cardiomyocyte growth [67,68].
In cardiomyocytes, AKAP-Lbc forms a p38-activating transduction unit that includes p38α and
its upstream activators protein kinase N α (PKNα), mixed lineage kinase-like mitogen-activated
protein triple kinase (MLTK), and mitogen-activated protein kinase kinase 3 (MKK3) (Figure 1) [27].
Cardiomyocyte-specific overexpression of a molecular disruptor of the interaction between AKAP-Lbc
and PKNα inhibits pressure overload-induced p38α activation and compensatory cardiac hypertrophy.
This leads to the appearance of early signs of heart failure including left ventricular dilation, increased
cardiomyocyte apoptosis, and depressed cardiac function [27]. The ability of the AKAP-Lbc/p38α
complex to promote compensatory hypertrophy is linked to the induction of mammalian target of
rapamycin (mTOR) and the consequent increase in protein synthesis (Figure 1) [27]. These results
indicate that AKAP-Lbc facilitates activation of p38α and mTOR in response to abrupt increases in the
afterload to promote hypertrophy and reduce cell death, which temporarily preserves the function of
the stressed heart. While the pathway linking the AKAP-Lbc/p38α complex and mTOR is currently
unknown, recent findings indicate that p38 can enhance cardioprotective mTOR signaling by regulating
the activity of the tuberous sclerosis complex (TSC) [69].
 
Figure 1. The role of the AKAP-Lbc signaling complex in mediating compensatory cardiac hypertrophy
and cardiac protection in response to hemodynamic and neurohumoral stresses. Upon pressure
overload, AKAP-Lbc promotes the formation of RhoA-GTP, which, in turn, triggers a signaling cascade
involving anchored PKNα, MLTK, MKK3 and p38α. Activated p38α, through an unknown mechanism,
enhances mTOR activity resulting in increased phosphorylation of 4E-BP1 and ribosomal protein S6
(S6rp), which leads to enhanced protein synthesis and cardiomyocyte growth. Pressure overload as
well as activation of Gq-coupled receptors by hypertrophic agonists (ET-1, Angiotensin II) also promote
the activation of AKAP-Lbc-anchored PKD1, which, in turn, phosphorylates HDAC5 and favors its
nuclear export. As a result, MEF2 becomes activated and promotes transcription of hypertrophic genes.
Activated PKD1 plays protective roles during compensatory hypertrophy by inducing the expression
of antiapoptotic genes such as Bcl-2 and by inhibiting transcription of pro-apoptotic genes such as Bax.
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3.1.2. The Role of AKAP-Lbc-Mediated Regulation of PKD1
Early work by Carnegie et al. showed that AKAP-Lbc can interact with PKD1 and PKCη
(Figure 1) [70]. They could demonstrate that stimulation of rat NVMs with agonists binding Gq-coupled
receptors, such as α1-ARs and ET1-Rs, enhances PKC activity, which, in turn, phosphorylates anchored
PKD1 at serine 944 and 948 to induce its activation. PKD1 is released from the complex when PKA
phosphorylates serine 2737 located in the PKD-binding site of AKAP-Lbc. Free PKD1 can then
phosphorylate HDAC5 an inhibitor of the prohypertrophic transcription factor MEF2. This facilitates
its HDAC5 nuclear export, derepression of MEF2 and activation of hypertrophic gene transcription
(Figure 1) [59].
Subsequent in vivo studies showed that gene-trap mice expressing a PKD1 binding deficient
mutant of AKAP-Lbc were not able to sustain compensatory cardiac hypertrophy in response TAC
or chronic treatment with hypertrophic agonists [28]. The impaired adaptive response to stress
was associated with exacerbated cardiomyocyte apoptosis, early-dilated cardiomyopathy and heart
failure. Interestingly, increased apoptosis was linked to a marked transcriptional downregulation of
antiapoptotic genes such as Bcl2 and the upregulation of the mRNA encoding pro-apoptotic proteins
such as Bax, Gzmm, and Dnm1l (Figure 1) [71]. Therefore, AKAP-Lbc-anchored PKD1 facilitates
activation of hypertrophic and cytoprotective gene programs to ensure cardiomyocyte survival and
adaptation during the early phase of cardiac remodeling.
3.2. AKAP-Lbc Mediates Protection against Doxorubicin-Induced Cardiomyocyte Toxicity
Doxorubicin (Dox) is an anthracycline antibiotic used for the past four decades as an anticancer
agent to treat a variety of tumors including leukemia and breast cancer. It exerts its antineoplastic
activity by impairing DNA replication, mainly through the inhibition of topoisomerase II, and by
promoting the formation of reactive oxygen species (ROS). However, this drug displays severe
cardiac side effects, which limit its clinical application and have become a serious concern for
cancer survivors [72,73]. Doxorubicin-induced chronic cardiotoxicity is dose-dependent and usually
occurs within the first year after treatment. The incidence is about 4% for a doxorubicin dose of
500–550 mg/m2, 18% for a dose of 551–600 mg/m2 and 36% for a dose exceeding 600 mg/m2 [74].
Cardiotoxicity is associated with the ability of Dox to alter Ca2+ homeostasis, to affect the
expression of sarcomeric proteins, to inhibit the electron transport chain and energy production,
and to promote the formation of ROS both in the mitochondria and in the cytoplasm of cardiomyocytes
through a series of redox reactions that require iron [75].
ROS production enhances oxidation of DNA [76], proteins and lipids [77], thus causing
mitochondrial damage and the activation of cardiomyocyte apoptosis. These effects are reinforced by
the profound inhibitory action of Dox on the expression of cytoprotective signaling proteins such the
kinase Akt1 and antiapoptotic regulators such as Bcl2 and BclxL [78–80]. In the clinic, the only currently
available drug that can partially diminish these cardiotoxic effects is dexrazoxane, an iron chelator
that reduces Dox-induced ROS formation [81]. However, the fact that a significant number of patients
receiving Dox still develop severe cardiac morbidity underscores the urgency of new therapeutical
strategies. In this respect, recent research efforts are now focused on identifying cardioprotective
signaling pathways that could efficiently reduce cardiac side effects [82].
Several evidences suggest that the activation of α1-ARs significantly reduces the toxic effects that
Dox exerts on cardiomyocytes [83]. Indeed, phenylephrine (PE) and dabuzalgron, two α1-AR agonists,
confer significant protection against Dox-induced cardiomyocyte apoptosis, pathological cardiac
remodeling, and depressed heart function in mice [80,84]. Interestingly, recent studies performed
on rat NVMs indicate that these protective effects could be mediated in part by AKAP-Lbc [29].
In particular, it has been shown that short-hairpin RNA (shRNA)-mediated suppression of AKAP-Lbc
expression in ventricular myocytes strongly impairs the ability of the α1-AR agonist phenylephrine
(PE) to reduce Dox-induced cardiomyocyte apoptosis. AKAP-Lbc-mediated cardiomyocyte protection
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requires the recruitment of PKD1 and the activation of two PKD1-dependent prosurvival signaling
cascades (Figure 2) [29].
Figure 2. The role of AKAP-Lbc in mediating protection against Dox induced cardiomyocyte
toxicity. Scaffolding of PKD by AKAP-Lbc facilitates α1-AR-mediated PKD1 activation resulting in the
phosphorylation and inactivation of the phosphatase SSH1L. As a consequence, phosphorylated cofilin2
accumulates and remains sequestrated in the cytoplasm. This inhibits Dox-induced translocation of
cofilin2/Bax complexes to mitochondria, and subsequent mitochondrial dysfunction and apoptosis.
Activated PKD1 also favors cAMP regulatory element binding protein (CREB)-mediated transcriptional
activation of the antiapoptotic gene Bcl-2 otherwise down regulated by Dox treatment.
In the first pathway, the AKAP-Lbc-anchored pool of PKD1 mediates the phosphorylation and
activation of the transcription factor cAMP regulatory element binding protein (CREB), which, in turn,
promotes upregulation of the antiapoptotic gene Bcl2. This efficiently prevents Dox-induced Bcl2
transcriptional downregulation (Figure 2). In the second pathway, AKAP-Lbc-facilitated activation of
PKD1 leads to the phosphorylation and deactivation of the cofilin2-phosphatase slingshot-1L (SSH1L),
which increases cofilin2 phosphorylation. This blocks Dox-induced translocation of cofilin2 and Bax
complexes to mitochondria, which reduces mitochondrial dysfunction, cytochrome C release, caspase
3 activation and apoptosis (Figure 2) [29,85].
Knowing that PKD1 also favors protection against hypoxia and oxidative stress [85],
and adaptation against pressure overload-induced early cardiac remodeling [28], one could suggest
that this kinase might confer cardiomyocyte protection against a variety of stresses.
It has been shown that infusion of α1-AR agonists such as PE in mice induce a significant
upregulation of cardiac AKAP-Lbc expression [57]. This raises the possibility that AKAP-Lbc-mediated
cardioprotective signaling could be enhanced by α1-AR agonists in vivo. Based on this assumption,
future studies will need to determine the impact of cardiac AKAP-Lbc suppression and overexpression
on Dox-induced chronic cardiac side effects.
3.3. The Cardioprotective Role of the AKAP-Lbc/HSP20 Complex
The small heat shock protein HSP20 has been shown to confer sustained protection against
cardiac stresses and insults including chronic β-adrenergic stimulation, ischemia/reperfusion (I/R)
and Dox exposure. Indeed, transgenic mice with cardiomyocyte-specific overexpression of HSP20
are protected against apoptosis induced by chronic ISO or Dox infusion and develop significantly
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smaller infarcts when subjected to I/R [47,48,86,87]. HSP20 mediates its antiapoptotic effects through
the inhibition of apoptosis signal-regulating kinase 1 (Ask1) and Bax (Figure 3) and the preservation
of the pro-survival activity of Akt1 [48,87]. Interestingly, these cardioprotective effects were shown
to require phosphorylation of HSP20 on serine 16 by PKA [88]. This was suggested by studies
showing that overexpression of a constitutively phosphorylated mutant (S16D) of HSP20 protects
adult cardiomyocytes from apoptosis induced by β-adrenergic agonists [47]. In a screening for
polymorphisms associated with human dilated cardiomyopathy, it was later found that a single base
change of C to T at nucleotide 59 in the N-terminus of HSP20, resulting in an amino acid substitution
from proline 20 to leucine (P20L), strongly impaired PKA-mediated phosphorylation of HSP20 [89].
Figure 3. Regulation of HSP20-mediated cardiomyocyte protection by AKAP-Lbc. By recruiting
phosphodiesterases 4 (PDE4), AKAP-Lbc maintains a low local concentration of cAMP, which prevents
activation of anchored PKA. Chronic β-adrenergic stimulation induces a sustained production of
cAMP, which saturates PDE4 and promotes anchored PKA activation. Activated PKA phosphorylates
AKAP-Lbc-bound HSP20 on serine 16, an event that has been shown to enhance the cardioprotective
function of HSP20. Indeed, phosphorylated HSP20 has been shown to suppress Ask1-dependent
signaling and to inhibit Bax leading to reduced cardiomyocyte apoptosis, decreased pathological
cardiac remodeling, and increased protection against ischemia. PKD1 can form a complex with HSP20
and promote its phosphorylation on serine 16. The relative contribution of PKA vs. PKD1 to the
phosphorylation of HSP20 in vivo remains to be elucidated.
Accordingly, in vitro experiments confirmed that HSP20 P20L was unable to confer protection
against I/R-induced cardiomyocyte apoptosis [90]. Recent studies indicate that AKAP-Lbc facilitates
PKA-mediated phosphorylation of HSP20 (Figure 3). In particular, it has been shown that AKAP-Lbc
stably interacts with HSP20, thus providing a physical link between PKA and the HSP [89].
Importantly, knockdown of AKAP-Lbc and overexpression of a PKA-binding deficient mutant of
the anchoring protein in rat NVMs reduce the phosphorylation of HSP20 on serine 16 and increase
isoproterenol-induced cardiomyocyte apoptosis [88]. This suggests that phosphorylation of HSP20 by
AKAP-Lbc-anchored PKA mediates cardiomyocyte protection. However, it remains to be established
whether the anchoring protein favors cardioprotective phosphorylation of HSP20 also in vivo. To this
end, future experiments might investigate whether the knockout of AKAP-Lbc in adult hearts affects
phospho-HSP20-dependent protective signaling.
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The phosphorylation status of HSP20 is also regulated by PDE4 family members, which directly
interact with the heat shock protein (Figure 3) [91]. Recruitment of PDE4 maintains the local
concentration of cAMP low, which reduces PKA activation and HSP20 phosphorylation under basal
conditions. Upon chronic β-adrenergic stimulation, cAMP levels rise in cardiomyocytes and overcome
the hydrolyzing capacity of the PDE, what favors HSP20 phosphorylation [91]. Knowing that PDE4
also interacts with AKAP-Lbc [92], one might raise the hypothesis that AKAP-Lbc might serve as a
molecular organizer coordinating the activity of PKA and PDE4 to confer spatiotemporal regulation of
HSP20 phosphorylation and antiapoptotic function.
It has been shown that serine 16 of HSP20 is also a substrate for PKD1 phosphorylation [93].
This suggests that PKD1 could mediate part of its cardioprotective effects through the regulation of
HSP20. The kinase has been shown to directly associate with HSP20 [93] but one could assume that
AKAP-Lbc could also target PKD1 in proximity of HSP20 [70]. Based on these new findings, it would
be interesting to evaluate the relative importance of PKA versus PKD1 as HSP20 kinases in vivo and
to determine their impact on the cardioprotective function of HSP20.
4. Conclusions and Perspectives
The ability of AKAPs to integrate and process multiple signals allows them to regulate several
physiological and pathological cardiac functions including contraction, heart rhythm, adaptation
to stress and transition to heart failure [10,23,24]. In this context, AKAP-Lbc has the peculiarity of
coordinating signaling pathways regulating the heart response to hemodynamic or chemical stresses.
While a number of studies have highlighted the protective role of AKAP-Lbc during the
compensated hypertrophic growth of the heart induced by pressure overload and neurohumoral
stress, it is currently not known whether this anchoring protein is also involved in later phases of
cardiac remodeling. On the one hand, one could speculate that AKAP-Lbc-mediated activation of
PKD1, p38α, and mTOR for periods of time that extend beyond the initial phase of compensation
might promote deleterious effects through the sustained induction of the fetal gene program and
alteration of cardiac contractility [59,94]. On the other hand, however, recent studies indicate that
chronic PKD1 and mTOR activation might actually promote cardioprotective effects through the
induction of antiapoptotic gene programs [85,95]. To address these contrasting hypotheses future
studies using inducible cardiomyocyte-specific AKAP-Lbc knockout mice will need to address the
impact of suppressing AKAP-Lbc expression at the end of the compensatory phase on subsequent
pathological remodeling.
By facilitating the activation of PKD1 in cardiomyocytes, AKAP-Lbc inhibits cardiomyocyte
apoptosis and protects mitochondrial function in response to abrupt increases in the left ventricular
afterload and anthracycline (doxorubicin) exposure [28,29]. These antiapoptotic effects are mediated
by the upregulation of Bcl2, the inhibition of the translocation of cofilin2 and Bax to mitochondria,
and possibly HSP20. Therefore, strategies aimed at stimulating the activity of AKAP-Lbc-anchored
PKD1 might represent a possible way to prevent early cardiac dysfunction in the stressed heart.
Knowing that α1-ARs are upstream activators of the AKAP-Lbc/PKD1 signaling pathway, one
could propose the use of α1-ARs selective agonists as cardioprotective agents. In this context,
dabuzalgron, an oral α1A-AR agonist that was originally developed to treat urinary incontinence,
could be repurposed to reduce the cardiac side effects of Dox-based anticancer chemotherapy and
possibly to limit cardiomyocyte apoptosis in hemodynamically challenged hearts [84].
We recently identified a small molecule able to inhibit AKAP-Lbc-mediated RhoA activation and
oncogenic signaling in metastatic prostate cancer cells [96]. While these studies suggest that AKAP-Lbc
might represent a potential target in anticancer therapy, one has to consider that compounds inhibiting
AKAP-Lbc signaling could potentially interfere with the protective function of the anchoring protein
in cardiac cells. Based on this possibility, it will be crucial to carefully evaluate the chronic effect of
such molecules on cardiac function.
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In conclusion, based on the experimental evidence accumulated over the past decade one could
postulate that manipulating the activity of cardioprotective signaling enzymes anchored to AKAP-Lbc
might confer early cardiac protection. However, additional investigations will be necessary to decipher
the impact of interfering with the AKAP-Lbc signaling properties on late cardiac remodeling and
transition to heart failure.
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Abstract: Evidence collected over the last ten years indicates that Epac and cAMP scaffold proteins
play a critical role in integrating and transducing multiple signaling pathways at the basis of cardiac and
lung physiopathology. Some of the deleterious effects of Epac, such as cardiomyocyte hypertrophy
and arrhythmia, initially described in vitro, have been confirmed in genetically modified mice for
Epac1 and Epac2. Similar recent findings have been collected in the lung. The following sections will
describe how Epac and cAMP signalosomes in different subcellular compartments may contribute to
cardiac and lung diseases.
Keywords: cAMP; Epac; compartmentalization; A-kinase anchoring proteins; phosphodiesterases
1. Introduction
In the current manuscript, we aim to highlight the most recent insights into signaling by one
of the most ancient second messengers cyclic AMP (cAMP). We focus on novel aspects of cAMP
scaffolds maintained by a diverse subset of proteins, among them receptors, exchange proteins,
phosphodiesterases, and A-kinase anchoring proteins. We will start with the cardiac system and will
then proceed with the lung.
2. Epac in Cardiac Disease
Cyclic AMP (cAMP) is one the most important second messengers in the heart because it regulates
many physiological processes, such as cardiac contractility and relaxation. The β-adrenergic receptor
(β-AR) belongs to the G protein-coupled receptor (GPCR) superfamily, and is essential for the
adaptation of cardiac performance to physiological needs. Upon stimulation of β-AR by noradrenaline
(released from cardiac sympathetic nervous endings) and circulating adrenaline, cAMP is produced
and activates protein kinase A (PKA), which phosphorylates many of the components involved in the
excitation-coupling mechanisms, such as L-type the calcium channel (LTCC), phospholamban (PLB),
cardiac myosin binding protein C (cMyBPC), and the ryanodine receptor 2 (RyR2), to modulate their
activity [1]. Activation of LTCCs produces an inward Ca2+ current (ICa) that activates RyR2 through
the mechanism known as Ca2+-induced Ca2+ release (CICR), which raises cytosolic Ca2+ concentration
and activates contraction. Whereas PKA-dependent LTCC and RyR2 phosphorylation results in
mobilization of Ca2+ available for contraction, PKA-mediated phosphorylation of phospholamban,
a peptide inhibitor of sarcoplasmic reticulum (SR) Ca2+-ATPase promotes increased Ca2+ reuptake
in the SR, thereby removing Ca2+ from the cytoplasm and accounting for relaxation [1]. In addition,
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binding of cAMP to hyperpolarization-activated cyclic nucleotide-gated (HCN) channels that carry
the pacemaker current, increases heart rate in response to a sympathetic stimulation (chronotropic
effect). From the three β-adrenergic subtypes expressed in the mammalian heart, regulation of cardiac
function is ascribed to the β1- and β2-adrenergic receptor subtypes [2].
Although acute stimulation of the β-AR pathway has beneficial effects on heart function,
a sustained activation of β-AR contributes to the development of pathological cardiac remodeling by
inducing ventricular hypertrophy, fibrosis, and ultimately, arrhythmia and heart failure (HF), one of
the most prevalent causes of mortality globally [3–5]. Toxic effects of sustained β-AR stimulation are
consistent with the finding that in HF patients, elevated plasma catecholamine levels correlate with the
degree of ventricular dysfunction and mortality [6]. However, β-blocker therapy in HF may appear
counterintuitive, as catecholamines represent the main trigger of cardiac contractility and relaxation.
Indeed, β-blockers restore the adrenergic signaling system which is desensitized by high and chronic
concentrations of catecholamines [3]. Thus, it is not so much to block the whole adrenergic signaling
which seems important, but rather to modulate its different aspects. It is in this context that several
research groups are interested in understanding the role of exchange proteins directly activated by
cAMP (Epac) proteins in the development of cardiac arrhythmia and HF [4].
Evidence collected over the last ten years indicates that Epac proteins play a critical role in
integrating and transducing multiple signaling pathways at the basis of cardiac physiopathology.
Some of the deleterious effects of Epac, such as cardiomyocyte hypertrophy and arrhythmia,
initially described in vitro, have been confirmed in genetically modified mice for Epac1 and Epac2.
The following sections will describe how Epac signalosomes in different subcellular compartments of
the cardiomyocyte may contribute to cardiac disease.
2.1. Epac Signalosome in Pathological Cardiac Remodeling
Given the importance of the β-AR-cAMP pathway in cardiac pathophysiology, several studies aim
to investigate the role of Epac proteins in the development of cardiac remodeling and HF. Remodeling
pathological disorder comprises multiple attacks of which the best described are the modification of the
geometry of the cardiac cavity associated with cardiomyocyte hypertrophy, fibrosis, and alterations of
calcium handling and energy metabolism [7]. In the long term, these changes affect cardiac contractility
and favor progression of HF, a process predominantly relying on cardiac signaling in response to the
β1-AR subtype.
Among the two Epac isoforms, Epac1 expression was found to be upregulated in various models
of cardiac hypertrophy, such as chronic catecholamine infusion and pressure overload induced by
thoracic aortic constriction, as well as in the end stages of human HF [8,9]. On the contrary, the
anti-hypertrophic action of some hormones and microRNA, including the growth hormone-releasing
hormone and microRNA-133, involves Epac1 inhibition [10,11]. A more direct evidence of Epac1’s
role in the regulation of cardiac remodeling came from the observation that Epac1 overexpression,
or its direct activation with the Epac1 preferential agonist, 8-pCPT-2-O-Me-cAMP (8-CPT), increased
various markers of cardiomyocyte hypertrophy, such as protein synthesis and hypertrophic genes in
primary ventricular myocytes [8,12,13]. It is hypothesized that in the setting of cardiac remodeling,
adaptive autophagy antagonizes Epac1-induced cardiac hypertrophy [14]. In vitro studies revealed
that the pharmacological inhibition of Epac1 by a tetrahydroquinoline analogue, CE3F4, prevented
the induction of cardiomyocyte hypertrophy markers in response to a prolonged β-AR stimulation in
rat ventricular myocytes [14–16]. These findings indicate that Epac1 signaling may provide a novel
means for the treatment of pathological cardiac hypertrophy. It is worth mentioning that Epac1 has
also been recently identified as a potential mediator of radiation-induced cardiomyocyte hypertrophy,
suggesting that this cAMP-sensor is involved in the side effects of anticancer therapy [17].
Compelling evidence indicates that Epac1 signalosome is highly compartmentalized and occurs
in several micro subcellular compartments, such as the plasma membrane, sarcoplasm, and the
nuclear/perinuclear region of cardiomyocytes [8,18–20]. A macromolecular complex containing the
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scaffolding protein β-arrestin, Epac1, and Ca2+/calmodulin-dependent protein kinase II (CaMKII),
has been reported in the heart [21]. Epac1 constitutively interacts with the β-arrestin in the
cytoplasm under basal conditions. Stimulation of β1-AR, but not β2-AR, induces the recruitment of
β-arrestin–Epac1 signaling complex at the plasma membrane, whereby it activates a pro-hypertrophic
signaling cascade involving the small GTPases Rap2 and Ras, and CaMKII [22]. This acts as a
trigger for histone deacetylase type 4 (HDAC4) nuclear export, which initiates a pro-hypertrophic
gene program (Figure 1). Interestingly, Epac1 is prevented from undertaking similar signaling
at the β2-AR, as the cAMP-hydrolyzing enzyme, phosphodiesterase (PDE)4D5, impedes the
interaction of Epac1 with β-arrestin, and therefore its recruitment to activated β2-AR. Of particular
importance, disruption of PDE4D5–β-arrestin complex formation with a cell-permeant peptide
promotes binding of Epac1–β-arrestin to β2-AR and, consequently β2-AR signaling switches to a
β1-AR-like pro-hypertrophic signaling to increase cardiac myocyte remodeling [22]. Taken together,
these data provide evidence that Epac compartmentalization contributes to the functional differences
between cardiac β-AR subtypes.
Besides its sarcolemma distribution, Epac1 is also concentrated in the nuclear/perinuclear region
of cardiomyocytes, positioned well to regulate nuclear signaling [8,20]. Specifically, it was shown that
Epac1 is scaffolded at the nuclear envelope with phospholipase C (PLC)ε and muscle-specific A-kinase
anchoring proteins (AKAPs) to regulate the hypertrophic gene program in primary cardiomyocytes [19,23,24]
(Figure 1). Interestingly, a detailed analysis of Ca2+ mobilization in different microdomains demonstrated
that Epac (probably Epac1) preferentially elevated Ca2+ in the nucleoplasm, correlating with the
perinuclear/nuclear localization of Epac1 [25]. Additional in vitro studies showed that Epac1, via its
downstream effector, the small G protein Rap2, activated PLC to promote the production of inositol
1,4,5-trisphosphate (IP3) [26]. Based on this finding, a working hypothesis has been proposed, whereby
Epac1 can activate PLC, causing nuclear Ca2+ increase via perinuclear IP3 receptor (IP3-R), which
results in the activation of Ca2+-dependent transcription factors involved in cardiac remodeling [25,27]
(Figure 1). Consistently, in cultured cardiomyocytes, it has been reported that Epac activates CaMKII
to induce the nuclear export of HDAC4 de-repressing the transcription factor myocyte enhancer
factor 2 (MEF2) which activates gene transcription, essential for the hypertrophic program [25,26].
Collectively, these findings point to Epac1 role in activating the excitation–transcription coupling,
the process by which Ca2+ activates gene transcription [27]. Additional Epac hypertrophic signaling
have been described and include the GTPase H-Ras, the Ca2+ sensitive protein, calcineurin, and its
downstream effector, nuclear factor of activated T cells (NFAT), which are key mediators of cardiac
remodeling [8,26].
More recently, the study of Epac gene deleted mice has made it possible to better understand the
role of these proteins in cardiac pathological remodeling. Global knockout (KO) mice for Epac1 or
Epac2, or double full KO for Epac1 and Epac2, do not present any cardiac abnormality, suggesting
that these guanine-nucleotide exchange factors activated by cyclic adenosine monophosphate
(cAMP-GEFs) do not play a major role during cardiac development [14,28,29]. None of the deletions
appreciably affected basal cardiac function. Although Epac has been shown to influence myofilament
Ca2+ sensitivity in rat cardiomyocytes [18,30], the effects of Epac activation in cell contractility
remain controversial, and may depend on the steady-state Ca2+ levels at which the myocyte is
functioning [18,31–33]. Overall, Epac proteins do not play a major role in the physiological regulation
of cardiomyocyte contractility in response to acute β-AR stimulation, compared with PKA, which
is the main cAMP effector in this process [29,34]. However, Epac1 genetic inhibition specifically
reduces cardiac remodeling induced by chronic activation of β-AR, which confirms the importance of
Epac1 in the β-adrenergic signaling during cardiac stress condition [14,28]. Moreover, Epac1 deleted
cardiomyocytes prevented 8-CPT-dependent HDAC5 translocation, consistent with its involvement in
pathological hypertrophy [20]. Of note, in another model of cardiac hypertrophy induced by aortic
stenosis, Epac1 knockdown fails to prevent cardiac hypertrophy, but only fibrosis and cardiomyocyte
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apoptosis, suggesting that the cardioprotective effects of Epac1 deletion with respect to hypertrophy
depend on the nature of stress [19].
 
Figure 1. Epac signalosome in cardiac hypertrophy and ischemia. Under adrenergic stimulation,
the Epac1–β-arrestin complex is recruited at the β1-AR, and activates a pro-hypertrophic signaling
pathway. Epac1 is also scaffolded at the nuclear envelope with phospholipase C (PLC)ε and
muscle-specific A-kinase anchoring proteins (mAKAP) to regulate the hypertrophic gene program.
In the nuclear/perinuclear region, PLCε increases nuclear Ca2+ content via the activation of the
perinuclear IP3 receptor (IP3-R). Epac1 hypertrophic signaling also involves CaMKII-dependent
phosphorylation of RyR2, leading to Ca2+ leak from the sarcoplasmic reticulum and subsequent
calcineurin (CaN) activation. The anti-hypertrophic action of the growth hormone-releasing hormone
(GHRH) or its agonistic analog, MR-409, involves the protein kinase A (PKA)-dependent inhibition of
Epac1 expression. MicroRNA-133 (miR-133) is cardioprotective, and targets several components of
β1-AR signaling. In the context of cardiac ischemia, mitochondrial Epac1 (MitEpac1) is activated
by cAMP produced by the soluble adenylyl cyclase (sAC), and increases Ca2+ overload and
ROS accumulation to promote mitochondrial permeability transition pore (MPTP) opening and
cardiomyocyte apoptosis. α-KG,α-ketoglutarate; β1-AR, β1-adrenergic receptor; AC, transmembrane
adenylyl cyclase; CaMKIIδ, Ca2+/calmodulin-dependent protein kinase II δ-isoform; cAMP, cyclic
adenosine monophosphate; DAG, diacylglycerol; GHRH-R, GHRH receptor; GRP75, chaperone
glucose-regulated protein 75; HDAC4, histone deacetylase 4; IDH2, isocitrate dehydrogenase 2;
IP3, inositol-1,4,5-trisphosphate; IP3R1, IP3 receptor 1; IP3R1, inositol-1,4,5-triphosphate receptor 1;
MEF2, myocyte enhancer factor-2; NFAT, nuclear factor of activated T-cells; PIP2, phosphatidylinositol
4,5-biphosphate; ROS, reactive oxygen species; Ser, serine; TCA, tricarboxylic acid cycle; VDAC1,
voltage-dependent anion channel 1.
2.2. Role of Epac in Heart Failure and Arrhythmia
Interestingly, Epac1 KO mice show better cardiac contractility (maintenance of the inotropic
reserve) and decreased susceptibility to HF in response to different hypertrophic stress conditions
(catecholamine infusion or myocardial pressure overload) [14,28]. Further evidence for the
cardioprotective effect of Epac1 inhibition came from the recent report that Epac1 deficiency attenuates
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type 5 adenylyl cyclase-mediated catecholamine stress-induced cardiac dysfunction [35]. It is
interesting to note that Epac1 and Epac2 deleted mice are protected from the incidence of atrial
and ventricular arrhythmia, respectively, suggesting a specific role of Epac isoforms in cardiac rhythm
disorders [28,29]. Conversely, direct pharmacological activation of Epac with the cAMP analogue 8-CPT
promotes ventricular arrhythmogenesis in isolated perfused mouse hearts [36]. Such arrhythmogenic
features were also observed in rat cardiomyocytes, but after sustained Epac activation [37]. Yet, Brette
and colleagues reported that 8-CPT induced an action potential lengthening in rat ventricular myocytes,
a process involved in the genesis of arrhythmia by predisposing cardiac myocytes to early after
depolarizations and dispersion of repolarization [38].
Mechanistically, few studies demonstrated that mainly Epac1 regulated the expression level
of proarrhythmic channels, such as the slow delayed-rectifier potassium K+-current (IKs) subunit
potassium voltage-gated channel and transient receptor potential canonical 3 and 4 channels that
enhance store-operated Ca2+ entry [39,40] (Figure 2). Epac function may also affect susceptibility to
arrhythmia via the regulation of gap junction formation [41,42]. Importantly, in isolated ventricular
myocytes, activation of Epac with either 8-CPT or β1-AR induces a spontaneous release of Ca2+ from
the SR (a process named Ca2+ sparks) via the CaMKII-dependent phosphorylation of RyR2 on Serine
2814 or 2815 (depending on the species), thereby causing diastolic Ca2+ leak in a PKA-independent
manner [29,31–33,43] (Figure 2). Consistent with the localization of Epac2 along T tubules in mouse
cardiomyocytes [20], it has been proposed that the increase of ectopic release of Ca2+ following
Epac2 (and not Epac1) activation by β1-AR, could be the cause of arrhythmogenic effects in
cardiomyocytes [29]. The recent finding that SR Ca2+ leak observed upon PDE4 inhibition involves
Epac2 suggests that the interaction of PDE4 and Epac2 are critical for coordinating the pro-arrhythmic
effect of cAMP [34]. Adding complexity to the matter, another study showed that Epac1 promoted PLB
hyperphosphorylation on Serine 16 via PKCε [28]. This could lead to SR Ca2+ overload with Ca2+ leak
and subsequent arrhythmia [28] (Figure 2). Based on the aforementioned studies, the beneficial effect of
Epac inhibition seems, therefore, very attractive for the development of novel therapies against HF and
arrhythmia. However, few controversies have been reported in the literature. Among them, Yang and
colleagues recently reported that pharmacological inhibition of Epac2 with ESI-05 was proarrhythmic
in rat [44]. Further pharmacological and genetic studies combining the use of Epac isoform-specific
ligands and conditional Epac KO mice are required to better decipher the role of Epac isoforms in
cardiac rhythm disorders.
2.3. Role of Mitochondrial Epac in Cardiac Ischemia
Acute myocardial infarction is a leading cause of mortality and morbidity worldwide. Early coronary
reperfusion has been established as the best therapeutic strategy to limit infarct size and improve
prognosis. However, the process of reperfusion can itself induce cardiomyocyte death, known as
myocardial reperfusion injury (I/R), for which there is still no effective therapy [45,46]. Mitochondria
have been recognized as playing a central role in both apoptotic and necrotic cell death [47]. Indeed,
during I/R injury, cardiomyocyte death is initiated by mitochondrial Ca2+ overload and an excessive
production of reactive oxygen species (ROS) which trigger the mitochondrial permeability transition
pore (MPTP) opening, resulting in mitochondrial depolarization, swelling, and rupture of the external
mitochondrial membrane. This leads to the uncoupling of the respiratory chain, and the efflux of
cytochrome c and other proapoptotic factors that may induce apoptosis or necrosis [48].
Depending on the nature of the stimulus and the cell type used in the study, Epac may play a
proapoptotic or antiapoptotic role [49]. For instance, in neonatal rat cardiomyocytes, Epac cooperates
with PKA in the antiapoptotic effects of exendin-4, a glucagon-like peptide-1 receptor agonist [50].
Similarly, activation of both PKA and Epac with cAMP analogues confers cardioprotection against I/R
injury in isolated rat heart [51]. Interestingly, it is suggested that long-term feeding of an obesogenic
high fat diet renders the myocardium less susceptible to I/R induced injury via Epac-dependent
signaling [52]. Yet, recent findings using isolated cardiomyocytes from ischemic rat hearts have
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implied that the cardioprotective effect induced by urocortin-1 involved the Epac2 pathway [53].
On the contrary, in vivo experiments showed that Epac1 genetic ablation in mice protected against
myocardial I/R injury with reduced infarct size and cardiomyocyte apoptosis [54]. Consistent with an
earlier finding showing the mitochondrial expression of transfected Epac1 in COS-7 cells [55], Epac1
is expressed in the mitochondrial inner membrane and matrix of cardiomyocytes. A form of Epac1
deleted in its mitochondrial-targeting sequence protects against hypoxia/reoxygenation (a condition
mimicking in vivo I/R)-induced cell death, indicating that mitochondrial Epac1 participates in
cardiomyocyte death during hypoxic stress [54]. Mechanistic studies demonstrated that during
hypoxia/reoxygenation, Epac1 was activated by the type 10 soluble adenylyl cyclase (sAC) to increase
mitochondrial Ca2+ uptake and ROS production, thereby promoting mitochondrial death signaling,
such as MPTP opening, cytochrome c release, and both caspase-9 and -3 activation [54]. However,
these results are not in agreement with another study, which reported that direct activation of sAC
with HCO3− prevented Ca2+-induced MPTP opening through Epac1, suggesting that Epac1 might
protect from cardiomyocyte death [56]. The higher amount of cAMP produced in the model of
hypoxia/reoxygenation, and subsequent massive increase in mitochondrial ROS and Ca2+ levels,
could potentially account for the observed differences.
 
Figure 2. Role of Epac in cardiac arrhythmia. Epac proteins increase the phosphorylation state of the
ryanodine receptor 2 (RyR2) via CaMKII, and subsequent Ca2+ leak from the sarcoplasmic reticulum
(SR) may trigger arrhythmia. Epac1-induced hyperphosphorylation of phospholamban (PLB) may
also contribute to the development of arrhythmia and heart failure. In addition, Epac enhances
store-operated Ca2+ entry (SOCE)-like activity, which is related to an increased amount of functional
transient receptor potential canonical (TRPC) 3 (TRCP3) and TRCP4 channels. This additional Ca2+
entry pathway in the cardiomyocyte and the downregulation of the potassium voltage-gated channel
subfamily E member 1 (KCNE1) participate in the proarrhythmic effect of Epac proteins. β1-AR,
β1-adrenergic receptor; AC, transmembrane adenylyl cyclase; CaMKII, Ca2+/calmodulin-dependent
protein kinase II; cAMP, cyclic adenosine monophosphate; CaN, Calcineurin; DAG, diacylglycerol; IP3,
inositol-1,4,5-trisphosphate; P, phosphorylation; PDE4, phosphodiesterase 4; PIP2, phosphatidylinositol
4,5-biphosphate; PKCε, protein kinase C epsilon type; PLB, phospholamban; PLCε, phospholipase C
epsilon type; SERCA, sarcoendoplasmic reticulum calcium transport ATPase.
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Interestingly, we found that Epac1 is highly compartmentalized in mitochondria and targets
key proteins involved in mitochondrial Ca2+ uptake and ROS production. Indeed, firstly, we
revealed that Epac1 interrelated with a macromolecular complex composed of the VDAC1 (voltage-
dependent anion channel 1), the GRP75 (chaperone glucose-regulated protein 75), and the IP3R1
(inositol-1,4,5-triphosphate receptor 1). This complex localized at the endoplasmic reticulum (ER)
junction is considered as a hot spot from Ca2+ transfer from the ER to the mitochondria [57]. Under
hypoxic condition, Epac1 activation increased the interaction with the VDAC1/GRP75/IP3R1 complex,
hence facilitating ER to mitochondrial Ca2+ transfer. Epac1-mediated mitochondrial Ca2+ overload
subsequently provoked MPTP opening, cytochrome c release, and ultimately, cardiomyocyte death [54]
(Figure 1). Secondly, our study revealed a key role for Epac1 in the accumulation of mitochondrial
ROS production during hypoxia. Surprisingly, we observed that Epac1 imported CaMKII into matrix
where they formed a multi-molecular complex with isocitrate dehydrogenase 2 (IDH2), a critical
mitochondrial enzyme of the tricarboxylic acid (TCA) cycle involved in ROS detoxification [54].
Mitochondrial Epac1 negatively regulates via the CaMKIIδ-dependent phosphorylation activity of
IDH2, and hence, decreases the antioxidant capabilities of the cardiomyocytes during I/R [54] (Figure 1).
Altogether, these findings identify Epac1 as a central mechanism for mitochondrial Ca2+ entry and
ROS production in myocardial cell death, and indicate that mitochondrial-targeted Epac1 inhibition
could prevent or reduce myocardial death in the setting of cardiac ischemia.
3. Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease (COPD) is one major health problem known to increase
morbidity and mortality all over the world. It is predicted that COPD will become the third leading
cause of death (~8.3 million), and the third leading cause of death by disability until 2030 [58]. Globally,
exposure to cigarette smoke (CS) is considered to be the primary cause for COPD. Inhalation of CS
causes the release of different cytokines, chemokines, and lipid mediators (such as tumor necrosis
factor-α (TNF-α), interleukin 8 (IL-8), transforming growth factor-β (TGF-β) and leukotriene B4) from
resident cells in the lung including epithelial cells and alveolar macrophages. Subsequently, these
mediators activate inflammatory cells which release large amounts of proteases, including elastase
and matrix metalloproteinases (MMPs), into the matrix compartment, thereby triggering the complex
process of remodeling, thus leading to obstruction of small airways, emphysema, with enlargement of
air spaces and destruction of lung parenchyma, loss of lung elasticity, and closure of small airways,
fibrosis, inflammation, mucus hyper-secretion, and pulmonary hypertension. Furthermore, more and
more evidence indicates that CS exposure also provokes an oxidant/antioxidant imbalance, which
in turn will subsequently induce COPD exacerbations [59,60]. Therefore, the most effective way to
prevent the development of COPD is smoke cessation [61,62]. Additionally, other factors including
exposure to indoor air pollutions from biomass fuels, particularly in developing countries, occupational
dusts, chemicals, and genetics, may also contribute toward disease morbidity and mortality [63,64].
Currently, the pharmacological management of COPD mainly relies on bronchodilator therapy, mainly
β2-agonists and anticholinergics, by activating different signaling pathways [65–68]. β2-Agonists
induce airway smooth muscle (ASM) cell relaxation through enhanced intracellular cAMP production,
whereas anticholinergics or antimuscarinic drugs antagonize muscarinic receptors (M1, M2 and
M3) to a certain extent, thus inhibiting ASM contraction, due to the reduction of intracellular Ca2+.
PDE4 inhibitors, which mediates cAMP breakdown (see below), are also approved to be used as
an add-on treatment for severe COPD patients associated with bronchitis and a history of frequent
exacerbations [69]. In addition, anti-inflammatory drugs, such as inhaled glucocorticosteroids, are
often used, mainly in patients with frequent exacerbations [70].
3.1. Compartmentalization of cAMP in the Lung
The production of cAMP is initiated by the stimulation of Gs-coupled receptors, such as the β-AR
and distinct subset of prostanoid receptors [71]. After receptor ligand binding, ACs are activated by the
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α subunit of the Gs-protein, thus resulting in cAMP synthesis from adenosine triphosphate (ATP) [72].
Intracellular cAMP levels are tightly controlled by cyclic nucleotide PDEs, which hydrolyze cAMP
to 5′-AMP, and thereby terminate its signaling [73]. Membrane clustering of Gs-coupled receptors
ACs and PDEs, which are localized in lipid rafts and caveolae, together with cAMP downstream
effectors, such as cAMP-gated ion channels, PKA, and Epac, dynamically regulate intracellular cAMP
signaling in the lung, including airway relaxation [74,75], reduction of inflammation [76–79], and
fibrosis [77,80]. In addition, AKAPs bind directly to PKA and its targeted proteins, and physically
tether these multi-protein complexes to specific locations, generating spatiotemporal discrete signaling
complexes [81,82], and subsequently controlling specific cellular responses (Figure 3).
Figure 3. cAMP compartmentalization in COPD. As one of main inducing factors, cigarette smoke
(CS) is able to modulate numerous molecular signals in both structural and inflammatory cells in
the lung. CS decreases the expressions of A-kinase anchoring protein (AKAP)5 and AKAP12, thus,
regulating the effect of β2-agonists on COPD pathological development. Moreover, CS interferes with
cAMP compartments by AKAP9, which binds and regulates the function of adenylyl cyclases (ACs).
In addition, intracellular cAMP concentration is further decreased by upregulating cAMP hydrolyzing
enzyme PDEs expression. β2-AR, β2-adrenergic receptor; AC, transmembrane adenylyl cyclase; cAMP,
cyclic adenosine monophosphate; ATP, adenosine triphosphate; PDE4, phosphodiesterase 4; AKAP,
A-kinase anchoring protein; PKA, protein kinase A; Epac, exchange protein directly activated by cAMP;
ROS, reactive oxygen species.
3.2. Cyclic Nucleotide Phosphodiesterases in COPD
PDEs, which comprise 11 family members and at least 21 isoforms with different splice variants [83],
are able to hydrolyze cyclic nucleotides (cAMP and cGMP) to their inactivate 5′ monophosphates
within subcellular microdomains, thereby modulating cyclic nucleotide signaling pathways.
PDE4 is the most extensively studied PDE, and it is widely expressed in almost all different kinds
of cells in the lung. From a clinical viewpoint, there are dramatic differences in the PDE4 isoforms’
expression in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers [84].
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PDE4A4 was significantly upregulated not only in lung macrophages from COPD patients, but also
in peripheral blood monocytes of smokers, together with PDE4B2 [84]. In isolated peripheral blood
neutrophils, significantly higher PDE4B and PDE4D, but not PDE4A or PDE4C, mRNA levels could
be observed in the COPD patients compared to healthy subjects. Yoon et al. reported the association
of a novel PDE4D single nucleotide polymorphism (rs16878037) with COPD from a genome-wide
association study [85]. PDE4 is also of importance in other pulmonary diseases, such as asthma.
It was shown by Trian et al. that β-agonist isoproterenol-induced cAMP production in asthmatics
ASM cells was dramatically decreased due to increased PDE4D expression, rather than an alteration
in PDE3A or PDE5A expression [86]. Furthermore, CS, as the primary cause for COPD, was also
proven to increase PDE4 isoforms’ expression and activity in different experimental settings. Higher
PDE4B and PDE4D mRNA levels could be detected after 6 h CS extract exposure in isolated peripheral
blood neutrophils [87]. Exposure with CS extract for 24 h upregulated PDE4 activity in differentiated
bronchial epithelial cells, with a markedly increased mRNA transcripts for PDE4B, while increments
in PDE4A and D transcripts remained below significance [88].
Other PDE family members also attracted the attention of researchers, such as PDE7, which is
encoded by PDE7A and PDE7B. PDE7B is expressed predominantly in brain, heart, and liver, but not in
lung [89,90]. However, PDE7A, which is widely expressed in airway structural cells, including airway
epithelial cells [91], ASM cells and lung fibroblast, and also human proinflammatory and immune
cells [92], has particularly drawn attention in the treatment of COPD [93]. It has been shown that the
protein expression of PDE7A1 is significantly increased in human monocytes during cell aging [94].
In addition, PDE3A is upregulated in human endobronchial biopsies obtained from patients with
asthma, indicating that PDE3 is also involved in the pathogenesis of lung diseases.
3.3. AKAPs in COPD
As one of the most vital pharmaceutical targets in COPD, β2-AR directly interacts with AKAP5
and AKAP12, which modulate either the downstream extracellular signal-regulated protein kinase
(ERK)1/2 activation or receptor resensitization [81,94–96]. Therefore, it is believed that AKAP5 and
AKAP12 play a pivotal role in modulating the effect of β2-agonists on COPD pathological development.
Poppinga et al. showed that less AKAP5 and AKAP12 proteins could be detected in CS-exposed
ASM cells, which was also confirmed using lung tissues from COPD patients [97]. Moreover, st-Ht31,
which disrupts global AKAP–PKA interactions (see Figure 3), increased the IL-8 secretion induced
by CS exposure in human ASM cells, and reduced the suppression of β2-agonist fenoterol through
disturbed ERK signaling [97]. On the contrary, AKAP5 and AKAP12 expression were not significantly
changed by CS in human bronchial epithelial cells [98], indicating a different regulatory pathway
involved other AKAP members in epithelial cells (Figure 3). Indeed, it has been demonstrated that
AKAP9, which binds and regulates ACs [99,100], was able to maintain epithelial barrier function [99]
(Figure 3). In addition, as a major site for energy generation and reactive oxygen species (ROS)
production, mitochondria cAMP compartments was regulated by a set of mitochondrial AKAPs.
In particular, AKAP121, tethering PKA to the outer wall of mitochondria, play a pivotal role in
mitochondrial function maintenance and keeping the tolerance to oxidative stress in vascular smooth
muscle cells [101], indicating a potential protective effect on CS-induced ROS production for future
studies (Figure 3).
3.4. Epac in COPD
In addition to PKA, as mentioned earlier, Epac is another downstream effector for cAMP [102].
Epac, which is able to be activated by PKA or cAMP in both a PKA-dependent and -independent
manner, has been proven to associate with diverse effectors, thus contributing to numerous cellular
processes, including airway relaxation, cytokine secretion, barrier function, cell proliferation, migration,
and protein translocation in the lung. Also, it has been demonstrated by Scott et al. that Epac
activation by 8-CPT could reverse neutrophils’ phagocytic impairment induced experimentally by
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using β2-agonists, without interfering with RhoA activity [103]. In addition, Epac activation by 8-CPT
changed methacholine-induced myosin light chain (MLC) phosphorylation in ASM cells, skewing the
balance between RhoA and Rac1 towards Rac1, and thus reducing the phosphorylation of MLC; a
process leading to ASM relaxation [75]. In addition, pharmacological activation of Epac attenuated CS
extract-induced IL-8 release from human ASM cells by activating the NF-κB inhibitory protein IκBα and
inhibiting p65 nuclear translocation, underling the inhibitory effect of Epac on NF-κB activation [104].
Two isoforms, Epac1 and Epac2, are expressed in most lung cell types, among them, ASM, epithelial
cells, fibroblasts, and some immune cells [103,105]. Intriguingly, a selective downregulation of Epac1,
rather than Epac2, expression was observed in both CS-exposed ASM cells and lung tissue from COPD
patients, pointing to distinct intracellular functions and locations of Epac1 and Epac2 [104]. It was
further demonstrated that the upregulation of miRNA7 expression in COPD patients was linked to the
downregulation of Epac1 [106]. Moreover, the role of Epac1 and Epac2 was further investigated in
Epac1(−/−) and Epac2(−/−) mice using an acute and short-term CS exposure model. Compared to
wild type mice exposed to CS, Epac1(−/−) mice showed increased MUC5AC and matrix remodeling
parameters (TGF-β, collagen I, and fibronectin) in the lung homogenates, however, Epac2(−/−) mice
had lower amount of inflammatory cells (total inflammatory cells, macrophages, and neutrophils)
in the bronchoalveolar lavage fluid, suggesting that Epac1 was able to inhibit remodeling process,
whereas Epac2 primarily increased inflammatory processes [107]. These differences between Epac1
and Epac2 indicate compartmentalized cAMP signaling in the lung, which needs to be further studied
in the future.
4. Conclusions and Future Perspectives
Evidence collected over the last decade indicates that Epac and the cAMP signalosome substantially
contribute to the development and progression of heart and obstructive lung disorders, as exemplified
here by studies focusing on COPD. Traditionally, research focused on PKA as one of the main targets
of cAMP. However, recent studies indicated that next to classical signaling pathways, there seem to be
substantial role for additional cAMP targets, such as Epac, and for the theme of compartmentalized
cAMP signaling. The latter topic involves next to cAMP-elevating receptors (for example the β-ARs),
cAMP-producing adenylyl cyclase and cAMP-degrading PDEs, a subset of AKAPs. Particularly,
studies on the levels of Epac and PDEs benefit from the recent development of pharmacological
tools [13,19,108], suggesting that the therapeutic arsenal to treat chronic disorders of the heart and the
lung will be substantially improved in the next decades. Unfortunately, the research on compartments
being stabilized and maintained by members of the AKAP superfamily still lacks the development of
subtype specific modulators, which will hopefully be the focus of future studies.
In the heart, research over the last years has shown that particularly Epac1 seems to act
cardioprotectively with regard to cardiac fibrosis and apoptosis, but that the role of Epac1 seems
to be rather distinct, and being largely dependent on the nature of the stress inducer. Such findings
nicely reflect the fact that our aging world population requires a vast majority of novel personalized
medicine-based drugs [19,71,109]. Distinct roles of Epac1 and Epac2 seemed to emerge in the field of
heart failure and arrhythmia, as well as cardiac ischemia. Here, interaction of Epac with members
of the AKAP family or PDE subtype, such as PDE4, seem to be leading next to a defined subcellular
targeting of Epacs to defined compartments, such as the nucleus and mitochondria. In the lung, it
seemed to be that PDEs are crucially involved in the compartmentalization of cAMP next to members
of the AKAP family and Epac. Interestingly, it seemed to be that subtypes of PDEs guide cAMP
properties in a rather response-specific manner, such as anti-inflammation and bronchodilation. Novel
anti-inflammatory drugs are urgently required, as under disease conditions being characterized by
an overload of ROS, the golden treatment standard, glucocorticosteroids, are ineffective. Most likely,
compartment-specific mode of actions of PDEs are supported by AKAPs and Epac. Future studies
should focus on unravelling compartmentalized signaling cues in the heart and lung.
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Abstract: The Popeye domain containing (POPDC) genes encode transmembrane proteins, which are
abundantly expressed in striated muscle cells. Hallmarks of the POPDC proteins are the presence
of three transmembrane domains and the Popeye domain, which makes up a large part of the
cytoplasmic portion of the protein and functions as a cAMP-binding domain. Interestingly, despite
the prediction of structural similarity between the Popeye domain and other cAMP binding domains,
at the protein sequence level they strongly differ from each other suggesting an independent
evolutionary origin of POPDC proteins. Loss-of-function experiments in zebrafish and mouse
established an important role of POPDC proteins for cardiac conduction and heart rate adaptation
after stress. Loss-of function mutations in patients have been associated with limb-girdle muscular
dystrophy and AV-block. These data suggest an important role of these proteins in the maintenance
of structure and function of striated muscle cells.
Keywords: Popeye domain; cAMP binding; effector protein; cardiac arrhythmia; limb-girdle
muscular dystrophy; atrioventricular block
1. Introduction
The second messenger cyclic adenosine 3′,5′-monophosphate (cAMP) activates an evolutionary
ancient and universally important intracellular signaling pathway. Several effector proteins have been
identified, which bind cAMP with high affinity causing their activation and leading to the execution of
a variety of biological activities (Figure 1).
The most important and prominent cAMP effector protein is protein kinase A (PKA), which upon
binding of up to four cAMP molecules to the regulatory subunit causes an activation of the catalytic
subunits leading to the phosphorylation of many protein substrates. It is estimated that around 350
proteins are phosphorylated in response to β1-adrenergic stimulation, many of which are targeted
by PKA [1]. PKA protein substrates are diverse but include proteins regulating energy metabolism,
cardiac pacemaking and excitation/contraction coupling. PKA is bound by a number of scaffolding
proteins called A kinase anchoring proteins (AKAPs) [2]. In cardiac myocytes, several AKAPs are
expressed including D-AKAP1, D-AKAP2, AKAP15/18, AKAP79/150, Yotiao, mAKAPβ, AKAP-Lbc,
Gravin and SKIP [3]. AKAPs are responsible to target PKA to specific subcellular domains such as
the plasma membrane, transverse (T)-tubules, sarcoplasmatic reticulum, myofilaments and nuclear
envelope [2]. AKAP proteins not only bind PKA but also protein substrates and other signaling
molecules [2]. Recent data suggest that at physiological cAMP concentrations, dissociation of the PKA
holoenzyme does not occur [4]. PKA being bound by different AKAPs in the cell is therefore only able
to phosphorylate substrates in its direct vicinity, which enhances specificity and compartmentation of
the cellular response.
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Figure 1. Four cAMP effector proteins are expressed in the heart. Norepinephrine (NE) secreted by
sympathetic neurons binds to the β-adrenergic receptor leading to Gs activation and synthesis of cAMP
by adenylate cyclase (AC). Acetylcholine (ACh) is secreted by parasympathetic neurons and binds
to muscarinergic ACh receptors leading to an activation of Gi causing AC inhibition. The balance of
sympathetic and parasympathetic input therefore determines the level of cAMP production. cAMP
production in cells is compartmentalized and this is mainly achieved by phoshodiesterases (PDE),
which limits cAMP diffusion through degradation. Four effector proteins sense cAMP levels. The
best-characterized effector protein is protein kinase A (PKA), which plays a role in cardiac pacemaking,
excitation/contraction coupling and cardiac metabolism. The exchange factor directly activated by
cAMP (EPAC) has been linked to cardiac hypertrophy, Ca2+-signaling and apoptosis. Often, PKA and
EPAC are bound by the same anchor protein (AKAP) along with protein substrates and other enzymes.
The hyperpolarization-activated cyclic nucleotide-gated (HCN) channels are important for cardiac
pacemaking and ventricular repolarization. Finally, the Popeye domain containing (POPDC) proteins
are the most recently identified class of effector proteins and important for cardiac pacemaking, the
survival of cardiac myocytes after ischemia/reperfusion and membrane trafficking.
EPAC (exchange factor directly activated by cAMP) is a guanine-nucleotide exchange factors for
the Ras-like GTPases, Rap1 and Rap2 [5]. Two EPAC isoforms, EPAC1 and EPAC2 exist in mammals
and are thought to modulate Ca2+-homeostasis and hypertrophy in cardiac myocytes [6]. Interestingly,
EPAC1 and EPAC2 differ regarding their subcellular localization. EPAC2 is mostly present at the
T-tubules and EPAC1 is localized perinuclear [7,8]. EPAC1 is also present in mitochondria and loss of
EPAC1 reduces infarct size and cardiomyocyte apoptosis induced by myocardial ischemia/reperfusion
injury [9]. EPAC also has pro-arrhythmic effects probably due its ability to decrease potassium
currents [10]. Chronic EPAC activation leads to cardiac hypertrophy [11].
Another important effector protein in cardiac myocytes is HCN4, which is a member of the
family of hyperpolarization-activated cyclic nucleotide gated channels (HCN). HCN genes encode
nonselective voltage-gated cation channels, which are abundantly expressed in cardiac pacemaker
cells in the sinoatrial (SAN) and atrioventricular nodes (AVN) but are also present in parts of the
ventricular conduction system [12]. Upon binding of cAMP, the HCN4 channel opens more rapidly
and completely [13]. This property has led to the assumption that the cAMP-mediated enhancement
of HCN channel activity is largely responsible for the increase in heart rate in response to β-adrenergic
stimulation. However, the importance of HCN4 in cardiac pacemaking remains controversial [14,15].
Heart rate adaptation in response to adrenergic stimulation remains intact after SAN-specific ablation
of the Hcn4 locus in mice [16]. Moreover, heart rate acceleration in response to adrenergic signaling is
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unaffected in patients carrying a cAMP-binding site mutation in HCN4 [17]. To accommodate these
facts, it has been proposed that HCN4 may act as a depolarization reserve and its main role may be to
counteract parasympathetic slowing of the heart rate [18,19]. In addition to its importance in cardiac
pacemaking, HCN channels apparently also have a role in impulse propagation in the SAN and are
also essential for ventricular repolarization [20,21]. Importantly, in cardiac hypertrophy, both HCN2
and HCN4 are induced in the ventricular working myocardium causing a prolongation of the cardiac
action potential and probably being responsible for the development of cardiac arrhythmia in the
hypertrophied ventricle [22].
Although the Popeye domain containing genes were isolated around the same time as EPAC
genes [23–26], it took more than a decade to realize that POPDC proteins constitute a novel class
of cAMP-effector proteins [27] and an additional four years to demonstrate that cAMP binding is
essential for its function [28]. Here we will review the multiple roles of the POPDC gene family in
striated muscle biology and disease.
2. The Popeye Gene Family
The POPDC gene family consists of three genes namely POPDC1 (also known as BVES), POPDC2
and POPDC3. In vertebrates, POPDC1 and POPDC3 are tandem-organized and in the human genome
are present on chromosome 6q21, while POPDC2 is located on chromosome 3q13.33. [26]. POPDC1
is the most complex gene with 8 exons, while POPDC2 and POPDC3 have only 4 exons. POPDC1
probably represent the ancestral gene and the other two paralogs were generated through two gene
duplication events. The first duplication likely took place at the base of chordate evolution [29].
In support of this view, basic chordates (Tunicates, Cephalochordates) have two tandem-organized
POPDC genes with homologies to POPDC1 and POPDC3. POPDC2, which is only found in vertebrates,
was probably generated by a second gene duplication event, which probably took place at the
base of vertebrate evolution. This view is supported by the fact that POPDC2 is only present in
vertebrates. Moreover, POPDC2 and POPDC3 display a similar gene structure and higher similarity at
the protein level [30]. The POPDC gene family also evolved independently in invertebrates, where
gene duplication events also took place. While molluscs, annelids and dipterans such as Drosophila
have only a single POPDC gene; many insects have two POPDC genes and some invertebrates (for
example the water flea) have multiple POPDC genes. Interestingly, there are also invertebrate species,
which lost their POPDC gene during evolution and a prominent example for this is Caenorhabditis
elegans. Thus, for some species, a lack of POPDC genes is fully compatible with life. We can trace the
presence of POPDC genes down to Hydra and the gene family is also found in some protozoan species.
We can therefore conclude that POPDC genes have evolved at the base of the animal kingdom. No
POPDC genes are found in plants or fungi. Interestingly, the cAMP-binding domain (CNBD) of the
bacterial catabolite activator proteins (CAP), also known as catabolite receptor protein (CRP), which
are involved in transcriptional regulation of metabolism display the highest similarity of a non-POPDC
protein to the Popeye domain.
3. POPDC Proteins
The POPDC proteins are medium-sized transmembrane proteins. They consist of a short
extracellular domain (ECD, Figure 2), which in case of POPDC1 has been shown to be subject to
N-glycosylation. Potentially, N-glycosylation is more extensive in skeletal muscle and brain than in
the heart [31,32]. A consensus sequence for N-glycosylation is also present in the ECD of POPDC2
and POPDC3. POPDC proteins all have three transmembrane domains. In the cytoplasmic part, the
conserved Popeye domain is present, which functions as a cAMP-binding domain [27].
The Popeye domain is slightly larger than a typical cyclic nucleotide monophosphate
(cNMP)-binding domain (CNBD), suggesting that additional functions other than cAMP-binding reside
in the Popeye domain. Indeed, the binding sites of KCNK2 (TREK-1) or CAV3 have been mapped to
the Popeye domain of POPDC1 [28,33] (Figure 2). Soon after its discovery, the dimerization of POPDC1
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was first described [31,32]. Dimerization is stabilized through disulfide bridge formation. In order to
map the sequences, which mediate dimerization, a series of experiments including carboxy-terminal
deletions, peptide-mapping and site-directed mutagenesis was utilized [34]. Dimerization appeared
to depend on two conserved lysine residues at the end of the Popeye domain. Mutation of the
dimerization motif interfered with cell adhesion, and epithelia formation. There are probably other
sequences in POPDC1 also responsible for dimerization as POPDC1 protein, which lacked these
sequences, were still able to homodimerize [37].
 
Figure 2. Structure of the Popeye domain containing proteins. (a) Schematic structure of the human
POPDC isoforms. The three POPDC proteins share a similar protein structure. In each case a 20–40
amino acid long extracellular domain (ECD), which harbors one or two N-glycosylation sites (asterisks)
is followed by three transmembrane (TM) domains (I–III, black boxes). The cytoplasmic portion of
the POPDC proteins consists of the Popeye domain (red box) and the carboxyterminal domain (CTD,
yellow box). The phosphate-binding cassette (PBC), which is thought to bind cAMP, consists of the two
tetrapeptides DSPE and FQVT. In case of POPDC1, the locations for the KCNK2 (TREK-1) [28] and
CAV3 [33] binding sites and the putative dimerization motif [34] are indicated (blue bars). POPDC2
generates three alternative splice products, which differ in their carboxy-terminus labeled by a grey
box. Mutations in POPDC1 and POPDC2, which have been identified in patients with muscle and
heart disease are indicated above each protein model. (b) 3-D structure of POPDC3. A homology-based
structural model was generated with the help of the Phyre 2 algorithm [35]. The resulting structure
was visualized with the help of First Glance in JMOL [36].
4. The Popeye Domain Is a Novel cAMP-Binding Domain
It is thought that the main function of the 150 amino acids long Popeye domain is to bind
cAMP [27]. The structural prediction of the Popeye domain revealed a similarity to the CNBD of
the catalytic subunit of PKA [27]. The structure of the CNBD is categorized as jelly-roll β-barrel fold,
which is found in many proteins. However, not all of these proteins bind cyclic nucleotides but other
ligands [38]. A conserved feature of the CNBD is the phosphate-binding cassette (PBC), which directly
makes contact to cAMP and consists of a short α-helix and a loop located between β-sheets 6 and 7.
Two conserved residues found in all PBCs include an arginine, which binds to the phosphate group of
cAMP and a glutamate that binds the 2′-OH group of the ribose [39]. Those proteins that share the
jelly-roll β-barrel fold structure but lack these arginine and glutamate residues, bind to ligands other
than cNMPs. It is, therefore, essential that sufficient experimental evidence will be generated that it
is unequivocally established that POPDC proteins bind cAMP despite their lack of a canonical PBC.
The non-canonical PBC of the Popeye domain is thought to consist of two conserved sequence motifs
(FL/IDSPEW/F) and FQVT/S), which are linked by a non-conserved sequence of variable length [27]
(Figure 3).
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Figure 3. Structure of the Popeye domain. A homology-based structural model of human POPDC1 was
generated. A space-filling model of cAMP was placed in the putative phosphate-binding cassette. The
DSPE and FQVT motifs, depicted as yellow halos, surround the cAMP molecule and as mutagenesis
studies suggest, seem to be directly involved in cAMP-binding.
Several of these evolutionary conserved residues were mutagenized by a charge-to-alanine
strategy in POPDC1 and POPDC2 and as expected, the resulting mutant proteins displayed a reduction
in the cAMP-binding affinity supporting their involvement in nucleotide-binding [27].
Assays were developed to demonstrate cAMP-binding by POPDC proteins. The first one, is
a cAMP agarose precipitation assay, which established cAMP-binding of native POPDC1 protein
extracted from the chicken heart [27]. POPDC1 was also precipitated by cGMP agarose and free cGMP
was able to elute POPDC1 from cAMP agarose and thus, at this stage it was unclear, whether POPDC1
binds cAMP selectively, or both cyclic nucleotides with equal affinity. The agarose-precipitation assay
also established that the three POPDC proteins are all able to bind cAMP [27].
A recombinant POPDC1 protein encompassing the cytoplasmic part of the protein was employed
in a competitive radio-ligand binding assay, which established an IC50 concentration of 118.4 ± 7.1 nM
for cAMP and of 5.27 ± 0.68 μM for cGMP [27]. The approximately 40-fold difference in affinity
between cAMP and cGMP is typical for a cAMP-binding protein and similar differences in affinities
for both nucleotides have been described for the CNBDs of PKA [40].
A third assay demonstrating cAMP binding was developed based on the interaction of POPDC1
with the two-pore potassium channel KCNK2 (TREK-1) [27]. A bimolecular fluorescence resonance
energy transfer (FRET) assay using CFP-tagged POPDC1 and YFP-tagged TREK-1 was utilized.
Addition of the β-adrenergic agonist isoproterenol or direct stimulation of adenylate cyclase by
forskolin caused a rapid decline of the YFP/CFP ratio with a kinetic, typical for an adenylate
cyclase-dependent process [27]. A mutant protein, carrying a mutation in D200, which is one of
the residues of the DSPE motif in the PBC of POPDC1 (Figure 3), did not cause any changes in the
FRET signal after the addition of isoproterenol. Likewise, nitroprussid, which raises cGMP levels in
cells, did not affect the FRET signal, which supports the notion that at physiological concentration
levels, POPDC1 protein binds cAMP but not cGMP.
Finally, evidence for cAMP-binding of POPDC proteins stems from the discovery of a
POPDC1S201F mutation, which is present in patients, which develop a limb-girdle muscular dystrophy
(LGMD) phenotype [28]. The serine residue 201 of POPDC1 is part of the PBC and change of serine
into phenylalanine is likely to reduce the cAMP-binding affinity. Indeed, measurements of cAMP
affinity established a loss of about 50% in case of the mutant protein [28]. Thus, there is ample of
experimental and genetic evidence, which establishes the Popeye domain as a novel cAMP-binding
domain with a highly divergent protein sequence [28]. However, so far, the molecular characterization
mostly dealt with POPDC1 protein and therefore it will be important to extend these experiments also
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to the other two family members and to determine, whether cyclic nucleotide specificity is the same for
each of the POPDC proteins, and whether all three POPDC isoforms bind cAMP with equal affinity.
5. Expression Pattern of POPDC Genes
RNA expression data for the POPDC family members revealed the highest expression level of
POPDC genes in striated muscle tissue (Figure 4) [26]. While POPDC2 is preferentially expressed
in the heart, POPDC1 and POPDC3 show higher expression levels in skeletal muscle. Of the three
genes, POPDC1 shows a more widespread expression than POPDC2 and POPDC3. In many tissues,
POPDC1 and at least one other POPDC gene is co-expressed. Apart from striated muscle, expression
was also observed in smooth muscle cells, neurons, and epithelial cells [41]. Conflicting data have
been published for the heart regarding the presence of POPDC1 in non-muscle cell types of the
heart. Several studies from my lab revealed an exclusive expression in cardiac myocytes [41–43], while
another group reported expression in cardiac myocytes but also presence of POPDC1 in the epicardium
and in coronary arteries [25,44,45]. The LacZ reporter gene, which was knocked into POPDC1 did
not reveal a significant expression in any of the non-muscle cell lineages in the adult heart [26,41].
However, a shortcoming of these data is the fact that the LacZ reporter gene may not fully recapitulate
the expression domains of the endogenous gene. On the other end, it is equally conceivable that
the antibodies employed may be cross-reactive. A thorough investigation of the expression patterns
of POPDC genes and proteins in vertebrate embryos and in the adult seems to be required to settle
this case.
Figure 4. Expression of POPDC genes in the human body. RNA seq data of POPDC1, POPDC2 and
POPDC3 in human tissue. RNA expression is quantified as reads per kilogram per million mapped
reads (RPKM). Data were copied from the Human Protein Atlas website [46–48].
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Immunolocalization of POPDC proteins revealed an expression at the plasma membrane of
isolated cardiac myocytes and a similar pattern was observed in cardiac tissues. POPDC proteins have
been described to be present at the lateral membrane, intercalated disks, costameres [33], t-tubules
and caveolae [33] (Figure 5). In addition, POPDC1 was also localized to the nuclear envelope [49],
and in the nucleoplasm [50]. Plasma membrane localization was also reported for skeletal muscle,
however no detailed analysis of the subcellular localization in different membrane compartments has
been reported [28]. A recent report, which was looking for novel intercalated disk proteins described
a preferential localization of POPDC2 in the intercalated disk of ventricular myocytes of the human
and canine heart, arguing for an important function of POPDC2 for electrical cell-to-cell coupling, and
impulse propagation [51].
 
Figure 5. Expression of POPDC1 and POPDC2 in cardiac myocytes. Isolated adult cardiac myocytes
were immunostained with (a) POPDC1 and (b) POPDC2 antibodies, respectively.
6. Animal Models to Define the Function POPDC Genes
In order to define the function of POPDC genes, the Popdc1 and Popdc2 genes were ablated in
mice by substituting the first coding exon with a LacZ reporter gene [27,52] (Table 1). The resulting
homozygous mutants were viable and no embryonic lethality has been reported. Phenotype analysis
was guided by the LacZ expression pattern [41]. In the adult mouse heart, Popdc1 and Popdc2
are expressed in cardiac myocytes, while no expression in smooth muscle or non-muscle cells is
observed [27,41]. Popdc1 displays higher level of expression in atria than in ventricles, while Popdc2
is evenly expressed in both chamber types [27]. Both genes display a strong expression in the
sinoatrial (SAN) and atrioventricular nodes (AVN) as well as in the ventricular conduction system [27].
The high-level expression of POPDC1 and 2 genes in the cardiac conduction system prompted the
investigation of the functional status of it in the null mutant animals. While both Popdc1 and Popdc2
null mutants displayed normal heart rhythm at rest, a stress-induced sinus bradycardia developed in
response to physical or emotional stress and after β-adrenergic receptor stimulation [27]. ECG analysis
revealed the presence of stress-induced sinus pauses. The length of each sinus pause was variable and
could be brief or more prolonged. Interestingly, the arrhythmia phenotype developed in both null
mutants in an age-dependent manner and was absent in young adults and gradually worsened with
increasing age [27]. The phenotype was also present in isolated Langendorff-perfused hearts and a
normal cholinergic response was observed after carbachol treatment, which suggests a primary defect
in the cardiac pacemaker.
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Table 1. Cardiac and skeletal muscle phenotypes in model organism and patients.
Species Mutation Heart Skeletal Muscle References
mouse
Popdc1-/- stress-induced sinus bradycardia regeneration defect [27,50]
ischemia-reperfusion damage not analyzed [33]
Popdc2-/- Stress-induced sinus bradycardia not analyzed [27]
zebrafish
popdc1 morphants AV-block, pericardial effusion muscular dystrophy [28]
popdc2 morphants AV-block, pericardial effusion muscular dystrophy [53]
popdc1S191F AV-block, pericardial effusion muscular dystrophy [28]
human
POPDC1S201F 2nd degree AV-block limb-girdle MD [28]
POPDC1del56 V217-K272 1st degree AV-block, limb-girdle MD [54]
POPDC2W188X 3rd degree AV-block no known phenotype [55]
Structural analysis of the sinoatrial node (SAN) morphology revealed significant structural
alterations. The SAN is located at the border between vena cava and right atrium and consists of
nodal myocytes, which also called spider and spindle cells due to their irregular shape and the long
neurite-like cellular extensions [56]. Nodal myocytes are embedded in a rich extracellular matrix and
are poorly electrically coupled. In both, Popdc1 and Popdc2 null mutants, pacemaker cells displayed a
reduced number of cellular extensions, and overall the SAN had a more compact structure. Moreover,
a reduction of nodal myocardium was noted in the inferior part of the SAN [27].
The molecular basis of the sinus node dysfunction in Popdc1 and Popdc2 null mutants is not well
understood. An attractive hypothesis involves a modulatory role of POPDC proteins for the pacemaker
current If. Therefore, If current density and activation time was measured in isolated SAN myocytes
from WT and Popdc2 null mutant mice [27]. Cells of both genotypes were indistinguishable in current
density under basal conditions and after superfusion with 8-Br-cAMP. While If was not investigated in
the Popdc1 null mutant, therefore an interaction of POPDC1 and HCN4 cannot be excluded, however,
the similarity of phenotypes of both Popdc1 and Popdc2 null mutants makes it very unlikely that If
function is modulated by POPDC1.
One of the first POPDC-interacting protein identified in the heart was the potassium channel
TWIK-related K+ channel 1 (TREK-1) or KCNK2 [27]. This ion channel is a member of the two-pore
domain potassium channel (K2P) family. TREK-1 gating is affected by a large number of stimuli
including stretch, pH, temperature, phosphorylation, and is also modulated through the interaction
with other proteins [57]. In the presence of POPDC1, TREK-1 produces a twofold higher current in
Xenopus oocytes [27]. The effect is also observed when POPDC2 or POPDC3 were co-expressed. The
doubling of TREK-1 current is probably due to an increase in membrane trafficking as more TREK-1
protein is detected at the cell surface when POPDC proteins are present. The effect of POPDC proteins
on TREK-1 is sensitive to cAMP and is lost when cAMP levels were increased after applying the general
PDE inhibitor theophylline or 8-Br-cAMP [27,28]. The interaction of POPDC proteins with TREK-1 has
been mapped to the Popeye domain by deletion analysis (Figure 2). Based on the interaction of POPDC1
and TREK-1, a bi-molecular Förster-resonance energy transfer (FRET) sensor was constructed. The
FRET ratio obtained at baseline decreased after the addition of isoproterenol or forskolin, suggesting
that cyclic nucleotide-binding affects the interaction of POPDC1 with TREK-1 [27]. A cardiac specific
knockout of Kcnk2, which encodes TREK-1, displays a stress-induced sinus bradycardia similar to the
one observed in Popdc1 and Popdc2 null mutants [58], suggesting that the sinus bradycardia in POPDC
mutants may in part be due to an impaired TREK-1 current.
However, it is likely that additional proteins may be involved. Cardiac pacemaking is governed by
two oscillatory mechanisms, the membrane clock and the Ca2+-clock [59]. The membrane clock initiates
depolarization in response to If but also involves the voltage-gated Ca2+-channels. The Ca2+-clock on
the other hand is active in late diastole when Ca2+ is released from the sarcoplasmatic reticulum by
the ryanodine receptors (RyRs) and exchanged for Na+ by NCX, which generates a depolarizing INCX
current. Both clocks are coupled by Ca2+, which enters the cell through the L-type Ca2+ channels, which
leads to a replenishment of the SR allowing the next pacemaker cycle to be initiated. Interestingly, it
was recently reported that the sodium calcium exchanger NCX1 is a POPDC2-interacting protein [60]
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and the loss of NCX1 causes SAN dysfunction similar to the one observed in POPDC mutants [61]. It
seems warranted to thoroughly investigate protein-protein interaction, subcellular localization, and
function of proteins of the membrane and Ca2+ clocks in the different POPDC mutants.
The impact of ischemia/reperfusion injury was studied in the Popdc1 null mutant [33].
Langendorff-perfused mutant hearts displayed a significantly lower functional recovery, while infarct
size was larger. Isolated cardiac myocytes from Popdc1 null mutants displayed altered Ca2+-transients
and increased vulnerability to oxidative stress. Apparently Popdc1 is involved in myocyte survival
through the suppression of the pro-apoptotic Bcl2 interacting protein 3 (Bnip3) gene [62]. While
skeletal muscle is not as well studied than cardiac muscle in POPDC null mutants, it has been shown
that muscle regeneration is impaired in Popdc1 null mutants, however, the underlying molecular
mechanism has yet to be elucidated [63].
In Popdc1 null mutant mice, the caveolar compartment is affected and caveolae were fewer in
number, however their size was increased [33]. POPDC1 interacts with CAV3 through a consensus
sequence present at the end of the Popeye domain (Figure 2). This could have profound effects on
cardiac signal transduction given that caveolae in cardiac myocytes are clustering membrane receptors,
signaling molecules, protein pumps and ion channels [64]. It has been reported that POPDC2 in human
and canine cardiac myocytes are predominantly present at the intercalated disk [51]. The intercalated
disk controls electrical coupling between cardiac myocytes and therefore is a major determinant of
cardiac conduction. It will be interesting to study the structure and function of the intercalated disk in
POPDC2 null mutants and to measure electrical conduction in Popdc2 null mutants.
Loss-of function experiments were also conducted in zebrafish and morpholino-mediated
knockdown of popdc1 and popdc2 caused cardiac arrhythmia and muscular dystrophy
phenotypes [28,53] (Table 1). The cardiac arrhythmia was already present in the embryo and
the severity of the phenotype increased in an age-dependent manner. In young larvae (4 days
post-fertilization, dpf) typically a type I AV-block was present. At increasing age total heart block or
even non-contracting hearts were also observed. The skeletal muscle phenotype in popdc1 and popdc2
morphants was characterized by an impaired formation of the myotendinous junction which probably
caused the myofiber rupture, which was seen in both morphants [28,53]. The heart of many popdc1 and
popdc2 morphants displayed a pericardial effusion, which is thought to indicate myocardial pumping
deficiency. However, in the case of popdc1 morphants, the pericardial effusion could also be based on a
defective barrier formation of the skin due to impaired tight junction formation [65]. The molecular
basis for the tight junction defect is probably due to abnormal accumulation of tight junction proteins,
which is caused by an aberrant localization of atypical protein kinase C (aPKC) [65]. Interestingly, it
has been demonstrated that another protein involved in cell contact formation, zonula occludens 1
(ZO1) is a POPDC1-interacting protein [66].
The contact structures between skeletal muscle fibers in the zebrafish tail musculature is formed
by the myoseptum or myotendinous junction (MTJ) [67]. The MTJ is a complex structure, which is
established by several plasma membrane proteins and various matrix proteins [68,69]. In the popdc1
and popdc2 morphants and in the popdc1S191F mutant, the MTJ is abnormal in structure and in the
popdc1S191F mutant lacks the collagen matrix, which probably is essential for the MTJ to withstand
the tensile forces of the contracting myofibers. Consistent with this hypothesis, large numbers of
hypercontracted myofibers that lost contact to the MTJ are seen in popdc1 and popdc2 morphants and
the popdc1S191F mutant [28,53].
7. Evidence for a Role of POPDC Genes in Human Heart and Skeletal Muscle
The first mutation of POPDC1 discovered in patients is the recessive POPDC1S201F mutation,
which was reported to be associated with cardiac arrhythmia and muscular dystrophy [28]. This
mutation alters serine 201, which is one of the invariant amino acids present in the putative cAMP
binding domain (DSPE motif) (Figure 2, Table 1). The serine residue is substituted by phenylalanine,
which may interfere with the cyclic nucleotide gaining access to the PBC. Measurement of the cAMP
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binding affinity revealed a 50% reduction in case of the mutant protein [28]. Moreover, the S201F
mutant caused an increased level of TREK-1 current compared to wildtype (WT) while membrane
transport of the channel protein was decreased [28]. This paradoxical finding of decreased membrane
transport and increased current may be explained on the basis that POPDC1 in a complex with
TREK-1 protein might be protected from getting inactivated by PKA-dependent phosphorylation [70].
Forced expression of POPDC1S201F in HL1 cells affected the action potential [28]. Three patients from
a 3-generation family of Albanian descent carried the POPDCS201F mutation to homozygosity and
developed an early onset second-degree AV-block and a late onset limb-girdle muscular dystrophy
(LGMD2X, OMIM: #61812) [28]. Serum creatine kinase levels were elevated, and muscle biopsies
showed dystrophic changes with increased fiber size variability, increased central nuclei, and a
few necrotic fibers. Electron microscopic analysis of skeletal muscle biopsies of one of the patients
carrying a POPDC1S201F mutation revealed the presence of membrane discontinuities [28]. Similar
discontinuities have been observed in patients with mutations in anoctamine-5 (ANO5). While
only found in a single patient, these discontinuities are possibly an indication for impaired repair
of the muscle plasma membrane [71]. Interestingly, another protein involved in membrane repair,
dysferlin, has also been shown to be an interaction partner of POPDC1 [28]. Expression of the
popdc1 disease-associated mutation (S191F) in zebrafish caused similar phenotypes as in the patients.
Skeletal muscle from homozygous popdc1S191F mutants showed myofibrillar misalignment, aberrant
formation of the myotendinous junction, myofiber detachment, and decreased membrane localization
of POPDC1 and POPDC2 [28]. Electron microscopy revealed an absence of extracellular matrix at the
myotendinous junction. Abnormalities of the zebrafish popdc1S191 mutant heart also resembled the
patient’s phenotype displaying an overall reduction in heart rate and stroke volume. Isoproterenol
caused an increase in the number of embryos displaying a 2:1 AV block.
Recently, another recessive mutation in POPDC1 was reported in a consanguineous family of
Algerian origin [54]. The splice site mutation (c.816 + 2T > C) affects the splice donor site in intron
8 and may cause skipping of exon 8 resulting in a mutant protein with a predicted loss of 56 amino
acids (POPDC1del56 V217-K272), (Figure 2, Table 1). Two siblings are affected, and both displayed a
first-degree atrioventricular (AV)-block, high serum creatine kinase levels and evidence for a mild
limb-girdle muscular dystrophy. Immunostaining of biopsies revealed a strong reduction in membrane
staining of both, the mutant POPDC1 protein and also of POPDC2. Thus, despite POPDC1S201F
and POPDC1del56 V217-K272 mutations are at different position in the protein they induce a similar
pathology and display impaired membrane trafficking [28,54]. The underlying molecular defects
require further characterization.
POPDC1 may also contribute to phenotype variability in other LGMDs. Interestingly,
heterozygous POPDC1 mutations were found in patients that also carried Lamin A (LMNA) or
dysferlin (DYSF) mutations. This putative genetic interaction is probably of significance as both
proteins, dysferlin and Lamin A also interact at the protein level with POPDC1.
Patients carrying a recessive POPDC2 mutation were recently discovered [55]. This mutation
(c.563G>A, p.Trp188Stop, POPDCW188X) resulted in the insertion of a premature stop codon at position
188 of POPDC2, leading in the protein to a deletion within the putative cAMP binding domain. Even
though the FQVT motif of the PBC of POPDC2 was deleted in this mutant, cAMP responsiveness
remained unaltered. Likewise, the interaction and modulation of the TREK-1 current remained
unaltered. Therefore, currently the pathogenic mechanism is not fully clear. The deletion of part of the
Popeye domain and the carboxyterminal domain may influence the kinetics of cAMP binding or could
interfere with protein-protein interaction.
8. Conclusions
We recently proposed four working models of how POPDC proteins might modulate proteins
in order to mediate cAMP signaling in striated muscle cells [68]. The first model, which is called the
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switch model, proposes that binding of cAMP to POPDC proteins causes an allosteric effect as it was
observed for PKA, EPAC and HCN4 [72].
The switch model assumes that allostery not only affects POPDC proteins but also interacting
proteins. Direct evidence for such a behavior is currently missing. Nonetheless, the TREK-1-POPDC1
FRET assay gives support for the presence of an allosteric effect. Experimental support is present
for the cargo model, which proposes that POPDC acts on proteins by modulating their membrane
trafficking. Strong support for this model comes from the observation that the POPDC1S201F mutant
not only affects membrane localization of the mutant protein but also of POPDC2. Similarly, membrane
localization of TREK-1 in Xenopus oocytes is modulated by POPDC1 and is cAMP-sensitive.
The shielding model is a variation of the switch model taking into account that POPDC proteins and
also some of the interacting proteins are getting phosphorylated in response to βAR activation [1]. It can
be envisioned that cAMP binding and phosphorylation of POPDC proteins may lead to conformational
changes that may also affect access of PKA or other kinases to their substrates.
Finally, the sponge model takes into account that POPDC proteins are abundant in cardiac and
skeletal muscle cells and display a complex subcellular localization. POPDC proteins have a high
affinity binding site for cAMP, which suggests that these proteins may have a strong impact on cAMP
compartmentalization. POPDC proteins may assist adenylate cyclases, phosphodiesterases, and AKAP
proteins to create nanodomains of cAMP signaling. Further work is required to confirm or refute these
working models.
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Abstract: 3′,5′-cyclic adenosine monophosphate (cAMP) signalling plays a major role in the cardiac
myocyte response to extracellular stimulation by hormones and neurotransmitters. In recent years,
evidence has accumulated demonstrating that the cAMP response to different extracellular agonists
is not uniform: depending on the stimulus, cAMP signals of different amplitudes and kinetics are
generated in different subcellular compartments, eliciting defined physiological effects. In this review,
we focus on how real-time imaging using fluorescence resonance energy transfer (FRET)-based
reporters has provided mechanistic insight into the compartmentalisation of the cAMP signalling
pathway and allowed for the precise definition of the regulation and function of subcellular
cAMP nanodomains.
Keywords: 3′,5′-cyclic adenosine monophosphate; protein kinase A; fluorescence resonance energy
transfer; real-time imaging; compartmentalisation; signalling; cardiac biology; phosphodiesterases;
A kinase anchoring proteins
1. Introduction
Cyclic nucleotides, such as 3′,5′-adenosine monophosphate (cAMP), are small molecules used by
cells to propagate extracellular information inside the cell and are referred to as second messengers.
cAMP is generated by intracellular adenylyl cyclases in response to a first, extracellular message that
activates a transmembrane G-protein coupled receptor (GPCR). This second messenger system is used
in many types of cells, from prokaryotes to human neurons, and in each cell type its synthesis can be
triggered by different extracellular stimuli with different functional outcomes. It is thus imperative to
understand how a universal signal like cAMP can be versatile enough to generate cellular effects that
are specific to each individual stimulus. This question demands sensitive quantification of the second
messenger and accurate comparison of cAMP signal amplitude, dynamics, and subcellular location in
response to different extracellular cues.
In the cardiovascular system, the first message that activates the cAMP pathway is provided by a
variety of biochemically diverse molecules. These include neurotransmitters, such as adrenaline and
noradrenaline; peptide hormones, such as glucagon; and lipid compounds, such as prostaglandins.
Each molecule binds to a distinct GPCR, coupling to different kinds of G-proteins with the ability
to activate or inhibit cAMP production [1]. Increases in cAMP can activate different families of
cAMP-binding proteins. In cardiomyocytes, these include cyclic nucleotide-gated ion channels
(CNGC) [2], exchange proteins directly activated by cAMP (Epacs) [3], Popeye domain-containing
(POPDC) proteins [4], and protein kinase A (PKA) [5]. The most extensively studied effector molecule
of cAMP is PKA. cAMP binding to the regulatory subunit of PKA results in activation of its catalytic
subunit. In cardiomyocytes, PKA-mediated phosphorylation modulates ion channels, transmembrane
receptors, and regulatory proteins, leading to increased heart rate, increased strength of contraction,
and enhanced relaxation. All these effects can improve haemodynamic performance in patients
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with a failing heart. Consequently, the cAMP signalling pathway is a unique point of interest in the
development of treatments for heart failure and congenital heart disease.
Interestingly, not all extracellular stimuli that activate cAMP signalling in the heart increase PKA
activity uniformly and to a similar degree throughout the cell. This was first hypothesised on the basis
of observations in biochemical fractions of cardiomyocytes, stimulated with either prostaglandins or
β-adrenergic receptor agonists [6]. Direct evidence of cAMP compartmentalisation, however, had been
difficult to obtain. Clean isolation of cardiomyocyte organelles, to map the heterogenic distribution of
cAMP across the cell on a micrometre scale, presents a considerable challenge. Another experimental
difficulty is the small molecular size of cAMP itself: cAMP occupies not more than 1.12 nm in a crystal
structure in complex with PDE4D (PDB 2PW3) [7], which is more than six times smaller than the
Gsα subunit of a heterotrimeric G protein (PDB 1AZT) [8]. A small molecular radius allows for high
diffusivity. In a medium with low molecular complexity, such as water, cAMP can reach a diffusion
velocity of up to 444 μm2/s. In molecularly crowded environments, such as the cytoplasm of an adult
cardiomyocyte, this can be slowed by more than a factor of ten [9]. Still, assessment of real-time signals
in response to cellular stimulation is a considerable challenge when using conventional biochemical
methods. To fully understand the conserved and divergent aspects of cAMP signalling downstream of
distinct cellular stimuli, temporal and spatial dissection of signalling events is crucial. Live, single cell
imaging methods based on fluorescence resonance energy transfer (FRET) provided the means to
dissect how cellular signalling occurs in space and time.
Real-time cAMP imaging techniques have greatly enhanced our understanding of the distribution
and nature of intracellular cAMP signalling domains. Temporal and spatial resolution of cAMP
signalling are among the main advantages that FRET-based imaging methods can offer to the field.
In combination with the reversibility of the response and real-time detection of cAMP changes in
living cells, this technique has revolutionised our understanding of cAMP signalling in the heart.
FRET-based imaging helped replace the coarse definition of cAMP concentration gradients between
biochemical fractions with our appreciation of sub-microscopic differences in cAMP signalling at
different organelles.
This review gives a brief account of the evolution of FRET-based imaging approaches in the study
of cAMP signalling. Different probes have been instrumental in addressing specific aspects of the
cAMP signalling pathway and have distinct strengths and weaknesses that are worth considering when
designing experiments. We also discuss how several cardiac compartments have been characterised
using real-time imaging of cAMP and present specific examples.
2. The Evolution of cAMP Imaging Techniques and Their Contribution to Our Understanding of
the Spatio-Temporal Compartmentation of cAMP Signalling
cAMP signalling in cardiac myocytes is compartmentalised. During a signalling event, the cyclic
nucleotide is not uniformly distributed through the entire cytoplasm, but it accumulates to a greater or
lesser extent in distinct loci within the cell. Due to its physicochemical properties and relatively high
diffusivity, this behaviour of cAMP is not intuitive, and the discovery and further analysis of cAMP
subcellular compartmentation was a multi-step process that is recounted in the following paragraphs.
A single cAMP compartment can be confined to a cellular substructure that involves only a small
number of proteins and thus operates on the nanometre scale. Such macromolecular substructures
have been termed cAMP nanodomains. cAMP domains contain functionally associated proteins,
or signalosomes, which together shape the effect of the cAMP signal within the domain. Signalosomes
are usually comprised of cAMP binding proteins, such as PKA and phosphodiesterases (PDEs), as well
as their regulators and targets.
cAMP compartmentalisation has a spatial and a temporal dimension. To adequately describe
cAMP signalling in cardiomyocytes, the toolkit for cAMP detection and quantification therefore
had to evolve considerably from bulk analysis of cAMP content in tissue or cell lysates to targeted,
real-time, and quantitative analysis of cAMP nanodomains in living cells (Figure 1). Each of the cAMP
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sensors described in the following has unique experimental advantages and caveats, including cAMP
sensitivity, dynamic range, or sensor biology. This review aims to highlight some of the considerations
to take into account when designing an experimental system.
 
Figure 1. Evolution of cardiac cAMP detection from bulk biochemical analysis to targeted real-time
imaging in living cardiomyocytes. In all panels, cAMP molecules are represented by golden
spheres; fluorophore molecules are represented by coloured spheres, with the colours indicating their
emission spectra. Exposure to light with the excitation spectrum of a fluorophore is represented
by a monochrome lightning bolt; emission of fluorescent light is represented by a halo around
the fluorophore. Fluorescence transfer is represented by a lightning bolt that originates from the
fluorescence donor, which matches the donor in colour and points towards the fluorescence acceptor.
EC50 for cAMP is indicated for all cAMP detection systems, as reported in the literature [10–13].
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2.1. Biochemical Protein Binding Assays for cAMP
Since the 1970s, detection of cAMP by calibrated amounts of cAMP binding proteins, including cAMP-
dependent protein kinase purified from bovine muscle [14] or cAMP-binding antibodies [15,16],
has allowed for sensitive and specific quantification of cAMP in tissue lysates, cell lysates,
or fractions thereof.
Bulk biochemical quantification of cAMP in membrane and cytosolic fractions from adult rabbit
cardiomyocytes revealed that selective stimulation of different families of G-protein coupled receptors
elicits distinct cAMP and PKA activation profiles. Concentration of cAMP increases in both the
membrane and the cytosolic fraction when β-adrenergic receptors are stimulated with isoproterenol.
Meanwhile, stimulation of the prostaglandin receptor with prostaglandin E1 (PGE1) only increases
cAMP in the cytosolic fraction [6].
Biochemical cAMP detection in combination with cell fractionation provided first evidence
that cAMP signalling in cardiomyocytes is not uniform and that cAMP can be compartmentalised
depending on the extracellular stimulus. Biochemical detection can be as sensitive as 1 nM cAMP
and is compatible with high throughput screening [17]. However, the technique requires disruption
of large numbers of cells. Consequently, it is limited to bulk analysis of a potentially heterogeneous
population of cells, and detection of real time dynamics of cAMP is impossible.
2.2. Cyclic Nucleotide Gated Channel (CNGC) Activity Measurements
cAMP can activate non-selective cation channels in the plasma membrane, known as cyclic
nucleotide gated channels (CNGC). Activation of these channels leads to a cation current, which can
be measured using the patch clamp technique [18]. CNGC activation also triggers an increase in
intracellular calcium, which can be quantified with calcium-sensitive dyes [19]. Such measurements
of CNGC activity are possible at a single cell level and in living cells; thus, they overcome major
limitations of biochemical techniques.
This approach added more detail to the biochemical finding that β-adrenergic and prostaglandin
receptors have different effects on membrane and cytosolic cAMP levels, by revealing a temporal
dimension: cAMP levels near the surface membrane transiently respond to PGE1 stimulation,
while bulk cellular cAMP rises to a steady level in the same time frame [20]. Furthermore,
this technique neatly couples cAMP concentration with cardiac physiology. Using patch clamp
to measure CNGC-mediated cation currents revealed that β-adrenergic receptors are functionally
coupled to nearby Ca2+ channels via local elevations of cAMP [21].
While CNGC-based functional assays enabled real-time detection of changes in cAMP
concentrations for the first time, CNGC biosensors are restricted to one compartment, the sarcolemma.
This precludes studies of other important subcellular structures in cardiomyocytes, such as the
sarcomere and sarcoplasmic reticulum. In addition, native CNGCs have comparatively low
cAMP/cGMP selectivity [2]. While mutagenesis improves the affinity of the channel to cAMP versus
cGMP, the popular E583M single point mutant still retains some affinity for cGMP [22].
2.3. PKA-Based bi-Molecular FRET Sensors
2.3.1. FlCRhR Probes
To create a highly selective probe that can measure cAMP in living cells, Roger Tsien, Susan Taylor,
and colleagues made use of the heterotetrameric structure of the cAMP effector PKA [23]. Catalytic and
regulatory subunits of PKA were expressed in bacteria as recombinant proteins, and each was
tagged with chemical fluorophores of different spectral properties (fluorescein on the catalytic
and rhodamine on the regulatory subunits). Upon microinjection into living cells, these labelled
subunits form heterotetramers, comprising two catalytic and two regulatory subunits. Their close
proximity in the heterotetramer enables fluorescence energy transfer of the fluorescein donor on
one of the catalytic subunits to the rhodamine acceptor on one of the regulatory subunits. Thus,
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if fluorescein is excited with the appropriate excitation wavelength, energy transfer occurs within
the heterotetramer, and rhodamine fluorescence emission is detectable. Upon cAMP binding, the
heterotetramer dissociates, which leads to release and activation of the catalytic subunit, decrease of
fluorescence energy transfer, and a concomitant decrease of rhodamine emission relative to fluorescein
emission [23].
Using this probe, intracellular cAMP concentrations were measured in response to short
β-adrenergic stimulation of isolated frog ventricular myocytes and correlated to the ensuing calcium
transients [24]. This demonstrated that the dynamics of intracellular cAMP concentration and
intracellular calcium transients are distinct from each other in response to β-adrenergic stimulation.
Thus, the FlCRhR probe constituted an important step towards the dissection of temporal sequences in
the cardiac cAMP signalling cascade.
While this technique allowed for specific measurement of cAMP in living cells on a single-cell level,
the requirement for production of chemically labelled PKA subunits and microinjection of correctly
folded proteins renders it practically challenging. Critically, both the process of microinjection and the
non-physiologically high concentrations of PKA catalytic subunits in the cell produce a considerable
amount of cytotoxicity that limits the number of cell types that are amenable to this technique.
2.3.2. Genetically Encoded, Tetrameric cAMP FRET Probes
While FlCRhR was an important proof of concept for the use of tetrameric PKA-based FRET in
living cells, there was a need to incorporate the probe into a more ubiquitously applicable genetic
system. This was generated by tagging the genes for catalytic and regulatory subunits of PKA with
the coding sequence for two fluorescent proteins with overlapping emission and excitation spectra.
Genetically encoded FRET sensor pairs can be co-transfected into living cells, which leads to their
transient expression by the host cell expression system [25]. Similar to the FlCRhR probes, an increase
of cAMP leads to dissociation of the PKA heterotetramer and a decrease in energy transfer.
This technique was widely applied to measure changes in intracellular cAMP concentrations in
diverse cellular systems. Once expressed, genetically encoded PKA tetramers are compartmentalised
by binding to PKA scaffolds called A-Kinase anchoring proteins (AKAPs) [26]. AKAPs can be found in
many cardiac subcellular domains proximal to and distal from the sarcolemma, including the T tubules,
the sarcoplasmic reticulum, and the Z lines. cAMP measurement with the PKA-based FRET probes
revealed that adrenergic stimulation of neonatal rat cardiac myocytes leads to a non-homogeneous
increase in cAMP concentrations, providing, for the first time, direct evidence that the activation of
β-adrenergic receptors leads to the generation of multiple distinct subcellular cAMP pools. The cAMP
domains aligned with AKAP-centred domains, and free diffusion of the second messenger was limited
by the activity of phosphodiesterases (PDEs) [26]. The important contribution of different families
of PDEs to nanodomain regulation in cardiomyocytes has recently been reviewed elsewhere [27].
Subsequent analysis of the nature of these PDEs revealed that in rat cardiac myocytes, PDE4 is the
major cAMP degrading enzyme to shape amplitude and duration of cAMP responses to adrenergic
stimulation. Crucially, PDE4 was shown to localise to distinct cardiomyocyte compartments that were
different from other PDE isoforms, for example PDE3 [28]. A later study found that the adrenergic
cAMP response over Z lines in cardiomyocytes from PDE4D−/− knock out mice, as measured with the
tetrameric FRET probe, was higher than in wild-type cardiomyocytes. Critically, PDE4D−/− knock out
mice exhibited accelerated progression of heart failure following myocardial infarction and were highly
susceptible to cardiac arrhythmias during exercise followed by low-dose epinephrine injection [29].
The ability to measure real-time intracellular cAMP changes in intact, living cells also enabled
studies towards understanding the integration of sympathetic and parasympathetic stimulation in
cardiomyocyte cAMP signalling [30]. Using this sensor, it was demonstrated directly for the first
time that termination of parasympathetic, muscarinic stimulation causes a transient increase in cAMP
activity, providing important integrative data on the autonomic control of cardiac function.
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Tagged with a peptide sequence that is post-translationally myristoylated and palmitoylated,
the PKA-based sensor can be selectively directed to the plasma membrane [31]. In HEK cells,
this strategy corroborated the biochemical finding that cAMP levels at the plasma membrane can
transiently respond to PGE1 stimulation.
The development of genetically encoded cAMP sensors has strongly facilitated the spatio-temporal
dissection of cAMP signalling in cardiomyocytes. However, the multimeric nature of PKA presents
several technical limitations for high temporal resolution of intracellular cAMP quantification.
As catalytic and regulatory PKA subunits with acceptor and donor fluorophores are transfected and
expressed from two different plasmids, equal level of expression cannot be guaranteed. Additionally,
each sensor subunit can potentially interact with endogenous PKA subunits, limiting the number of
functioning FRET pairs. Both these effects may skew the formation of FRET-competent heterotetramers
and make signal termination difficult to assess. As dissociation of the PKA heterotetramer requires
cooperative binding of four molecules of cAMP to the two regulatory subunits, sensor kinetics
are relatively slow, which may lead to underestimation of cAMP propagation within the cell [32].
PKA tetramers are compartmentalised by binding to AKAPs [26] and/or due to their anisotropic
diffusion [24], which limits their applicability to total cytosolic cAMP measurements in cardiomyocytes.
Lastly, while the endogenous expression system limits the amount of PKA produced, the tagged
catalytic subunits of the sensor retain catalytic activity. This slightly elevated PKA activity can still be
toxic in some cell types [33]. However, this remains the only available sensor that can directly report
on kinetics of PKA activation in intact cells [34].
2.4. Intramolecular FRET Sensors
To overcome cooperativity and remaining toxicity concerns, single-chain cAMP FRET sensors
were developed using the cyclic nucleotide binding domains (CNBDs) obtained from a number of
different cAMP binding proteins.
2.4.1. Epac-Based Single-Chain FRET Sensors
Several generations of unimolecular FRET sensors based on exchange protein directly activated
by cAMP (Epac) are available to date. Epac is a guanine nucleotide exchange factor (GEF) for Ras-like
small GTPases. Binding of cAMP to a unique binding domain induces a conformational change in the
inactive Epac protein to expose both the catalytic domain [35] and a targeting domain [36], stimulating
GEF activity. In Epac-based sensors, fluorescence donor and acceptor proteins are fused to the N- and
C-terminus of either a single cAMP binding domain of human Epac1, a single cAMP binding domain
of murine Epac2, full length human Epac1, or truncations of human Epac1 [32,37,38]. While the initial
sensors had a limited dynamic range, giving between 10% and 30% FRET change, their range has been
significantly improved to over 150% by sequential engineering of both the spectral properties of the
FRET pairs and the way they are assembled with the CNBDs [39–41].
The uniform cytosolic distribution, particularly of the sensors based on a single cAMP binding
domain, uncoupled the site of cAMP detection from any particular cellular structure and allowed
for detection of bulk cytosolic cAMP. However, the site of cAMP detection could be chosen
deliberately by fusing these sensors to specific targeting sequences or domains. Directing the sensor
to nuclei, mitochondria, or the mitochondrial matrix, for example, allowed for measurement of the
dynamic local changes in cAMP concentrations in response to PGE1 or adrenergic stimulation [37],
revealing differential dynamics of cAMP signalling in response to the activation of either receptor.
Using these sensors coupled to the targeting domain from different PKA isoforms demonstrated that
in cardiac myocytes, compartmentalised PKA-RI and PKA-RII respond to distinct, spatially restricted
cAMP signals, which leads to phosphorylation of unique subsets of downstream targets [42].
An Epac-based single-chain FRET sensor, in its untargeted form, was used in combination
with scanning ion conductance microscopy (SICM). After local receptor stimulation of either β1-
or β2-adrenergic receptors, cAMP was found to be differently distributed across the healthy
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cardiomyocyte membrane. As a consequence of β2-adrenergic receptor redistribution in heart failure,
such cAMP compartmentation was altered [43].
Epac-based sensors are versatile and easy to use, but their properties may need to be adjusted to
suit a particular cellular system. Some of the Epac-based sensors, including the popular Epac1-camps,
have high cAMP sensitivity (ca. 1 μmol/L, [32]). This can lead to fast saturation and limited coverage
of the physiological cAMP concentration spectrum, especially in cells with high basal cAMP levels such
as cardiomyocytes. Furthermore, the spectral properties of the ECFP/EYFP-containing sensors are
relatively sensitive to changes in the intracellular microenvironment, for example intracellular pH [44],
which has been improved in later versions of the sensors [41]. However, the critically limiting factor of
this system pertains to its molecular design. In all the targeted versions of this sensor [37,42,45–47],
the targeting domain is directly attached to one of the fluorophores. This affects the FRET properties
that depend on the targeting domain of choice, making direct comparison of cAMP signals detected at
different intracellular sites difficult [12].
2.4.2. CNGC-Based Single-Chain FRET Sensors
The sensitivity of Epac-camps sensors to cAMP is a concern in cardiomyocytes with high basal
cAMP concentrations, and so a sensor that sandwiches an alternative cyclic nucleotide binding domain
between its fluorophores was developed. Here, fluorescence donor and acceptor proteins are fused
to the cAMP binding domain of the hyperpolarization-activated, cyclic, nucleotide-gated potassium
channel 2 (HCN2) [33].
With this sensor, contributions of different PDE isoforms to cAMP hydrolysis in adult mouse
cardiomyocytes after adrenergic stimulation were assessed, which ranked the activity of PDE4
above PDE2 and PDE3 [33]. Measuring cAMP propagation after selective stimulation of β1- and
β2-adrenergic receptors indicated that cAMP signals that emanated from β1 receptors propagate over
a distance involving multiple sarcomeres in adult cardiomyocytes. In contrast, the cAMP signal on β2
stimulation remained strictly confined [33].
While this sensor addresses some limitations of the Epac-based cAMP sensors in cardiomyocytes,
the main issue of comparability between targeted sensors remained unresolved.
2.4.3. PKA-Based Single-Chain FRET Sensors
To minimise potential interference of the targeting domain with FRET, a novel cAMP sensor
named CUTie (cAMP Universal Tag for imaging experiments) was developed based on the CNBD of
the PKA regulatory subunit IIβ. The unique feature of this new sensor is that CUTie enables fusion of
the targeting domain distal to the FRET fluorophore pair. This is attained by fusion of the FRET donor
to the C-terminus of the CNBD and insertion of the FRET acceptor in an intra-domain loop of the
CNBD, leaving the N-terminus free for the targeting domain. In this configuration, targeting domain
and FRET module are physically separated from each other and steric hindrance on the conformational
change required for energy transfer is minimised. As a result, the dynamic range of the sensor in
different compartments is now comparable [12]. This is not necessarily the case for other reporters
that have been targeted to subcellular sites. For studies involving targeted sensors, it is important
to keep in mind that their cAMP-binding and spectral properties can be influenced by the targeting
domain and its impact on the overall fold of the polypeptide chain. Comparison of the cAMP response
at different sites must therefore be interpreted with caution, unless accurate calibration curves are
available for the targeted reporters.
The demonstrable independence of the sensor FRET response from the chosen targeting domain,
in combination with in-cell calibration techniques, paved the way for accurate quantitation of cAMP
concentrations at different compartments of healthy and hypertrophic myocytes. Direct quantitative
comparison of cAMP levels obtained with CUTie sensors, targeted to plasmalemma, sarcoplasmic
reticulum, or sarcomere, suggested that the size of cAMP subcellular compartments can be
sub-microscopic. Importantly, it was observed that the amplitude of the local cAMP signal is
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independent of the distance from the site of cAMP synthesis. It was also dependent on the activity
of phosphodiesterases, indicating that compartmentalisation of cAMP is not simply the result of
limited diffusion due to the complex intracellular structure but is an actively regulated phenomenon.
The study also showed that the effect of phosphodiesterases is most profound at the sarcomeric
nanocompartment. Application of targeted CUTie reporters that were used to compare healthy
and diseased hearts revealed that nanodomains can be differentially affected by misregulation of
β-adrenergic signalling in heart failure [12]. This highlights the opportunities inherent to selective
targeting of cardiac compartments in heart failure therapy. Focussing therapeutic interventions on the
compartments that are selectively affected in heart failure may reduce the adverse outcomes of current
inotropic agents in long-term treatment [48].
2.5. Single-Wavelength Fluorescent Sensors for cAMP
In cardiomyocytes, cAMP signalling is closely linked to calcium signalling. It is possible to
use ECFP/EYFP FRET sensors in combination with Fura-2, a calcium imaging dye with absorption
peaks at 340 nm (Ca2+-bound) and 380 nm (Ca2+-free), and follow the activation of both pathways
simultaneously [49]. To streamline such multi-colour measurements for off-the-rack microscope setups,
several single-wavelength sensors for cAMP have been developed. In Flamindo and Flamindo2,
the cAMP binding domain of Epac1 is sandwiched between two halves of the EYFP variant Citrine.
Binding of cAMP decreases Citrine fluorescence intensity [50]. In the newly developed cAMPr sensor,
circularly permuted GFP is flanked by the full-length catalytic subunit of PKA on one, and a regulatory
subunit of PKA lacking the dimerization/docking domain on the other, side. Binding of cAMP
separates the PKA subunits and increases GFP fluorescence [51]. Both sensors have been used in
combination with calcium sensing dyes, albeit not in cardiomyocytes.
2.6. PKA Activity Sensors
The most extensively studied effector of cAMP in the heart is protein kinase A (PKA) [52]. A family
of single-chain FRET sensors was developed to assay PKA-mediated phosphorylation in cells. In these
A-kinase activity reporters (AKARs), a phosphorylatable PKA consensus sequence is combined with
a phosphate-binding domain into a single polypeptide chain. The two domains of the sensor are
flanked by a FRET pair of fluorophores [53]. Phosphorylation of the PKA consensus leads to the
interaction of the phosphate-binding domain with the now phosphorylated sequence, which mediates
the conformational change necessary for FRET to occur. Since its first conception, the sensor has been
optimised in several rounds to give a maximum FRET efficiency of 60% in the latest version [54–56].
An important feature of later versions of this sensor is that it allows for dephosphorylation of the
probe. As such, these sensors provide information on both PKA activity, which increases FRET,
and phosphatase activity directed against PKA targets, which decreases FRET [54].
Similar to cAMP probes, these sensors are theoretically targetable to any cellular compartment
or signalosome. As such, they are useful reporters of the functional effects of cAMP signalling on
effector proteins within a pre-defined compartment. Tethering of AKAR reporters to AKAP-binding
domains, for example, shortened the response time of the sensor to adenylate cyclase stimulation,
whereas tethering to a nuclear localisation sequence prolonged it [53]. This emphasised the importance
of proximity in determining which substrates are preferentially phosphorylated by the anchored
PKA kinase.
The use of AKAR reporters is extremely effective in real-time quantification of PKA-mediated
phosphorylation in a given cellular compartment. It is important to keep in mind that this is an indirect
measure of the cAMP signal in this compartment, as signal intensity not only depends on the cAMP
concentration but also on the availability of functional PKA to mediate AKAR phosphorylation, and
on the level of counteracting phosphatase activity.
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3. Cardiac Nanodomains Studied Using FRET-Based cAMP Sensors
Development of genetically encoded cAMP sensors greatly enhanced our ability to describe the
biochemical properties of cAMP in living cells through real-time visualisation of cAMP responses.
The sensors allowed for more accurate definition of the diffusive properties of the small signalling
molecule in a cellular context. Physical barriers in the structurally highly complex adult cardiomyocytes,
for example, considerably slow down diffusivity of cAMP compared to the loosely structured
neonatal cardiomyocyte [9]. Accurate physiological calibration of the sensors also enabled precise
measurement of cAMP binding to cAMP-dependent proteins, such as PKA, in their actual intracellular
context [57]. Importantly, genetically encoded cAMP sensors were used to demonstrate, for the first time,
that gradients of cAMP are formed within intact cardiac myocytes upon adrenergic stimulation [26].
The possibility to target FRET sensors to distinct subcellular structures makes them an ideal molecular
tool for monitoring confined intracellular cAMP nanodomains (Figure 2). cAMP nanodomains often
contain a combination of PKA targets and regulators, as well as domain-specific PKA anchoring proteins,
PKA itself, and phosphodiesterases. We now know that each nanodomain comprises a unique set
of, and combination of, these proteins. PKA targets can be structurally and functionally diverse,
including, for example, mechanoenzymes [58], structural proteins [59], regulatory proteins [60], or ion
channels [61]. There are at least forty known PKA anchoring proteins, and new ones are still being
discovered [62,63]. Depending on the type of regulatory subunit, PKA complexes themselves are
targeted to different subcellular sites [64]. Phosphodiesterases are a diverse family of enzymes that
can be grouped into 11 families (PDE1-PDE11), with each family often containing distinct variants that
are differentially expressed and localised [65]. FRET-based cAMP sensors have been instrumental in
detailing the components of signalosomes in different compartments and thus in defining biochemical
and physiological effects of local cAMP signalling in cardiomyocytes.
 
Figure 2. Scales of cAMP signalling domains in adult cardiomyocytes. Continued development
of cAMP detection methods improved the resolution of cAMP signal measurement within adult
cardiomyocytes. (a) Initially, whole-cell and fractionation assays across a 100μm long adult cardiomyocyte
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were performed. (b) Later, differences in cAMP concentrations were measured along the sarcolemmal
crest and T tubules, which are spread across the membrane roughly every 2 μm. (c) Targeted sensors
showed differential cAMP signalling between cytosol and mitochondrial matrix, which can be located
under 1 μm apart from each other in cardiomyocytes. (d) Even differences between mitochondrial
outer membrane and matrix, or sarcoplasmic reticulum and T tubules, in cardiomyocytes ca. 100 nm
apart, can be detected. (e) Future sensors might be able to quantify signalling events within single
signalosomes that are few nanometres apart, such as the protein complexes of the sarcomere.
3.1. cAMP Signalling in the Nucleus
Transcriptional regulation of nuclear genes can alter metabolic and developmental programmes,
and changes in transcriptional profile are strongly associated with pathological conditions, such as
cardiac hypertrophy [66]. Major targets of the cAMP signalling pathway in the nucleus are transcription
factors, including the Nuclear factor of activated T-cells (NFAT) and cAMP response element-binding
protein (CREB) families, as well as Class II histone deacetylases (HDACs), which regulate gene
transcription by increasing the compaction state of DNA. Transcription factors and HDACs can shuttle
between nucleus and cytoplasm. Whether cAMP signalling affects them inside the nucleus, outside,
or both, is not fully resolved. This is particularly interesting, because G-protein coupled receptors
couple predominantly to plasma membrane adenylate cyclases (pmACs), i.e., the primary site of
cAMP production after their activation is the plasma membrane. Hence, for nuclear targets of the
cAMP pathway, this production site of the second messenger is considerably far removed from their
site of activity (Figure 2a). However, there is a soluble adenylate cyclase (sAC) that localises to the
nucleus [67,68], raising interesting questions about origin and propagation of cAMP in relation to
nuclear signalling.
As detected by Epac-based cAMP FRET sensors targeted with a nuclear localisation sequence
(NLS), cAMP concentration in the nucleus increases after stimulation of β-adrenergic or prostaglandin
receptors in human embryonic kidney (HEK 293) and airway smooth muscle (ASM) cells [31,37,69].
The increase in cAMP in this compartment reached a plateau after 2 min. However, the increase in
cAMP was not immediately followed by an increase in PKA substrate phosphorylation, as measured
with the functional PKA sensor AKAR, likewise targeted to the nucleus. Instead, the AKAR
response showed a delayed onset of 5–10 min, giving a plateau only after 30 min [37,55]. This delay
was inconsistent with activation of resident nuclear PKA by cAMP after β-adrenergic stimulation.
It instead favoured a hypothesis that cytoplasmic PKA catalytic subunits, activated in the cytoplasmic
compartment, need to translocate to the nucleus to phosphorylate any nuclear targets. In a different
study, exclusive nuclear targeting of sAC along with nuclear AKAR revealed that cAMP generated
directly in the nucleus of HEK 293 cells can, in fact, activate nuclear PKA immediately after
stimulation [70]. Interestingly, even the transmembrane adenylate cyclases can activate nuclear
PKA activity much faster, provided PDEs, particularly PDE4, are inhibited, or PKA anchoring to
AKAPs is prevented [70].
The direct mechanism of nuclear PKA activation does not seem to be conserved in cardiomyocytes.
PDE inhibition in neonatal rat ventricular myocytes does not accelerate nuclear AKAR phosphorylation,
despite rapid nuclear cAMP accumulation after co-treatment with adenylate cyclase activators and
PDE inhibitors [71]. Disruption of PKA anchoring likewise does not enhance the kinetics of nuclear
PKA activity. This suggests that, in cardiomyocytes, translocation from the cytoplasm is the limiting
step in nuclear PKA activity. This mechanism may help prevent onset of transcription factor-mediated
hypertrophy during transient sympathetic activation.
3.2. cAMP Signalling at the Sarcolemma
The sarcolemma has distinct microscopic domains. T tubules (Figure 2b) reach deep into the
cardiomyocyte, increasing its surface area and facilitating rapid delivery of extracellular ions to the
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core of the cardiomyocyte. Moreover, T tubules contain unique proteins compared to other membrane
areas, and they form close contacts with the sarcoplasmic reticulum (Figure 2c,d). Both features cause
unique signalling events to take place in T tubular membrane sections. Another smaller membrane
compartment, which is best visualised in electron microscopy images, is specialised membrane pits
called caveolae. Caveolae, too, increase the membrane surface area and facilitate the formation of
signalling complexes.
Using plasma membrane-targeted cAMP sensors, it was established that proximity to the plasma
membrane can have a temporal effect on the onset of cAMP signalling. For example, in one study
the response time of the Epac-based cAMP sensor ICUE1 targeted to the plasma membrane was 40%
reduced over its diffuse cytoplasmic counterpart upon β-adrenergic stimulation [37]. To address the
functional effects of such differences in signal initiation, plasma membrane targeted and untargeted
AKAR probes were compared in neonatal cardiomyocytes [72]. This study showed that PKA
phosphorylation gradients in response to local cAMP production depended predominantly on
restricted cAMP diffusion, PDE-mediated cAMP degradation, and PKA-mediated cAMP buffering.
Moreover, the different effects of prostaglandins and adrenergic stimulation on cAMP signalling in
cardiomyocytes were further described in this study. Prostaglandins stimulated higher PKA activity in
the cytosol than at the sarcolemma, whereas β-adrenergic stimulation triggered faster sarcolemmal
responses than cytosolic [72].
Not only the agonist, but also the receptor subtype affected the propagation of cAMP in
cardiomyocytes. While β1-adrenergic stimulation lead to Epac-based cAMP detection throughout the
entire cell, β2-adrenergic stimulation responses were locally confined by an unknown mechanism [33].
β2-adrenergic signalling was similarly confined in human embryonic kidney (HEK 293) cells [40]. Here,
β2-adrenergic signalling detected by an untargeted Epac-based sensor, ICUE3, could be amplified by
disrupting membrane rafts through cholesterol depletion. In cardiomyocytes, β1-adrenergic receptors
can be found in both caveolar and extra-caveolar fractions of the sarcolemma, while prostaglandin
receptors are excluded from caveolar fractions. Disruption of caveolae by cholesterol depletion did
not lead to significant differences in cytosolic cAMP responses for either of these receptors [73],
indicating that the extracaveolar receptor fraction dominates cAMP production in cardiomyocytes.
A study combining Epac-based cytosolic cAMP sensors with SICM confirmed that β1-adrenergic
receptors can be found across the entire sarcolemma. Yet, β2-adrenergic receptors were exclusively
localised to T tubules [43]. Critically, this functional compartmentation is perturbed in failing hearts,
leading to loss of the restricted nature of the β2-adrenergic cAMP signal. Later, it was shown using
the same technique that caveolin 3 promotes compartmentation of β2-adrenergic cAMP signalling
to the T tubules, and overexpression of caveolin 3 in failing cardiomyocytes can partially restore the
delocalised signal [74].
Downstream of β1-adrenergic signalling, but not β2-adrenergic signalling, PDE4B-mediated
degradation of cAMP is activated in cardiomyocytes [75]. PKA inhibition in wild type, but not
PDE4B knock out myocytes, triggered a significant increase of adrenergic receptor generated
cAMP levels in the sarcolemmal compartment, indicating that a combination of PKA and PDE4B
activity is required to maintain physiological cAMP levels in the β1-receptor domain. These FRET
measurements with a plasma membrane-targeted Epac-based sensor thus provided first evidence for
a localised, β1-adrenergic receptor-coupled feedback mechanism in cardiomyocytes. This feedback
proved essential in the regulation of the amplitude of intracellular calcium currents after adrenergic
stimulation. Calcium levels after adrenergic stimulation were higher in PDE4B knock out mice than
in controls, which highlights the delicate balance in cAMP production and degradation that healthy
cardiomyocytes must maintain in response to sympathetic activation.
3.3. cAMP Signalling at the Mitochondria
In adult cardiomyocytes, mitochondrial fatty acid beta-oxidation is the major source of energy.
For this reason, cardiomyocytes are tightly packed with mitochondria (in a healthy heart, about 95% of
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the heart’s ATP production takes place there [76]). This energy is needed to fuel sarcomeric contraction
and ATP-dependent ion flux between compartments. Heart failure is associated with significant
reductions in mitochondrial respiratory capacity and mitochondrial membrane disruption [77].
cAMP signalling plays important roles in mitochondrial calcium handling, mitochondrial
metabolism, and protection against cytochrome c-mediated apoptosis in cardiomyocytes.
Close proximity (Figure 2c,d) between cardiomyocyte mitochondria and sarcoplasmic reticulum
facilitates calcium-dependent regulation of mitochondrial respiration upon sympathetic activation.
Metabolic activity of the muscle cell is thus tightly synchronised with myocyte activation [78–81].
Ischaemia-reperfusion injury of the heart is associated with a dramatic change in mitochondrial
morphology. Changes in mitochondrial structure impact their function and have been shown to
induce cyotochrome c-dependent cardiomyocyte apoptosis [82]. Interestingly, cAMP signalling after
pharmacological β-adrenergic stimulation or stress and exercise could counteract this programme. [83].
To specifically describe mitochondrial cAMP signalling, FRET-sensors were fused to different
mitochondrial targeting domains. An Epac-based FRET sensor, fused to the mitochondrial PKA scaffold
protein AKAP1, showed a similar FRET response to β-adrenergic stimulation as in the cytosol [37].
AKAP1 binds to the outer mitochondrial membrane and faces the cytosol [84]. The same sensor was
targeted to the mitochondrial matrix, using the first 12 amino acids of human cytochrome oxidase c
(subunit IV). The matrix-targeted sensor responded to β-adrenergic stimulation, initially suggesting
that membrane-generated cAMP can enter mitochondria and activate downstream signalling in the
matrix [37]. This view of a continuous cAMP gradient shared between cytosol and mitochondria was
contested by observations made with AKAP-targeted PKA activity sensors. Baseline phosphorylation
of the sensor was much higher than its cytosolic equivalent, and phosphodiesterase inhibition even
enhanced this difference [55]. Therefore, the cytosolic surface of mitochondria seemed to regulate
downstream cAMP signalling differently from the cytosol. This was confirmed with a later generation
of PKA activity sensors tagged with the OMM-targeting peptide yTOM70 [85]. When PKA-mediated
phosphorylation after extracellular signal termination was monitored in this system, phosphorylation
at the mitochondria persisted for longer than in the cytosol. The corresponding outer membrane
cAMP concentrations, studied with an OMM-targeted Epac-based sensor, on the contrary, mirrored the
bulk cytosol. A matrix-targeted sensor, however, was unable to detect cAMP generated at the plasma
membrane. Two separate studies showed that cAMP is unable to permeate the inner mitochondrial
membrane [45,85], although both groups found evidence for cAMP signalling within the mitochondrial
matrix. The discrepancy between the initial study and follow-up research is most likely due to
imprecise targeting of the first sensor. While the authors could demonstrate that some of the sensor was
indeed localised to the mitochondrial matrix [37], a significant proportion remained cytosolic [37,45].
This provides key learnings for the design of targeted FRET sensors. It highlights the importance of
exclusive targeting of the sensor to the compartment of interest.
In contrast to cAMP generated at the sarcolemma, calcium release from the ER or capacitative
calcium influx from the extracellular medium could activate the matrix cAMP sensor [45]. The soluble
adenylate cyclase activator bicarbonate, similarly, increased both matrix cAMP concentrations [45] and
matrix PKA phosphorylation [85]. As a result, cAMP in the matrix is now thought to be generated by
a mitochondrial sAC. The cAMP FRET response in the matrix was further increased by panspecific
inhibition of phosphodiesterases, suggesting that matrix cAMP is modulated by phosphodiesterases.
Functionally, cAMP signalling in the mitochondrial matrix domain enhances mitochondrial metabolism.
Activation of sAC or treatment with phosphodiesterase inhibitors increased mitochondrial ATP
production, as measured in a mitochondrially-targeted luciferase assay. PKA inhibition reduced
mitochondrial ATP production [45].
Using OMM-, and matrix- and untargeted Epac-based sensors, the outer mitochondrial membrane
cAMP nanodomain was subsequently dissected further. It was confirmed that this domain on the
mitochondrial surface is supplied by plasma membrane adenylate cyclases and is independent of
any cAMP generated in the mitochondrial matrix by sAC [86]. Instead of regulating mitochondrial
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metabolism, this pool of cAMP is involved in regulation of mitochondrial dynamics and protects them
from ionomycin-induced apoptosis.
3.4. cAMP Signalling at the Sarcoplasmic Reticulum
The sarcoplasmic reticulum (SR) of mammalian adult cardiomyocytes is a highly differentiated
organelle and the main regulator of calcium transients in these cells. Its proximity to cadiomyocyte T
tubules (Figure 2c,d) facilitates rapid translation of adrenergic activation in the T tubular membrane
compartment to induction of calcium ion (Ca2+) currents from the SR. Cardiac Ca2+ homeostasis is vital
in maintaining the ability of the cardiomyocyte to contract and relax, as Ca2+ is a necessary co-factor
for the force-generating module in the sarcomere [87].
Calcium cycling at the SR is heavily regulated by PKA. PKA phosphorylates the channels
that release Ca2+ from the SR to enable contraction (ryanodine receptors, RyR) [61,88], as well
as phospholamban (PLN), a protein that regulates the sarco/endoplasmic reticulum Ca2+-ATPase
(SERCA) [89]. Ca2+ handling by the SR is often dysfunctional in heart diseases, including heart
failure [90].
An Epac-based cAMP sensor, fused to full-length phospholamban using a flexible linker,
was used to investigate propagation of adrenergic signals to the SR. The SR compartment was
found to be predominantly under β1-adrenergic control [46]. β2-adrenergic signals were not strong
enough to produce a cAMP increase at the SERCA microdomain that was detectable with the
phospholamban-anchored sensor. β1-adrenergic stimulation, on the other hand, produced a cAMP
signal at the SR that even surpassed the cytosolic cAMP signal in amplitude. The robust effect of
β1-adrenergic stimulation in the SR compartment was corroborated in rabbit cardiomyocytes using a
PKA activity sensor targeted to the SR with only the transmembrane domain of phospholamban [91].
Interestingly, this sensor also detected a small but significant change in PKA activity upon
β2-adrenergic stimulation, although this signal was significantly lower than after β1-adrenergic
stimulation [91]. This could mean that either cAMP compartmentalisation differs slightly between
species or the amplification of the cAMP signal by PKA is necessary to render the signal
detectable. Pan-specific adrenergic stimulation induces a rapid and significant increase in both cAMP
concentrations and PKA activity at the SR, as measured by a CUTie sensor targeted to the SR with full
length AKAP18δ or the phospholamban PKA activity sensor [12,91,92]. Direct pharmacological
activation of adenylyl cyclases induced much slower and smaller increases in PKA-mediated
phosphorylation at the SR than activation of the cyclase following adrenergic stimulation, raising the
question of how the adrenergic signal is more efficiently relayed to the SR compartment [92].
This could be increasingly relevant as transverse aortic constriction (TAC), which causes
pressure overload-induced cardiac hypertrophy in the heart, reduces any differences in cAMP
between SR and cytosol observed after adrenergic stimulation [46]. Phosphodiesterases act to
counterbalance loss of cAMP gradients. The adrenergic cAMP concentration gradient between
SR and cytosol can be reduced upon additional inhibition of phosphodiesterases [46]. This was
confirmed when cAMP concentrations at the SR were compared to nanodomains at the sarcolemma or
sarcomere using CUTie sensors fused to full length AKAP18δ (SR), AKAP79 (sarcolemma), or cardiac
troponin I (sarcomere) [12]. While low-level, pan-specific adrenergic stimulation resulted in different
concentrations of cAMP in each compartment, this difference was completely abolished by concomitant
inhibition of phosphodiesterases. Measurement of PKA activity in the same compartments with a PKA
activity sensor fused to the transmembrane domain of phospholamban (SR), a membrane targeting
peptide from Kras (sarcolemma), or the C-terminus of troponin T (sarcomere) confirmed differential
regulation of these compartments for β2-adrenergic signals [91]. Strikingly, phosphodiesterase
inhibition levelled cAMP concentrations, even in diseased hearts, in which adrenergic responses
in the SR and sarcomeric compartments were dampened [12]. Differential analysis of the contribution
of specific families of phosphodiesterase revealed that their contribution to reducing phosphorylation
in the three compartments varies depending on the health of the myocyte [91]. Both of these results
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emphasise the importance of local phosphodiesterases in shaping cAMP gradients in both normal and
disease conditions.
3.5. cAMP Signalling at the Sarcomere
The sarcomere is the proteinaceous force generator within the cardiomyocyte that mediates muscle
contraction. It contains more than 600 structural, regulatory, and associated proteins [93]. The main
functional units of the sarcomere are interlaced actin and myosin filaments (Figure 2c). The sarcomere
contains some of the most-studied PKA targets in the cardiomyocyte (Figure 2e). PKA phosphorylation
at the sarcomere increases contractility by enhancing actin-myosin cross-bridge formation by cardiac
myosin binding protein [94]. PKA also mediates relaxation via troponin I phosphorylation by reducing
the affinity of the troponin complex for Ca2+ [60,95]. In doing so, it ensures the speedy recovery of the
sarcomere in preparation for the next cycle.
Taking into account the important functional role of PKA activity in sarcomere contraction, it is
interesting that this cellular compartment undergoes the smallest change in cAMP in response to
adrenergic signalling in healthy cardiomyocytes. Comparing cAMP levels quantified with CUTie
sensors targeted to the sarcomere with full length cardiac troponin I to sarcolemmal and SR-targeted
sensors, low level adrenergic stimulation generated only about 60% as much cAMP at the sarcomere
than at the other compartments [12]. Calibration of the sensor allowed translation of the measured
FRET value to PKA activity, and it was estimated that the amount of cAMP measured at the sarcomere
with the CUTie sensor would only activate PKA to about 5% of its maximal activation, in which the
activity in resting cells was measured to be ca. 3% [12]. This correlates well with measurements in
rabbit myocytes using sarcomere-targeted PKA activity sensors [91], in which the sarcomere was
shown to be less sensitive to adrenergic stimulation than sarcolemma and sarcoplasmic reticulum.
For example, in cells exclusively stimulated through the β2-adrenergic pathway, sarcomeric PKA
phosphorylation was barely detectable by FRET, whereas sarcolemma and sarcoplasmic reticulum
showed robust responses [91]. Both the mouse and the rabbit studies show that inhibition of PDEs
elevates cAMP and PKA signalling at the sarcomere.
3.6. cAMP Signalling at A Kinase Anchoring Proteins (AKAPs)
AKAPS are intracellular scaffolding proteins that provide a platform for the assembly of
PKA-containing signalosomes. AKAPs were first discovered in the 1970s and 80s [96] and then
catalogued in different tissues using interaction screens with the PKA dimerization/docking domain
that contained an AKAP-binding consensus [97,98].
Targeting FRET sensors to distinct AKAPs can be utilised to directly describe cAMP fluctuations
around defined PKA signalosomes in cardiomyocytes. CUTie sensors were used to quantitatively
compare cAMP concentrations in the vicinity of AKAP79 at the plasma membrane or AKAP18δ
at the sarcoplasmic reticulum with cytosolic cAMP concentrations after adrenergic stimulation of
cardiomyocytes. These studies revealed that cAMP concentrations around AKAPs can be detectibly
higher than in the bulk cytosol [12].
AKAPs interact with PKA through AKAP-binding domains on the regulatory (R) subunits.
Of note, different isoforms of R subunits preferentially interact with distinct AKAPs. By tethering
Epac-based cAMP reporters to the dimerization/docking domains of RI and RII, it was possible to
specifically dissect molecular components that shape cAMP pools around these different PKA isoforms
in cardiomyocytes [42]. Both compartments have access to cAMP at similar levels after direct activation
of adenylate cyclase. However, β-adrenergic stimulation leads to a stronger increase in cAMP at the
PKA-RII containing compartments, whereas glucagon-like peptide, glucagon, and prostaglandins
activate cAMP signalling around PKA-RI. These differences were abolished by simultaneous inhibition
of all major phosphodiesterases, highlighting their critical role in shaping distinct receptor-mediated
cAMP responses. More detailed analysis of the two compartments by combining β-adrenergic receptor
stimulation with family-specific phosphodiesterase inhibitors revealed that, while PDE2 inhibition
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affected cAMP concentrations in both the RI and the RII compartments, PDE3 inhibition only increased
cAMP in the RI compartment [99]. Using a targeted PKA activity sensor confirmed that elevated
cAMP levels after co-treatment with β agonist and PDE2 inhibitor lead to increased PKA-dependent
phosphorylation in the RII compartment versus the RI compartment. This is significant, because
PDE2 inhibition in cardiomyocytes that are chronically stimulated with a β agonist prevented their
hypertrophic growth through PKA-mediated phosphorylation of NFAT [99]. Phosphorylation inhibits
translocation of the transcription factor to the nucleus and thus activation of the hypertrophic gene
transcription programme under its control [100,101]. A different study with the RI and RII-targeted
cAMP sensors found that crosstalk with other signalling pathways could help shape the cAMP signal
in PKA compartments [102]. Local co-stimulation of cyclic GMP signalling after adrenergic stimulation,
for example, selectively reduces the cAMP response around PKA-RII, levelling cAMP signal intensity
in PKA-RI and PKA-RII compartments. This study highlights the value of FRET-based cAMP detection,
not only for describing the cAMP pathway in isolation, but also for addressing signal integration with
other simultaneously active pathways in cardiomyocytes.
Genetically encoded, tetrameric PKA-RII containing FRET probes naturally localise to AKAPs in
cardiomyocytes. These probes identified a prominent role for PDE2 in shaping the cAMP response
to catecholamines [103]. Inhibiting PDE2, while quantifying cAMP with the anchored FRET sensors,
suggested tight coupling of PDE2 to the pool of adenylyl cyclases activated by β-adrenergic receptor
stimulation. This coupling resulted in a feedback control loop, in which activation of β3-adrenergic
receptors counteracted cAMP generation by β1/β2-adrenoceptors.
To dissect the role of AKAPs on cAMP signal compartmentation themselves, cytosolic FRET
responses were compared in neonatal cardiac myocytes from wild type and AKAP5 knock out
mice [104]. While there was a clear difference in the amount of cAMP detected after selective β1- or
β2-adrenergic stimulation in the wild type, AKAP5 knockout myocytes produced equal cytosolic
cAMP levels in response to β1- or β2-adrenergic stimulation.
4. Conclusions
The use of FRET-based cAMP and PKA activity sensors has greatly enhanced our understanding
of spatial organisation in the cAMP signalling cascade, as well as the mechanisms that generate a
uniquely patterned cAMP response through cardiomyocytes as they react to defined stimuli.
Localised FRET sensors have refined our ability to monitor cAMP signalling events. The sensors
constantly evolve (Figure 1), thus increasing the resolution of cAMP monitoring around distinct
signalosomes (Figure 2). Initial biochemical studies drew attention to the cAMP concentration gradients
between sarcolemma and bulk cytosol of adult cardiomyocytes. This was later confirmed by CNGC
activity assays and FRET. cAMP measurements with FRET-based probes, especially in combination
with other powerful techniques such as SICM, allowed for narrowing down single cAMP signalling
domains to individual T-tubules, which are spread across the sarcolemma of adult cardiomyocytes
ca. 2 μm apart from each other [43]. Development of targeted sensors first highlighted differences
in cytoplasmic and mitochondrial matrix cAMP concentrations [45,85,86], i.e., in compartments that
are only few micrometres apart [105]. This was further refined by sensors targeted to different
compartments of the mitochondria itself [85,86]. Likewise, sensors targeted to the sarcoplasmic
reticulum were unable to detect cAMP generated by β2-adrenergic receptors in the T tubules [46],
even though these organelles are juxtaposed a few hundred nanometres apart from each other at the
dyadic junction of a cardiomyocyte [106]. Recent data suggests that there are differential responses in
cAMP signalling even between the troponin complex and myosin binding protein C [12], which are
located only a few nanometres apart from each other within the sarcomere [107].
FRET-based sensors for cAMP and downstream PKA activity have evolved from a highly
demanding technique into a universally applicable tool over the last two decades. In the future,
fine tuning this approach by targeting sensors to additional compartments, adjusting their
sensitivity accordingly, and improving their dynamic range through engineering the fluorophores
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in a FRET pair will undoubtedly continue to refine our understanding of cAMP-regulated
cardiomyocyte compartments.
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Abstract: Cyclic nucleotides 3′,5′-cyclic adenosine monophosphate (cAMP) and 3′,5′-cyclic guanosine
monophosphate (cGMP) are important second messengers that regulate cardiovascular function
and disease by acting in discrete subcellular microdomains. Signaling compartmentation at these
locations is often regulated by phosphodiesterases (PDEs). Some PDEs are also involved in the
cross-talk between the two second messengers. The purpose of this review is to summarize and
highlight recent findings about the role of PDE2 and PDE3 in cardiomyocyte cyclic nucleotide
compartmentation and visualization of this process using live cell imaging techniques.
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1. Introduction
Cyclic nucleotides 3′,5′-cyclic adenosine monophosphate (cAMP) and 3′,5′-cyclic guanosine
monophosphate (cGMP) are ubiquitous intracellular second messengers that regulate multiple
physiological functions as well as pathological conditions. In cardiomyocytes, there are at least three
pathways that normally trigger their production after initial first messenger stimuli: (i) the β-adrenergic
pathway for cAMP production, (ii) the nitric oxide, and (iii) the natriuretic peptide (NP) receptor
pathways for cGMP synthesis.
1.1. The cAMP and β-Adrenergic Pathway
In healthy cardiomyocytes, sympathetic activation mainly via β-adrenergic receptor (β-AR)
signaling leads to the production of cAMP and thereby to increased contractile force (inotropy),
heart rate (chronotropy), and cell relaxation (lusitropy) [1]. When a ligand binds to a G protein-coupled
receptor (GPCR) located on the plasma membrane, a conformational change occurring in the receptor
leads to G-protein activation. Activated G-proteins can in turn, activate or inhibit cAMP-forming
enzymes adenylyl cyclases (ACs) which generate cAMP from ATP. Subsequently, cAMP acts in cells
via one or more of the following effector proteins:
(a) cAMP-dependent protein kinase (PKA), which is responsible for phosphorylation of several
calcium handling proteins involved in cardiac excitation-contraction coupling (ECC) including
L-type Ca2+ channel (LTCC) at the plasmalemma, phospholamban, and ryanodine receptors at the
sarcoplasmic reticulum (SR), myosin-binding protein C, and troponin I at the myofilaments [1,2].
PKA is the main effector protein in the cAMP cascade, while Ca2+-inhibited AC5 and AC6 are
the predominant cAMP generating adenylyl cyclases in adult (AC5 and AC6) and fetal (AC6)
ventricular cardiac tissue [3];
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(b) exchange proteins directly activated by cAMP (Epac1 and Epac2) [4], which are implicated in
pathological cardiomyocyte growth [5,6];
(c) cyclic nucleotide gated ion channels (CNGCs) including HCN channels located in the sinus
node, which regulate the capacity of cardiac cells to initiate spontaneous action potentials
(automaticity) [7–9];
(d) the recently introduced Popeye-domain-containing proteins which affect cardiac pacemaking [10,11].
1.2. NO/sGC/cGMP Pathway
Biosynthesis of cGMP is catalyzed by two discrete guanylyl cyclase (GC) families, one being
activated in the presence of nitric oxide (NO) and called soluble guanylyl cyclase (sGC) and the
other acting as membrane receptors for natriuretic peptides (NPs), also called particulate guanylyl
cyclase (pGC).
NO, alternatively known as “endothelial-derived relaxant factor” (EDRF) [12,13], is produced for
example by endothelial cells after acetylcholine administration. It increases cGMP levels, activates
cGMP-dependent protein kinase (PKG), and behaves in a way similar to nitrovasodilators [14,15].
Seminal work on the field [16–18] has firmly established that NO is produced by a family of NO
biosynthetic enzymes called nitric oxide synthases (NOS). It includes neuronal (NOS-1 or nNOS),
inducible (NOS-2 or iNOS), and endothelial nitric oxide synthases (NOS-3 or eNOS) [19], all of
which having been detected in heart and vessels [20–24]. iNOS is an inducible biosynthetic enzyme,
while eNOS and nNOS are both constitutive and inducible enzymes [25]. NO activates sGC by
binding to both heme and non-heme sites [26–28], which leads to the production of cGMP [29] and its
subsequent downstream effects [25,30,31].
1.3. NP/pGC/cGMP Pathway
Natriuretic peptides (NPs) constitute important cardiovascular regulators of inotropy and blood
pressure [32] with atrial (ANP), brain (BNP), and C-type natriuretic peptides (CNP) being the most
well-known ligands. In response to neurohumoral (catecholamines or angiotensin II) or mechanical
(e.g., increased myocardial stretch or blood pressure) stimuli [33,34], ANP and BNP are produced and
released by the atria and the ventricles of the heart, while CNP is produced mainly by endothelial cells
of the vasculature [34].
These NPs can bind and activate several pGCs, two of which are expressed in the heart and exert
the majority of their physiological effects. NPR1 (also called NPR-A or GC-A) is the receptor that
binds both ANP and BNP with relatively high affinity (ANP > BNP) [35–37]. After ligand binding at
its extracellular domain, pGCs undergo a conformational change upon which its intracellular domain
generates cGMP [25]. As a widely distributed receptor in the cardiovascular system (heart, vessels,
and kidneys), NPR1 regulates blood pressure, exerts antihypertrophic action, and preserves body
homeostasis [35–37]. NPR2 (also called NPR-B or GC-B) is the CNP-specific receptor responsible
for vascular regeneration and endochondral ossification. It is mainly localized in fibroblasts [38],
the sympathetic nervous system [39], and the vascular endothelium and smooth muscle [40] and exerts
antihypertrophic effects in cardiomyocytes [41,42].
Both NO/sGC and NP/pGC pathways stimulate cGMP synthesis and participate in the homeostasis
of the cardiovascular system via (i) PKG-mediated protein phosphorylation [29–31], (ii) the activation
of CNGCs, and (iii) the regulation of PDEs [25]. Physiologically, cGMP binds to specific sites in
the regulatory domains of PKG, CNGC, or PDE in order to induce conformational changes and
downstream effects. Disruption of downstream cascade at any level can initiate pathophysiological
effects and may lead to hypertension, atherosclerosis, pulmonary hypertension, hypertrophy, ventricular
remodeling, myocardial ischemia, dystrophy-related cardiomyopathies, mitochondrial metabolism,
or heart failure [25].
Apart from the classical cyclic nucleotides, cyclic cytidine (cCMP) and cyclic uridine monophosphates
(cUMP) have been recently introduced as non-canonical second messengers generated by ACs and
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GCs [43,44]. However, available published data provides limited information regarding their effector
proteins and physiological significance, so further studies are required to fully elucidate their role in
the cardiovascular system.
2. Compartmentation of cAMP and cGMP Signaling
The fact that multiple receptor stimuli can trigger diverse intracellular effects generated via the
production of just a few second messengers such as cAMP and cGMP led to a currently accepted
theory of cyclic nucleotide compartmentation. Compartmentation refers to the mechanisms by which
multiple spatially segregated cAMP/PKA and cGMP/PKG signaling pathways exert different or even
opposing functional effects in distinct subcellular microdomains of the same cell [9,45]. It appears
to be of critical importance for cardiovascular system, since local cyclic nucleotide actions and the
interplay of the cAMP and cGMP signaling pathways have been implicated in physiological functions
or pathological conditions.
Several proteins [46–50] contribute to cyclic nucleotide compartmentation, which spatially,
temporally, and functionally controls the downstream effects of cyclic nucleotides (extensively
studied for cAMP) in the cardiovascular system [25,51–53]. They include (a) GPCRs located in
lipid rafts [54,55], at transverse tubules [56] and in non-caveolar membrane domains [57]; (b) ACs
and GCs [58,59]; (c) Scaffold proteins [60–62]) such as A-kinase anchoring proteins (AKAPs) [52,63,64]
and Calveolin-3 [54,65–67]; (d) physical barriers—e.g., mitochondria, cAMP buffering by PKA,
cAMP export [68,69] are some of the mechanisms that create locally confined intracellular domains
regulating signaling; and (e), the most prominent and extensively studied of all, the PDE-mediated
hydrolysis of cyclic nucleotides, which is of high pharmacological and clinical interest [64,70,71].
PDEs can control cAMP and cGMP compartmentation by providing their local hydrolytic
degradation and creating spatial second messenger gradients [72]. Although much fewer scientific
data are available on cGMP compartmentation, the role of PDEs in local confinement of cGMP pools
has recently been elucidated, especially that of PDE2, PDE5, and PDE9 [25,73]. Furthermore, spatial
organization of PKG and GCs in distinct subcellular complexes appears to be another important aspect
of cGMP microdomain regulation [74]. It still remains to be established whether, for example, myosin,
NPR1, and troponin T could act as PKG scaffolding proteins [75].
Among the relevant experimental evidence, studies on knockout mice do also highlight the
importance of the crucial role PDEs play in the cAMP/cGMP signaling pathways and their respective
crosstalk [76]. The interplay among the β-adrenergic and NO/cGMP/PKG pathways can be interpreted
as a network phenomenon arising from the molecular selectivity of PDEs to cAMP and cGMP [77].
3. Phosphodiesterases (PDEs)
PDEs are the hydrolyzing enzymes that terminate intracellular effects of cyclic nucleotides by
their hydrolysis to fine-tune the signaling and to prevent continuous activation of the downstream
effector proteins. These cyclic nucleotide-degrading enzymes constitute one of the most important
mechanisms, by which cyclic nucleotides are spatially, temporally, and functionally compartmentalized
in cardiomyocytes and other cells. Of the 12 PDE families [78,79], there are seven, namely PDE1 [80],
PDE2 [81], PDE3 [76], PDE4 [82], PDE5 [83], PDE8 [84], and PDE9 [73] that have been reported to
be expressed and active in mammalian cardiomyocytes (Figure 1). They are an integral part of the
multimolecular signaling/regulatory complexes, i.e., signalosomes [52,64,76,84]. This review will
particularly explore the so-called cGMP-regulated PDEs, especially PDE2 and PDE3, which critically
regulate cGMP-to-cAMP cross-talk and cyclic nucleotide actions in cardiomyocyte microdomains.
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Figure 1. PDE activity, specificity, and cyclic nucleotide effector proteins. PDE4, PDE7, and PDE8
selectively degrade cAMP. PDE5, PDE6, and PDE9 selectively degrade cGMP. PDE1, PDE2, PDE3,
PDE10, and PDE11 are dual-specificity phosphodiesterases that hydrolyze both cAMP and cGMP.
Downstream effectors include PKA, PKG, Epacs, PDEs, CNG channels and Popeye domain-containing
proteins. Adapted from Ahmad et al., 2015 [76].
3.1. Phosphodiesterase 2
PDE2 is a dual-substrate enzyme, which hydrolyzes both cAMP and cGMP with similar maximal
rates in bovine adrenal and heart tissues [85]. Only one gene (Pde2a) gives rise to three known PDE2A
isoforms, which are differentially located in the cytosol, mitochondria, and cellular membranes [58].
It is characteristic of this PDE family that the cGMP-mediated control of cAMP hydrolysis arises,
when cGMP binds allosterically to the GAF-B domain of PDE2A, so that cAMP hydrolysis occurs
with a 10-fold higher rate [86–88]. In this manner, cGMP via PDE2A is able to negatively regulate
cAMP levels [51] and therefore to initiate a negative cGMP-to-cAMP cross-talk [89] (Figure 2).
Initially cloned from rat brain [90] and purified from bovine or calf tissues (heart, liver adrenal
gland, and platelets) [85,91], the PDE2A protein is also found in endothelial cells, macrophages,
and brain [92,93]. Platelet aggregation [94], aldosterone secretion [95], and regulation of calcium
channels [96] require PDE2A-mediated hydrolysis of cAMP. Recently, a PDE2A isoform regulating
the mitochondrial respiratory chain has been detected, discovering a possible new pathway for the
drug-induced control of mitochondrial function [97]. Of particular importance are those studies
referring to PDE2A expression in isolated cardiomyocytes and myocardium. In cardiomyocytes,
PDE2A together with PDE5 is also involved in the degradation of sGC-synthesized cGMP, whereas
pGC-synthesized cGMP is preferentially hydrolyzed by PDE2A [72,98,99].
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Figure 2. PDE2- and PDE3-mediated cyclic nucleotide crosstalk. cGMP synthesis occurs by pGCs
such as GC-A, which serves as a membrane receptor for ANP and BNP, or by NO-activated
sGC, e.g., downstream of eNOS and β3-adrenoreceptor (β3-AR). Binding of cGMP to PDE2 can
allosterically increase its hydrolytic activity, lowering cAMP levels in subcellular microdomains. PDE3 is
a “cGMP-inhibited” phosphodiesterase that upon cGMP binding and degradation in the catalytic
domain shows reduced rates of cAMP hydrolysis, generating a positive cGMP-to-cAMP cross-talk.
3.2. Phosphodiesterase 3
Another important cGMP-regulated PDE is PDE3. This enzyme hydrolyzes both cAMP and
cGMP. Often referred to as cGMP-inhibited PDE, PDE3 shows higher catalytic rates for cAMP but
relatively high affinity for cGMP, which acts as a competitive inhibitor of cAMP hydrolysis [100,101].
This creates the so-called positive cGMP-to-cAMP cross-talk (Figure 2). PDE3A and PDE3B are the
two PDE3 subfamilies, with the former being abundant in cardiomyocytes, oocytes, vascular smooth
muscle and platelets and the latter being expressed in the pancreas, liver, and adipose tissue [100].
PDE3A controls myocardial contractility by interacting with the sarcoplasmic/endoplasmic reticulum
calcium ATPase (SERCA2a) [102]. By utilizing their direct positive inotropic effects, PDE3 inhibitors
are used for acute treatment of end-stage heart failure (HF) [103], albeit presenting increased mortality
as well as incidence of arrhythmias and sudden death after chronic use [104,105]. In contrast, PDE3B
seems to be more actively engaged in energy metabolism [106,107], but it can also protect the heart
from ischemia/reperfusion injury [108]. Knockout models have revealed that PDE3A, but not PDE3B,
exerts inotropic and chronotropic effects after treatment with PDE3 inhibitors [109] because PDE3A
regulates SERCA2a activity and subsequent SR Ca2+ uptake [102]. By chronically suppressing its
expression or action, myocyte apoptosis in vitro [110] or deterioration of ischemia/reperfusion-induced
apoptosis and cardiac injury in vivo [111] have been observed. Similarly, disruption of PDE3B
interaction with phosphoinositide 3-kinase γ, which can serve as an AKAP, has deleterious
effects [112–114] such as arrhythmias [114], necrotic cardiac tissue damage, and fibrosis [112].
PDE3 along with other PDEs constitutes an integral part of cAMP degradation. Evidence
suggests that it may also controls cGMP levels [108,115], atrial dynamics, and myocyte ANP release,
depending on the involved induction mechanism [72,116]. In terms of cGMP and cAMP pathway
interactions, cGMP binding to PDE2 enhances the hydrolytic activity of the enzyme and enables the
negative cGMP-to-cAMP cross-talk [75]. Conversely, cGMP binding to the catalytic domains of PDE3
reduced the rate of cAMP degradation, thereby mediating the positive cGMP-to-cAMP cross-talk.
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The previously reported experimental data regarding the affinity, specificity, and enzymatic activity of
PDE2 and PDE3 can largely explain their crucial role in cGMP/cAMP crosstalk [75].
4. Visualization of Compartmentalized cAMP and cGMP
Initially, the idea of compartmentalized action of cyclic nucleotides was conceived [117] and
revealed by several research groups [118–122] with Buxton and Brunton (1983) [122] using classical
biochemical methods to show that prostaglandin induces different PKA activity rates in particulate
and soluble fractions of cardiac myocytes after cAMP generation. Later on, Juvericius and Fischmeister
(1996) [123], by utilizing a combination of two-barrel microperfusion and whole patch clamp techniques,
further confirmed the compartmentation theory in frog ventricular cells, where local application of
a β-adrenergic agonist preferentially stimulated the LTCCs close to activated receptors.
To detect cAMP compartmentation in health and disease, multiple techniques have been
employed that were only able to detect global concentrations of cyclic nucleotides and required
plenty of tissue material [124]. However, biochemical (radio- and enzyme-linked immunoassays)
or even electrophysiological approaches (patch-clamp technique), though sensitive and specific,
are limited in their capability to record and analyze cyclic nucleotide gradients directly in subcellular
microdomains under physiological conditions [124]. Therefore, novel live cell imaging techniques have
been developed for the visualization of cyclic nucleotide signaling and its compartmentation in real
time with high temporal and spatial resolution [9,124]. Such techniques are mostly based on Förster
Resonance Energy Transfer (FRET) biosensors.
FRET biosensors report a non-radiative energy transfer from an excited fluorescent molecule
that acts as a donor to a neighboring (located at nm distance) molecule that acts as an acceptor
with subsequent fluorescence emission without the direct excitation of the acceptor [125]. Multiple
FRET-based biosensors for cGMP [115,126–130] and cAMP [81], and for the activity of the downstream
effector proteins such as PKA [131–136], Epac [137–141], or CNG channels [142–144], have been
developed and successfully used to visualize cGMP and cAMP gradients [124,145,146]. They can
be further combined with other techniques such as scanning ion conductance microscopy (SICM),
which can be used to deliver receptor ligands onto defined membrane structures to targeted distinct
cAMP or cGMP pools and to study receptor–microdomain interactions. SICM is a non-optical imaging
technique that uses a small glass nanopipette to obtain a highly resolved morphological profile of
a living cell membrane based on ion current measurement [147–150]. It can also be combined with FRET
for more accurate and specific detection of microdomain alterations in health and disease [149,151,152].
5. Imaging of cGMP-to-cAMP Crosstalk via PDE2 and PDE3
Employing FRET for live cell imaging, recent studies have revealed strongly remodeled
cAMP/cGMP microdomains and subcellular concentration profiles in various cardiac pathologies,
leading among other mechanisms to a putatively enhanced involvement of PDE2 in cAMP/cGMP
breakdown and crosstalk compared to the other cardiac PDEs.
As mentioned above, the hydrolytic activity of PDE2 can be allosterically stimulated by cGMP to
limit cAMP levels, referred to as a negative cGMP-to-cAMP crosstalk. In cardiomyocytes, cGMP can be
produced by either pGC after ANP, BNP, and CNP stimulation or by the NO-dependent sGC. Sources
for NO include both synthesis in other cell types (e.g., by endothelial cells) and inside cardiomyocytes,
e.g., by β3-adrenoreceptor (β3-AR) stimulated pathway, which via inhibitory G-proteins leads to NOS
activation (Figure 2). PDE2 hydrolyzes cAMP (e.g., produced in response to the β1/2-adrenergic
agonists such as noradrenaline), but its stimulation can be in turn limited by its cGMP hydrolyzing
activity, which increases in importance when cGMP concentration rises [51,89]. It has been suggested
that PDE2-dependent cAMP hydrolysis might have a more critical effect on cardiomyocyte function,
at least under adrenergic overdrive conditions [81,153,154].
The specific role of PDE2 in orchestrating the cyclic nucleotide compartmentation (i.e., cAMP)
was supported by experimental evidence coming from a study that demonstrated that, in neonatal
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rat ventricular myocytes, activation of PDE2 was ineffective in counteracting the forskolin-mediated
rise in intracellular cAMP levels [81]. It could also be inferred that, at least in part, stimulation of
PDE2-mediated cAMP hydrolysis occurs via a β3-AR/eNOS/sGC pathway (Figure 2). On the contrary,
evidence from other studies [155–158] showed that PDE2 was effective in blocking intracellular
increases of cAMP levels mediated by catecholaminergic activation of β-adrenergic receptors or
forskolin-mediated AC activation under hypertrophic conditions. By inhibiting the subsequent
inotropic effects, these groups were able to argue for a distinct subcellular localization and activity of
PDE2 within cardiomyocytes.
More recently, Mehel and colleagues [155] were able to show that myocardial PDE2 is unregulated
in human and experimental heart failure and blocks cAMP increase after acute β-AR stimulation.
PDE2 upregulation may act as a counterbalance, neutralizing neurohormonal (i.e., β-adrenergic)
hyperactivity typically seen in heart failure [155,159]. Furthermore, specific PDE2 inhibition has
restored β-AR-mediated signal in diseased cardiomyocytes, while PDE2 overexpression has completely
abolished catecholamine effects and hypertrophy without affecting basal contractility [155]. In addition,
cAMP hydrolysis via PDE2 mediated the reduction of aldosterone production in adrenal cells,
suggesting beneficial synergy between cardiovascular and renal systems [88]. However, for every
experimental study, the limitations dictated by the in vitro acquired results might not reflect the in vivo
PDE functions, and further experiments in large animal models are required to fully explore the PDE2
role in heart failure pathophysiology. Nevertheless, the overexpressed PDE2 activity may constitute
a potential approach to effectively control the deleterious effects of heart failure, e.g., by augmenting
its microdomain-specific actions.
On the other hand, there are also studies in which PDE2 may not necessarily exert beneficial
effects, but rather contribute to hypertrophy. In cell-based experiments, another pool of cAMP/PDE2
was found to modulate hypertrophic growth of cardiac myocytes by regulating PKA-dependent
phosphorylation of nuclear factors of activated T cells (NFAT) [156]. In this study, Zoccarato
and colleagues [156] showed that PDE3 and PDE4 inhibition increase cAMP levels and result in
hypertrophy, whereas PDE2 inhibition is antihypertrophic despite an increase in cellular cAMP
content. Live cell imaging of intact cardiomyocytes revealed that PDE2 inhibition exerted its
antihypertrophic effects by generating a locally confined cAMP microdomain, in which PKA type II
plays a significant role by phosphorylating NFAT. These are clearly contradicting reports showing
remarkable discrepancies especially in the in vivo actions of cardiac PDE2. Further experimental work
is required to fully elucidate this question as well as the role of PDE2 in different subcellular cAMP
microdomains. It will be especially important to develop and study a tissue-specific knockout mouse
model for PDE2.
Another live cell imaging study has developed the first in vivo model expressing a cAMP
biosensor targeted to SERCA2a in transgenic mouse cardiomyocytes [157]. Using FRET imaging,
it was able to unveil impaired cAMP signal communication between β1-AR located at the membrane
and sarcoplasmic reticulum microdomains during early heart failure. By inhibiting PDE2, the authors
demonstrated its higher contribution to the regulation of local cAMP levels under pathological
conditions [157]. These data suggest that PDE2, when locally or globally upregulated, might potentially
contribute to cardioprotective effects in certain microdomains.
Moreover, an elegantly-designed study by Perera et al. [158] proved experimentally for the first
time that, in early compensated cardiac hypertrophy preceding heart failure, cGMP-sensitive PDE2
and PDE3 were already physically and functionally rearranged between β1- and β2-AR-associated
cAMP microdomains despite unchanged whole cell expression levels and activities. More specifically,
the switch of PDEs from PDE3 to PDE2 at the β2-AR, accompanied by a reduction of PDE2 at the β1-AR,
led to a turnaround of cAMP cross-talk in a way that, in this pathological setting, the ANP/cGMP
signaling pathway by this mechanism could enhance β-AR-mediated cardiac contractility inducing
positive inotropic and chronotropic effects following β-AR stimulation (Figure 3). The provided
evidence shed light on the poorly understood early microdomain remodeling mechanisms. It has
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been suggested that, in this way, the heart can compensate for the increased contractility demand
under pressure overload [158]. However, our knowledge about microdomain-related contractility
mechanisms in early disease is still in its infancy and has to be improved.
Figure 3. PDE2 and PDE3 redistribution in early cardiac hypertrophy changes cGMP-to-cAMP
cross-talk. β2-AR microdomain is normally controlled by PDE3, while PDE2 is functionally associated
with β1-AR. In disease, redistribution of PDE2 from β1- to β2-AR-associated membrane microdomains
leads to a decrease of the local β2-AR-cAMP and to an increase of global β1-AR-cAMP pool under
elevated ANP and cGMP levels observed in hypertrophy. This relocation of cGMP-regulated PDEs leads
to a turnaround of cGMP-to-cAMP cross-talk between both β-AR microdomains. By this mechanism,
elevated ANP can augment β-adrenoceptor-stimulated contractile function. NE: norepinephrine,
the physiological β-AR agonist. Adapted from [158].
The ability of PDE2 to compartmentalize local pools of cAMP has been in part attributed to a much
higher speed of cAMP hydrolysis by this PDE as compared to its synthesis by ACs based on FRET
imaging in aldosterone producing cells [139]. The most recent finding in regard to cGMP-sensitive
cyclic nucleotide compartmentation via PDE2/3 is described in a study using a cardiomyocyte-specific
PDE2 transgenic mouse model [159]. In fact, it was shown that endogenous PDE2 contributes to heart
rate control under physiological conditions and that PDE2 overexpression protects against arrhythmias
and enhances inotropic performance after myocardial infarction [159], providing evidence in support
of PDE2 overexpression and highlighting its beneficial role in diseased heart. However, the conclusions
from such data obtained from a transgenic mouse model overexpressing this PDE several folds above
the endogenous level should be treated with caution since excessive amounts of PDE2 might vanish
the boundaries between at least some cAMP microdomains.
Trying to further elucidate the NO/cGMP or NPs/cGMP and cAMP crosstalk, which was
also demonstrated in CMs, additional studies utilizing previously developed targeted FRET
biosensors [160] and live cell imaging techniques uncovered that the interconnection between
cGMP and cAMP in CMs is closely linked to the intracellular locus of regulation [161]. Depending
on the recruited cyclase (soluble or particulate) and the associated PDE, cGMP can either
augment or inhibit the cAMP levels after catecholamine stimulation and further affect downstream
phosphorylation of PKA and contractility. In fact, cGMP can inhibit PDE3 as a competitive
substrate for cAMP and allosterically stimulate PDE2A-mediated cAMP hydrolysis [72] locally
without largely affecting global cAMP levels in the cell [161]. Induction of cGMP by catecholamine
stimulation was found to differentially regulate intracellular cAMP pools that either activate
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PKA-RI/PDE3- or PKA-RII/PDE2-associated compartments and provoke opposing effects on local
cAMP signals [161]. Low basal cGMP levels (~10–50 nmol/L) which could be detected by FRET in
adult cardiomyocytes [115] can even facilitate cGMP hydrolyzing activity of PDE3, while higher
(between 200 and 500 nmol/L) cGMP levels can activate PDE2A and inhibit PDE3 towards cAMP
hydrolysis [162]. Similarly, NO donors via sGC affect both the PKA-RI and PKA-RII compartments,
whereas ANP via pGC limits cGMP action to the PKA-RII compartment only [161]. This evidence
supports that cGMP exerts local but not global cAMP control in the cardiomyocyte in neonatal
rat ventricular myocytes (NRVMs) when isoproterenol is administered in a microdomain-specific
manner [161]. For instance, cGMP diminishes cAMP gradients by PDE2 activity when sGC and
ANP/pGC mediate its production, while it augments cAMP gradients by inhibiting PDE3 when
sGC does so. It is evident that PDE2 exerts cardioprotective regulation against excessive adrenergic
stimulation by interconnecting β1/2-AR/cAMP and β3-AR/cGMP pathways [163] and paves the way
for further experimental exploration.
Recently, Li and colleagues (2015) [164] showed that PDE2A overexpression blunted BNP-mediated
effects by decreasing cGMP production and negatively affecting downstream effectors such as calcium
current, intracellular calcium transient, and neurotransmitter release. PDE2A inhibition was also
sufficient to reverse the abrogated BNP response. It was also observed that the stellate neurons of the
prohypertensive rats express higher PDE2A levels as compared to the normotensive control. These data
again underpin the importance of PDE2A upregulation in preventing the BNP-mediated inhibition of
sympathetic transmission with subsequent maladaptive changes. Nevertheless, further experimental
evidence is required to support whether the BNP-cGMP-PDE2A pathway is actually impaired in
hypertensive and heart failure models.
More recently, Meier and colleagues [165] demonstrated the beneficial effect of CNP on β1- and
β2-adrenoceptor signaling in rat hearts through cGMP-cAMP crosstalk, when PDE3 is inhibited by
cGMP. The CNP-mediated interplay of the signaling pathways was unaffected both in healthy and
failing hearts, while BNP was not able to regulate similar cAMP-mediated effects in any experimental
group. This study analyzed mechanisms of cyclic nucleotide crosstalk, trying to explain the lack of
long-term positive effects of natriuretic peptide in therapeutic schemes for heart failure.
In general, the use of family-selective PDE inhibitors and of genetic knock-down or
knock-out models is another way to assess the contribution of individual PDE families in the
compartmentalization of cAMP signaling pathways in cardiac myocytes [81,134,156,161,166,167].
It would be interesting to generate a tissue-specific PDE2 knock-out mouse line and explore the role of
this particular phosphodiesterase in cardiovascular disease. This goal has remained unattainable due
to perinatal lethality of global PDE2 knockout mice. The effect of PDE2 overexpression or upregulation
e.g., by inflammation, remains to be clarified as to whether it counterbalances or further deteriorates
cardiovascular disease in response to pathologic stimuli.
6. Conclusions
In conclusion, cAMP and cGMP signaling pathways as well as their crosstalk offer a high
level of intracellular organization and constitute an interesting pharmacological topic in health
and disease. The positive or negative cGMP-mediated regulation of cAMP response that occurs
in intracellularly confined loci controlled by distinct PDE isoenzymes could potentially pave the way
for novel pharmacological approaches in heart failure treatment. Despite the encouraging evidence,
there is still a long way to go before we can fully decipher and understand the exact mechanisms by
which these distinct molecular effectors maintain homeostasis and induce maladaptive changes in
the heart.
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Abstract: 3′-5′-cyclic adenosine monophosphate (cAMP) is a signaling messenger produced in
response to the stimulation of cellular receptors, and has a myriad of functional applications
depending on the cell type. In the heart, cAMP is responsible for regulating the contraction rate and
force; however, cAMP is also involved in multiple other functions. Compartmentation of cAMP
production may explain the specificity of signaling following a stimulus. In particular, transverse
tubules (T-tubules) and caveolae have been found to be critical structural components for the
spatial confinement of cAMP in cardiomyocytes, as exemplified by beta-adrenergic receptor (β-ARs)
signaling. Pathological alterations in cardiomyocyte microdomain architecture led to a disruption in
compartmentation of the cAMP signal. In this review, we discuss the difference between atrial and
ventricular cardiomyocytes in respect to microdomain organization, and the pathological changes
of atrial and ventricular cAMP signaling in response to myocyte dedifferentiation. In addition,
we review the role of localized phosphodiesterase (PDE) activity in constraining the cAMP signal.
Finally, we discuss microdomain biogenesis and maturation of cAMP signaling with the help of
induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). Understanding these mechanisms
may help to overcome the detrimental effects of pathological structural remodeling.
Keywords: cAMP; phosphodiesterase; FRET; atrial; ventricle; iPSC-CMs; T-tubule; caveolae; development
1. Introduction
The fascination about 3′-5′-cyclic adenosine monophosphate (cAMP), a second messenger
molecule, is with its ability to activate multiple signalling pathways having different effects on
cellular physiology in many cell types. Cardiomyocytes, in particular, have been studied in detail for
the regulation of cAMP production as a result of extracellular stimulation [1,2]. Buxton and Bruton
indicated a paradox whereby stimulation of a cell via various receptor pathways provided diverse
cellular responses despite generating the same cAMP second messenger [3]. It was further elucidated,
that these multiple spatially confined cAMP compartments may be the result of different protein
kinase A (PKA) isoforms and other cAMP-sensitive downstream targets having restricted access to
cAMP [4]. Studies have since been directed at understanding how these vital compartments of cAMP
are maintained within the cell.
The localized synthesis of cAMP by one of 10 different adenylate cyclase (AC) isoforms is
crucial in providing initial first step in signalling cascade, however, the manner in which cAMP
is compartmentalized within the cell is essential to elicit a specific cellular response.
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Saucerman et al. proposed several mechanisms that might be involved in cAMP compartmentalization
including: local degradation, physical barriers, and cell shape [5]. There are many factors that
come together to give rise to cAMP compartments. In this review, we focus on the role of cardiac
microdomains and phosphodiesterases (PDEs).
2. β-Adrenergic Pathway
The heart responds to catecholamines with increases in rate, force of contraction, and speed of
relaxation [6]. The main catecholamine-responsive receptors on the surface of cardiac myocytes are
β-adrenergic receptors (β-ARs), an important class of G-protein-coupled receptors (GPCR). To generate
these responses, β-ARs are coupled to Gs proteins, which activate AC and, thus, induce cAMP
production. The cAMP binds to effector proteins including, PKA [7] (preferentiality PKA-RII in the
case of β-AR [8]), exchange protein directly activated by cAMP (EPAC) [7], cyclic nucleotide gated
ion channels (CNGCs) [9], and Popeye-domain-containing proteins (Popdc) [10]. PKA is the major
effector protein and phosphorylates a large number of target proteins which are for example involved
in excitation-contraction coupling (ECC) [6].
β-AR stimulation is however more complex. In the late 1960s, Lands et al. studied the activity
of sympathomimetic amines in different tissues and concluded that there are two isoforms of β-ARs:
β1-AR and β2-AR [11,12]. In the heart, β1-AR is the predominant isoform [12]. The important role
of β1-AR for the heart was demonstrated through targeted disruption in mice. The Adrb1 null
mutant displayed impaired cardiac performance and prenatal lethality [13]. In contrast, the β2-AR is
apparently less important for the heart and more active in the respiratory system [12]. Both receptor
types differ in their G-protein coupling, while β1-AR couples only to Gs proteins, β2-AR couples
to both Gs and Gi proteins. Adrb2 mutants display normal resting heart rate and blood pressure,
but develop hypertension in response to epinephrine infusion or to the cardiovascular stress induced
by exercise [14]. Interestingly, human ventricular tissue display a higher expression level of β1-AR in
comparison to β2-AR with a ratio of approximately 77:23 [15]. The predominance of β1-AR provides
an explanation for the fact that mice lacking β2-AR experience alterations during exercise to their
vascular tone and energy metabolism [14], but nothing more fatal. The low cardiac expression level of
β2-AR together with its ability to either stimulate (via Gs) or inhibit (via Gi) cAMP synthesis suggests
an involvement in the ‘fine-tuning’ of cardiac contractility. Importantly, β2-AR are thought to have
protective effects on cardiac function [16]. In addition to differences in expression level and G-protein
coupling, the functional properties of β-ARs can also be affected by their spatial localization at the
plasma membrane [16].
An important downstream effector molecule of β-AR signalling is AC. Stimulation of β-AR
leads to activation of ACs catalysing the conversion of ATP to cAMP. The two major isoforms of
ACs expressed in the heart are AC5 and AC6. Patch clamp recordings of ventricular myocytes from
Adcy5 (AC5) and Adcy6 (AC6) knock-out mice, demonstrated the divergent roles of these adenylyl
cyclase isoforms [17]. An AC5-mediated increase of the calcium current was recorded from T-tubules,
and was mediated by both β1-AR and β2-AR [17]. In contrast, AC6 was shown to interact with β1-AR
alone. Interestingly, upon genetic ablation of Adcy5, it was shown that AC5 is protective against
cardiac dysfunction in pressure overload induced cardiac hypertrophy [18], thus suggesting that the
stimulation of AC5 could potentially be a protective therapeutic approach in heart failure. Introducing
AC6 was able to restore the cAMP-generating capacity in a murine cardiomyopathy model [19,20].
The targeted deletion of Adcy6 caused a marked impairment of cAMP synthesis and sarcoplasmic
reticulum calcium release [21]. The differing effects on cardiac function upon gene ablation suggests
that these AC isoforms provide different functions to the heart.
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3. Transverse Axial Tubular System
Important and highly-complex compartments in the cardiac myocyte are the transverse tubules
(T-tubules). These deep, penetrative sacrolemmal invaginations are a characteristic of ventricular
myocytes, and openings of these tubules can be visualized on the cellular surface in Z-groove
structures [22]. These microdomains act as a framework for several ion channels and proteins essential
for regulating the strength and synchronicity of each cardiac contraction [23]. These proteins and
effector molecules are grouped in specific protein complexes along the plasma membrane [24].
The complexity of the transverse axial tubular (TAT) system has received more attention over the
years, due to the presence of axial (also known as longitudinal) elements becoming more apparent [22,25].
The increase in axial elements raises questions of their functional importance. Studying healthy
ventricular myocytes have demonstrated that small mammals have a more prominent T-tubular
system compared to those from larger mammals [26,27]. Detailed studies in rabbits demonstrated that
the diameter of the T-tubules is approximately two-fold wider than in mice [26]. This suggests that the
abundant presence of T-tubules seen in mice is likely due to myocyte’s requirement to accommodate
ECC proteins in order to achieve a proper contractile response. In addition, it is possible that wider
T-tubules are able to accommodate the required ECC proteins in fewer structures, which provides
an explanation for the patchy tubular system seen in larger animals. These structural differences
between species are likely the result of the vast differences in heart rate that exists between small and
large mammals; thus, the structure is adjusted to meet the species-specific requirements. Therefore,
the regularity and structural environment of these microdomains is crucial for physiological signalling
of receptors and ion channels in both atrial and ventricular myocytes [28,29].
It has been long thought that atrial myocytes either lack, or contain only a rudimentary TAT
network [30–34]. However, more recently it became evident that atrial myocytes are more diverse.
Gadeberg et al. have shown that in atrial myocytes of larger mammals including humans a TAT
network is present, with cell size being a determinant for T-tubular density [30]. Interestingly, murine
atrial myocytes display a predominantly axial tubular structure, and the diameter of these tubules is
wider than in ventricular myocytes [31,32]. Moreover, the most organized atrial myocytes resemble
ventricular myocytes with regard to the TAT network.
The atria are structured as two separate “pockets”, with the right atrium containing anatomical
structures (i.e., crista terminalis and sinoatrial node), which are not present in the left atrium. Yamashita
et al. have shown that, although the length to width ratio remains the same, myocytes isolated from the
crista terminalis are larger than from pectinate muscle [33]. Therefore, differently structured myocytes
may be derived from different atrial regions. Investigations of small mammals also demonstrated
the requirement of the TAT structure in the atria and further highlighted the heterogeneous structure
in these myocytes [34,35]. Glukhov et al. studied rat atrial myocytes utilizing confocal microscopy
with scanning ion conductance microscopy (SICM) to demonstrate the existence of three populations
of myocytes: organized, disorganized, and empty cells [34] (Figure 1A). These distinct populations
of atrial myocytes have been found in both small and large mammals in multiple independent
studies [34–36].
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Figure 1. The heterogeneity of myocytes found in the rat heart. (A) Representative confocal images of
Di-8-ANNEPS-stained myocytes from the atria and the ventricle. Atrial cells were categorized based on
the T-tubule organization and density into three distinct subgroups with organized TAT, disorganized
TAT and myocytes lacking all T-tubular structure. Parts of images were binarised as shown and used to
calculate the density and demonstrate a clear representation of the structural changes between groups;
(B) Topographical scans of myocytes demonstrating the occurrence of T-tubule opening at the Z-lines
of myocytes in relation to their cell size. Arrows indicate T-tubules, crests, and non-structured areas.
Adapted from Glukhov et al. 2015 [34].
4. Caveolae
Caveolae are 50–100 nM-wide flask-shaped membrane invaginations. These microdomains
are dense in cholesterol and are lined with specialized scaffolding proteins, which are key features
distinguishing caveolae from other lipid raft structures [32]. Caveolae are responsible for the spatial
organization of signalling proteins, lipid storage, and membrane homeostasis. Although it is well
known that the caveolar coat is comprised of oligomers of the scaffolding proteins caveolin and
cavin, the process of assembly and recycling of these membrane domains remained debatable for
many decades. Recently, Hayer et al. highlighted the multistep process of caveolae assembly [37].
This involves the homo-oligomerisation of caveolin-1 (Cav1) into 8S complexes in the Golgi where they
undergo conformational changes and associate with cholesterol, thus assembling into 70S complexes.
These newly-assembled caveolin scaffolds are transported to the plasma membrane where they are
able to act as functional caveolar domains.
Caveolae have the ability to act as membrane reservoirs allowing the cell to increase its surface
area in response to osmotic stress [38–40]. Furthermore, Sinha et al. and others have shown that acute
mechanical stress induced by osmotic swelling or stretching, reduced the interaction of caveolin with
cavin-1. It increased the concentration of free caveolin proteins at the plasma membrane, thus resulting
in a rapid disappearance of caveolae [38,41]. Mohan et al. further elucidated that Cavin-1 regulates
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caveolae dynamics, by targeting Cavin-3 to caveolae where it interacts with the scaffolding domain of
Cav1 [42]. Loss of Cavin-3 resulted in an increase in the long-term stability of caveolae at the plasma
membrane, suggesting that it regulates the lifetime of caveolae.
Calaghan et al. studied the dynamic nature of caveolae in response to mechanical stimuli;
subjecting adult rat hearts to left ventricular ballooning and the time-dependent effect of stretch on the
distribution of caveolin-3 (Cav3) and other caveolar proteins [43]. The authors observed a progressive
loss of Cav3 from caveolae, similar to what is seen after chemical disruption of caveolae via cholesterol
depletion, thus indicating a mechanotransductive role of caveolae domains in the heart. A key example
of caveolae organizing cellular compartmentation of signalling proteins is the interaction of Cav3 with
AC5, PDE4B, and PDE4D [17].
5. Microdomains of cAMP Signalling in Healthy Ventricular Myocytes: T-Tubules and Caveolae
Visualization of cAMP signal propagation using flurorescent cAMP sensors has become more
sophisticated over recent years, which led to the definition of spatially localized cAMP pools
(or nanodomains) [44]. These pools may be located either within a close proximity to receptors
and ion channels, or may be distributed throughout the cell. Evidence from adult mouse ventricular
myocytes demonstrates the response to stimulation of β1-AR is a far-reaching cAMP signal, compared
with the local response upon stimulation of β2-AR [44]. The difference in the way Gs-coupled β-ARs
compartmentalise cAMP, is linked to two key factors: (i) the localization of the receptor and (ii) the
occurrence of cAMP-degrading enzymes.
To identify the different cAMP pools produced by β-ARs, a combination of SICM and Förster
resonance energy transfer (FRET) was utilized. SICM identifies specific microdomains (T-tubule
and crest) by producing a detailed topographical image of the cell surface (Figure 1B) [34]. β-AR
stimulation was then applied locally to adult rat ventricular myocytes, using the SICM nanopipette
to a microdomain of interest. cAMP synthesis was measured, using FRET, in response to local
(site-specific) stimulation [16,45,46]. This high-tech approach made it possible for Nikolaev et al.
to demonstrate that β1-AR-induced cAMP signalling occurs both at the T-tubule and non-T-tubule
areas. In contrast the β2-AR-induced cAMP response arises from the T-tubules only [16]. In addition,
to assessing the cAMP response of β2-AR irrespective of its coupling to Gi-proteins, PTX was used and
caused no difference in cAMP compartmentalisation [44]. The larger diffusion pattern of β1-AR-cAMP
thus explains β1-ARs’ ability to produce such a response, as a result of activating far-reaching proteins
involved in ECC.
Caveolae are found in both the T-tubule and the crest membranes in rabbit ventricular
myocytes [47]. Caveolae localized at the sarcolemma appear to have a four-fold higher density,
compared to those located at the T-tubular membrane [48]. These microdomains act as platforms for
the assembly of receptors, signalling components, and their associated targets. They, therefore, undergo
dynamic regulation to allow agonist-stimulated receptors to interact efficiently with their respective
effectors [49]. Thus the dynamic properties and overall stability of the caveolar microdomains in
cardiomyocytes has sparked significant interest over the last decades. Specifically, it is due to these
structures being involved in mechanisms responsible for creating distinct β1- and β2-AR-dependent
cAMP signalling. The distribution and clustering of these GPCRs and their downstream signalling
components, within or outside of caveolar domains, are important factors in promoting efficient
and accurate functional responses to β-ARs stimulation. Multiple studies report the clustering of
β2-ARs along with its associated signalling elements, including Gs, Gi, AC5, and AC6, and protein
kinase A (PKA) within the caveolar membrane fractions [50,51]; which have also been shown to
co-immunoprecipitate with Cav3 [24,52]. β1-AR, on the other hand has been shown to be located
in both caveolar and non-caveolar compartments in adult rat ventricular myocytes [51,53]. Thus,
a cholesterol/caveolin-3 rich environment is key in building the macromolecular structure, particularly
for β2-AR.
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The description of nanodomains of cAMP signalling will be incomplete without mentioning A
kinase anchoring proteins (AKAPs), scaffolding proteins which constrain PKA to specific subcellular
locations in physical proximity to PKA targets. AKAPs, to a large extent, determine a unique
phosphorylation pattern downstream of the kinase. In cells undergoing response to a stimulus,
the location of some AKAPs can change, thus altering the functional outcome of cAMP signals.
However, the detailed look into the function of AKAPs falls beyond the scope of the present review as
it is reviewed extensively elsewhere [54,55].
6. PDEs and cAMP Compartmentation in Ventricular Myocytes
PDEs are a family of enzymes that degrade cyclic nucleotides [56–58]. By acting as functional
barriers, they create subcellular cAMP gradients by preventing its free diffusion throughout the
cell [59]. They have been divided into 11 families based on their structure, catalytic properties,
and their differential affinity for cyclic nuclotides [60,61]. Each family of PDEs has isoforms, which
vary according to the following properties: tissue distribution, intracellular localization, and the
involvement in cellular signalling. PDE 1–3, 10, and 11 are responsible for degrading both cAMP
and cGMP. PDE 4, 7, and 8 are specific for the hydrolysis of cAMP and PDE 5, 6, and 9 are
cGMP-specific [62]. It has been shown that blocking all PDEs, using isobutyl-methyl-xanthine (IBMX),
after β-AR stimulation leads to changes in physiological response due to the spatial and temporal
regulation of cAMP [63,64]. Therefore, this infers that the extensive assortment of PDEs provides
routes for cardiomyocytes to modulate cAMP signalling.
The complexity of the various functional abilities of the PDE families is further increased by
the concept of cross-talk between cAMP and cGMP pathways. For example, cGMP stimulates PDE2
leading to degradation of both cAMP and cGMP, thus increases in cGMP can alter cAMP hydrolysis.
Cyclic GMP can also activate PDE5 and increase the rate of its own degradation [65–68]. PDE3 has dual
specificity with a higher catalytic rate for cAMP, therefore, it can be considered as a cGMP-inhibited
cAMP-hydrolysing enzyme [65,68].
Compartmentation of cAMP to specific microdomains at the plasma membrane and in
the cytoplasm requires a vast variety of PDEs, and their presence or absence in a particular
location is also species-specific. To explore the functionality of receptors and enzymes, utilizing
genetically-engineered knock-out/overexpression models has become a powerful methodology in
cardiovascular research. Employing these methods has determined the vast impact that PDE3
and PDE4 have in cAMP-hydrolytic activity and calcium handling [69]. In addition, it has been
highlighted that isoforms of a single family of PDEs can localize to specific compartments. PDE3
has been specifically shown to associate with T-tubule microdomains and with internally-organized
sarcoplasmic reticulum structures [63,70]. Investigating the function of PDEs using knock-out mice and
inhibitors has collectively provided evidence suggesting each PDE subgroup contains isoforms that
have different microdomain locations and functions. The use of mouse knock-out models and selective
PDE3 inhibitors have indicated PDE3A to be responsible for chronotropic and inotropic effects [71],
whereas PDE3B serves to acutely protect the heart after biomechanical stress [72]. Specifically,
PDE3A1 controls the Phospholamban (PLB) and sarcoplasmic reticulum calcium ATPase2 (SERCA2)
activity and the re-uptake of calcium in the SR, leading to an increase in cAMP-dependent calcium
transients, without affecting L-type calcium channels (LTCCs) [72]. Therefore, Movesesian suggests
a PDE3A1-specific inhibitor could potentially improve contractile performance and provide therapy
for heart failure (HF) [73].
Unlike PDE3, PDE4 is shown to localize to the sarcolemma [70] and play an important role in
cardiomyocytes [74,75]. Although the expression of PDE4 is species-specific, the relative amount of
PDE4 compared to overall PDE activity is conserved between humans and rodents. However, the overall
cAMP-hydrolytic activity of PDE4 is estimated to be higher in rodents compared to humans [74].
The inhibition of PDE4 was specifically shown to extensively increase cAMP levels. In addition,
the PDE4 activity has presented to be specifically enhanced by β-AR stimulation [44,56]. PDE4 has
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also been demonstrated to be a predominant isoform that hydrolyses cytoplasmic cAMP produced
following β1-AR, but not β2-AR stimulation [44]. Melsom et al. demonstrated that combined PDE4
and PDE3 inhibition increased the potency of adrenaline on PTX treated β2-AR [76]. This suggests
that it is possible that PDE4 plays a significant role with β2-ARs. Subgroups of PDE4, mainly: PDE4A,
PDE4B, and PDE4D are expressed in the heart (see Conti 2017 [77] for an extensive review on PDE4).
Previous studies have shown the importance of PDE4D, in particular through its involvement with
the PLB/SERCA2A complex [78], the cardiac ryanodine receptors and the calcium release channel
complex [79]. In addition, mice lacking PDE4D develop an age-dependant cardiomyopathy and
exercise-induced arrhythmias [79]. Moreover, PDE4D appears to control cAMP levels in subcellular
compartments, thus having an impact on myocyte contractility [78].
In addition, PDE2 was shown to hydrolyse cAMP after β-AR stimulation in adult mouse
ventricular myocytes. Here, the inhibition of PDE2 releases a higher level of cAMP than that after
PDE3 inhibition [44]. Although not extensively studied, measuring cAMP in ventricular myocytes
demonstrated that PDE2 affects the regulation of heart rate. Inhibition of PDE2 caused an increased
heart rate, while overexpression reduced the heart rate [80], suggesting that the expression levels do
not directly relate to functional integrity, and that perhaps a minor PDE2 fraction could play a larger
role in specific microdomains.
7. cAMP Compartmentation and PDEs in Atrial Myocytes
In comparison to ventricular myocytes, cAMP compartmentalisation in atrial myocytes remains
relatively poorly investigated. The ultrastructural organisation of atrial myocytes differs with
ventricular and this suggests differential receptor localization and spatial pools of cAMP leading
to unique signaling patterns. So far, to map signalling differences between atrial and ventricular
myocytes two major methods have been utilized: electrophysiological methods and expression
analysis of β-AR and PDEs. It has now become apparent that in ventricular myocytes caveolae
are involved in controlling β-AR signalling [40,43,45,46,48,49,52,53]. Accordingly, an even higher
abundance of caveolae in rat atrial myocytes [34] would suggest their important role in the spatial
control of cAMP nanodomains in this cell type. Atrial myocytes are thinner and contain less complex
TAT networks. Due to their small size, atrial myocytes may not require a complex internal structural
architecture. Utilizing methyl-β-cyclodextrin (MβCD)-treated ventricular rat myocytes to disrupt
caveolae, β1-AR has been found in both caveolae and non-caveolae regions, while β2-AR were
confined to the caveolae compartment [53]. It has been demonstrated in human atrial myocytes using
the whole-cell voltage-clamp that PDE4 reduces cAMP when combined with either PDE3 inhibition
or β-AR stimulation [81]. These earlier studies into atrial myocytes warrant the assumption that
although β1-AR might have a rather similar role to that seen in ventricular myocytes, β2-AR may
assume a larger role, due to these receptors being denser, largely because of the increase in caveolar
number. To understand the role of PDEs and to establish the principal differences between atrial versus
ventricular cardiomyocytes, expression analysis in the mouse right atria (RA) and right ventricle (RV)
was performed. PDE2A was shown to be equally expressed across the RA and RV, whereas PDE3B,
PDE4B and PDE4D were all expressed at higher levels in the atria [82]. Similar studies have been
conducted in rat and human tissue to determine species-specific differences. In contrast to rodent
myocytes, human PDE4 is not the predominant subtype regulating cAMP levels. Nevertheless, it was
shown that PDE4 inhibition led to the positive inotropic effect of β-AR stimulation, increasing the
susceptibility to atrial arrhythmias, and a marked prolongation in cAMP rise [75]. This work is highly
suggestive that PDE4 plays a significant role in compartmentation of cAMP. It is possible that PDE4
is more closely associated with caveolae and less with T-tubules, thus explaining why PDE4 has
a stronger impact in atrial cells. What would be interesting is to understand how β-AR signalling is
propagated in atrial myocytes, and how this impacts the activity of PDEs to compartmentalize cAMP.
204
J. Cardiovasc. Dev. Dis. 2018, 5, 25
8. Failing Myocardium Represents Progressive Reduction in the Complexity of Structure and
Receptor Function
Studies in rat ventricular myocytes isolated from failing hearts have shown that the progression
of disease causes TAT structure to become more disorganized and diminished [45,83]. In comparison
to normal cells, the TAT structure in human chronic unloaded HF also presents a decrease in regularity,
and for the first time using 3D imaging, demonstrated a sheet-like T-tubule phenotype [84]. In rats,
axial elements were increased during early HF, but reduced as HF progressed [45]. These different
tubular structures that are present in failing myocytes are not well characterised. In addition, it is not
fully understood what causes the reduced density of the TAT structure.
Lyon et al. have demonstrated that surface structures (Z-grooves) in the human myocardium were
lost from the cell surface during HF [85]. A similar study conducted in rats measured the Z-groove
index, demonstrating loss of these structures in HF [86]. Hence, it is apparent that the relative changes
in the TAT system occur in both large and small animals during HF [27,45,84–88].
The continuous structural adaptation, in response to alterations of mechanical load during HF has
become a hallmark of cardiac disease. Patients with severe HF, can be fitted with a left ventricular assist
device (LVAD), which reduces the mechanical load to the heart in an attempt to regain cardiac function.
Studies on myocytes isolated from such failing hearts have shown that implantation of an LVAD
could only be beneficial to those hearts that possess a relatively preserved myocyte TAT structure [84].
In comparison, chronic unloading in rat hearts demonstrated a reduction in the density and regularity
of the TAT system, in addition to surface changes [86]. Damage to the heart is inhomogeneous, and so
it could be said that TAT density loss would occur to a higher extent in certain regions compared
to others. This difference in density would initially be identified by the weak contractility of the
heart [36].
Structural adaptations that occur in chronic HF come with a functional price—the relocalization
of β-ARs. The change in localization of these receptors generates a modified downstream response.
Namely, β2-AR signalling is altered, such that cAMP signalling is seen to spread from both the crest
and T-tubule regions, with smaller signalling amplitudes compared to healthy cells [16]. The alterations
seen in β2-AR signalling became apparent as early as four weeks post-myocardial infarction (MI) in rats,
and progressively worsens over 16 weeks post-MI. It has become evident that as disease progressively
worsens, transverse elements are lost and axial elements are gained (Figure 2) [45]. The increase in
β2-AR cAMP signalling has been thought to be a compensatory mechanism for decreased β1-AR cAMP
signalling [16]. This indicates that a myocyte attempts to maintain orderly signalling, as conditions
deteriorates, which as a result changes the dynamics of cellular signalling.
The expression of Cav3 has also been demonstrated to decrease during HF, and this is important
for both the TAT system and caveolae [45,89]. The disruption of Cav3 has been shown to be a significant
cause of the far-reaching β2-AR-cAMP signals [46]. In support of this, a large portion of β2-ARs have
been shown to localize to caveolae [24]. Moreover, it was found that caveolar microdomains, as well
as housing β-ARs, also contain LTCCs, a critical ion channels activated by cAMP signalling which
regulate ECC. A recent study has suggested that the LTCCs located in caveolae have more impact on
hypertrophy than contractile function of the heart [90]. Therefore, it is clear that a better understanding
is needed of receptors and ion channel function within caveolae and what impact they have on the
contractile function of the heart.
As a result of the breakdown of structural microdomains, PDEs are relocated and they lose
connectivity with their native environments; thus losing the capacity to perform their inherent function.
PDE4 was shown to lose its influence on the confinement of cAMP during early HF [91]. In agreement
with this, Lehnart et al. suggested that deficiency in PDE4D was pro-arrhythmogenic and that
it was associated with HF in mice [79]. This is suggestive of the PDE4 isoform being localized
in the vicinity of cAMP microdomains during healthy cardiac functionally, allowing for precise
cAMP compartmentation. Therefore, when structural microdomains are lost, for example in cardiac
hypertrophy, not only are β-ARs relocated and functionally altered, but PDE4 that would normally act
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as a barrier to cAMP diffusion has locally changed [92]. It is believed that the decompartmentation of
PDEs initially compensates for the deficient cAMP synthesis by β-ARs, however, the long-term effects
of this leads to a loss of cAMP compartments.
Figure 2. Progressive loss of the t-tubules and the increase of axial (longitudinal) elements of the TAT
system demonstrate the change in cAMP signalling in the ventricular myocytes isolated from hearts
with myocardial infarction (MI). Focus on the way in which β2-ARs are relocated and become more
dispersed throughout the cell. As the disease progressively worsens, the loss of TAT structure deviates
further and further away, but still attempts to generate signalling that keeps myocytes functional.
Taken from Schobesberger et al., 2017 [45].
PDE2 activity was demonstrated to play a vital role in improving ventricular function. PDE2 is
able to provide protective effects under chronic and acute β-AR activation [80]. Whilst the expression of
both PDE3 and PDE4 was been shown to be reduced in HF, PDE2 expression was shown to be increased
in both animals models and in humans [93]. Therefore, this indicates that cardiac pathophysiology
modulates both structure and function of PDEs and the resulting compartmentalization of cAMP.
Similar to ventricular cardiomyocytes, the structural architecture of atrial cardiomyocytes is disrupted
in disease [70–72]. Glukhov et al. reported that T-tubule structure was diminished in failing rat atrial
cardiomyocytes, despite cellular hypertrophy. This was accompanied by a deterioration in structural
surface topography [34]. In spite of this finding, atrial myocytes have not been studied sufficiently for
conclusions to be made on their function during HF.
Until now, studies on human tissue with persistent atrial fibrillation and HF have shown a decrease
in PDE activity, with a selective decrease in PDE4. This has led to the suggestion that PDE4 has
a protective role in human atria [75]. It would be interesting to evaluate atrial myocytes structural
changes during the HF progression to understand how the TAT structure changes in relation to the
caveolae occurrence. This would aid in understanding not only how important Cav3 is to the structure,
but how much input caveolae have functionally. Caveolae could be more involved in cellular signalling
of atrial versus ventricular myocytes, with resulting changes in PDE compartmentation.
9. Biogenesis and Maturation of Structural Microdomains during Differentiation of Myocytes
from Stem Cells
There is an increasing need for the development of effective models of cardiac diseases in order to
address the progressive decline in structural and physiological “output” of cardiomyocytes. The use
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of induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) provides an unprecedented
opportunity to develop in vitro models of numerous cardiac diseases and for drug discovery
to drive the field of personalized medicine. Currently, we face major obstacles in generating
cardiomyocytes with precise morphological and functional features resembling healthy adult myocytes,
making modelling and understanding of treatments for late-onset diseases more challenging.
However, the enthusiasm in the field of cardiac regeneration has been passionately fuelled
by recent developments in driving iPSC-CM maturation in order to obtain structurally- and
functionally-stable cardiomyocytes.
It has been widely shown that cultured and diseased myocytes undergo rapid T-tubular
remodelling; such studies highlight the importance of impaired βAR signalling in cardiac disorders.
There is now a particular interest in understanding the developmental processes involved in early
cardiomyocytes as many studies have shown that myocytes of failing hearts tend to dedifferentiate
into foetal-like phenotypes. On the other hand, the activation of dormant pathways developed early in
cellular differentiation has also been suggested [92]. Due to the known challenges in obtaining human
embryos for such detailed investigations, many studies resort to the use of iPSC-CMs as an in vitro
model of cardiomyogenesis. Below, we discuss the development of cardiac microdomains in early
cardiomyocytes and the emergence of β-AR-induced cAMP signalling.
T-tubules are thought to be absent in embryonic and neonatal cardiomyocytes [94] and only begin
to develop after birth [95]. It is well understood that cultured and diseased cells rapidly undergo
a process of T-tubular remodelling; however, very little is known about the processes involved in
T-tubule biogenesis. Understanding the underlying mechanisms of T-tubule formation and correct
clustering of ion channels within these microdomains would reveal the key processes required for
iPSC-CMs to mature into an adult cardiomyocyte phenotype with functionally-developed membrane
structures for efficient ECC machinery.
Multiple membrane scaffolding proteins have been associated with T-tubule biogenesis, such as
Cav3, junctophilin-2 (Jph2), and bridging integrator-1 (Bin1). Recent work by Fu et al. indicates that
Bin1 assists trafficking and clustering of LTCCs, microdomain organization and T-tubule membrane
regulation [96]. Furthermore, they showed that transgenic mice with deletions of these individual genes
reveal that the primary t-tubule invaginations still exist [96]. This indicates that a single protein alone is
not sufficient for tubulogenesis. Rusconi et al. have developed a mimetic peptide (MP) which functions
by modulating the trafficking and life cycle of the LTCC. This study has shown that introducing this
peptide successfully restores physiological levels of LTCC in the plasma membrane [97]. This may
indicate a potential to drive correct channel localization within the cell membrane. Healthy adult
cardiomyocytes are characterized by sarcomeric structures that consist of parallel myofilaments,
sarcomeric Z-disk, A-, I-, and H-bands which, altogether, allow for an effective and efficient ECC;
therefore, maturation of these structures is pivotal for successfully driving maturation of sarcomeres
and T-tubules of early cardiomyocytes. Wang et al. have recently shown that long-term treatment
with Puerarin, a traditional Chinese medicine used for the treatment of cardiovascular disease, such as
MI, can improve myofibril arrays and significantly enhance T-tubule development in embryonic stem
cell-derived cardiomyocytes. The mechanism of action has been suggested through the repression
of a specific micro-RNA, miR-22, an important target of Cav3, and the up-regulation of Cav3, Bin1,
and Jph2 transcript levels [98]. This strongly supports the role of these proteins in T-tubule biogenesis
and stability.
While early myocytes do not have well-developed tubular structures, they possess abundant
caveolae structures that may represent sites where receptors and their associated signaling molecules
are clustered. Furthermore, it has been suggested that caveolae may be precursors of T-tubules in
early cardiomyocytes, or at least fulfil some of the same signalosome functions [99]. Cav3 induces the
formation of caveolae, which plays an important role as a cell signaling hub and in the developing
T-tubule system. In a recent study maturation of caveolae in human iPSC-CMs, it has been found to be
dramatically increased at day 60 in culture and further increased by day 90, as reflected by the Cav3 gene
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and protein expressions [100]. Furthermore, a study conducted by Rebiero et al. also addressed the
issue of the foetal-like misalignment of iPSC-CM membrane structures. They reported that culturing
cells on micropatterns helped mature the alignment of myofibrils and improved contractile activity,
calcium flow, cell electrophysiology, as well as T-tubule formation [101]; thus, providing cells with
specific mechanical cues may encourage cell maturation.
The positive and negative chronotropic responses to isoproterenol and carbamylcholine
demonstrated the presence of functional adrenergic and cholinergic receptors, respectively,
in pacemaker cells. A major pathway of the β-AR–dependent chronotropic response is the activation of
AC and the consequent rise in cytosolic cAMP and stimulation of PKA. The positive chronotropic effect
exerted by forskolin, a direct activator of AC, and by IBMX, a phosphodiesterase inhibitor, suggests
that this signalling pathway is already present early in human cardiomyocyte differentiation [102].
Primitive β-AR signalling responses have been detected as early as 13–15 days of differentiation of
mouse and human embryonic stem cell-derived cardiomyocytes (ESC-CMs) [92].
Jung et al. further investigated the evolution of the expression and function of the components
involved in the βAR signalling pathway in early human iPSC-CMs. It was found that β2ARs are
the primary source of cAMP/PKA signalling in “early” cardiomyocytes; whereas increasing time
in culture leads to the β1-AR dependent cAMP production to increase to 60% rise from day 30 to
day 60 [99]. Similarly, Wu et al. reported a dramatic increase in β2AR gene expression at days 12, 30,
and 60 of differentiation, although no significant changes in β1AR were seen until day 30. Furthermore,
with the use of β1AR- and β2AR-specific blockers they showed that iPSC-CMs only responded to
β2-AR receptor activation. At day 60, a switch of β-AR subtype dependence was seen, indicating
a dynamic regulation of the receptor dependence of the β-AR signalling pathway during maturation
of cardiac myocytes. They also highlighted a significant increase in AC expression after day 12 of
differentiation, a level comparable to that of adult human left ventricle tissue. In addition, both PDE3A
and PDE4D expression rose by day 60 of maturation [103].
The dysregulation of the β-AR pathway is associated with a spectrum of cardiac diseases.
For instance, an iPSC model of dilated cardiomyopathy has shown a blunted response to isoproterenol
stimulation. Further, epigenetic changes of the PDE genes were found in tissue from a DCM patient
and in iPSC-CMs derived from this, leading to an up-regulation of PDE2A and PDE3A genes [103].
However, these signalling mechanisms have only been minimally investigated, and that too at the
whole-cell level. To understand the full functional capacity of these critical regulatory mechanisms
in iPSC-CMs, in-depth investigation into how compartmentation can direct these pathways at the
subcellular levels remains to be performed.
10. Conclusions
Understanding the detailed organization of cAMP signalling microdomains in mature myocytes
of both atria and ventricles will provide an excellent reference point to which immature or failing
myocytes are to be compared. Progressive changes in the microdomain structure and function in HF
and dedifferentiation may be deconstructed in order to attempt to reverse these changes. The success
of this reversal may correlate with the success of inducing maturation of hiPSC-derived myocytes.
In particular, the role or assembly of nascent T-tubules within, or in the vicinity of, caveolae needs
further investigation. Equally, PDE isoforms, which are specific for different microdomains need to be
further characterized.
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Abstract: A-kinase anchoring proteins (AKAPs) belong to a family of scaffolding proteins that bind to
protein kinase A (PKA) by definition and a variety of crucial proteins, including kinases, phosphatases,
and phosphodiesterases. By scaffolding these proteins together, AKAPs build a “signalosome” at
specific subcellular locations and compartmentalize PKA signaling. Thus, AKAPs are important
for signal transduction after upstream activation of receptors ensuring accuracy and precision of
intracellular PKA-dependent signaling pathways. Since their discovery in the 1980s, AKAPs have
been studied extensively in the heart and have been proven essential in mediating cyclic adenosine
monophosphate (cAMP)-PKA signaling. Although expression of AKAPs in the heart is very low,
cardiac-specific knock-outs of several AKAPs have a noteworthy cardiac phenotype. Moreover, single
nucleotide polymorphisms and genetic mutations in crucial cardiac proteins play a substantial role in
the pathophysiology of cardiovascular diseases (CVDs). Despite the significant role of AKAPs in the
cardiovascular system, a limited amount of research has focused on the role of genetic polymorphisms
and/or mutations in AKAPs in increasing the risk of CVDs. This review attempts to overview the
available literature on the polymorphisms/mutations in AKAPs and their effects on human health
with a special focus on CVDs.
Keywords: A-kinase anchoring proteins; single nucleotide polymorphisms; genetic mutations;
cardiovascular diseases; protein kinase A
1. Introduction
The cardiovascular system, which is made up of heart, blood, and blood vessels, is essential
for our survival [1]. The human heart provides oxygenated blood to itself and other tissues via
a network of blood vessels supplying them with nutrients, and also removes carbon dioxide and other
wastes from them. Proper blood circulation is required for effective regulation of these functions.
Therefore, the continuous and flawless functioning of the heart becomes a very crucial indicator of
normal cardiac physiology. Periodic beatings of the heart are regulated by a plethora of complex
intracellular signaling cascades. Similarly, under acute (pregnancy, exercise, etc.) and chronic
(pathophysiological stimulations) stress, the heart undergoes physiological and pathophysiological
hypertrophy, respectively. Such changes in the anatomy of the heart at the cellular and molecular levels
are governed by respective changes in the expression of hypertrophic transcription factors. Expression
of essential transcription factors is also regulated by a complex network of intracellular signaling
pathways [2,3].
Studying key proteins that are involved in regulating multiple intracellular signaling pathways
has always interested cardiovascular scientists across the globe. By participating in the network of
several signal transduction processes, these proteins play a central role in cardiac physiology and
pathophysiology. A-kinase anchoring proteins (AKAPs) are one such type of proteins that belong to the
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family of scaffolding proteins. AKAPs have no intrinsic activity of their own, but their crucial function
is to bind protein kinase A (PKA) and other signaling proteins [4,5]. PKA-mediated phosphorylation
is critical for the physiological functioning of the heart [6]. AKAPs build a “signalosome” at various
subcellular locations in the heart and regulate PKA-dependent signaling locally. Similarly, AKAPs
speed up the PKA-mediated substrate phosphorylation by bringing all required components into close
proximity with each other. Hence, by binding PKA and its substrates in the same scaffold, AKAPs
monitor spatial and temporal PKA signaling [7].
AKAPs belong to a class of scaffolding proteins that are structurally not related to each other,
but share key structural and/or signaling features. More than 70 AKAPs have been reported so far in
humans. To be classified as an AKAP, proteins should have three properties:
(i) All AKAPs, though structurally different, have 14–18 α-helix amphipathic amino acid sequence
that binds to regulatory subunits of PKA.
(ii) They have a targeting domain that tethers AKAPs to specific subcellular organelles,
like mitochondria, the nucleus, and plasma membrane, among others.
(iii) Lastly, all AKAPs contain multiple binding domains by which they bind to other kinases than
PKA, phosphatases, phosphodiesterases, and so on.
As the list of AKAPs is growing, the list of their binding partners is also rising. Hence,
at a specific time, AKAPs bind only a subset of their binding partners, which depend on the cellular
environment in which they are present [8]. Over the period of the last decade, several AKAPs have
been identified in the cardiovascular system. So far, about 17 AKAPs have been discovered in the
heart and the list will continue to grow further [9]. Efforts were made to understand the function
of individual AKAPs by creating their specific knockouts. To mention a few, our laboratory had
developed one such mouse model and has shown that gravin (AKAP12) mutant mice respond better
to isoproterenol-induced stimulation than their wild-type counterparts with an improved cardiac
profile [10]. Additionally, our unpublished data indicate that AKAP12 scaffolding is crucial for
isoproterenol-mediated heart failure, and loss of function of AKAP12 scaffolding can act as a treatment
strategy for heart failure [11]. Others have demonstrated that muscle-specific AKAPβ (mAKAPβ)
scaffolds crucial signaling proteins around the nuclear envelope of cardiomyocytes that modulate
cardiac remodeling. Conditional cardiac-specific deletion of mAKAPβ in adult mice was found to
protect the heart from pressure overload and isoproterenol-induced cardiac stress [12]. The AKAP150
scaffold is also one of the promising targets for heart failure treatment. AKAP150 knock-out mice
were prone to develop cardiomyopathy under pressure overload and expression of AKAP150 was
significantly lower in failing mouse hearts [13].
Despite their importance in cardiac physiology and pathophysiology, there are very limited
publications available showing the role of polymorphisms and/or mutations in AKAP in the
cardiovascular system. In fact, our laboratory was the first to publish that single nucleotide
polymorphisms in mAKAP alter binding propensities of phosphodiesterase4D3 (PDE4D3) and
PKA to mAKAP [6]. Therefore, this review will attempt to address all the published literature
on polymorphic and mutant AKAP, their role in the cardiovascular system, and their occurrence in
other human diseases.
2. Role of AKAPs in Cardiovascular Physiology
AKAPs play a crucial role in human health and disease because of their control over local
PKA signaling [3]. As PKA is a cAMP-dependent protein kinase, AKAPs are able to regulate the
compartmentalization of cAMP and, therefore, the cAMP/PKA signaling pathway. The cAMP/PKA
pathway is ubiquitous and a plethora of biological processes depend on it. Hence, AKAPs have an
incomparable contribution in the physiology and pathophysiology of various human diseases [14,15].
In fact, pharmacological targeting of various AKAP-protein interactions has been proved beneficial in
cardiovascular diseases, cancer, and other disorders, as shown in animal models of their respective
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diseases [5,14,16]. To be specific, AKAPs have become very promising drug targets for cardiovascular
disease (CVD) due to their role in regulating and coordinating complex cardiac signaling pathways.
The literature on cardiac AKAPs reveals their importance in cardiac health and disease. AKAP-Lbc
(AKAP13) is one such AKAP which is a pro-hypertrophic and pro-fibrotic AKAP, where hypertrophy
is mediated via interleukin-6 (IL-6) and fibrosis is mediated via the Rho-guanine nucleotide exchange
factor, respectively [17,18]. Deletion of AKAP13 in mice exhibited defective cardiac development
and embryonic lethality [19]. AKAP150 (AKAP5, AKAP79) has multiple effects on heart function.
On one hand, the loss of AKAP150 activates pathological cardiac hypertrophy by interfering with
calcium dynamics and myocardial ionotropy, showing that its expression is critical for normal heart
function [13]. On the other hand, by activating protein kinase C (PKC), AKAP150 mediates cardiac
glucotoxicity [1]. Deletion of AKAP1 (AKAP121, AKAP149) leads to cardiac mitophagy and apoptosis
after cardiac insult, thus indicating its role in the mitochondrial function in the heart [20]. mAKAP
(AKAP6) is also a pro-hypertrophic AKAP that regulates pathological cardiac hypertrophic signaling
pathways by directing the expression of transcription factors nuclear factor of activated T cells,
cytoplasmic (NFATc), hypoxia-inducible factor 1 alpha subunit (HIF-1α), myocyte enhancer factor
2D (MEF2D), and histone deacetylase 4 (HDAC4). For this reason, AKAP6 is called the master
scaffold for cardiac remodeling [21]. AKAP18 (AKAP15, AKAP7) acts as a nexus of signaling at the
sarcoplasmic reticulum by regulating cardiac ionotropy. By binding to both protein phosphatase
inhibitor-1 (I-1) and protein phosphatase-1 (PP-1), AKAP18 bi-directionally modulates phospholamban
(PLB) phosphorylation and, thus, serves as a crucial regulator of cardiac function [22,23].
Yotiao (AKAP9) is an important AKAP regarding the electrophysiological coupling of the heart.
By binding to the potassium channel (KCNQ), this AKAP maintains the slow outward potassium
ion current. Specifically, mutations that prevent binding of yotiao and KCNQ result in long QT
syndrome [24]. Studies in stem cell-derived cardiomyocytes indicate that AKAP10 (D-AKAP2) is
essential in controlling the heart rate and rhythm [25]. Recently, it was shown that AKAP10 is
crucial in erythropoietin signaling and heme biosynthesis at the outer mitochondrial membrane [26].
Cardiac phosphoinositide 3-kinase gamma (PI3Kγ) is an AKAP that binds phosphodiesterase3B
(PDE3B) and phosphatidylinositol (3,4,5)-trisphosphate (PtdIns(3,4,5)P3) along with PKA regulating
cAMP and PtdIns(3,4,5)P3 signaling. The crosstalk between cAMP and PtdIns(3,4,5)P3 is crucial in
monitoring β-AR desensitization [27]. The catalytic subunit of PI3Kγ (p110γ) knockout mice exhibited
significantly lower PDE3B activity leading to an abrupt increase in cAMP activity. Under stress,
p110γ-null mice showed an uncontrolled rise in cAMP with the development of cardiomyopathy [28].
Gravin (AKAP12), on the other hand, is crucial in the β2-AR desensitization pathway. Our laboratory
data revealed that gravin mutant mice performed better under acute isoproterenol stimulation as
compared to their wild-type littermates [10]. Overall, these findings strongly suggest the role of AKAPs
in cardiac physiology.
3. Polymorphisms/Mutations in AKAPs and CVDs
3.1. DAKAP2 (AKAP10)
Even though AKAPs have been implicated in cardiac disorders, there is a very limited number
of publications on the impact of the genetics of AKAPs on CVDs. The first evidence of the direct
interaction between polymorphic AKAP and heart disease came in 2003, where the I646V (A to G)
polymorphism in D-AKAP2 (AKAP10) was found to be associated with changes in PR interval in
the electrocardiography (ECG) of an older population [29]. The PR interval in ECG represents the
time starting from the onset of atrial depolarization (the beginning of the P wave) until the onset of
ventricular depolarization (the beginning of the QRS complex). It was reported in this study that
homozygous valine variants of this old population showed a significantly lower PR intervals (slower
atrial depolarization) than individuals who are homozygous for isoleucine. Experimental studies
further suggested that this valine variant in AKAP10 had approximately three-fold higher binding
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to the PKA regulatory subunit RI alpha (PKA-RIα) than with isoleucine. AKAP10 is located in the
outer mitochondrial membrane within the cardiomyocyte. Although PKA signaling with respect to
AKAP10 is not known, AKAP10 contains a PDZ binding motif which could physically interact with
transmembrane receptors and ion channels. Additionally, AKAP10 also contains two regulator of G
protein signaling (RGS) domains by which AKAP10 might co-ordinate Gs activation and downstream
PKA pathway [29]. Therefore, AKAP10 might scaffold a cardiac ion channel or exchanger. Thus,
changes in the localization of PKA-RIα near this region, due to the polymorphic AKAP10, might
have a significant impact on phosphorylation states of cardiac ion channel or exchanger leading to
modulation of cardiac contraction. [29].
Lower PR intervals in homozygous valine population might be partially due to overactivation of
ion channels or exchangers in the heart, and vice versa. Involvement of other possible unknown cell
signaling pathways might be possible in the pathophysiology of functional AKAP10 variants. Due to
the observed differences in PKA binding and respective changes in ECG due to AKAP10 polymorphism,
research from this study showed, for the first time, that functional variants of AKAPs might have
direct consequences on the etiology of CVDs. In subsequent studies, it was also shown that the I646V
SNP of AKAP10 was common in 122 patients having coronary heart disease, as identified in the Heart
and Soul Study (University of California, San Francisco, CA, USA; UCSF) [25]. It was revealed that
homozygous carriers of the valine polymorphism had significantly higher heart rates than homozygous
isoleucine carriers. Heart rate variability (HRV) and standard deviation of normal-to-normal (SDNN)
R-R intervals, where R is the peak of a QRS complex, were found to be significantly lower in these
patients. Low HRV and SDNN of R-R intervals are both indicators of sudden cardiac death in patients
with some forms of CVDs.
In another study, statistical data revealed that the effects of AKAP10 polymorphisms were
independent of age, gender, race, and other heart-related risk parameters [25]. In the same study,
and to understand the underlying mechanism, homozygous and heterozygous AKAP10 mutant mice
were generated from AKAP10 mutant mouse embryonic stem cells (mESCs) having mutations in
AKAP10’s PKA binding domain. Both in vivo and in vitro data from this study displayed increased
contractile response to cholinergic agonists indicating that AKAP10 variants lead to the increase in
vagal nerve sensitivity. Vagal inhibition of the heart was known to reduce pre-disposition to arrhythmia
and sudden cardiac death. Hence, changes in vagal nerve sensitivity due to unknown molecular
mechanisms contribute to the development of cardiac arrhythmia and death.
Interestingly, it was also found that the 646I allele is exclusively common only in humans,
while 15 other non-human animals, including chimpanzees, exhibit valine at 646 [25]. These results
were further supported by a larger sample of a healthy middle-aged population of men and women
having European ancestry. Association analysis on 1033 unrelated middle-aged men and women
showed that participants with homozygous 646V had greater baseline HR and lower HRV values
than homozygous 646I individuals. This analysis was done such that the results were not dependent
on age, gender, smoking and drinking habits, exercise levels, and blood glucose [30]. In all the
studies described above, the valine variant at position 646 was found to be 40% frequent, whereas the
isoleucine variant was 60% frequent in all participants. Altogether, these results clearly suggest that
the I646V functional variant of AKAP10 affects the sensitivity of heart’s pacemaker cells to sympathetic
stimulation. In another study of a larger cohort of Japanese individuals, it was revealed that valine at
646 of AKAP10 was significantly associated with higher cases of myocardial infarction (MI) than in
people with no history of hypercholesterolemia. The authors concluded that 646V was the risk factor
for MI, although the molecular mechanism was not studied [31]. Thus, the AKAP10 I646V variant
leads to abrupt heart rate (HR) and HRV changes along with increased risk of MI, possibly making
healthy humans susceptible to an increased risk of arrhythmia and sudden cardiac death (Table 1).
In addition to the above-mentioned middle-aged and elderly population studies, the genetics of
AKAP10 were also studied in newborns and infants. In polish newborns, 646V homozygous healthy
infants showed longer QTc (corrected QT) intervals, but not out of the normal range, than isoleucine
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homozygous infants, suggesting a possible association between AKAP10 polymorphisms to the QTc
interval [32]. Similarly, another study showed significantly higher mean blood pressure (BP) on the
day one and the day three post-birth in Polish newborns carrying valine at the 646 position of AKAP10
as compared to isoleucine carriers [33]. Higher cholesterol cord blood concentration was also observed
in Polish newborns at the time of birth due to I646V polymorphism in AKAP10. Homozygous valine
carrier newborns (GG) had significantly increased levels of cholesterol than heterozygous (AG) and
homozygous (AA) isoleucine carriers [34]. Another recent research report identified SNPs in AKAP10
in fetuses with ventricular septal defects and pulmonary stenosis, suggesting AKAP10 as a potential
target for these cardiac conditions [35]. These reports suggest that functional AKAP10 variants affect
cardiac parameters of newborns and infants, though the underlying molecular mechanisms were not
studied. Taken together, AKAP10 polymorphisms play a significant role in increasing the susceptibility
of humans of all age groups to develop specific CVDs (Table 1).
3.2. Yotiao (AKAP9)
Pharmacogenomics is a branch of pharmaceutical sciences which comprises studies to understand
how genetics affect individual’s responses to drugs. Drug-induced prolongation of the QTc interval
is a very serious adverse drug reaction causing drug withdrawal [36]. Nearly 1–5% of patients
on anti-arrhythmic drug therapy have this severe complication. In one of the studies involving
1351 individuals it was noted that three novel AKAP polymorphisms were related to congenital
arrhythmia. SNP in AKAP9 Gln3531Glu was found to be one the novel rare AKAP variants that was
observed in congenital arrhythmia cases, which was also highly common in drug-induced Long-QT
syndrome (LQTS) (Table 1) [37]. LQTS is one of the inheritable arrhythmia syndromes characterized
by prolongation of the QT interval in ECG. LQTS patients undergo syncope, seizures, or cardiac arrest
under physical or mental stress [38]. The QT interval indicates the time that is required for the heart
muscle to send an electrical impulse through the ventricles and then recharge. LQTS generally occurs
due to mutations in cardiac ion channels leading to a defective flow of ions in the heart. If the QT
interval is longer than usual, then it will likely lead to a life-threatening ventricular arrhythmia called
torsade de pointes.
The inheritable S1570L missense mutation in yotiao (AKAP9) was the first report of
a disease-causing mutation in an AKAP [39]. Binding of slowly activating delayed rectifier potassium
channel alpha subunit (KCNQ1) and yotiao is crucial for delayed rectifier current, which is important
during the cardiac cycle of the human heart. Cardiac repolarization is mainly dependent upon
rapid and slow delayed-rectifier potassium currents mediated by human ether-a-go-go-related (hERG)
gene and the KCNQ1 gene, respectively. KCNQ1 potassium channels become activated after the
rapid current in late repolarization phase of the cardiac cycle and both these currents determine the
length of action potential duration [40]. Phosphorylation of KCNQ1 is crucial for slow-activating
delayed potassium current (IKs). It was shown that PKA-mediated phosphorylation of KCNQ1 at
serine 27 is critical for IKs. Yotiao (AKAP9) effectively scaffolds PKA and protein phosphatase-1
(PP-1) to KCNQ1, maintaining its phosphorylation levels during upstream receptor activation [41].
The S1570L mutation was found in the KCNQ1-binding domain of yotiao, representing 2% of
the clinically-robust LQTS-exhibiting patients. Molecular mechanistic studies showed that this
mutation partially inhibits protein-protein interactions of KCNQ1-AKAP9, leading to decreased
PKA-mediated phosphorylation of KCNQ1. Decreased phosphorylation of KCNQ1 subsequently
resulted in prolonged repolarization of ventricular relaxation due to the elimination of the functional
response of IKs to cAMP. This research displayed a direct link between genetic variants of AKAP and
cardiac disease [39]. Furthermore, polymorphisms in AKAP9 were also found to be a modifier of
LQTS in the South African population [42]. Four intronic AKAP9 polymorphisms, rs11772585 (C/T),
rs7808587 (A/G), rs2282972 (C/T), and rs2961024 (A/C), were studied with or without the presence
of the founder mutation, A341V. The rs11772585 T allele, along with the A431V founder mutation,
increased the risk of cardiac events by more than two-fold, along with significantly increasing the
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severity of CVDs. The rs7808587 GG genotype polymorphism increased the risk of developing cardiac
events by 74%. Interestingly, the rs2961024 GG genotype increased the QTc interval in the aging
population in the absence of A341V mutation while the rs2282972 T allele altered the heart rate and
QTc interval [42]. Thus, AKAP9, for the very first time, was shown to modify cardiac disease due to
the presence of genetic polymorphisms (Table 1).
3.3. AKAP-Lbc (AKAP13)
Type 2 diabetes (T2D) is a risk factor for coronary artery disease as high blood glucose is known
to increase the thickness of the arterial wall. AKAP-Lbc (AKAP13) is a cytoskeleton AKAP that binds
to many proteins, including MEK1/2, extracellular signal-regulated kinase-1/2 (ERK1/2), PKCη,
and protein kinase D (PKD). The mitogen-activated protein kinase (MAPK) signaling pathway is
found to be common in both T2D and coronary artery disease [43]. As AKAP13 binds proteins that
are involved in the MAPK pathway, SNPs in AKAP13 were found to be significantly linked with
these diseases (Table 1) [43]. Other meta-analysis data on a Genome-Wide Association Study (GWAS)
identified SNP in the AKAP13 gene from a Korean population for possible association with high
blood pressure [44]. Researchers found that intronic rs11638762 (A/T) SNP in AKAP13, which lies in
the GATA-3 binding site, was significantly reproduced in a duplication study done in a completely
different group of individuals. AKAP13 scaffolds RhoA along with PKA to mediate activation of
Rho family GTPase. Moreover, these GTPases are involved in cardiac hypertrophic signaling and
the expression of AKAP13 is upregulated in hypertrophy. Changes in AKAP13 expression were also
found to alter the expression of cardiac developmental genes, mainly myocyte enhancer factor 2C [44].
Neonatal death in AKAP10 knock-out mice due to thin-walled heart formation proved that AKAP13
expression is important for the development of the heart. Therefore, the authors hypothesized that
the rs11638762 SNP might alter the expression of AKAP13 leading to defective cardiac development,
which may have caused alterations in blood pressure levels [44].
3.4. Other AKAPs
Chronic kidney disease is one of the essential risk factors for CVDs. The intronic rs756009
A to G polymorphism in gravin (AKAP12) was associated with a higher risk of chronic kidney
disease in Japanese patients with condition that also involves hypertension, diabetes, and high serum
cholesterol [45]. However, the underlying molecular mechanisms of this AKAP12 polymorphism on
the associated CVD were not studied (Table 1). The obesity-dependent parameters, body mass index
(BMI) and waist-hip ratio (WHR), are proven risk factors for T2D and CVD. As such, a GWAS
identified that the AKAP6 rs12885467 SNP was significantly associated with higher BMI [46].
Moreover, our unpublished data suggest that mAKAP polymorphisms might make humans more
susceptible to cardiovascular diseases by altering cAMP/PKA signaling [47]. Additionally, AKAP7
Gln112Arg and AKAP6 Val839Ala SNPs were reported to be novel rare variants in congenital
arrhythmia that were frequently found in drug-induced LQTS [37]. Overall, current evidence on
polymorphisms/mutations in AKAPs strongly suggests a significant correlation of genetic variants of
AKAPs with the pathophysiology of CVDs.
Table 1. Polymorphisms/mutations in AKAPs and CVDs.
AKAPs SNPs/Mutations and Heart Disease Reference
AKAP6 SNP Val839Ala; cardiac arrhythmia [37]
SNP rs12885467; higher BMI [46]
AKAP7 SNP Gln112Arg; cardiac arrhythmia [37]
AKAP9 SNP Gln3531Glu; cardiac arrhythmia [37]
Mutation Ser1570Leu; long-QT syndrome [39]
Four SNPs; long-QT Syndrome Type 1 [42]
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Table 1. Cont.
AKAPs SNPs/Mutations and Heart Disease Reference
AKAP10 SNP Ile646Val; decrease in PR interval [29]
Mutations; cardiac arrhythmia [25]
SNP Ile646Val; myocardial infarction [31]
SNP Ile646Val; blood pressure [33]
SNP Ile646Val; hypercholesterolemia [34]
SNP Ile646Val; heart rate variability [30]
SNP Ile646Val; long QTc interval length [32]
Copy number variations; ventricular septal defects [35]
AKAP12 SNP with multiple alleles; chronic kidney disease [45]
AKAP13 Genetic locus; coronary artery disease [43]
SNP; high blood pressure [44]
4. Polymorphisms/Mutations in AKAPs and Other Human Diseases
4.1. Neurological Disorders
AKAPs have been implicated in human diseases other than CVDs, especially diseases involving
the brain, as well as other neurological disorders. Whole exome sequencing analysis of a Chinese
family having idiopathic scoliosis (spinal deformity) identified the A2645C mutation in AKAP2 to
be inherited in an autosomal dominant fashion [48]. It was also previously shown that disruption
of AKAP2 expression, via de novo translocation, may contribute to Kallmann syndrome and bone
anomalies [49]. Hence, AKAP2 may have a significant role in the pathogenesis of scoliosis. The K873R
SNP in AKAP9 was linked to increased risk of developing schizophrenia in a Spanish population [50].
The AKAP9 SNPs rs144662445 (A/G, I to M) and rs149979685 (C/T, S to L) were found in seven African
American Alzheimer’s disease patients and replicated successfully in the Alzheimer Disease Genetics
Consortium (ADGC) population of 1037 cases and 1869 controls [51]. R3233C and R3832C variants of
AKAP9 were identified and found to be prevalent in high-risk autism families [52]. In fact, AKAPs
might have an incomparable role in etiology of autism spectrum disorders (ASDs). Single nucleotide
polymorphisms in six AKAPs (AKAP7, AKAP10, AKAP11, microtubule-associated protein 2 (MAP2),
moesin (MSN), and neurobeachin (NBEA)) were identified with possible association with ASDs.
Especially, the SNP rs5918959 near the MSN gene displayed genome-wide significance [53]. The DNA
copy variants in eight AKAP genes (AKAP5, AKAP8, AKAP9, AKAP10, AKAP13, MAP2, MSN,
and NBEA) were also found in individuals with ASDs [53].
In yet other studies, AKAP5, shown to be present in all levels of the human brain, was observed
to have a variable copy number in schizophrenia, bipolar disorder, and major depression behavior [54].
AKAP5 is involved in post-synaptic G-protein-coupled receptors (GPCRs)-mediated intracellular
signaling which is known to have a role in modulating emotional behavior. Furthermore, studies
involving AKAP5 polymorphisms revealed that the P100L polymorphism (rs2230491) affected the
behavioral response of its carriers. Proline-carrying individuals had higher behavioral performance
and working memory for emotional faces, while the less common leucine carriers exhibited greater
control of their anger, but poor control of physical aggression [55,56]. Additional studies in the
search of finding molecular mechanisms behind these behavioral changes showed that leucine carriers
activated the anterior cingulate cortex (ACC), while proline homozygous individuals activated the
orbitofrontal cortex (OFC) in the brain, as identified during emotional evaluation studies [56]. mAKAP
(AKAP6) is one of the well-studied AKAPs in the heart. AKAP6 is expressed in cardiac muscle,
skeletal muscle, and brain. In addition to its role in the heart, AKAP6 polymorphisms were found
in GWAS studies to be related to various other human disorders. The intronic rs2383378 SNP was
found to be associated with anorexia nervosa [57] and another intronic rs4296166 SNP was found
to increase the risk of developing Alzheimer’s disease [58]. The rs17522122 SNP was found to be
one of the genetic variants that significantly affect general fluid cognitive functioning in middle and
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old-age population of 53,949 individuals in the Cohorts for Heart and Aging Research in Genomic
Epidemiology (CHARGE) consortium [59]. In a recent study, the rs17522122 T allele (found in UTR-3)
SNP was associated with poor performance with respect to episodic memory in older populations,
as identified in the Personality And Total Health (PATH) study [60]. Thus, polymorphisms in AKAPs
were found to be significantly associated with a plethora of neurological disorders in humans.
4.2. Cancers
Genetic variants of AKAPs have been reported to be very common in the patient populations of
various cancers. The whole genome and transcriptome sequencing data have shown that the AKAP2
gene is mutated in gastric and peritoneal metastatic cancer [61]. Yotiao (AKAP9) is a crucial AKAP
with an important role in cell cycle progression, centrosome, and cell membrane function. Genetic
mutations in AKAP9 are linked to a variety of cancers. Four AKAP9 mutations were associated
with gastric cancer and 20 mutations were linked to colorectal cancer [62]. The single nucleotide
polymorphisms M463I, 1389G > T and N2792S, 8375A > G in AKAP9 were found to increase the risk of
familial breast cancer in German women [63]. The non-synonymous SNP M463I (rs6964587) in AKAP9
was also found to be very an important breast cancer susceptibility polymorphism [64]. The T allele
of rs6964587 was frequent in African American, Asian, and European women. The AKAP9 M463I
variant was also associated to increase the susceptibility of lung cancer in a large United Kingdom
Caucasian population [65]. We previously discussed that the functional polymorphism I646V in
D-AKAP2 (AKAP10) has a significant role in the cardiovascular system. In addition, heterozygous
and homozygous expression of this valine variant in AKAP10 was also significantly increased in
women with colorectal cancer as compared to isoleucine carriers [66]. Additionally, the valine AKAP10
variant carriers were also found to have increased risk of developing familial breast cancer [67].
Furthermore, the AKAP13 K526Q SNP, along with I646V in AKAP10, further augmented the risk
for breast cancer [67]. Since AKAP13 plays a crucial scaffolding role in Rho GTPase intracellular
signaling, SNPs in this protein may also affect various cancers. The polymorphisms R494W, K526Q,
N1086D, and G2461S in AKAP13 were all found in familial breast cancer patients with K526Q having
the highest association among all of these SNPs [68]. SNPs in gravin (AKAP12) were also identified to
be significantly associated with breast cancer risk and osteosarcoma [69,70]. In conclusion, mutated
and/or polymorphic AKAPs have been associated with the increased risk of different types of cancers
in humans.
4.3. Other Human Disorders
In addition to neurological diseases and cancers, polymorphic AKAPs were also associated
with a few other human disorders. The heterozygous mutation in AKAP4 (887G > A; G296N) was
found in men with low sperm motility, a condition known as asthenozoospermia [71]. AKAP4 is
a testis-specific AKAP and its removal in mice leads to reduced sperm motility, resulting in infertility.
As this mutation was absent in matched control males, this AKAP4 mutation might be the probable
cause of male infertility [71]. Another report found that mutations in AKAP4 may cause sperm fibrous
sheath dysplasia [72]. In another study, SNPs in the AKAP ezrin were found to increase the risk and
development of age-related cataracts [73]. Finally, the AKAP11 genetic locus was identified in the
GWAS to be significantly associated with osteoporosis [74]. In summary, genetic variations in AKAPs
have also been significantly implicated in other human diseases along with CVDs (Figure 1).
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Figure 1. Genetics of AKAPs and human diseases.
5. Conclusions
AKAPs are a group of proteins that scaffold PKA by definition. Along with binding and localizing
PKA to specific subcellular compartments, AKAPs also scaffold other proteins in the vicinity of
PKA, thus efficiently regulating intracellular PKA-dependent signaling cascades. Additional proteins
that AKAPs bind include a variety of other kinases, phosphatases, phosphodiesterases, GPCRs,
and signaling proteins. Moreover, AKAPs have been reported to play a pivotal role in both the
physiology and the pathophysiology of human diseases. However, the role of genetics in AKAPs
with respect to human diseases has been underappreciated, especially in the cardiovascular system
where polymorphisms/mutations in AKAPs have been shown to increase the risk of developing
various CVDs. Molecular mechanisms behind increasing the risk of CVDs were also studied in certain
candidate AKAPs. Similarly, numerous SNPs were identified that increased the susceptibility of
individuals to develop cancers, brain disorders, male infertility, and eye disorders. We believe that the
majority of the literature only mentions the SNPs and/or mutations in AKAPs with their respective
human disorders. However, we think that genetic variants in AKAPs should also be further studied
with respect to the molecular mechanisms involved in these disorders. Although very few attempts
were made in studying the mechanistic pathways in increasing the risk of developing cardiovascular
disease, a substantial amount of additional research should be done with respect to CVDs, as well as
other human diseases.
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Abstract: Cardiovascular disease (CVD), including myocardial infarction (MI) and peripheral or
coronary artery disease (PAD, CAD), remains the number one killer of individuals in the United States
and worldwide, accounting for nearly 18 million (>30%) global deaths annually. Despite considerable
basic science and clinical investigation aimed at identifying key etiologic components of and potential
therapeutic targets for CVD, the number of individuals afflicted with these dreaded diseases continues
to rise. Of the many biochemical, molecular, and cellular elements and processes characterized to date
that have potential to control foundational facets of CVD, the multifaceted cyclic nucleotide pathways
continue to be of primary basic science and clinical interest. Cyclic adenosine monophosphate
(cyclic AMP) and cyclic guanosine monophosphate (cyclic GMP) and their plethora of downstream
protein kinase effectors serve ubiquitous roles not only in cardiovascular homeostasis but also in
the pathogenesis of CVD. Already a major target for clinical pharmacotherapy for CVD as well as
other pathologies, novel and potentially clinically appealing actions of cyclic nucleotides and their
downstream targets are still being discovered. With this in mind, this review article focuses on
our current state of knowledge of the cyclic nucleotide-driven serine (Ser)/threonine (Thr) protein
kinases in CVD with particular emphasis on cyclic AMP-dependent protein kinase (PKA) and cyclic
GMP-dependent protein kinase (PKG). Attention is given to the regulatory interactions of these
kinases with inflammatory components including interleukin 6 signals, with G protein-coupled
receptor and growth factor signals, and with growth and synthetic transcriptional platforms
underlying CVD pathogenesis. This article concludes with a brief discussion of potential future
directions and highlights the importance for continued basic science and clinical study of cyclic
nucleotide-directed protein kinases as emerging and crucial controllers of cardiac and vascular
disease pathologies.
Keywords: cyclic nucleotide; G protein-coupled receptor; interleukin 6; myocardial infarction;
inflammation; protease-activated receptor; protein kinase; Smad3; Stat3; vascular smooth muscle
1. Introduction
Cardiovascular disease (CVD) is a complex and multifaceted class of diseases or disorders of the
heart and/or blood vessels and constitutes the number one killer of individuals in the United States [1]
and worldwide, accounting for ~18 million (>30%) global deaths annually [2]. Of the many forms of
CVD including arterial or venous thromboses, myocarditis, hypertension and valve dysfunction,
myocardial infarction (MI) and peripheral or coronary artery disease (PAD, CAD, respectively)
represent two of the most significant and account for the vast majority of CVD-related deaths [1].
Notwithstanding significant advances in our understanding of many of the foundational elements
J. Cardiovasc. Dev. Dis. 2018, 5, 6 229 www.mdpi.com/journal/jcdd
J. Cardiovasc. Dev. Dis. 2018, 5, 6
underlying CVD realized through extensive basic and clinical investigation, precise and fully effective
therapeutic targets have yet to be identified and the prevalence of CVD continues to rise and is expected
to afflict ~44% of the US population by the year 2030 [1]. In parallel, the economic burden of CVD,
currently estimated over $316 billion per year for direct and indirect costs in the United States alone,
is anticipated to surpass $900 billion by 2030 [1]. Undoubtedly, the health and economic impacts of
CVD are of utmost significance, and in turn, identification and characterization of key underpinnings
in the pathogenesis of CVD in an effort to discern potential therapeutic effectors and/or strategies is
most warranted.
In this light, over many years a plethora of bioactive elements and signaling processes has been
identified as serving a wide variety of roles in cardiovascular physiology and disease. Of these, the
ubiquitous and multifunctional cyclic nucleotide second messenger systems, comprised primarily
of purine 3′,5′-cyclic adenosine monophosphate (cyclic AMP) and purine 3′,5′-cyclic guanosine
monophosphate (cyclic GMP) and their downstream serine (Ser)/threonine (Thr) protein kinase
effectors, serve a multitude of roles in normal vessel physiology and homeostasis and also in
the pathogenesis of cardiac and vascular disorders [3]. Of particular interest in cardiovascular
tissues are members of the cyclic nucleotide-driven AGC family of Ser/Thr protein kinases: cyclic
AMP-dependent protein kinase (PKA), cyclic GMP-dependent protein kinase (PKG), and calcium
(Ca2+)-activated phospholipid-dependent protein kinase C (PKC) [4]. These robust signaling molecules
serve extensive roles in many homeostatic and pathologic processes. Moreover, considering the
documented promiscuity and cross-talk amongst protein kinase family members [5–8] and interactions
with associated kinases including protein kinase B (PKB/Akt), protein kinase D (PKD), and adenosine
monophosphate (AMP)-activated protein kinase (AMPK), the expansion of the biological impact of
these kinases is of potential clinical importance in CVD. This review article focuses on our current state
of knowledge of the cyclic nucleotide-driven Ser/Thr protein kinases and their related kinase effectors
as emerging and important controllers of cardiac and vascular disease pathology [3].
Many functional processes contribute to the development and/or maintenance of CVD depending
on the exact nature of the disease or disorder. As mentioned, CVD comprises a large and diverse class,
with MI and arterial diseases considered the most critical and clinically significant. In the causation of
MI and arterial disease pathologies, primary functional events associated with tissue perfusion include
disruption of blood flow or ischemia with ensuing hypoxia and localized acidosis and complications
associated with re-establishment of blood flow or re-perfusion injury. Additional contributors to
these pathologies can include extensive tissue inflammation, cell necrosis and apoptosis/necroptosis
with compromised tissue function, and loss of a quiescent homeostatic phenotype with onset of
aberrant cellular growth/wound healing leading to adverse tissue remodeling [6,9,10]. At the
biochemical and molecular level, a host of mechanisms underlie these functional changes and include,
notably, an array of immune and inflammatory responses, membrane receptor-mediated signals
including G protein-coupled receptor (GPCR) and growth factor pathways, and transcriptional
platforms for synthetic and proliferative proteins. In this respect, this review article discusses
the biological significance of inflammatory interleukin-6 (IL-6) signaling, acidosis-sensitive GPCRs
and protease-activated receptors (PARs), synthetic transforming growth factor-β (TGF-β) and its
primary Smad-dependent processes, and a transcriptional Smad/FoxO relationship during CVD.
Particular attention is then given to the regulatory influence of cyclic nucleotide-directed Ser/Thr
protein kinases on these processes as foundational elements of cardiac and vascular pathology. This
review concludes with a short synopsis of key findings and highlights the importance for continued
basic science and clinical study of cyclic nucleotide-directed protein kinases in CVD.
2. Cyclic Nucleotides and Cyclic Nucleotide-Directed Protein Kinases
As mentioned, the purine-based second messengers cyclic AMP and cyclic GMP are firmly
established as essential modulators of wide-ranging cellular functions in mammalian tissues including
those in the cardiovascular system. Detailed biomolecular mechanisms for the generation of cyclic
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AMP and cyclic GMP have been previously described [7,10–12]. In brief, synthesis of cyclic AMP occurs
via multiple processes including stimulation of adenylate cyclase (AC) by direct ligand agonism, by
β-adrenergic induction, or by GPCRs coupled to stimulatory G proteins (Gs). Following AC stimulation,
dephosphorylation of adenosine triphosphate (ATP) yields cyclic AMP and pyrophosphate (PPi).
In like fashion, cyclic GMP is synthesized via activation of guanylate cyclase (GC), which can occur by
natriuretic peptides (NPs) which activate particulate, membrane-bound GC, or by gaseous ligands such
as nitric oxide (NO) or carbon monoxide (CO) which activate soluble GC (sGC). Activated GC then
dephosphorylates guanosine triphosphate (GTP) to yield cyclic GMP and PPi. Following synthesis,
cyclic AMP and cyclic GMP predominantly exert their effects through respective Ser/Thr AGC kinase
family members PKA and PKG [4,5,7,10]. Cyclic AMP can also operate through alternate non-canonical
kinase-directed pathways [5], through direct ion current modulation via cyclic nucleotide-gated
(CNG) ion channels [13], via binding to Popeye domain-containing (POPDC) proteins [14,15], or
through exchange proteins directly activated by cyclic AMP (EPAC) [16,17]. Similarly, cyclic GMP can
activate CNG ion channels [13], can act on alternate non-canonical kinases besides PKG and can have
kinase-independent effects as well [9]. Cyclic nucleotide signaling can be largely governed by internal
localization via scaffolding proteins such as A-kinase anchoring protein for cyclic AMP [18] and inositol
1,4,5-triphosphate (IP3) receptor-associated cGMP kinase substrate (IRAG) and Huntingtin-associated
protein 1 (HAP1) for cyclic GMP [19,20]. Lastly, persistence of cyclic AMP and cyclic GMP signals is
largely governed by specific phosphodiesterases (PDEs), which cleave their phosphodiester bonds and
degrade them into inactive 5′-monophosphates [21]. The schematic in Figure 1 depicts primary routes
for synthesis of cyclic AMP and cyclic GMP, their main regulatory modulators, and their respective
activation of downstream targets including protein kinase pathways.
Protein kinases have the capacity to serve in a host of physiological and pathophysiological
processes and represent one of the most diverse and ubiquitous families in the human genome,
constituting ~2% of human genes with over 500 human protein kinases identified thus far [5,22].
Through reversible phosphotransferase-mediated, site-specific (Ser/Thr) phosphorylation of effector
proteins, PKA and PKG provoke robust signal transduction cascades with the capacity to control a
myriad of intracellular processes. Comprehensive reviews on the mechanisms of action of these protein
kinases and others have been published [23,24] and herein only a brief synopsis is provided. In sum,
ATP binds to an active site in a conserved catalytic domain (~250 amino acids in length) located between
one lobe of N-terminal β-sheets and a second lobe of C-terminal α-helices [25]. Following binding, a set
of conserved residues in the catalytic domain transfers the terminal γ-phosphate of ATP to the hydroxyl
oxygen of the receiving residue (Ser/Thr) on the target [23,26], after which substrate is released, ADP
is removed and phosphorylation-driven activation or inactivation of the downstream effector ensues.
This kinase-driven, post-translational, phosphorylation-specific modification of effector proteins then
dictates enzyme and protein expression and/or activities and downstream functions including those
elemental to cardiac and vascular disease or dysfunction. Uniquely, despite this common mechanism
across diverse protein kinases, kinase specificity is imparted by differences in hydrophobicity of surface
residues, unique aspects of the active catalytic site and differential kinetics of ATP binding, the overall
charge of the enzyme, and presence or absence of anchoring or scaffolding proteins and other accessory
proteins along with sub-cellular localization of the kinase.
A caveat must be mentioned when discussing the kinase-mediated impact on target proteins.
While Ser/Thr kinases (as well as Tyr kinases) typically act on their preferred residue, they are also
attracted to residues flanking their canonical phosphoacceptor site. Among similar substrate family
members, the catalytic cleft of these kinases has the capacity to interact with common recognition
sequences adjacent to their preferred substrate (Ser/Thr, Tyr), thereby reducing kinase specificity and
permitting ‘promiscuous’ kinase signal transduction. Our research team and others have documented
promiscuity and signaling cross-talk for not only the cyclic nucleotide-driven kinases but also for their
upstream modes of activation including the second messengers themselves [5–10,27–33]. In this regard,
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kinase ‘cross-talk’ affords broad impact of upstream kinase activation but also lends difficulty in
determining discrete downstream signaling pathways and effector targets of kinase-mediated events.
Figure 1. Schematic of cyclic adenosine monophosphate (cyclic AMP) and cyclic guanosine
monophosphate (cyclic GMP) signaling. Following activation of adenylate cyclase (AC) by
upstream processes including direct ligand agonism, B-adrenergic stimulation, or by stimulatory
G protein-coupled receptors (GPCRs), adenosine triphosphate (ATP) is dephosphorylated to yield
cyclic AMP and pyrophosphate (PPi). In similar fashion, stimulation of membrane-bound or soluble
guanylate cyclase (GC) by natriuretic peptides or gaseous ligands nitric oxide (NO) and/or carbon
monoxide (CO), GTP is dephosphorylated to yield cyclic GMP and PPi. Persistence of cyclic nucleotide
signaling can be governed by the presence of scaffolding proteins including A-kinase anchoring protein
for cyclic AMP or IP3 receptor-associated cGMP kinase substrate (IRAG) and Huntingtin-associated
protein 1 (HAP1) for cyclic GMP, and by degradation into inactive 5′-monophosphates by a family of
phosphodiesterases (PDEs). Cyclic AMP can operate through kinase-independent pathways, through
binding to cyclic nucleotide-gated (CNG) ion channels or Popeye domain-containing proteins (POPDC),
via exchange proteins directly activated by cyclic AMP (EPAC), through non-canonical protein kinases
or by activation of PKA. In like manner, cyclic GMP can signal through kinase-independent pathways,
by binding to CNG ion channels, through non-canonical protein kinases or via PKG. The predominant
protein kinases for cyclic AMP and cyclic GMP, PKA, and PKG, can then stimulate Ser/Thr residues on
many diverse downstream effector targets to help control normal physiology and homeostasis as well
as wide-ranging pathophysiological processes in cardiac and vascular tissues.
It warrants brief mention that in opposition to the Ser/Thr protein kinases a family of
dephosphorylating Ser/Thr protein phosphatases (PPs) exists that serves to maintain phosphorylative
balance [34,35]. Removal of a phosphate group or groups from Ser/Thr residues by PPs curbs
phosphorylation-mediated events in Ser/Thr kinase-targeted proteins and helps to moderate
kinase-driven processes. Interestingly, only about 30 Ser/Thr PPs have been identified in the human
genome (compared to >400 Ser/Thr protein kinases [5,22,34,35]), which is attributed to their unique
combination of homoenzymes from shared catalytic subunits and their large number of regulatory
subunits [35]. With respect to cardiovascular physiology and disease, Ser/Thr PPs in addition to their
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complementary Ser/Thr kinases must be considered for full evaluation of the phosphorylative balance
and its potential therapeutic utility [8,36].
From a clinical perspective, mutations in Ser/Thr protein kinases have been linked to human
diseases, and protein kinases currently represent a large percentage of all putative protein drug
targets [37–40]. In fact, many protein kinases presently serve as discrete targets for use in precision
medicine for cardiac and vascular diseases [3] and they likely represent the next major drug
development target for diseases and disorders of the cardiovascular system (and others) in the next
century [41,42].
3. Vascular Physiology & Pathology
Excellent comprehensive reviews have been published recently that highlight important aspects
of blood vessel anatomy and function under homeostatic and pathologic conditions [7,9,43]. In sum,
normal arterial anatomy consists of three primary layers: tunica intima, tunica media and tunica
externa. A single layer of vascular endothelial cells (VEC) encircle the blood-containing lumen and
constitutes the tunica intima. Intimal VECs are normally exposed to laminar shear stress and provide
an important interface between flowing thrombogenic blood and the blood vessel wall [43]. In this
capacity VECs are responsible for secreting bioactive substances, including the vasodilators NO, CO
and prostaglandin I2 (PGI2) and the vasoconstrictors thromboxane A2 (TXA2) and angiotensin II
(Ang II), that communicate with the underlying vascular smooth muscle (VSM) through the basement
membrane in order to control vascular tone [43]. The tunica media, the blood vessel inner layer,
contains vascular smooth muscle cells (VSMCs) as well as structural collagen and elastin and is
responsible for maintaining normal vascular contraction and dilation. This vessel reactivity, in turn,
controls localized intravascular pressures and tissue perfusion [44]. Medial VSMCs are known to be
much more plastic than other vessel wall cells because they handle many functions such as contraction
and dilation as well as proliferation and extracellular matrix (ECM) synthesis [44]. The outward
component of the vessel wall is the tunica externa or adventitia which contains sparse fibroblasts
and VSMCs, a vasa vasorum blood supply, and local nerve endings and inflammatory cells spaced
throughout the supporting connective tissue [43]. Perivascular adipose tissue located on the outside of
the tunica adventitia plays a role in support and anchoring of the vessel yet has also been suggested
to serve a role in energy metabolism, regulation of vascular tone, the release of adipokines, and in
the storage of free fatty acids and triglycerides [43]. A schematic depicting these key elements in a
cross-section of a blood vessel wall is shown in Figure 2.
The predominant overall function of the arterial vasculature is to provide blood flow and nutrients
to essential downstream tissues in order to ensure their proper function under homeostatic as well
as abnormal conditions. In return, the venous system serves as the conduit for removal of metabolic
byproducts and wastes including carbon dioxide for elimination from the body. Based on the amount
and functionality of local VSM, most blood vessels have ability to constrict or relax as needed in
order to adequately control blood flow and, in turn, to properly supply tissues with blood and
nutrients including oxygen as needed per local metabolic demand. In this light, the vasculature
provides a basal state of tonic contraction termed vascular tone (or ‘myogenic tone’ if derived
from the VSM itself). In brief, to first summarize vessel contraction, extracellular calcium entry
(via voltage-gated, ligand-gated, and/or stretch-activated Ca2+ channels) induces intracellular Ca2+
levels to rise (via the release of Ca2+ from intracellular stores). This elevated intracellular Ca2+ then
binds to calmodulin and sequentially activates cytosolic Ser/Thr myosin light chain kinase, which
then phosphorylates regulatory myosin light chain and activates myosin ATPase activity. This ATPase
then initiates actin-myosin cross-bridge formation and cycling and the establishment/maintenance
of vessel contraction [10,11]. For vessel relaxation, removal of intracellular Ca2+ is the first step and
this can occur via re-sequestration back into intracellular stores and/or removal from the cell by Ca2+
channels. Following the Law of Mass Action, Ca2+ unbinds from calmodulin, myosin light chain kinase
activity decreases, myosin phosphatase dephosphorylates myosin light chains, which in turn reduces
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myosin ATPase activity and muscle tension is decreased. Vascular tone can be regulated by extrinsic
(neurohumoral elements, CNS innervation) and intrinsic (VSM-derived, myogenic) elements and
so can be determined by numerous influences including competing vasoconstrictor and vasodilator
factors and local metabolic demand of downstream tissues in organ- and tissue-specific fashion.
Low-level vascular tone results from numerous and differential states of cross-bridge formation that
can develop which leads to various contractile states of the VSM including notably a basal steady-state
level of contraction (tone). Regarding cyclic nucleotide control of vascular tone, both cyclic AMP/PKA
and cyclic GMP/PKG can operate via several mechanisms to reduce intracellular Ca2+, to inhibit
myosin light chain phosphorylation, and to stimulate Ca2+-activated potassium channels and promote
hyperpolarization, all resulting in reduction in vascular contractility and tone and promotion of vessel
relaxation (loss of tone) [10,11].
Figure 2. Layers of a blood vessel. Cartoon cross-sectional image of a blood vessel with major layers
and cell types depicted. The outermost perivascular fat (A) lends support and anchoring for the
vessel as well as mediates adipocyte production and influences cellular metabolism. The outermost
layer of the vessel proper, the tunica adventitia (B); is largely a structural layer of the vessel wall and
is comprised of extracellular matrix (ECM) containing resident immune cells, an internal vascular
supply (vasa vasorum), sparse nerve endings and fibroblasts. The majority of the arterial vessel wall is
comprised of the tunica media (C); mostly vascular smooth muscle cells (VSMCs) and ECM. Medial
VSMCs are responsible for vasoconstriction and relaxation (i.e., vessel tone) that controls luminal blood
flow. The innermost layer of the blood vessel is the tunica intima (D) and is comprised of a single layer
of vascular endothelial cells (VECs) that surround the lumen of the vessel, that form a critical interface
between flowing blood and the vessel wall, and that communicate with the underlying VSMCs to help
regulate tone and direct inflammatory responses. Arrow indicates direction of luminal blood flow.
Despite the essential role that our circulatory system plays in normal cardiovascular health,
pathological conditions such as vascular disease, dysfunction or injury constitute the number one
contributor to CVD [2]. Two primary components in the pathogenesis of vascular disease or injury
include overt inflammation of the intimal endothelial lining and abnormal synthesis and growth of
medial VSMCs [9,45,46]. In diseased or dysfunctional VECs, production and release of inflammatory
cytokines along with increased substrate adhesiveness contribute to the recruitment of leukocytes,
which adhere to the (activated) cells, transmigrate and provoke an inflammatory response [47]. In this
process, increased expression of vascular cell adhesion molecules, cytokines, and chemokines is
essential for the VEC-leukocyte interaction and subsequent inflammation; thus, identification and
characterization of molecular mediators and events that regulate VEC inflammation and adhesion
is critical. In this light, key VEC inflammatory mediators have been identified including E-selectin,
ICAM-I, and VCAM-1 that have potential to serve as therapeutic targets to combat VEC inflammation
in the context of CVD [48]. Complementing VEC-driven inflammation is the VSM-dependent
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proliferative, synthetic ‘evolution’ phase of CVD pathogenesis [5,9,10,49]. In response to pathologic
insult, VSMCs undergo phenotypic switching from homeostatic and contractile to synthetic, migratory
and proliferative. This phenotypic conversion is manifested as reduced contractility and a reorganized
architecture complete with medial wall remodeling and stenotic neointima development [9,44,50].
This neointimal growth involves fibroblast and cellular accumulation in the perturbed intimal space
that results in excessive synthesis and deposition of ECM components and loss of luminal caliber
resulting in altered or occluded blood flow [51]. Although vascular remodeling and neointimal
formation initially serve as adaptations they can soon progress into uncontrolled, pathologic and
self-perpetuating cascades with severe clinical repercussions.
Vessel wall remodeling and neointimal hyperplasia can provoke and serve as a key component
of atherogenesis, the process of the build-up of fats and cholesterol (along with numerous cells,
matrix components, etc.) in an occlusive plaque on the inner blood vessel wall. Atherosclerosis is the
major cause of adverse cardiovascular events including stroke, MI, and peripheral limb ischemia or
claudication [1]. Atherosclerosis is multifactorial and complex, combining elements of inflammation
and cellular adhesion, VEC dysfunction, formation of reactive oxygen and nitrogen species and
oxidative/nitrosative stresses, foam cell development, VSMC migration and proliferation, enhanced
ECM development, and formation and evolution of a stenotic plaque within the lumen. If plaque
complication and rupture ensue, thrombus formation and adverse cardiovascular events including MI
and/or stroke can rapidly develop.
4. Cardiac Physiology & Pathology
The heart is a crucial pump that utilizes the circulatory system to provide the driving force for
maintenance of blood pressure and to deliver essential blood flow to target organs. However, any
decrement in cardiac function and its ability to serve as a central pump can lead to hypo-perfusion of
distal tissues and organs and, in turn, eventuate in organ failure and multi-system dysfunction and
ultimately death. In this section, an overview of some general concepts in cardiac physiology and
pathology is presented that will be discussed in subsequent sections.
Central to the role of the heart as a pump are several important physiological concepts, and a
brief refresher is warranted: chronotropy refers to the generation of pacemaker action potentials in
the sinoatrial (SA) node that allow for depolarization of adjacent cells via gap junctions and therefore
determines heart rate [52]; SA nodal rate and speed of conduction may by modulated by changes in
atrioventricular (AV) nodal depolarization in dromotropy [53]; electrical conduction is converted into
mechanical contractility by excitation-contraction coupling via Ca2+-induced Ca2+ release [54]; cardiac
inotropy describes the force of contraction that results from electrical-mechanical coupling and, when
combined with chronotropy and dromotropy, determines cardiac output; and following contraction
the rate by which the ventricles relax due to sequestration of Ca2+ back into internal stores is known as
lusitropy [55].
Structurally, the heart is comprised of several primary cell types. Cardiomyocytes comprise
the bulk of the organ and are categorized as either specialized conductive cells [56] or as the
cells responsible for myocardial contraction [57]. Fibroblasts are responsible for the structure and
maintenance of the cardiac ECM which provides support for the structure of the heart as well as
contributing to formation of cardiac valves. VECs and VSMCs comprise the blood vessels within the
heart, the coronary circulation [58]. Additionally, resident leukocytes such as macrophages, innate
lymphoid cells, and mast cells can be found within the myocardium [59]. Each of these cell types and
physiological concepts is critical to maintaining healthy cardiac function. Modulation of both cyclic
nucleotide-directed protein kinase signaling and inflammatory processes can be exploited clinically
to rescue cardiovascular function in the presence of a pathological state or exacerbation of disease
processes such as in myocarditis, myocardial infarction, ischemia-reperfusion (I/R) injury, and the
development of heart failure (HF) [3].
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Epidemiologic studies indicate CVD as the leading cause of morbidity and mortality in the
United States with an estimated 1,255,000 new or recurrent events of myocardial infarction (MI) occur
per year [60]. This review will focus primarily on pathologies and sequela related to MI including
I/R injury as well as HF due to adverse cardiac remodeling following MI. Current medical opinion
divides MI into two distinct categories separated by their underlying etiology, Type 1 and Type 2 [61].
Type 1, or spontaneous, MI is considered the prototypical example of an infarction and is the most
common type of MI [62]. As discussed above in vascular pathology, ischemia occurs when a vessel
becomes occluded by either a thrombus or less often by an embolus. Commonly, luminal blockages of
a coronary artery result paradoxically from normal wound healing and clotting responses gone awry.
Coronary thrombosis occurs when a complicated atherosclerotic plaque spontaneously ruptures, and
the initial recruitment of platelets to the site of injury begins to block the already narrowed arterial
lumen. Ultimately, blood flow to distal portions of the myocardium becomes obstructed.
Although the most common pathological mechanism for initiation of MI, rupture of atherosclerotic
plaques are not the only means of inducing myocardial ischemia or MI. When oxygen demand outpaces
oxygen supply, such as during strenuous exercise [63] or during coronary vasospasm [64], injury can
occur. Myocardial oxygen supply-demand mismatch in the absence of coronary thrombosis is classified
as a Type 2 MI and is another leading cause of MI. It is important to note that in Type 1 or Type 2 MI,
total luminal occlusion of a coronary artery is not required to induce ischemia because any decrease in
coronary flow resulting in inadequate oxygen distribution will result in ischemia and if unresolved
ultimately cardiomyocyte death [62]. Although Types 1 and 2 MI are the most common etiologies,
there exist several classifications relevant to clinical discrimination of MI. Type 3 MI is an entirely
clinical subdivision and reflects sudden cardiac death of unknown etiology, but acute myocardial
ischemia is strongly suspected [65]. The gold-standard treatment for Type 1 and Type 2 infarcts is
reperfusion by percutaneous coronary intervention (PCI), thrombolysis, or coronary artery bypass
grafting (CABG) which has led to two new classifications of Types 4 and 5 MI and indicate iatrogenic
origins. Type 4 MI results from PCI or stent placement and involves myocardial ischemia that occurs
during the procedure or secondary to vessel restenosis [63,66]. Type 5 MI is very similar to Type 4
except that ischemic complications are secondary to CABG. While most Types 4 and 5 infarcts are due
to technical failure that limits resolution of ischemia, some are associated with successful intervention
in the face of an excessive inflammatory response to reperfusion.
Ischemia is a condition whereby inadequate blood flow results in inadequate oxygen supply [67].
Mechanisms that ultimately lead to cardiomyocyte death are tied strongly to cellular susceptibility
to hypoxia. The myocardium has an incredibly high metabolic demand: making delivery of oxygen
by way of the coronary arteries crucial in support of normal cardiac function. Occlusion of one or
more coronary arteries leads to ischemia in areas distal to the blockage and, in turn, compromises
tissue metabolism and function. Thus, ischemia leads to hypoxic injury in distal tissue, which if left
unresolved eventuates in cell/tissue death known as infarct [62]. Hypoxic injury to the myocardium
results from an inability to generate sufficient ATP via oxidative phosphorylation causing a shift to
anaerobic glycolysis [62]. Anaerobic glycolysis results in intracellular acidosis from the accumulation of
intracellular hydrogen ions (H+), thereby disturbing the sodium (Na+)/H+ exchanger [68]. Depletion of
available ATP inactivates Na+/potassium (K+) ATPase [69]. The combined ionic disturbances result
in Na+ overload. As a result, Na+-Ca2+ exchanger attempts to compensate for the ionic disturbance
by pumping Ca2+ into the cytoplasm and Na+ out of the cell. However, the intracellular Ca2+
overload induces cardiomyocyte death [62,64,68,69]. The cytosolic oversaturation with Na+ or Ca2+
results in increased cytoplasmic osmolality resulting in cellular edema [64]. Excess Ca2+ uptake by
cardiac mitochondria induces opening of the mitochondrial permeability transition pore (mPTP)
leading to mitochondrial lysis, the release of cytochrome C, and induction of apoptosis [70–72].
Intracellular Ca2+ concentration also activates phospholipases that serve to degrade cardiomyocyte cell
membranes [68,69]. The cascade of events following an initial ischemic insult, as highlighted above,
contribute to cell/tissue death and ultimately the condition of MI. An overview of some of these key
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elements that serve as foundations for cardiac dysfunction and disease following an ischemic episode
is shown in Figure 3.
Figure 3. Overview of mechanisms contributing to cell death following ischemia. Ischemia results
in ion channel dysfunction following decreased production of ATP and increased hydrogen ion (H+)
production leading to cellular acidosis. Ultimately excessive intracellular calcium (Ca2+) triggers
activation of phospholipases and the opening of the mitochondrial permeability transition pore (mPTP)
in turn inducing cell death.
To salvage myocardial tissue and rescue normal cardiac function it is imperative to rapidly
restore coronary blood flow following onset of cardiac dysfunction and/or MI. Clinically, blood flow
can be restored through medical interventions such as thrombolytic therapy, PCI, or CABG [73,74].
The goal of MI treatment, restoration of blood flow, however can paradoxically result in further
myocardial injury, known as reperfusion injury [68]. Reperfusion injury broadly encompasses several
adverse events including arrhythmia, myocardial stunning, and microvascular damage [64,68,69,75,76].
Although the manifestations of reperfusion injury are diverse, in many respects the underlying
mechanisms mirror many of the processes witnessed in primary ischemic injury. Complicating the issue
of revascularization and reperfusion is the tendency for the aberrant and pathological proliferation
of coronary artery VSMCs leading to vascular restenosis through inflammatory processes and
growth/remodeling [77,78]. As will be discussed below, data generated over the past decade has also
strongly implicated regulatory roles for cyclic nucleotides and their multifunctional protein kinases in
these cardiac pathologies [31,36,79–81].
Reactive oxygen species (ROS) play a fundamental role in mediating cardiac reperfusion injury.
Surges of oxygen occurring with the restoration of blood flow generate superoxide anion and/or
peroxynitrite by cardiomyocyte mitochondria [64,82]. The impact of ROS on reperfusion injury are
varied and involve triggering: the activity of protein kinases and subsequent pathways, peroxidation of
lipid membranes, apoptosis, and dysfunction in Ca2+ handling [82–84]. Ca2+ handling in reperfusion
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injury is influenced by cytosolic influxes in Na+. Exchange of Na+ for Ca2+ leads to high cytosolic Ca2+,
and the overload of Ca2+ leads to rigor-type contracture of the myocardium. Rigor-type contraction
contributes to the development of myocardial dysfunction. As observed in ischemia, fluctuations in
Ca2+ released from the sarcoplasmic reticulum stimulate the opening of the mPTP [70–72]. Once the
mPTP opens the ionic gradient required for synthesis of ATP rapidly dissipates and water can flood
into mitochondria causing swelling [64] and rupture of the mitochondria which triggers apoptosis [68].
Another critical component of reperfusion injury results from leukocyte trafficking to the
area of injury which occurs shortly after re-establishment of blood flow [64]. Initially, during
reperfusion neutrophils move to areas of ischemia to phagocytose dead tissue, releasing cytokines
to further mediate the immune response [64,85,86]. Factors secreted by neutrophils which include
ROS, cytokines, and chemokines which promote inflammation may also damage previously viable
tissue [68]. Neutrophils obstruct post-capillary venules contributing to microvascular dysfunction [85]
which is thought to mediate no-reflow phenomenon associated with reperfusion injury [68,85,87].
Platelets recruited to sites of injury may also contribute to reperfusion injury and microvascular
dysfunction by secreting vasoactive thromboxane A2 and 5-HT. Infiltrating monocytes to the zone
of infarction further mediate the inflammatory response to ischemia and reperfusion releasing
proteases capable of infarct expansion through proteolysis [68,69,85]. Restoration of flow is required
to re-establish oxygenation, so ways to reduce the attendant inflammatory response constitute a
significant area of interest in improving recovery from acute ischemic injury.
Following MI the most significant predictor the development of HF is infarct size [88] determined
by the death of cardiomyocytes from ischemia or reperfusion injury. Therefore, mitigation of injury size
after MI is of chief concern for patient prognosis [89]. The homogeneous cell death pathways triggered
by MI lead to release of pro-inflammatory cytokines and danger signals [90], which activate the immune
system to respond to the initial cardiac insult clearing the infarcted area of cellular and ECM debris.
The initial injury response gives way to a reparative response partially mediated by TGF-β/Smad
signaling [91,92], culminating in the formation of a non-contractile scar that significantly diminishes
cardiac inotropic capacity and subsequently compromises cardiac output leading to decompensated
HF. A cartoon showing an overview of cellular processes during reperfusion and ensuing injury is
shown in Figure 4.
 
Figure 4. Overview of mechanisms contributing to reperfusion injury. Reperfusion injury results
following revascularization and restoration of blood flow to the ischemic myocardium. As with
ischemic injury intracellular calcium (Ca2+) overload leads to increased myocardial injury through
multiple pathways. Reactive oxygen species (ROS) also contribute to myocardial injury in turn
promoting inflammation and altering mitochondrial function.
238
J. Cardiovasc. Dev. Dis. 2018, 5, 6
5. Inflammation & IL-6 Signaling
Inflammation can be broadly defined as a response to stress or injury by the immune system,
and the inflammatory response results from complex interactions between immune cells such as
leukocytes and molecular mediators such as cytokines and chemokines and the damaged or infected
cell. Inflammation serves as a host defense process that ensures timely and adequate disposal of
dead or dying cells and/or invading pathogens thereby leading to repair of damaged tissues and
paving the way for repair and restoration of tissue and organ function. As discussed, inflammation
plays a crucial role in response to bodily insult and is critical to injury repair, particularly in cardiac
and vascular tissues. However, perturbations in the typical inflammatory response or unresolved or
uncontrolled inflammation plays a pivotal role in the etiology of CVD including but not limited to
atherosclerosis [93], MI [94], I/R injury [68], vasculitis [95], neointimal hyperplasia and restenosis [96],
hypertension [97], and HF [98].
Cytokines serve as essential proteins that play critical roles in cell-cell communication in response
to injury and in the initiation, maintenance, and resolution of inflammation. There is a strong
association with elevated levels of circulating cytokines and CVD. In humans with CAD, it has been
shown that elevated serum concentrations of IL-1β, TNFα, IL-8, and IL-27 are present during events
of unstable angina or are elevated in exacerbations of HF [99,100]. IL-1β and TNFα in addition to
IL-18 are responsible for enhanced surface expression of the selectins VCAM-1 and ICAM-1 [101–103],
which indicate endothelial activation due to inflammation and may play roles in vascular changes
associated with particle exposure and no-reflow phenomenon associated with reperfusion following
ischemia [85,104]. IL-1 family cytokines including IL-18 have also been shown to contribute to LV
dysfunction [105,106]. TNFα is associated with cardio-depression and dysfunction following MI [107].
IL-2 is a pro-inflammatory cytokine key to T cell differentiation, thereby promoting helper Th1 and Th2
while inhibiting Th17 and T follicular helper cells [108]. Infusion of exogenous IL-2 has been shown
to induce heart failure and myocarditis [109,110]. Considering the overall impact on cardiovascular
dysfunction directly attributed to pro-inflammatory cytokines in addition to secondary damage from
leukocyte recruitment, cytokines play key roles in mediating cardiovascular dysfunction and expansion
of cardiac injury.
Interleukin-6 (IL-6) is a pleiotropic cytokine with both pro-inflammatory and anti-inflammatory
properties [111–113]. Increased levels of pro-inflammatory IL-6 are associated with atherosclerosis [93],
vasculitis [114], MI [94] and HF [115]. Despite the apparent connection between IL-6 and CVD, the
IL-6 receptor is only expressed on hepatocytes and in certain leukocytes [116]. The process when IL-6
binds to a membrane-bound IL-6 receptor to induce signal transduction is referred to as classical IL-6
signaling. This limited expression of the IL-6 receptor has traditionally been considered a constraint to
the biological significance of classical IL-6 signaling; however, an alternative mechanism by which IL-6
may act directly on the cells of the cardiovascular system has been identified as IL-6 trans-signaling
and through this mechanism the biological impact of IL-6 processes are significantly expanded.
Interleukin-6 trans-signaling may serve to override negative feedback mechanisms of classical
IL-6 signals in addition to allowing cells without the IL-6 receptor to respond to IL-6. Adding to its
biological impact, IL-6 trans-signaling has been implicated in the pathogenesis of conditions including
atherosclerosis [117], hemorrhagic trauma [118], and inflammation-based CVD [119]. Over the past
decades, much investigation has focused on the role of IL-6 in the pathogenesis of CVD; however,
with the recently discovered soluble IL-6 receptor and its trans-signaling mechanism interest has
returned to investigating IL-6 in CVD. As a result, this review will focus primarily on the roles IL-6
and trans-signaling in the development or abrogation of CVD.
The interplay and balance of several soluble factors modulate the ability of IL-6 trans-signaling
to exert its effects in cardiovascular tissues: a soluble IL-6 receptor (sIL-6R) or soluble glycoprotein
130 (sgp130) act to promote or inhibit IL-6 trans-signaling, respectively. Over time, cardiac injury
induces aberrant increases in IL-6 trans-signaling and in turn, mediates adverse cardiac remodeling
and exacerbation of HF. Inhibition of IL-6 signal transduction with a blocking IL-6 receptor antibody
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in a murine model has been shown to ameliorate left ventricular remodeling following MI [120].
Previous work regarding IL-6 biology has focused specifically on classical IL-6 pathways or has sought
to attenuate the effects of IL-6 signaling indiscriminately by blocking both classical and trans-signaling
through IL-6 receptor blockade. However, this approach neglects the distinct possibility that classical
and trans-signaling may play independent biological roles in the cardiovascular injury response.
A schematic depicting mechanisms of classical IL-6 signal transduction and IL-6 trans-signaling is
shown in Figure 5.
The balance between IL-6 classical and trans-signaling is crucial to physiological function, whereby
they have the capacity to produce divergent effects on inflammation and ensuing pathologies [121].
Both mechanisms of IL-6 signaling activate Janus-Kinase (JAK)/Signal Transducer and Activator of
Transcription (STAT) pathways, which primarily lead to the activation of STAT3 [122], which has been
shown to have cardioprotective effects by acutely promoting cardiomyocyte survival and compensatory
hypertrophy [123]. However, prolonged expression of STAT3 has also been demonstrated to negatively
impact cardiac function following MI [124].
Of interest, IL-6 signaling may further modulate cardiovascular function by mediating, or
getting mediated by, cyclic nucleotide-driven protein kinases. IL-6 signaling has been implicated
in decreased cardiac inotropy in adult rat ventricular myocytes mediated by the cyclic GMP/PKG
pathway via IL-6 transcriptional upregulation of iNOS [125]. Although IL-6 may induce impaired
myocardial function via PKG signals, chronic activation of β-adrenergic receptors, as occurs in HF,
can induce IL-6 expression through cyclic AMP/PKA and the induction of STAT3 through IL-6 may
induce cardiomyocyte hypertrophy [126], thereby implicating IL-6 signaling in the progression to
decompensated HF. However, it remains unclear whether IL-6 classical or trans-signaling is responsible
for these observations.
 
Figure 5. Classical versus interleukin-6/(IL-6) trans-signaling. A simplified schematic depicts
classical IL-6 signaling whereby IL-6 binds to membrane-bound IL-6 receptor (IL-6R) initiating signal
transduction via glycoprotein 130 (GP130) to increase intracellular STAT3 via JAK (A); Alternatively,
in (B) IL-6 trans-signaling occurs whereby IL-6 binds to soluble IL-6 receptor (sIL-6R) which then
complexes to membrane-bound GP130/JAK to initiate STAT3 signal transduction. Inhibition of IL-6
trans-signaling can occur by the decoy soluble GP130 (sGP130) (C).
6. Cardiac Physiology/Pathology & Cyclic Nucleotide-Directed Protein Kinases
The complex processes that lead to the development of CVD and particularly MI, I/R injury, can
to a certain degree be attenuated or exacerbated by the activity of certain cyclic nucleotide-dependent
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protein kinases. One such protein kinase responsible for the mitigation of I/R injury is cyclic
GMP-driven PKG. Ischemia has been demonstrated to modulate intramyocardial levels of cyclic
GMP in multiple animal models, initially increasing cyclic GMP content within the first few minutes of
ischemia [127,128]. Furthermore, experimental models of preconditioning prior to an ischemic episode
have shown increased myocardial cyclic GMP content compared to tissues exposed to ischemia
alone [129]. In the heart, NO is mostly responsible for sGC activation and conversion of GTP
to cyclic GMP and subsequent activation of PKG. Ca2+ homeostasis can be modulated by PKG
interactions with both IP3 receptors [130] as well as with ryanodine receptors (RyR) [131]. Additionally,
Ca2+-sequestering phospholamban can act as a substrate for PKG [132]. Ca2+ handling can also be
modulated by PKG activity via interaction with L-type Ca2+ channels and Ca2+-activated potassium
channels, which can all negatively influence cardiac inotropy and chronotropy in addition to reducing
VSM tone within the coronary circulation. Cardiac inotropy can also be modulated by interactions
of PKG with troponin, thereby decreasing the contractile responsiveness to Ca2+ [79,133]. The ability
of PKG to modulate cardiac ischemia-reperfusion injury through its actions on thromboxane A2
receptor and then to inhibit ensuing signal transduction potentially limits platelet activation and
aggregation through desensitization [80,134,135], which may ultimately attenuate vascular occlusion
due to atherosclerotic rupture or no-reflow phenomenon after reperfusion. Recently and of importance,
Frankenreiter and Lukowski and colleagues reported that cyclic GMP and PKG are able to exert
cardioprotective effects through stimulation of cardiomyocyte-specific big potassium (BK) channels,
demonstrating acute infarct sparring as well as decreased myocardial dysfunction following MI by
cyclic GMP/PKG signals [136].
Another critical cyclic nucleotide-directed pathway involved in cardiovascular physiology
and pathology involves cyclic AMP-stimulated PKA. As described, PKA is activated by cyclic
AMP following its generation from ATP by AC following a variety of mechanisms including
catecholamine-mediated stimulation of β-adrenergic receptors [41]. Similar to PKG, PKA has been
demonstrated to interact with RyR [137] and L-type Ca2+ channels [81,138] to increase cytoplasmic
Ca2+ concentrations thereby stimulating myocardial contraction while also enhancing Ca2+ uptake
via phospholamban and increasing cardiac lusitropy [139]. PKA can increase myocardial contraction
through phosphorylation of cardiac troponin I (cTnI) inducing accelerated cross-bridge cycling
by sensitizing actinomyosin ATPase to Ca2+ [140]. Phosphorylation of cardiac myosin binding
protein (cMyBP) by PKA induces inotropy by modulating the interaction between thick and thin
filaments [141]. Interestingly, hypo-phosphorylation of cMyBP has been demonstrated to be associated
with worsening failure HF in animal models [142,143] and in failing hearts in humans [144]. Like PKG,
the role of PKA in CVD and particularly MI is multifold and can have direct effects on cardiac
function and injury as well as indirect effects that can modulate injury and function which, in
many cases, overlap with PKG signaling in apparently antagonistic fashion. While NO ultimately
activates downstream PKG and is responsible for decreasing cardiac inotropy, lusitropy, chronopropy,
dromotropy, and automaticity, the actions of PKA generally promote cardiac inotropy, lusitropy,
chronopropy, dromotropy, and automaticity.
7. G Protein-Coupled Receptor Signaling
The family of GPCRs constitutes the broadest and most diverse group of membrane receptors
identified in the human genome that has the capacity to control a myriad of cellular functions.
The receptor is integrated into the plasma membrane by seven transmembrane loops, and upon
binding of an extracellular agonist a conformational change in the receptor occurs. The cytoplasmic
carboxyl tail of the receptor interacts with nearby heterotrimeric (α, β, γ) G proteins, GDP (bound to
Gα) is replaced by GTP (which activates stimulatory Gαs), the β and γ subunits dissociate (remaining
as a dimer), and intracellular signaling ensues via Gαs-GTP, other Gα subunits, and Gβγ [145].
Both activated Gα subunits and the βγ dimer can interact with numerous membrane proteins to
induce broad and diverse signal transduction processes. In fact, activation of a single GPCR can
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provoke thousands of downstream second messenger signals including commonly AC-mediated
cyclic AMP, diacylglycerol and IP3, and intracellular Ca2+. In opposition to activation by Gαs-GTP,
stimulation of the inhibitory subunit (i/o) of Gα results in inhibition of AC and reduction of cyclic
AMP synthesis and downstream PKA signaling [3,7,145]. This complex and highly regulated signal
transduction system affords GPCRs the control of innumerable cardiovascular functions and makes
GPCRs a critically important target for modern medicinal drugs [146–151].
A unique family of acidosis/pH-sensing heterotrimeric GPCRs has been identified and
characterized as extracellular proton sensors and is comprised of G protein-coupled receptor 4 (GPR4),
T cell death-associated gene 8 (TDAG8 or GPR65), ovarian cancer G protein-coupled receptor 1 (OGR1
or GPR68), and G protein-coupled receptor G2 accumulation (G2A or GPR132) [152–158]. This family
of GPCRs are activated via acidic protonation of histidine residues on the extracellular amino binding
domain and signal predominantly through the intracellular subunits Gαs (AC/cyclic AMP stimulation),
Gαq/11 (PLC/DAG/IP3 and Ca2+ stimulation), Gα12/13 (RhoGEFs/RhoA/Ras stimulation), as well
as through the Gβγ subunit (PI3K, GRKs, PLC and Ca2+ stimulation) [157]. Obviously, these GPCRs
then have the capacity to moderate broad downstream kinases including PKA and PKC as well as
MAPKs/ERKs. Cardiovascular tissues and inflammatory cells including leukocytes contain all of these
pH-sensing GPCRs, yet interestingly, VECs predominantly express GPR4 [152,158–160] while VSM
and cardiomyocytes largely express GPR68 [155,157,161].
During deleterious conditions as found in CVD and other disorders, dysregulated and largely
glycolytic anaerobic cellular metabolism occurs which, along with impaired blood perfusion and
several other processes, causes acidic byproducts to accumulate, in turn acidifying the local tissue
microenvironment. Considering that acidosis is a strong cellular stressor, redundant modes exist for
the sensing of extracellular acidosis and the facilitation of downstream signaling and modulation of
cellular responses. While it has been theorized that acid-sensing GPCRs may play key roles in the
detection of extracellular acidosis and/or in the development or maintenance of cardiovascular
pathologies, fundamental mechanisms responsible for the ability of these important GPCRs to
moderate cardiovascular dysfunction and their potential interaction with cyclic nucleotide-dependent
protein kinases remain to be fully elucidated. Recent work in human umbilical vein endothelial
cells (HUVECs) and lung microvascular and pulmonary VECs showed that isocapnia (as found in
metabolic acidosis) or hypercapnia (such as respiratory acidosis) independently activate GPR4 to
induce broad inflammation characterized by significant upregulation of pro-inflammatory genes
including members of the CXC and CCL families of cytokines and chemokines, vascular cell adhesion
molecules E-selectin, VCAM1 and ICAM1, members of the TNF and NF-κB signaling systems,
elements in the prostaglandin-endoperoxidase synthase family, and transcription factor early growth
and stress response genes [159,160]. Using Gene Ontology (GO) Enrichment with the GATHER
systems approach [162], the families of acid/GPR4-induced genes correlate with immune, defense
and inflammatory responses, consistent with the induction of the inflammatory response through
acidosis and GPR4 [160]. It has also been determined that acidic pH induces gene expression of
the vascular cell adhesion molecules E-selectin, VCAM1 and ICAM1 and that it does so in cyclic
AMP/GPR4-dependent fashion [152,157,159,160]. Complementing these observations, additional work
by Yang and colleagues [159,160] showed that acidosis and GPR4, alone or in synergy, significantly
increase adhesiveness of monocytes to a confluent VEC monolayer and that this occurs under both
static [159] and flow [160] conditions.
Complementing these pro-inflammatory, adhesive characteristics of GPR4, in the original report
on GPR68 in human VSMCs [163], acidic pH was found to markedly elevate cyclic AMP (likely
occurring via Gαs/Gαq/11) and to increase intracellular Ca2+ and prostacyclin production at an
acute time point. In another study the long-term effects of extracellular acidification on GPR68
signals in human VSMCs were examined and the authors observed ability of acidic pH to induce
COX-2 signaling, prostacyclin production, MAPK phosphatase, and plasminogen activator inhibitor
(PAI-1) [161]; however, many of these results including the observation that acidic pH inhibits cell
242
J. Cardiovasc. Dev. Dis. 2018, 5, 6
proliferation were believed to be independent of GPR68 [161]. In line with this theory, acidification
has, in general, been reported to influence VSM-mediated vessel dilation and growth [164,165], yet
comprehensive documentation of precise involvement of GPR68 (or other pH-sensing GPCRs) in the
VSM response to acidosis and/or in pathologic vascular growth is lacking.
The potential role of acidosis/pH-sensing heterotrimeric GPCRs in cardiac disease and
dysfunction is emerging. Acidosis is a critical byproduct of many cardiac disease states including
ischemia and therefore may be a potential target for the treatment of cardiac disorders. Although GPR4
and GPR68 have been identified primarily in VECs and VSMCs, respectively, whether or not these
GPCRs are localized to cardiomyocytes remains unclear. Recent investigations have indicated that
experimental MI in a murine model results in greatly increased GPR68 expression in cardiomyocytes
within the border zone of the infarcted region 7 days following occlusion [166]. These results concur
with preliminary experiments in our own lab that show significant (p < 0.05) upregulation of GPR68
protein expression (normalized to total protein; n = 4/group) in mouse cardiac homogenates subjected
to a 24 h permanent coronary artery ligation compared to naïve control homogenates (data not shown).
It is interesting to note that we have not observed upregulation of GPR68 when myocardial ischemia
and acidosis has been corrected by reperfusion (I/R; data not shown). Furthermore Russell et al.,
provided data suggesting that activation of GPR68 following ischemia was responsible for the
upregulation of pro-survival and cardioprotective pathways [166]. GPR4 has also been implicated in
mediating outcomes following MI, whereby antagonization of GPR4 was able to completely reduce
28-day mortality following a permanent coronary artery occlusion compared to vehicle controls [167].
Despite both GPR4 and GPR68 having apparent roles in the pathophysiology of cardiac ischemia, it
may be that they have opposing roles in cardiomyocytes in the presence of ischemic insult. Of course,
it is also possible that in the case of GPR4, there may be no direct effect on cardiomyocytes and the
observed reduction in mortality observed following inhibition of GPR4 was due to primary effects on
VECs within cardiac circulation and a decreased VEC-mediated inflammatory response. The role of
acidosis/pH-sensing heterotrimeric GPCRs in cardiac ischemia with the gold standard therapeutic,
reperfusion, has yet to be thoroughly investigated and poses additional questions to how to modulate
pH-sensing GPCRs in the treatment of cardiac disease.
Another GPCR family that has the capacity to exert significant biological effects on cardiac
and vascular tissues and that are dependent in part on cyclic nucleotide-driven protein kinases are
the protease-activated receptors (PARs). Extracellular serine proteases serve pivotal roles in many
aspects of cardiovascular homeostasis and physiology yet are also involved in the pathogenesis
of cardiac and vascular disorders largely through activation of their respective PARs [168,169].
PARs are proteolytically cleaved and activated by these proteases, thereby revealing a new
amino-terminus which acts as an intramolecular ligand leading to sustained receptor activation [170].
Following activation, PARs can be rapidly down-regulated by β-arrestin-mediated desensitization and
endocytosis followed by lysosomal targeting and degradation [168–170]. PARs are normally expressed
abundantly in platelets and in relatively low levels in VECs and VSMCs and in cardiac myocytes and
fibroblasts [168,171,172]. In VECs PARs operate to regulate vascular tone via induction of NO release
and subsequent sGC activation and cyclic GMP/PKG induction [168,173], and in stimulated VSM PARs
mediate contraction, migration, proliferation, hypertrophy and ECM production which contribute to
the development of vascular lesions and CVD pathogenesis [173–175]. Increasing evidence [168,175]
supports involvement of PARs in CVD pathophysiology yet their discrete mechanisms have yet to
be solidified.
To date four PAR family members have been identified: PAR1, PAR3 and PAR4 are cleaved and
activated predominantly by thrombin whereas PAR2 is activated primarily by trypsin and mast
cell tryptase [176]. Of these PARs, PAR1 was the first discovered [168] and has since been the
most investigated. Early studies identified a role for PAR1 in regulating platelet activation as an
underpinning of thrombosis, in turn leading to the creation of Vorapaxar (SCH530348), a selective,
competitive antagonist of PAR1. Vorapaxar received FDA approval in 2014 after the Thrombin-Receptor
243
J. Cardiovasc. Dev. Dis. 2018, 5, 6
Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events trial (TRA 2◦P-TIMI 50)
found it to significantly reduce secondary ischemic events compared to placebo controls [177]. In rat
VSMCs, PAR1 was shown to be induced following balloon catheter-induced injury [178] and to be
upregulated in a hypertensive model [179]. While PAR1 has been more extensively researched as
a key player in cardiovascular pathology, recent evidence that PAR2 also plays a regulatory role.
PAR2 has been implicated in mediating inflammatory changes in human VSMCs via interaction
with soluble dipeptidyl peptidase 4 (DPP4), a ubiquitously expressed cell-surface protease [172], and
apolipoprotein E/PAR2 double knockout mice demonstrated significant decreases in atherosclerotic
lesion development and aortic inflammatory cytokine release compared to wild-type controls [180].
Preliminary data generated in our lab show upregulation of both PAR2 and PAR4 protein expression
as well as phosphorylated Erk1/2 as an indicator of PAR activity in balloon-injured rat carotid arteries
compared to uninjured arteries 30 post-injury (data not shown), and in cultured VSMCs activation
of PAR2 or PAR4 show co-dependency following pharmacologic activation or inhibition (data not
shown). Indeed, the central role of serine proteases and PARs in cardiac and vascular physiology and
pathology warrants continued study as plausible clinical targets against CVD.
Regarding mechanisms of cellular signaling, PARs primarily operate via Gαi/o (to inhibit AC and
cyclic AMP synthesis), through Gα12/13 (to activate RhoGEFS/RhoA/Ras) and via Gαq/11 (to moderate
PLC/IP3/DAG and Ca2+ signaling), as well as through dissociated Gβγ (to induce PI3K, GRKs,
PLC and Ca2+ signaling). These processes then lead to modulation of PKA, PKC and MAPK/ERK
pathways, in turn eventuating in the regulation of inflammation- and growth-specific functional
processes. A schematic depicting a generic pH-sensing GPCR and PAR as well as some of their
activated effectors is shown in Figure 6.
Figure 6. Generalized G protein-coupled receptors: pH-sensing and protease-activated receptors.
A schematic depicting a typical pH-sensing GPCR and a protease-activated receptor (PAR) GPCR
under non-activated conditions. Both GPCRs are 7 trans-membrane receptors with an extracellular
amino terminus and an intracellular carboxyl end associated with G protein subunits. Activation of the
pH-sensing GPCR involves extracellular amino terminal histidine sensing of acidic protons (H+) while
PAR activation involves cleavage of the extracellular amino terminus by serine proteases, thrombin,
trypsin and other agonists and creation of an activating tethered ligand. These GPCRs then stimulate a
cascade of G protein-mediated intracellular signals that have the capacity to govern a wide array of
inflammation- and growth-regulatory processes in cardiac and vascular tissues.
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8. TGF-β/Smad Signaling
The TGF-β superfamily of growth factors are multifunctional cytokines responsible for regulating
key developmental and homeostatic cellular functions such as proliferation, differentiation, recognition,
apoptosis, adhesion, and migration and have become of major scientific focus over the past several
decades [181]. TGF-β can exert its actions in context-specific fashion, sometimes showing different
and even opposite effects in varying cell types and environments. Even though non-Smad pathways
exist, one primary route through which TGF-β exerts its functions is through the recruitment and
phosphorylation of intracellular Smad proteins [181].
In short, TGF-β-dependent Smad signaling is initiated by binding of a TGF-β ligand (existing
in three isoforms: TGF-β1, β2, or β3) to a TGF-β type II receptor (TβR-II), thereby causing a
TGF-β type I receptor (TβR-I) to co-localize with the TβR-II. While both receptors contain an
intracellular Ser/Thr kinase domain, the kinase domain of TβR-II is constitutively active and its
phosphorylation is independent of ligand binding. Once the two receptors become associated, the
kinase domain of TβR-II phosphorylates the kinase domain of TβR-I and subsequently transmits
the signal through phosphorylation of intracellular Smad [182–184]. There are 8 members within the
Smad family of proteins that are divided into 3 distinct groups: receptor-regulated Smads (R-Smads),
common-mediator Smad (Co-Smad), and inhibitory Smads (I-Smads). The R-Smads (Smads1, 2, 3, 5,
and 8, with Smads2 and 3 of primary interest in cardiovascular tissues) are directly phosphorylated by
TβR-I and bind with the Co-Smad4 to form a heteromeric complex that can then travel to the nucleus
to act as a transcription factor. This process is negatively regulated by inhibitory Smad6 and Smad7
through competing with R-Smads for TβR-I, interacting with Co-Smad4, and/or by initiating the
degradation of TGF-β receptors [181].
Recent studies have shown that a correlation exists between the activation of synthetic and
growth-promoting TGF-β1, the most abundant and important isoform in the cardiovascular system,
and the pathology of CVD [185,186]. Cell-to-cell adhesion through components of the ECM is
required for normal growth conditions; however, these adhesive interactions have also been linked
to CVD pathogenesis. TGF-β1 is thought to synthesize ECM elements through a Smad3-dependent
pathway [187–189]. Considering this correlation between TGF-β1 and CVD, studying its regulation
and mechanistic effects on cell proliferation and migration could prove beneficial in combatting
CVD pathologies. Past studies involving TGF-β1-directed Smad3 have shown conflicting effects of
Smad3, reportedly switching between pro-growth and anti-growth phenotypes depending cell type,
concentration, and density [190,191].
The impact of TGF-β signaling on cellular dynamics have been shown at least in part to
be regulated by cyclic nucleotide-directed protein kinases. A recent study in fibroblasts showed
that pretreatment with cyclic GMP in the presence of TGF-β significantly reduced the amount of
phosphorylated Smad3 translocated into the nucleus, in turn limiting its transcriptional capacity [192].
A similar result occurred in pulmonary artery VSMCs where translocation of phosphorylated Smad3
into the nucleus was inhibited by the sequestering of phosphorylated Smad3 to cytosolic β2-tubulin
via actions of cyclic GMP-directed PKG [193]. Additionally in this study, treatment with a PDE5 led to
an increase in the bioavailability of cyclic GMP/PKG and enhanced its inhibition of Smad3 signaling.
Following PDE5 inhibition in cells that were pretreated with TGF-β, fibroblast proliferation and
alpha smooth muscle actin (α-SMA) were markedly reduced compared to TGF-β only treatment [194].
These findings indicate that cyclic GMP/PKG act to limit the effects of TGF-β signaling by diverting
phosphorylated Smad3 away from the nucleus so that it can no longer act, along with Smad2
and Smad4, as a transcription factor and offer support for cyclic GMP/PKG as a transcriptional
regulator of Smad-dependent signal transduction. Figure 7 shows a cartoon of TGF-β/Smad signaling
and transcriptional control along with depiction of PKG-mediated cytosolic retention of Smad and
suppression of these processes.
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Figure 7. Schematic of transforming growth factor-β (TGF-β) signaling. Binding of an active TGF-β
ligand initiates the co-localization of the type II (TβR-II) and type I (TβR-I) TGF-β receptors. The TβR-II
remains constitutively phosphorylated and when co-localized phosphorylates the Ser/Thr kinase
domain (KD) of the TβR-I. The intracellular signal is subsequently transmitted by phosphorylation
of Smad proteins, primarily Smad2/3 in cardiovascular tissues. The phosphorylated Smad proteins
combine with Smad4, a common Smad, to form a heterotrimeric complex that can then be shuttled
through the nuclear membrane ultimately acting as a transcription factor for inflammatory, synthetic,
and growth-promoting genes. The cyclic GMP/PKG system is known to inhibit this pathway by
sequestering p-Smad in the cytosol, in turn not allowing it to be shuttled into the nucleus and affect
gene transcription.
9. FoxO Transcriptional Signaling
A subgroup of the Forkhead family of transcription factors, Forkhead box O (FoxO) proteins,
are characterized by their DNA-binding domain consisting of three α-helices and two loops
resembling a butterfly wing motif [195]. Only four mammalian FoxO members are currently
known, FoxO1, 3, 4, and 6, and these have been implicated in various cellular processes
including cell-cycle regulation, differentiation, apoptosis, and oxidative stress response [196–199].
FoxO transcription factors are tightly regulated by Akt-mediated phosphorylation via the insulin-like
growth factor-1 (IGF-1)/phosphatidylinositol-3-kinase (PI3K)/Akt pathway at three conserved amino
acid residues [200]. Phosphorylation of FoxO can cause both retention in the cytoplasm or translocation
from the nucleus into the cytoplasm, both processes inhibiting it from influencing transcriptional gene
regulation and targeting it for degradation [201].
As previously described, VSMC migration and proliferation are key cellular components of CVD.
Over the past decades, the impact of FoxO members on cellular dynamics has been studied in relation
to CVD pathogenesis. FoxO3a has been implicated in CVD pathology yet the mechanism through
which FoxO3 may exacerbate or ameliorate CVD is currently unknown. FoxO3 has been proposed
to modulate cell proliferation and cell death pathways [202–204]. Overexpression of FoxO3a was
shown to increase gene expression of the cell cycle-dependent kinase inhibitor (CdkI) p27 (Kip1),
resulting in cell cycle arrest and attenuation of growth in VSMCs and muscle precursor cells [205,206].
Furthermore, cysteine-rich angiogenic protein 61 (Cyr61), a gene expressed immediately following
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growth factor stimulation, was inhibited by binding of FoxO3 at the Cyr61 promoter region, illustrating
another mechanism by which FoxO3 inhibits vascular cell growth [207].
It has been theorized that a dynamic relationship exists between Smad3 and FoxO3 transcription
factors. The gene expression of muscle-specific RING finger-1 (MuRF-1), a ubiquitin ligase, was altered
by the levels of FoxO3 and/or Smad3 expression [208]. Smad3 binding to the promoter region of
MuRF-1 was shown to increase the abundance of FoxO3 bound to that same promoter region and
necessary for optimal FoxO3-induced MuRF-1 gene transcription. Additionally, overexpression of
Smad3 increased FoxO3 protein abundance and a synergistic effect was observed on FoxO-induced
transcription with co-expression of these transcription factors [208]. In endothelial cells, FoxO and
Smad synergistically induced expression of the CdkIs p15Ink4b and p21Cip1 [209,210]. Considering
both Smad3 and FoxO transcription factors are implicated in the pathogenesis of CVD, further studies
aimed at elucidating Smad3/FoxO3 interactions in VSM could prove beneficial in combatting the
etiologies associated with CVD.
While the relationship between elements in FoxO signaling and cyclic nucleotide-directed protein
kinases has not been thoroughly investigated, FoxO proteins have been associated with the ability of
NO to modulate proliferation and migration in damaged VECs [211]. NO-induced inhibition of cell
growth occurs through cyclic GMP and PKG, leading to activation of the PI3K/Atk pathway [212,213].
As a result, FoxO, a downstream phosphorylation target of activated PI3K/Atk, is either maintained
in the cytoplasm or, if nuclear, is shuttled into the cytoplasm, in turn targeting it for degradation
and preventing its growth-inhibitory, cytostatic effects. Further investigation into the regulation of
FoxO proteins, their relationship with growth-promoting synthetic Smads, and their control by cyclic
nucleotide-driven protein kinases is necessary to understand the mechanisms underlying growth
pathologies in cardiovascular tissues.
10. Summary & Future Directions
Despite ample basic science and translational investigation, CVD remains the major cause of
morbidity and mortality in the United States and worldwide, and all estimates suggest an increasing
trend in their prevalence over the next several decades. While some authorities suggest that many
of the causes behind CVD are preventable, cumulative efforts must continue in order to gain a more
thorough understanding of the key elements that serve as the basis for CVD. Only through these
endeavors can we hope to better understand crucial aspects of cardiac and vascular pathologies with
the aim of expanding our clinical knowledge and therapeutic efficacy. The cyclic nucleotide-driven
protein kinase systems represent wide-ranging and multi-functional processes capable of controlling
many mechanisms underlying CVD and can serve as current and emerging targets for intervention.
Only through expanded knowledge of these many facets of cyclic nucleotide-driven protein kinases
and their diverse downstream effectors including their promiscuous ‘associated kinases’ can we
advance our control of these dreaded diseases. In this light, future efforts should be aimed at more
completely establishing cyclic nucleotide-driven protein kinases as a therapeutic target to combat and
perhaps eliminate CVD, possibly through genetic manipulation/editing or transcriptional control
(i.e., Smad/FoxO) of inflammatory/synthetic/growth elements, with pre- and/or post-conditioning
interventions [201], or via personalized or precision medicine approaches [3].
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Abstract: Cyclic GMP regulates multiple cell types and functions of the cardiovascular system.
This review summarizes the effects of cGMP on the growth and survival of vascular smooth
muscle cells (VSMCs), which display remarkable phenotypic plasticity during the development
of vascular diseases, such as atherosclerosis. Recent studies have shown that VSMCs contribute
to the development of atherosclerotic plaques by clonal expansion and transdifferentiation to
macrophage-like cells. VSMCs express a variety of cGMP generators and effectors, including
NO-sensitive guanylyl cyclase (NO-GC) and cGMP-dependent protein kinase type I (cGKI),
respectively. According to the traditional view, cGMP inhibits VSMC proliferation, but this concept
has been challenged by recent findings supporting a stimulatory effect of the NO-cGMP-cGKI axis on
VSMC growth. Here, we summarize the relevant studies with a focus on VSMC growth regulation by
the NO-cGMP-cGKI pathway in cultured VSMCs and mouse models of atherosclerosis, restenosis,
and angiogenesis. We discuss potential reasons for inconsistent results, such as the use of genetic
versus pharmacological approaches and primary versus subcultured cells. We also explore how
modern methods for cGMP imaging and cell tracking could help to improve our understanding
of cGMP’s role in vascular plasticity. We present a revised model proposing that cGMP promotes
phenotypic switching of contractile VSMCs to VSMC-derived plaque cells in atherosclerotic lesions.
Regulation of vascular remodeling by cGMP is not only an interesting new therapeutic strategy,
but could also result in side effects of clinically used cGMP-elevating drugs.
Keywords: cyclic guanosine 3′-5′ monophosphate; nitric oxide; vascular smooth muscle cells;
cGMP-dependent protein kinase type I; atherosclerosis; cell plasticity; transdifferentiation; cell
fate mapping; imaging
1. Introduction
Cyclic guanosine 3′-5′ monophosphate (cGMP) is a versatile intracellular signaling molecule
present in many cell types. It controls numerous physiological processes, from cell contractility,
secretion, and permeability to cell differentiation, growth, and survival [1,2]. In mammals, two types
of guanylyl cyclases (GCs) have been identified that can generate cGMP from GTP: intracellular
NO-sensitive GCs (“soluble” GCs or NO-GCs) [3] and transmembrane GCs (“particulate” GCs or
pGCs), such as GC-A, GC-B, and GC-C [4]. The activity of NO-GC is stimulated by the gaseous
signaling molecule NO, which is generated by NO synthases (NOSs) [5]. Several pGCs are receptors for
peptide hormones. GC-A binds atrial and B-type natriuretic peptide (ANP, BNP), GC-B binds C-type
natriuretic peptide (CNP), and GC-C is stimulated by guanylin and uroguanylin [4]. Levels of cGMP are
also controlled by cGMP-hydrolyzing phosphodiesterases (PDEs), such as PDE5. The effects of cGMP
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are mediated by its binding to three classes of cGMP effector proteins: cyclic nucleotide-gated (CNG)
cation channels, cGMP-dependent protein kinases (cGKs, also known as PKGs), and cGMP-regulated
PDEs [6–8]. While CNG channels play a more restricted role in the sensory system, many tissues and
cell types express PDEs and cGKs.
Cardiovascular diseases are frequently linked to dysfunctions in vascular smooth muscle cells
(VSMCs). VSMCs express various components of the cGMP signaling cascade [3,4,9]. They can
generate cGMP in response to NO and natriuretic peptides via NO-GCs and pGCs, respectively,
and they express PDEs that degrade cGMP (e.g., PDE5) or cAMP (e.g., PDE3). An interesting aspect
is that cAMP hydrolysis by PDE3 is inhibited in the presence of high concentrations of cGMP [7,10].
This inhibition of PDE3 enables crosstalk between cGMP and cAMP signaling in VSMCs in that an
increase of cGMP can also result in an elevation of cAMP. A major cGMP effector in VSMCs is cGK
type I (cGKI, also known as PKG1), which is encoded by the prkg1 gene and belongs to the Ser/Thr
protein kinase family. cGKI comprises an N-terminal regulatory domain with two cGMP-binding
sites and a C-terminal catalytic domain. Two cGKI isoforms are known, cGKIα and cGKIβ, and both
are expressed in VSMCs. However, whether cGKIα and cGKIβ have specific functions in vivo is not
clear [11,12].
In vascular biology, the classical effects of NO and natriuretic peptides are vasodilation and
regulation of blood flow. It is well-accepted that these acute effects are beneficial and mediated by
activation of GCs and the cGMP-cGKI pathway in VSMCs [8,9]. NO and natriuretic peptides also have
long-term effects on vascular diseases, such as atherosclerosis and restenosis. However, as previously
summarized by us [13] and others [14,15], it is still debated whether the cGMP-cGKI axis is involved
and, if so, whether it has a positive or negative impact on vascular remodeling and disease. In this
review, we will focus on recent in vivo studies that identified a previously unknown form of VSMC
plasticity in the context of atherosclerosis and indicate a stimulatory role of the NO-cGMP-cGKI
pathway on the growth/survival and phenotypic switching of VSMCs in atherosclerotic plaques.
We will also discuss potential reasons for the apparent discrepancy of these studies with a number
of studies that reported an anti-proliferative effect of NO, cGMP, or cGKI in VSMCs. Furthermore,
we will outline how the use of innovative technologies, such as cGMP imaging and cell tracking, could
help to further clarify the role of cGMP in vascular plasticity in the future.
2. Role of VSMCs in Physiology and Pathophysiology
2.1. Vasodilation via the NO-cGMP-cGKI Pathway
VSMCs are contractile cells that regulate blood flow and their abnormalities contribute to a range
of diseases [16]. Numerous studies have demonstrated that activation of the cGMP-cGKI axis in
VSMCs leads to vasodilation [9]. The canonical NO-cGMP-cGKI pathway for vasodilation is depicted
in Figure 1a. It comprises generation of NO in the endothelium via endothelial NOS (eNOS) followed
by diffusion of NO into VSMCs in the vascular media, where NO-GC is stimulated to generate cGMP.
The increased cGMP concentration activates cGKI, which triggers relaxation of VSMCs, likely by
phosphorylating several substrate proteins, whose identity has not been completely established [8,11].
Note that vascular NO can also be derived from non-endothelial sources, such as neuronal NOS
(nNOS) in neurons or inducible NOS (iNOS) in inflammatory cells [5]. It is generally assumed that
activation of the cGMP pathway also dilates resistance-type blood vessels and, thus, lowers blood
pressure. Indeed, mouse mutants with impaired NO-GC activity show an elevated basal blood
pressure [17–20]. In contrast, the analysis of cGKI knockout mice indicated that cGKI is not required for
basal blood pressure homeostasis, but mediates blood pressure drops in response to the administration
of NO-releasing drugs [21,22]. These findings suggest that NO-GC-derived cGMP regulates blood
pressure, but the contribution of the cGMP-cGKI downstream pathway to endogenous mechanisms
that control blood pressure under basal conditions is probably less important than previously thought.
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Figure 1. cGMP signaling and vascular smooth muscle cell (VSMC) plasticity. (a) The canonical
NO-cGMP-cGKI pathway in the vessel wall; (b) Concept of VSMC plasticity and (c) VSMC-derived
cells and VSMC transdifferentiation in atherosclerotic plaques and potential role of cGMP. Note that
monocyte-derived macrophages and other plaque cells are not shown. For further explanations,
see main text. eNOS, endothelial NO synthase; iNOS, inducible NO synthase; nNOS, neuronal
NO synthase.
2.2. VSMCs in Vascular Diseases
In addition to blood flow regulation, VSMCs are involved in vascular remodeling during
vascular diseases, such as atherosclerosis and restenosis. “Contractile” VSMCs with low proliferative
activity and abundant contractile protein expression adapt to the disease situation by changing
to highly proliferative “synthetic” cells that have low contractility and produce large amounts of
extracellular matrix [23] (Figure 1b). Thus, VSMCs display a remarkable ability to modulate their
phenotype in response to changing internal and external stimuli in the context of vascular disease,
a process also referred to as phenotypic plasticity. Before discussing the effects of cGMP signaling on
vascular plasticity and disease, we will briefly outline the general role of VSMCs in atherosclerosis
and restenosis.
2.2.1. Atherosclerosis
Atherosclerosis leads to myocardial infarction and stroke and is the major cause of death in
the western world. It is a chronic inflammatory condition that results from complex interactions of
modified lipoproteins and various cell types, including monocyte-derived macrophages and cells of the
vessel wall [24–26]. How each particular cell type contributes to the development of an atherosclerotic
lesion is not completely understood [27–30]. One unsolved issue is the role of mature VSMCs that
reside in the vascular media [31,32]. It is well-known that medial VSMCs generate VSMCs that retain
contractile protein expression and cover the plaque on its luminal side forming the so-called fibrous
cap (Figure 1c). Fibrous cap VSMCs are thought to stabilize the plaque by synthesis of extracellular
matrix proteins and, thus, to be beneficial. On the other hand, it was a long-standing matter of debate
whether medial VSMCs also contribute to the makeup of the plaque core region, which was assumed
to contain mainly monocyte-derived lipid-loaded macrophages, also known as foam cells [33]. Fifteen
years ago, we established a Cre/lox-based genetic inducible fate mapping system to track medial
VSMCs during atherogenesis in mice. Surprisingly, our initial lineage tracing studies identified a large
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number of VSMC-derived cells in the core region of atherosclerotic plaques [34,35] and some of them
were positively stained for the macrophage marker Mac-2 [34]. These in vivo findings were also
consistent with data from cultured VSMCs [36] and led us to put forward the hypothesis that VSMCs
can transdifferentiate to macrophage-like cells during atherogenesis [34]. In line with our hypothesis,
immunostainings of human plaque sections revealed that some intimal cells co-express markers of
smooth muscle cells and macrophages, suggesting the existence of a VSMC–macrophage chimeric
cell type in human lesions [37,38]. In 2014, we could indeed demonstrate by definitive lineage tracing
and co-staining of VSMC-derived plaque cells with smooth muscle and macrophage markers that
medial VSMCs can undergo clonal expansion and convert to macrophage-like cells that have lost
classic smooth muscle marker expression and make up a major component of advanced atherosclerotic
lesions [39]. This study, as well as the results of other groups that have used similar experimental
approaches and reached similar conclusions [40–43], provide strong in vivo evidence for a major role
of VSMC plasticity in atherosclerosis and call for a revised look at the pathogenesis of this devastating
disease [33,44]. According to the new model, mature VSMCs that are present in the media of the
non-atherosclerotic vessel wall possess the potential to become activated during plaque development
and transdifferentiate to macrophage-like cells and perhaps also to other cells that reside within the
lesion and have lost expression of VSMC markers (Figure 1c). Interestingly, the VSMC-derived plaque
cells have a clonal origin in the vascular media and can make up a major fraction of the intimal
cells [39,42,43]. It is likely that previous studies that were based on immunostaining of plaque cells for
smooth muscle markers have vastly underestimated the role of VSMC plasticity in atherosclerosis.
2.2.2. Restenosis
Advanced atherosclerotic lesions or plaque rupture can result in occlusion of blood vessels and
severe restriction of blood flow [26]. The common approach to restore blood flow in these stenotic
vessels is balloon angioplasty or the use of vascular stents. However, these intra-arterial interventions
may disrupt normal blood vessel integrity and lead to a long-term risk of restenosis, i.e., the remodeling
and eventual re-occlusion of treated arteries. Restenosis is characterized by the formation of a so-called
neointima that consists mainly of VSMCs. The exact mechanism of restenosis is still unclear. It involves
an inflammatory response and activation of quiescent medial VSMCs with subsequent proliferation
and extracellular matrix deposition, thereby forming a neointima [45]. Recent lineage tracing data
showed that, similar to atherosclerosis, the neointima is formed by clonal expansion of a small number
of medial VSMCs. However, in contrast to the core of atherosclerotic lesions, VSMCs in the neointima
exist in a largely contractile and smooth muscle marker-positive state [42]. These findings suggest that
neointimal VSMCs may resemble the phenotype of fibrous cap VSMCs in plaques and that the extent
of VSMC transdifferentiation is less pronounced in restenosis than in atherosclerosis.
Taken together, vascular remodeling in atherosclerosis and restenosis shows interesting similarities
and differences with respect to the behavior of VSMCs. While clonal VSMC expansion is involved
in both diseases, VSMC transdifferentiation to other cell types seems to contribute to the formation
of atherosclerotic lesions, but not neointima, in the setting of restenosis. Considering the crucial role
of VSMC phenotypic plasticity in these vascular diseases, a better understanding of the underlying
signaling mechanisms will help to develop novel therapeutic approaches. As discussed in the following
sections, shifting the VSMC phenotype from potentially detrimental macrophage-like cells to beneficial
fibrous cap cells with drugs that target the NO-cGMP-cGKI signaling pathway in VSMCs could be
a novel strategy to treat atherosclerosis.
3. cGMP and VSMC Plasticity in Cell Culture
It has long been known that VSMCs grown in vitro lose properties associated with the contractile
phenotype (e.g., expression of contractile proteins) and gain “synthetic” features (e.g., proliferation and
extensive synthesis of extracellular matrix) [46,47] (Figure 1b). This process is called phenotypic switching
or modulation and takes place already during primary culture (e.g., in cells isolated from the aorta, plated
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on plastic dishes, and grown for 3–7 days) and is further enhanced by subculturing (passaging) of primary
VSMCs [48]. Under certain conditions, the loss of contractile marker proteins can be accompanied by
expression of marker proteins for other cell types. For instance, after cholesterol loading, cultured VSMCs
can modulate to macrophage-like cells [36,49]. Thus, cultured VSMCs appear to provide a useful cell
model to study VSMC plasticity, including the process of VSMC-to-macrophage transdifferentiation.
Studies with cultured VSMCs have linked components of the cGMP signaling pathway to VSMC
proliferation and marker protein expression, indicating a role of cGMP in phenotypic switching of
VSMCs. In particular, the mechanism and therapeutic relevance of cGMP-regulated VSMC plasticity via
the NO-cGMP-cGKI axis has been intensively investigated over the past few decades [9,13,15,35,50–52].
However, it is still debated if stimulation of this cascade inhibits or promotes the growth of VSMCs. In this
section, we will summarize previous data obtained with cultured VSMCs and provide explanations for
the seemingly contradicting results.
A general problem in cGMP research is the lack of highly specific activators and inhibitors of
pathway components, in particular for use in experiments with intact cells [53]. Many studies with
VSMCs applied cGKI activators and inhibitors, but few of them determined the actual efficiency and
specificity of the compounds used in the respective experiments. For instance, “cGKI-specific” cGMP
analogues may have effects independent of cGKI [54,55]. KT5823, which was frequently used as
cGKI-specific inhibitor, might stimulate rather than inhibit cGKI in intact cells [56]; Rp-PET-8-Br-cGMP,
which is considered one of the most permeable, selective, and potent cGKI inhibitors, was demonstrated
to be a partial agonist of cGKIα rather than an antagonist [57]; and another frequently used cGKI
inhibitor, DT-2, was shown to lose its specificity in intact cells [58]. One way to tackle the problems
associated with the pharmacological manipulation of cGMP signaling in VSMCs is to combine these
tools with genetic deletion or RNA knockdown models of the NO-cGMP-cGKI pathway.
Data obtained with subcultured VSMCs indicated that activation of the NO-cGMP pathway
promotes a shift of VSMCs towards the contractile phenotype reflected by reduced proliferation
and/or increased contractile marker protein expression [15]. For example, Garg and Hassid [59]
showed that NO donors and the membrane-permeable cGMP analogue 8-Br-cGMP (which activates
cGKI and other cGMP effectors) reduced the proliferation of subcultured rat aortic smooth muscle cells
(RASMCs). Similar results were obtained by application of YC-1 [60], a stimulator of NO-GC [61–63].
After adenoviral expression of cGKI in subcultured RASMCs, Chiche et al. confirmed this observation
and, in addition, showed an increase in apoptosis after enhancing cGMP signaling [64]. As the
overexpression of cGKI in subcultured VSMCs led to increased contractile protein expression (e.g.,
SM-MHC, calponin), a role for cGKI in maintaining a differentiated/contractile phenotype was
postulated [52,65,66].
In contrast to the results obtained with subcultured VSMCs, studies with primary VSMCs revealed
a stimulation of VSMC growth and survival by the NO-cGMP-cGKI pathway. Hassid and colleagues
demonstrated that the growth-promoting effect of fibroblast growth factor 2 on primary RASMCs was
potentiated by NO/cGMP [67]. Interestingly, they did not detect this growth potentiation with cells of
higher passages. Another study reported an activation of the mitogen-activated protein kinase pathway
(commonly known to be pro-proliferative) by cGMP analogues in freshly isolated RASMCs [68].
We observed a growth-promoting effect of 8-Br-cGMP in primary VSMCs from mouse aorta, and
by comparing cGKI-expressing and cGKI-deficient VSMCs, we were able to prove that growth
stimulation by cGMP was mediated by cGKI [35]. In the same study, we demonstrated opposing
concentration-dependent effects of NO on the growth of primary VSMCs. While a low concentration
(0.5 μM) of the NO donor diethylenetriamine NONOate (DETA-NO) enhanced proliferation via
a cGKI-dependent pathway, high concentrations of DETA-NO (100 μM) strongly reduced VSMC
growth independent of cGKI. A cGMP-independent, anti-proliferative effect of NO in VSMCs was
also observed by other groups [50,69]. In sum, there is strong evidence that low/physiological NO
concentrations promote VSMC growth via the cGMP-cGKI axis, whereas high/pathophysiological
concentrations of NO inhibit VSMC growth in a cGMP/cGKI-independent manner.
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Based on the previous studies, it appears that cGMP promotes the growth and survival of primary
VSMCs, while it inhibits subcultured VSMCs. Indeed, Weinmeister and colleagues [70] demonstrated
that the relatively strong cGKI-dependent growth-promoting effect of 8-Br-cGMP in primary VSMCs
(to ≈200–300% of control cells without cGMP) was lost after the first passage and even reversed to
a weak growth inhibition in later passages (to ≈90% of control cells without cGMP). These observations
imply that passaging of VSMCs results in functional changes of the endogenous NO-cGMP-cGKI
signaling pathway and/or more general alterations of the cells’ growth response. Considering the
relative magnitudes of cGMP-mediated growth effects, the strong growth stimulation observed in
primary VSMCs might be (patho-)physiologically more relevant than the weak inhibition detected in
subcultured cells.
Weinmeister et al. [70] also addressed the mechanism underlying growth stimulation of primary
VSMCs via the cGMP-cGKI pathway. It was mainly due to a higher efficiency of cell adhesion in the
presence of elevated cGMP, while proliferation and apoptosis played minor roles. A known substrate
of cGKI that is involved in cell adhesion is the small GTPase RhoA [71,72]. Phosphorylation by cGKI
stabilizes RhoA in an inactive cytosolic RhoA-GTP/GDI complex [73,74]. Indeed, the RhoA/Rho
kinase signaling pathway was suppressed by activation of the cGMP-cGKI pathway in VSMCs. This
led to activation of β1/β3 integrins and enhanced adhesion of primary VSMCs [70].
Recently, Segura-Puimedon and colleagues [50] analyzed the phenotype of VSMCs from knockout
mice lacking the α1 subunit of the cGMP-generating NO-GC. Compared to wild-type VSMCs, NO-GC
knockout cells showed less proliferation and migration and increased expression of contractile marker
proteins. These data are in line with the results obtained with cGKI knockout VSMCs [35]. Together,
these in vitro studies support a model in which increased NO-cGMP-cGKI signaling promotes the
growth and survival of VSMCs and stimulates their modulation towards a synthetic phenotype
(Figure 1b).
4. cGMP and Vascular Diseases
The critical role of NO and natriuretic peptides in the cardiovascular system has been known for
a long time. NO-releasing organic nitrates have been used for the treatment of angina pectoris for
more than a century. Novel functions of cGMP and clinical applications of cGMP-based drugs are
continuously being discovered [75,76]. Indeed, drugs that increase cGMP concentration have emerged
as one of the most successful areas in recent drug development and clinical pharmacology [77,78]. For
example, the PDE5 inhibitor sildenafil is used for erectile dysfunction, the GC-C agonist linaclotide
for chronic idiopathic constipation and irritable bowel syndrome, and recently a combination
drug consisting of valsartan (an angiotensin II receptor blocker) and sacubitril, which inhibits the
ANP-/BNP-degrading endopeptidase neprilysin, was approved for use in heart failure [79]. The
NO-GC stimulator riociguat is used for several forms of pulmonary hypertension [80]. Currently,
a plethora of preclinical and clinical studies are testing NO-GC stimulators and activators for their
therapeutic potential in various diseases, including heart failure, aortic valve calcification, achalasia,
and fibrosis [75,78,80].
The clinical data is supported by genetic association studies, which have implicated dysfunctions
of the cGMP signaling cascade in hypertension, coronary artery disease, and myocardial infarction
in humans [81]. Importantly, even subtle changes due to genetic variants in components of this
pathway (e.g., NO-GC, ANP, BNP; PDEs) significantly influence blood pressure and cardiovascular
disease risk [82–86]. Interestingly, genetic mutations in NO-GC or cGKI found in humans are causally
associated with altered vascular structure and remodeling [87,88]. However, the effects of genetic
polymorphisms on the expression level and/or enzymatic activity of the respective proteins are not
always known and, because the genetic alterations are present in all cells of the body, it is difficult
to identify the causative cell type(s) (e.g., endothelial cells, platelets, VSMCs, etc.). Although it is
commonly thought that the net effect of cGMP signaling on cardiovascular disease is protective, it is
conceivable that an increase of cGMP in different cell types can have different, and even opposing,
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effects on disease progression. In particular, the in vivo relevance of vascular plasticity regulated by
the NO-cGMP-cGKI cascade is not completely understood.
In recent years, knockout mouse models for NOS, NO-GC, and cGKI have been established.
Table 1 summarizes the vascular phenotypes of the respective mouse mutants. Conventional null
mutants that lack the β1 subunit of NO-GC [89] or cGKI [22] “chronically” in all cells have a strongly
reduced life span limiting their use for long-term experiments, such as the analysis of atherosclerosis.
Another drawback of conventional knockout technology is the fact that the gene mutation is present
in all cells, making it difficult to assign a phenotype to a specific cell type. To circumvent problems
associated with global gene knockouts, time- and tissue-specific mutagenesis utilizing the Cre/lox
recombination system can be performed [90], and conditional alleles of NO-GC [89] and cGKI [91]
have been generated.
Table 1. Genetic mouse models of NO-cGMP-cGKI signaling and their vascular phenotypes.
Gene Mouse Model Effect of Mutation on Vascular Remodeling References
eNOS Null mutation Enhanced atherosclerosis on ApoE−/− 1 background [92–94]
Enhanced neointima formation after vascular injury [95–97]
Impaired angiogenesis [98–100]
nNOS Null mutation Enhanced atherosclerosis on ApoE−/− background [101]
Enhanced neointima formation after vascular injury [102]
iNOS Null mutation Reduced atherosclerosis on ApoE−/− background [103,104]
Reduced neointima formation after vascular injury [105]
Reduced pathological neovascularization in the
ischemic retina [106]
NO-GC
α1-subunit Null mutation Reduced atherosclerosis on ApoE
−/− background [50]
Reduced neointima formation after vascular injury




(tamoxifen-inducible) Reduced arteriogenesis in hindlimb ischemia model [108]
Null mutation Reduced arteriogenesis in hindlimb ischemia model [108]
cGKI Smooth muscle-specific knockout(tamoxifen-inducible) Reduced atherosclerosis on ApoE
−/− background [35]
Smooth muscle-specific knockout No effect on neointima formation after vascularinjury [51]
Null mutation Reduced angiogenesis [109,110]
1 Apolipoprotein E (ApoE).
4.1. Role of cGMP in Atherosclerosis
Several genetic mouse studies investigated the role of NO-cGMP signaling for the development of
atherosclerotic plaques, a process strongly dependent on VSMC plasticity. Interestingly, the phenotypes
of NOS knockout mice indicated an ambivalent role of NO in atherosclerosis (Table 1). While
NO generated by eNOS [92,94] and nNOS [101] was atheroprotective, NO synthesized by iNOS,
which is upregulated under inflammatory conditions and generates high amounts of NO, promoted
atherosclerosis [103,104]. Interestingly, publications on the effects of pharmacological activation of
NO-GC on atherosclerosis are scarce [62]. One study reported that the NO-GC stimulator YC-1
prevents foam cell formation and atherosclerosis [111]. The opposing effects of NO might be related to
the different spatiotemporal profile (cell types, time) and quantity of NO generation by eNOS/nNOS
versus iNOS [112]. These results are also consistent with in vitro data showing that NO can promote
and inhibit VSMC growth via cGMP-dependent and cGMP-independent pathways, respectively
(see Section 3, “cGMP and VSMC Plasticity in Cell Culture”). Clearly, the interpretation of in vivo
knockout phenotypes is complicated if the gene mutation is present in all cells and/or the mutant
mice display multiple phenotypes that could influence each other. For instance, eNOS-deficient mice
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are also hypertensive and it is debated whether or not this may be another reason for their enhanced
atherosclerosis independent of a potential direct effect of NO on VSMC plasticity [92,93].
Using an inducible smooth muscle-specific cGKI knockout model that was combined with genetic
tracking of VSMC fate during plaque development, we demonstrated that the cGMP-cGKI axis in
VSMCs promotes the growth of atherosclerotic lesions [35]. After postnatal ablation of cGKI in VSMCs,
mutant mice developed smaller plaques. In these plaques, cells derived from cGKI-deficient VSMCs
were almost exclusively located in the media but not the plaque core region. In contrast, cells derived
from wild-type VSMCs were found in both the vascular media and inside the plaque. These cell-fate
mapping data indicated that cGKI is involved in the development of VSMC-derived plaque cells,
which were later identified as macrophage-like cells (see Section 2, “Role of VSMCs in Physiology
and Pathophysiology”). Thus, it is tempting to speculate that cGMP-cGKI signaling promotes smooth
muscle-to-macrophage transdifferentiation in atherosclerosis (Figure 1c).
In line with a pro-atherogenic role of the NO-cGMP-cGKI signaling cascade, Segura-Puimedon
and colleagues recently demonstrated that deletion of the α1 subunit of NO-GC led to a reduced size
of atherosclerotic plaques [50]. Their in vitro and in vivo results clearly confirm and further extend
the atherosclerosis data obtained with cGKI mouse mutants [35]. Together, these studies suggest
that the activated NO-cGMP-cGKI pathway promotes the phenotypic switching of VSMCs from
a contractile/quiescent phenotype to a synthetic/proliferative state including macrophage-like plaque
cells. It is important to note that cGMP-dependent plaque growth is not necessarily an unfavorable
process. Indeed, the cGMP-mediated increase in lesion size is associated with an altered plaque
composition, which may or may not stabilize the plaque. These questions as well as the role of NO-GC
and cGKI in multiple cell types involved in atherosclerosis (e.g., VSMCs, endothelial cells, platelets,
immune cells) should be further addressed in future studies with conditional knockout mice.
4.2. Role of cGMP in Restenosis
Paralleling the effects of NOS-derived NO in atherosclerosis, studies using knockout models in the
setting of restenosis (Table 1) demonstrated vasculoprotective effects of eNOS [95–97] and nNOS [102]
and a vasculoproliferative effect of iNOS [105]. The dual role of NO in vascular remodeling might
be the reason why NO-releasing drugs, to our knowledge, have not been reported to exert beneficial
effects on atherosclerosis or restenosis. In contrast to the strong in vivo evidence supporting a role of
the NO-cGMP-cGKI axis in atherosclerosis, data proving an influence of this signaling pathway on the
development of neointima during restenosis are scarce. Adenoviral transduction of the constitutively
active kinase domain of cGKI led to an attenuated formation of neointima in vascular injury models of
rat and swine [113]. It is important to note that this kinase construct is not regulated by cGMP and lacks
the N-terminus, which is responsible for substrate specificity [8,9]. In the same study, the transduction
of the full-length cGKIβ isoform did not affect the formation of neointima. Lukowski and colleagues
showed that smooth muscle-specific ablation of cGKI and treatment of wild-type mice with the PDE5
inhibitor sildenafil had no significant effect on restenosis in various models of vascular injury, except
for a slight reduction of neointima formation in a short vessel segment of cGKI mutants after wire
injury of the carotid artery [51].
Pharmacological approaches applying the NO-GC stimulator YC-1 [114,115] or the NO-GC activator
cinaciguat [116] indicated a vasculoprotective role of NO-GC activation in rat models of restenosis. It is,
however, not clear whether these effects were related to drug action on VSMCs and/or other cell types.
It should be considered that pharmacological activation of NO-GC can exert hypotensive [61,62,117] and
anti-inflammatory effects [111,118], which could influence restenosis. Furthermore, YC-1 is known to
have cGMP-independent effects [62,117]. In contrast to the pharmacological studies, Vermeersch et al.
reported that NO-GC might promote restenosis based on their finding that global knockout of the
NO-GC α1 subunit resulted in a reduction of neointima formation in male mice [107]. Together with
the analysis of cGKI mouse mutants, these genetic knockout studies suggest that the NO-cGMP-cGKI
cascade is not critically involved in the regulation of VSMC growth during restenosis. If at all, this
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pathway may slightly promote rather than inhibit neointima formation, which points to the same
direction as the growth-promoting effect of cGMP during atherosclerosis. However, the effects of
cGMP on restenosis appear relatively weak and it is unlikely that the effects of NO on restenosis are
mediated by the cGMP-cGKI pathway. Presumably, the spatiotemporal profile, the amount of NO
synthesized, and the source of its production after vascular injury result in the activation of alternative
mechanisms, such as redox regulation of target proteins [119]. The preclinical evidence summarized
above also indicates that the contribution of cGKI-mediated mechanisms to vascular remodeling is
context-specific, and arguably more important in atherosclerosis than in restenosis. A disease-specific
role of the cGMP-cGKI axis is plausible considering our hypothesis that this pathway acts on smooth
muscle-to-macrophage transdifferentiation (see above, this section), a process that seems to contribute
to the formation of atherosclerotic lesions, but not neointima in the setting of restenosis (see Section 2,
“Role of VSMCs in Physiology and Pathophysiology”).
4.3. Role of cGMP in Angiogenesis
Another process influenced by the phenotypic plasticity of VSMCs is the formation of blood
vessels. It is known that NO induces postnatal neovascularization through both angiogenesis
(the development of new blood vessels derived from existing vessels) and vasculogenesis (blood
vessel formation de novo from progenitor cells), but the respective mechanisms are still unclear [112].
Hindlimb ischemia is a common model to investigate blood vessel formation during pathological
conditions, as angiogenesis is the natural response to restore blood supply after ischemia. In this
model, the pro-angiogenic effect of NO was demonstrated by using a NOS inhibitor [120] or eNOS
knockout models with impaired NO generation [100] (Table 1). Pro-angiogenic effects of eNOS [98,99]
and iNOS [106] were also observed in other models of neovascularization. A recent study identified
NO-GC as a component of cGMP-mediated angiogenesis [108]. By comparison of ischemia-induced
angiogenesis in global, endothelial-, and smooth muscle-specific NO-GC β1 knockout mice, the authors
showed that NO-GC expression in VSMCs, but not endothelial cells, improved neovascularization.
In line with the role of NO and NO-GC, several studies also suggested a pro-angiogenic function for
cGKI. Yamahara and colleagues reported that angiogenesis in response to hindlimb ischemia was
increased in mice that overexpressed cGKIα, while it was significantly reduced in heterozygous cGKI
knockout mice [110]. Aicher et al. confirmed the pro-angiogenic cGKI effects observed by Yamahara
using a cGKIα leucine zipper mutant unable to interact with downstream targets [109]. Furthermore,
this study reported reduced blood vessel formation of cGKI-null mutants in a disc neovascularization
model. Moreover, Senthilkumar and colleagues proposed a cGKI-dependent pro-angiogenic effect
of sildenafil [121]. Taken together, these studies strongly suggest a pro-angiogenic function of the
NO-cGMP-cGKI pathway.
5. Limitations and Future Directions
Clearly, the present data call for more studies on the mechanisms and therapeutic relevance of
cGMP-regulated vascular remodeling. These studies should address how cGMP signaling affects
VSMC phenotype and vice versa. The relevance of cGMP-triggered VSMC transdifferentiation should
be analyzed in detail as well as the effects of cGMP on other cell types involved in vascular disease,
such as endothelial cells, platelets, and immune cells. To answer these and other interesting questions,
it will be instrumental to monitor the spatiotemporal profile of cGMP signals generated in living
vascular cells and tissues, and to track the cells’ fate after endogenous or pharmacological modulation
of the cGMP pathway.
A major obstacle in drawing a complete picture of cGMP signaling in VSMCs is their phenotypic
heterogeneity. It is likely that the initial state of a VSMC influences the effect of cGMP on it. Therefore,
it is important to investigate cGMP signaling at the single-cell level. To some extent, this is possible
by classical immunostainings of VSMC populations in cell culture or tissue sections for cGMP,
“marker” proteins, or other proteins of interest. However, this method does not allow one to follow
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dynamic changes and it is limited by the availability of specific antibodies. With the development of
genetically-encoded fluorescent cGMP sensors, it is now possible to visualize cGMP in living cells
by fluorescence microscopy [122,123]. Recently, we have generated transgenic mice expressing the
cGMP indicator cGi500 [124] either ubiquitously or in specific cell types [125]. The cGMP sensor mice
are a convenient source to isolate sensor-expressing primary cells [122,125] and tissues [126,127] for
ex vivo cGMP imaging, or they can be used directly for intravital cGMP imaging in vivo [128]. Thus, it
is possible to monitor dynamic cGMP changes in real time in individual VSMCs in culture or in a living
tissue/animal under close-to-native conditions. In contrast to conventional end point cGMP assays,
which measure cGMP in cell/tissue extracts, the cGMP sensor mice allow for monitoring of cGMP
levels in single cells in response to multiple stimulations [122,125]. This will help to correlate cGMP
responses elicited by different cGMP-elevating agents with the phenotypic state of individual VSMCs
and, thereby, deepen our understanding of the role of cGMP in phenotypic plasticity. Furthermore,
the cGMP-modulating effects of PDE inhibitors or other substances can be investigated at the single-cell
level as was recently shown for neurons [129]. Besides this, spatiotemporal differences of cGMP signals
can be analyzed in intact tissues, which has already provided new insights about cGMP signaling in
the cochlea [126] and oocytes [127].
It is increasingly recognized that previous studies have underestimated the importance of VSMC
phenotypic plasticity in atherosclerosis and the impact a single VSMC can have on disease progression.
With the use of genetic cell-fate mapping, it was shown that individual medial VSMCs can expand
clonally and transdifferentiate to macrophage-like cells in atherosclerotic plaques. These studies also
showed that classification of cell types exclusively via immunostainings for “specific” marker proteins,
which they might lose or gain during phenotypic switching, can lead to misinterpretations concerning
the cells’ origin. We anticipate that genetic lineage tracing will continue to discover new aspects of
VSMC plasticity in vascular diseases, such as conversion to bone-like cells and other cells. Recently,
a new mouse model for cell tracking with positron emission tomography (PET) was described [130].
This cell tracking mouse allows for non-invasive imaging of specific cell types by PET and should
further improve data quality with a reduction in the number of animals needed. Importantly, we can
now track VSMCs over time in an individual living animal without the need to sacrifice it. In the
future, combining cGMP imaging and VSMC tracking will help to improve our understanding of
cGMP’s role in VSMC plasticity in vivo.
6. Conclusions
The cGMP signaling pathway has a strong impact on human cardiovascular physiology and
pathophysiology and is an attractive drug target to tackle an array of major human diseases. As discussed
in this review article, in vitro and in vivo data support an important role of the NO-cGMP-cGKI axis
in vascular remodeling, particularly in the context of atherosclerosis and angiogenesis. It is likely that
many of these effects are related to stimulation of VSMC growth and plasticity by this signaling pathway
(Figure 1b). A major future challenge is to evaluate the relevance of cGMP-regulated vascular plasticity
for human health and disease. Preclinical studies strongly support the notion that the cGMP-cGKI axis
increases VSMC growth and survival. Similar growth/survival-promoting effects of cGMP have been
reported in other cell types, including cardiomyocytes [131–134], hematopoietic [135] and vascular [109]
progenitor cells, stroma cells in the bone marrow [136], erythrocytes [137], platelets [138], osteoblasts [139],
sensory hair cells [140], and melanoma cells [141]. Thus, we propose that stimulation of cell growth
and survival by cGMP is a common mechanism in many cell types and tissues. The growth-promoting
effects of cGMP could be highly relevant for pharmacotherapies. Inhibition of the cGMP-cGKI pathway
could be a novel strategy to treat proliferative diseases, such as atherosclerosis and cancer. Stimulation
of this pathway might counteract cell degeneration and death in settings such as heart attack, stroke,
or noise-induced hearing loss. However, cGMP-elevating drugs used in clinics might also have unwanted
side effects related to stimulation of cell growth and survival. Indeed, two recent clinical studies reported
that use of PDE5 inhibitors in men is linked to a modest increase in melanoma risk [142,143]. We [141]
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and others [144] discovered a growth-promoting cGMP pathway in melanoma cells that might provide
a mechanistic basis for this clinical finding [145]. In the future, it will be interesting to evaluate the effects
of cGMP-modulating drugs on atherosclerosis and other diseases that are associated with cell growth
and plasticity.
Acknowledgments: The authors would like to thank Michael Paolillo for reading the manuscript as well as
the current and past members of the Feil laboratory for critical discussions. We apologize to all our colleagues
whose work could not be cited due to space limitations. The work in the authors’ laboratory is supported by the
Fund for Science, Karl Helmut Eberle Stiftung, European Research Area Network on Cardiovascular Diseases
(ERA-CVD), and Deutsche Forschungsgemeinschaft (FOR 2060 projects FE 438/5-2 and FE 438/6-2, KFO 274
projects FE 438/7-1 and FE 438/8-2).
Author Contributions: All authors contributed to the conceptual drafting, writing, and editing of this manuscript.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Beavo, J.A.; Brunton, L.L. Cyclic nucleotide research—Still expanding after half a century. Nat. Rev. Mol.
Cell Biol. 2002, 3, 710–718. [CrossRef] [PubMed]
2. Kemp-Harper, B.; Feil, R. Meeting report: cGMP matters. Sci. Sign. 2008, 1, pe12. [CrossRef] [PubMed]
3. Friebe, A.; Koesling, D. The function of NO-sensitive guanylyl cyclase: What we can learn from genetic
mouse models. Nitric Oxide 2009, 21, 149–156. [CrossRef] [PubMed]
4. Kuhn, M. Molecular physiology of membrane guanylyl cyclase receptors. Physiol. Rev. 2016, 96, 751–804.
[CrossRef] [PubMed]
5. Forstermann, U.; Sessa, W.C. Nitric oxide synthases: Regulation and function. Eur. Heart J. 2012, 33, 829–837.
[CrossRef] [PubMed]
6. Biel, M.; Michalakis, S. Cyclic nucleotide-gated channels. In cGMP: Generators, Effectors and Therapeutic
Implications; Schmidt, H.H.H.W., Hofmann, F., Stasch, J.-P., Eds.; Springer: Berlin/Heidelberg, Germany,
2009; pp. 111–136.
7. Francis, S.H.; Blount, M.A.; Corbin, J.D. Mammalian cyclic nucleotide phosphodiesterases: Molecular
mechanisms and physiological functions. Physiol. Rev. 2011, 91, 651–690. [CrossRef] [PubMed]
8. Hofmann, F.; Feil, R.; Kleppisch, T.; Schlossmann, J. Function of cGMP-dependent protein kinases as revealed
by gene deletion. Physiol. Rev. 2006, 86, 1–23. [CrossRef] [PubMed]
9. Feil, R.; Lohmann, S.M.; de Jonge, H.; Walter, U.; Hofmann, F. Cyclic GMP-dependent protein kinases and
the cardiovascular system: Insights from genetically modified mice. Circ. Res. 2003, 93, 907–916. [CrossRef]
[PubMed]
10. Aizawa, T.; Wei, H.; Miano, J.M.; Abe, J.; Berk, B.C.; Yan, C. Role of phosphodiesterase 3 in NO/cGMP-mediated
antiinflammatory effects in vascular smooth muscle cells. Circ. Res. 2003, 93, 406–413. [CrossRef] [PubMed]
11. Surks, H.K. cGMP-dependent protein kinase i and smooth muscle relaxation: A tale of two isoforms. Circ. Res.
2007, 101, 1078–1080. [CrossRef] [PubMed]
12. Weber, S.; Bernhard, D.; Lukowski, R.; Weinmeister, P.; Worner, R.; Wegener, J.W.; Valtcheva, N.; Feil, S.;
Schlossmann, J.; Hofmann, F.; et al. Rescue of cGMP kinase I knockout mice by smooth muscle specific
expression of either isozyme. Circ. Res. 2007, 101, 1096–1103. [CrossRef] [PubMed]
13. Feil, R.; Feil, S.; Hofmann, F. A heretical view on the role of NO and cGMP in vascular proliferative diseases.
Trends Mol. Med. 2005, 11, 71–75. [CrossRef] [PubMed]
14. Kemp-Harper, B.; Schmidt, H.H.H.W. cGMP in the vasculature. In cGMP: Generators, Effectors and Therapeutic
Implications; Schmidt, H.H.H.W., Hofmann, F., Stasch, J.-P., Eds.; Springer: Berlin/Heidelberg, Germany,
2009; pp. 447–467.
15. Lincoln, T.M.; Wu, X.; Sellak, H.; Dey, N.; Choi, C.S. Regulation of vascular smooth muscle cell phenotype by
cyclic GMP and cyclic GMP-dependent protein kinase. Front. Biosci. 2006, 11, 356–367. [CrossRef] [PubMed]
16. Somlyo, A.P.; Somlyo, A.V. Signal transduction and regulation in smooth muscle. Nature 1994, 372, 231–236.
[CrossRef] [PubMed]
17. Buys, E.S.; Sips, P.; Vermeersch, P.; Raher, M.J.; Rogge, E.; Ichinose, F.; Dewerchin, M.; Bloch, K.D.; Janssens, S.;
Brouckaert, P. Gender-specific hypertension and responsiveness to nitric oxide in sGCα1 knockout mice.
Cardiovasc. Res. 2008, 79, 179–186. [CrossRef] [PubMed]
269
J. Cardiovasc. Dev. Dis. 2018, 5, 20
18. Groneberg, D.; Konig, P.; Wirth, A.; Offermanns, S.; Koesling, D.; Friebe, A. Smooth muscle-specific deletion
of nitric oxide-sensitive guanylyl cyclase is sufficient to induce hypertension in mice. Circulation 2010, 121,
401–409. [CrossRef] [PubMed]
19. Mergia, E.; Friebe, A.; Dangel, O.; Russwurm, M.; Koesling, D. Spare guanylyl cyclase NO receptors ensure
high NO sensitivity in the vascular system. J. Clin. Investig. 2006, 116, 1731–1737. [CrossRef] [PubMed]
20. Thoonen, R.; Cauwels, A.; Decaluwe, K.; Geschka, S.; Tainsh, R.E.; Delanghe, J.; Hochepied, T.; De Cauwer, L.;
Rogge, E.; Voet, S.; et al. Cardiovascular and pharmacological implications of haem-deficient NO-unresponsive
soluble guanylate cyclase knock-in mice. Nat. Commun. 2015, 6, 8482. [CrossRef] [PubMed]
21. Koeppen, M.; Feil, R.; Siegl, D.; Feil, S.; Hofmann, F.; Pohl, U.; de Wit, C. cGMP-dependent protein kinase
mediates NO- but not acetylcholine-induced dilations in resistance vessels in vivo. Hypertension 2004, 44,
952–955. [CrossRef] [PubMed]
22. Pfeifer, A.; Klatt, P.; Massberg, S.; Ny, L.; Sausbier, M.; Hirneiss, C.; Wang, G.X.; Korth, M.; Aszodi, A.;
Andersson, K.E.; et al. Defective smooth muscle regulation in cGMP kinase I-deficient mice. EMBO J. 1998,
17, 3045–3051. [CrossRef] [PubMed]
23. Owens, G.K.; Kumar, M.S.; Wamhoff, B.R. Molecular regulation of vascular smooth muscle cell differentiation
in development and disease. Physiol. Rev. 2004, 84, 767–801. [CrossRef] [PubMed]
24. Libby, P.; Ridker, P.M.; Hansson, G.K. Progress and challenges in translating the biology of atherosclerosis.
Nature 2011, 473, 317–325. [CrossRef] [PubMed]
25. Moore, K.J.; Tabas, I. Macrophages in the pathogenesis of atherosclerosis. Cell 2011, 145, 341–355. [CrossRef]
[PubMed]
26. Ross, R. Atherosclerosis—An inflammatory disease. N. Engl. J. Med. 1999, 340, 115–126. [CrossRef] [PubMed]
27. Doherty, T.M.; Shah, P.K.; Rajavashisth, T.B. Cellular origins of atherosclerosis: Towards ontogenetic
endgame? FASEB J. 2003, 17, 592–597. [CrossRef] [PubMed]
28. Gomez, D.; Owens, G.K. Smooth muscle cell phenotypic switching in atherosclerosis. Cardiovasc. Res. 2012,
95, 156–164. [CrossRef] [PubMed]
29. Iwata, H.; Manabe, I.; Nagai, R. Lineage of bone marrow-derived cells in atherosclerosis. Circ. Res. 2013, 112,
1634–1647. [CrossRef] [PubMed]
30. Moore, K.J.; Sheedy, F.J.; Fisher, E.A. Macrophages in atherosclerosis: A dynamic balance. Nat. Rev. Immunol.
2013, 13, 709–721. [CrossRef] [PubMed]
31. Nguyen, A.T.; Gomez, D.; Bell, R.D.; Campbell, J.H.; Clowes, A.W.; Gabbiani, G.; Giachelli, C.M.;
Parmacek, M.S.; Raines, E.W.; Rusch, N.J.; et al. Smooth muscle cell plasticity: Fact or fiction? Circ. Res. 2013,
112, 17–22. [CrossRef] [PubMed]
32. Tang, Z.; Wang, A.; Wang, D.; Li, S. Smooth muscle cells: To be or not to be? Response to Nguyen et al.
Circ. Res. 2013, 112, 23–26. [CrossRef] [PubMed]
33. Bennett, M.R.; Sinha, S.; Owens, G.K. Vascular smooth muscle cells in atherosclerosis. Circ. Res. 2016, 118,
692–702. [CrossRef] [PubMed]
34. Feil, S.; Hofmann, F.; Feil, R. SM22α modulates vascular smooth muscle cell phenotype during atherogenesis.
Circ. Res. 2004, 94, 863–865. [CrossRef] [PubMed]
35. Wolfsgruber, W.; Feil, S.; Brummer, S.; Kuppinger, O.; Hofmann, F.; Feil, R. A proatherogenic role for
cGMP-dependent protein kinase in vascular smooth muscle cells. Proc. Natl. Acad. Sci. USA 2003, 100,
13519–13524. [CrossRef] [PubMed]
36. Rong, J.X.; Shapiro, M.; Trogan, E.; Fisher, E.A. Transdifferentiation of mouse aortic smooth muscle cells
to a macrophage-like state after cholesterol loading. Proc. Natl. Acad. Sci. USA 2003, 100, 13531–13536.
[CrossRef] [PubMed]
37. Allahverdian, S.; Chehroudi, A.C.; McManus, B.M.; Abraham, T.; Francis, G.A. Contribution of intimal
smooth muscle cells to cholesterol accumulation and macrophage-like cells in human atherosclerosis.
Circulation 2014, 129, 1551–1559. [CrossRef] [PubMed]
38. Andreeva, E.R.; Pugach, I.M.; Orekhov, A.N. Subendothelial smooth muscle cells of human aorta express
macrophage antigen in situ and in vitro. Atherosclerosis 1997, 135, 19–27. [CrossRef]
39. Feil, S.; Fehrenbacher, B.; Lukowski, R.; Essmann, F.; Schulze-Osthoff, K.; Schaller, M.; Feil, R.
Transdifferentiation of vascular smooth muscle cells to macrophage-like cells during atherogenesis. Circ. Res.
2014, 115, 662–667. [CrossRef] [PubMed]
270
J. Cardiovasc. Dev. Dis. 2018, 5, 20
40. Shankman, L.S.; Gomez, D.; Cherepanova, O.A.; Salmon, M.; Alencar, G.F.; Haskins, R.M.; Swiatlowska, P.;
Newman, A.A.; Greene, E.S.; Straub, A.C.; et al. KLF4-dependent phenotypic modulation of smooth muscle
cells has a key role in atherosclerotic plaque pathogenesis. Nat. Med. 2015, 21, 628–637. [CrossRef] [PubMed]
41. Albarran-Juarez, J.; Kaur, H.; Grimm, M.; Offermanns, S.; Wettschureck, N. Lineage tracing of cells involved
in atherosclerosis. Atherosclerosis 2016, 251, 445–453. [CrossRef] [PubMed]
42. Chappell, J.; Harman, J.L.; Narasimhan, V.M.; Yu, H.; Foote, K.; Simons, B.D.; Bennett, M.R.; Jorgensen, H.F.
Extensive proliferation of a subset of differentiated, yet plastic, medial vascular smooth muscle cells
contributes to neointimal formation in mouse injury and atherosclerosis models. Circ. Res. 2016, 119,
1313–1323. [CrossRef] [PubMed]
43. Jacobsen, K.; Lund, M.B.; Shim, J.; Gunnersen, S.; Fuchtbauer, E.M.; Kjolby, M.; Carramolino, L.; Bentzon, J.F.
Diverse cellular architecture of atherosclerotic plaque derives from clonal expansion of a few medial SMCs.
JCI Insight 2017, 2. [CrossRef] [PubMed]
44. Swirski, F.K.; Nahrendorf, M. Do vascular smooth muscle cells differentiate to macrophages in atherosclerotic
lesions? Circ. Res. 2014, 115, 605–606. [CrossRef] [PubMed]
45. Marx, S.O.; Totary-Jain, H.; Marks, A.R. Vascular smooth muscle cell proliferation in restenosis. Circ. Cardiovasc.
Interv. 2011, 4, 104–111. [CrossRef] [PubMed]
46. Chamley-Campbell, J.; Campbell, G.R.; Ross, R. The smooth muscle cell in culture. Physiol. Rev. 1979, 59,
1–61. [CrossRef] [PubMed]
47. Owens, G.K. Regulation of differentiation of vascular smooth muscle cells. Physiol. Rev. 1995, 75, 487–517.
[CrossRef] [PubMed]
48. Worth, N.F.; Rolfe, B.E.; Song, J.; Campbell, G.R. Vascular smooth muscle cell phenotypic modulation in
culture is associated with reorganisation of contractile and cytoskeletal proteins. Cell Motil. Cytoskel. 2001,
49, 130–145. [CrossRef] [PubMed]
49. Vengrenyuk, Y.; Nishi, H.; Long, X.; Ouimet, M.; Savji, N.; Martinez, F.O.; Cassella, C.P.; Moore, K.J.;
Ramsey, S.A.; Miano, J.M.; et al. Cholesterol loading reprograms the microRNA-143/145-myocardin axis
to convert aortic smooth muscle cells to a dysfunctional macrophage-like phenotype. Arterioscler. Thromb.
Vasc. Biol. 2015, 35, 535–546. [CrossRef] [PubMed]
50. Segura-Puimedon, M.; Mergia, E.; Al-Hasani, J.; Aherrahrou, R.; Stoelting, S.; Kremer, F.; Freyer, J.;
Koesling, D.; Erdmann, J.; Schunkert, H.; et al. Proatherosclerotic effect of the alpha1-subunit of soluble
guanylyl cyclase by promoting smooth muscle phenotypic switching. Am. J. Pathol. 2016, 186, 2220–2231.
[CrossRef] [PubMed]
51. Lukowski, R.; Weinmeister, P.; Bernhard, D.; Feil, S.; Gotthardt, M.; Herz, J.; Massberg, S.; Zernecke, A.;
Weber, C.; Hofmann, F.; et al. Role of smooth muscle cGMP/cGKI signaling in murine vascular restenosis.
Arterioscler. Thromb. Vasc. Biol. 2008, 28, 1244–1250. [CrossRef] [PubMed]
52. Dey, N.B.; Foley, K.F.; Lincoln, T.M.; Dostmann, W.R. Inhibition of cGMP-dependent protein kinase reverses
phenotypic modulation of vascular smooth muscle cells. J. Cardiovasc. Pharmacol. 2005, 45, 404–413.
[CrossRef] [PubMed]
53. Butt, E. cGMP-dependent protein kinase modulators. In cGMP: Generators, Effectors and Therapeutic
Implications; Schmidt, H.H.H.W., Hofmann, F., Stasch, J.-P., Eds.; Springer: Berlin/Heidelberg, Germany,
2009; pp. 409–421.
54. Gambaryan, S.; Geiger, J.; Schwarz, U.R.; Butt, E.; Begonja, A.; Obergfell, A.; Walter, U. Potent inhibition
of human platelets by cGMP analogs independent of cGMP-dependent protein kinase. Blood 2004, 103,
2593–2600. [CrossRef] [PubMed]
55. Marshall, S.J.; Senis, Y.A.; Auger, J.M.; Feil, R.; Hofmann, F.; Salmon, G.; Peterson, J.T.; Burslem, F.; Watson, S.P.
Gpib-dependent platelet activation is dependent on src kinases but not MAP kinase or cGMP-dependent
kinase. Blood 2004, 103, 2601–2609. [CrossRef] [PubMed]
56. Burkhardt, M.; Glazova, M.; Gambaryan, S.; Vollkommer, T.; Butt, E.; Bader, B.; Heermeier, K.; Lincoln, T.M.;
Walter, U.; Palmetshofer, A. KT5823 inhibits cGMP-dependent protein kinase activity in vitro but not in
intact human platelets and rat mesangial cells. J. Biol. Chem. 2000, 275, 33536–33541. [CrossRef] [PubMed]
57. Valtcheva, N.; Nestorov, P.; Beck, A.; Russwurm, M.; Hillenbrand, M.; Weinmeister, P.; Feil, R. The commonly
used cGMP-dependent protein kinase type I (cGKI) inhibitor Rp-8-Br-PET-cGMPS can activate cGKI in vitro
and in intact cells. J. Biol. Chem. 2009, 284, 556–562. [CrossRef] [PubMed]
271
J. Cardiovasc. Dev. Dis. 2018, 5, 20
58. Gambaryan, S.; Butt, E.; Kobsar, A.; Geiger, J.; Rukoyatkina, N.; Parnova, R.; Nikolaev, V.O.; Walter, U.
The oligopeptide DT-2 is a specific PKG I inhibitor only in vitro, not in living cells. Br. J. Pharmacol. 2012,
167, 826–838. [CrossRef] [PubMed]
59. Garg, U.C.; Hassid, A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate
inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J. Clin. Investig. 1989, 83,
1774–1777. [CrossRef] [PubMed]
60. Tulis, D.A.; Bohl Masters, K.S.; Lipke, E.A.; Schiesser, R.L.; Evans, A.J.; Peyton, K.J.; Durante, W.; West, J.L.;
Schafer, A.I. YC-1-mediated vascular protection through inhibition of smooth muscle cell proliferation and
platelet function. Biochem. Biophys. Res. Commun. 2002, 291, 1014–1021. [CrossRef] [PubMed]
61. Evgenov, O.V.; Pacher, P.; Schmidt, P.M.; Hasko, G.; Schmidt, H.H.; Stasch, J.P. NO-independent stimulators
and activators of soluble guanylate cyclase: Discovery and therapeutic potential. Nat. Rev. Drug Discov.
2006, 5, 755–768. [CrossRef] [PubMed]
62. Stasch, J.P.; Pacher, P.; Evgenov, O.V. Soluble guanylate cyclase as an emerging therapeutic target in
cardiopulmonary disease. Circulation 2011, 123, 2263–2273. [CrossRef] [PubMed]
63. Follmann, M.; Griebenow, N.; Hahn, M.G.; Hartung, I.; Mais, F.J.; Mittendorf, J.; Schafer, M.; Schirok, H.;
Stasch, J.P.; Stoll, F.; et al. The chemistry and biology of soluble guanylate cyclase stimulators and activators.
Angew. Chem. Int. Ed. Engl. 2013, 52, 9442–9462. [CrossRef] [PubMed]
64. Chiche, J.D.; Schlutsmeyer, S.M.; Bloch, D.B.; de la Monte, S.M.; Roberts, J.D., Jr.; Filippov, G.; Janssens, S.P.;
Rosenzweig, A.; Bloch, K.D. Adenovirus-mediated gene transfer of cGMP-dependent protein kinase increases
the sensitivity of cultured vascular smooth muscle cells to the antiproliferative and pro-apoptotic effects of
nitric oxide/cGMP. J. Biol. Chem. 1998, 273, 34263–34271. [CrossRef] [PubMed]
65. Boerth, N.J.; Dey, N.B.; Cornwell, T.L.; Lincoln, T.M. Cyclic GMP-dependent protein kinase regulates vascular
smooth muscle cell phenotype. J. Vasc. Res. 1997, 34, 245–259. [CrossRef] [PubMed]
66. Choi, C.; Sellak, H.; Brown, F.M.; Lincoln, T.M. cGMP-dependent protein kinase and the regulation of
vascular smooth muscle cell gene expression: Possible involvement of ELK-1 sumoylation. Am. J. Physiol.
Heart Circ. Physiol. 2010, 299, H1660–H1670. [CrossRef] [PubMed]
67. Hassid, A.; Arabshahi, H.; Bourcier, T.; Dhaunsi, G.S.; Matthews, C. Nitric oxide selectively amplifies
FGF-2-induced mitogenesis in primary rat aortic smooth muscle cells. Am. J. Physiol. 1994, 267, H1040–H1048.
[CrossRef] [PubMed]
68. Komalavilas, P.; Shah, P.K.; Jo, H.; Lincoln, T.M. Activation of mitogen-activated protein kinase pathways by
cyclic GMP and cyclic GMP-dependent protein kinase in contractile vascular smooth muscle cells. J. Biol.
Chem. 1999, 274, 34301–34309. [CrossRef] [PubMed]
69. Ignarro, L.J.; Buga, G.M.; Wei, L.H.; Bauer, P.M.; Wu, G.; del Soldato, P. Role of the arginine-nitric oxide
pathway in the regulation of vascular smooth muscle cell proliferation. Proc. Natl. Acad. Sci. USA 2001, 98,
4202–4208. [CrossRef] [PubMed]
70. Weinmeister, P.; Lukowski, R.; Linder, S.; Traidl-Hoffmann, C.; Hengst, L.; Hofmann, F.; Feil, R. Cyclic
guanosine monophosphate-dependent protein kinase I promotes adhesion of primary vascular smooth
muscle cells. Mol. Biol. Cell 2008, 19, 4434–4441. [CrossRef] [PubMed]
71. Ridley, A.J.; Hall, A. The small GTP-binding protein rho regulates the assembly of focal adhesions and actin
stress fibers in response to growth factors. Cell 1992, 70, 389–399. [CrossRef]
72. Burridge, K.; Wennerberg, K. Rho and Rac take center stage. Cell 2004, 116, 167–179. [CrossRef]
73. Rolli-Derkinderen, M.; Sauzeau, V.; Boyer, L.; Lemichez, E.; Baron, C.; Henrion, D.; Loirand, G.; Pacaud, P.
Phosphorylation of serine 188 protects RhoA from ubiquitin/proteasome-mediated degradation in vascular
smooth muscle cells. Circ. Res. 2005, 96, 1152–1160. [CrossRef] [PubMed]
74. Sauzeau, V.; Le Jeune, H.; Cario-Toumaniantz, C.; Smolenski, A.; Lohmann, S.M.; Bertoglio, J.; Chardin, P.;
Pacaud, P.; Loirand, G. Cyclic GMP-dependent protein kinase signaling pathway inhibits RhoA-induced
Ca2+ sensitization of contraction in vascular smooth muscle. J. Biol. Chem. 2000, 275, 21722–21729. [CrossRef]
[PubMed]
75. Friebe, A.; Sandner, P.; Schmidtko, A. Meeting report of the 8(th) international conference on cGMP
“cGMP: Generators, effectors, and therapeutic implications” at Bamberg, Germany, from June 23 to 25, 2017.
Naunyn Schmiedebergs Arch. Pharmacol. 2017, 390, 1177–1188. [CrossRef] [PubMed]
76. Kraehling, J.R.; Sessa, W.C. Contemporary approaches to modulating the nitric oxide-cGMP pathway in
cardiovascular disease. Circ. Res. 2017, 120, 1174–1182. [CrossRef] [PubMed]
272
J. Cardiovasc. Dev. Dis. 2018, 5, 20
77. Feil, R.; Kemp-Harper, B. cGMP signalling: From bench to bedside. Conference on cGMP generators,
effectors and therapeutic implications. EMBO Rep. 2006, 7, 149–153. [CrossRef] [PubMed]
78. Oettrich, J.M.; Dao, V.T.; Frijhoff, J.; Kleikers, P.; Casas, A.I.; Hobbs, A.J.; Schmidt, H.H. Clinical relevance of
cyclic GMP modulators: A translational success story of network pharmacology. Clin. Pharmacol. Ther. 2016,
99, 360–362. [CrossRef] [PubMed]
79. McMurray, J.J.; Packer, M.; Desai, A.S.; Gong, J.; Lefkowitz, M.P.; Rizkala, A.R.; Rouleau, J.L.; Shi, V.C.;
Solomon, S.D.; Swedberg, K.; et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure.
N. Engl. J. Med. 2014, 371, 993–1004. [CrossRef] [PubMed]
80. Sandner, P. From molecules to patients: Exploring the therapeutic role of soluble guanylate cyclase
stimulators. Biol. Chem. 2018. [CrossRef] [PubMed]
81. Leineweber, K.; Moosmang, S.; Paulson, D. Genetics of NO deficiency. Am. J. Cardiol. 2017, 120, S80–S88.
[CrossRef] [PubMed]
82. Ehret, G.B.; Munroe, P.B.; Rice, K.M.; Bochud, M.; Johnson, A.D.; Chasman, D.I.; Smith, A.V.; Tobin, M.D.;
Verwoert, G.C.; Hwang, S.J.; et al. Genetic variants in novel pathways influence blood pressure and
cardiovascular disease risk. Nature 2011, 478, 103–109. [CrossRef] [PubMed]
83. Emdin, C.A.; Khera, A.V.; Klarin, D.; Natarajan, P.; Zekavat, S.M.; Nomura, A.; Haas, M.; Aragam, K.;
Ardissino, D.; Wilson, J.G.; et al. Phenotypic consequences of a genetic predisposition to enhanced nitric
oxide signaling. Circulation 2018, 137, 222–232. [CrossRef] [PubMed]
84. Erdmann, J.; Stark, K.; Esslinger, U.B.; Rumpf, P.M.; Koesling, D.; de Wit, C.; Kaiser, F.J.; Braunholz, D.;
Medack, A.; Fischer, M.; et al. Dysfunctional nitric oxide signalling increases risk of myocardial infarction.
Nature 2013, 504, 432–436. [CrossRef] [PubMed]
85. Kessler, T.; Wobst, J.; Wolf, B.; Eckhold, J.; Vilne, B.; Hollstein, R.; von Ameln, S.; Dang, T.A.; Sager, H.B.;
Moritz Rumpf, P.; et al. Functional characterization of the GUCY1A3 coronary artery disease risk locus.
Circulation 2017, 136, 476–489. [CrossRef] [PubMed]
86. Maass, P.G.; Aydin, A.; Luft, F.C.; Schachterle, C.; Weise, A.; Stricker, S.; Lindschau, C.; Vaegler, M.; Qadri, F.;
Toka, H.R.; et al. PDE3A mutations cause autosomal dominant hypertension with brachydactyly. Nat. Genet.
2015, 47, 647–653. [CrossRef] [PubMed]
87. Guo, D.C.; Regalado, E.; Casteel, D.E.; Santos-Cortez, R.L.; Gong, L.; Kim, J.J.; Dyack, S.; Horne, S.G.;
Chang, G.; Jondeau, G.; et al. Recurrent gain-of-function mutation in prkg1 causes thoracic aortic aneurysms
and acute aortic dissections. Am. J. Hum. Genet. 2013, 93, 398–404. [CrossRef] [PubMed]
88. Herve, D.; Philippi, A.; Belbouab, R.; Zerah, M.; Chabrier, S.; Collardeau-Frachon, S.; Bergametti, F.;
Essongue, A.; Berrou, E.; Krivosic, V.; et al. Loss of α1β1 soluble guanylate cyclase, the major nitric oxide
receptor, leads to moyamoya and achalasia. Am. J. Hum. Genet. 2014, 94, 385–394. [CrossRef] [PubMed]
89. Friebe, A.; Mergia, E.; Dangel, O.; Lange, A.; Koesling, D. Fatal gastrointestinal obstruction and hypertension
in mice lacking nitric oxide-sensitive guanylyl cyclase. Proc. Natl. Acad. Sci. USA 2007, 104, 7699–7704.
[CrossRef] [PubMed]
90. Feil, R. Conditional somatic mutagenesis in the mouse using site-specific recombinases. In Conditional
Mutagenesis: An Approach to Disease Models; Feil, R., Metzger, D., Eds.; Springer: Berlin/Heidelberg, Germany,
2007; pp. 3–28.
91. Wegener, J.W.; Nawrath, H.; Wolfsgruber, W.; Kuhbandner, S.; Werner, C.; Hofmann, F.; Feil, R. cGMP-dependent
protein kinase I mediates the negative inotropic effect of cGMP in the murine myocardium. Circ. Res. 2002, 90,
18–20. [CrossRef] [PubMed]
92. Chen, J.; Kuhlencordt, P.J.; Astern, J.; Gyurko, R.; Huang, P.L. Hypertension does not account for the
accelerated atherosclerosis and development of aneurysms in male apolipoprotein e/endothelial nitric oxide
synthase double knockout mice. Circulation 2001, 104, 2391–2394. [CrossRef] [PubMed]
93. Knowles, J.W.; Reddick, R.L.; Jennette, J.C.; Shesely, E.G.; Smithies, O.; Maeda, N. Enhanced atherosclerosis
and kidney dysfunction in eNOS(−/−)Apoe(−/−) mice are ameliorated by enalapril treatment. J. Clin. Investig.
2000, 105, 451–458. [CrossRef] [PubMed]
94. Kuhlencordt, P.J.; Gyurko, R.; Han, F.; Scherrer-Crosbie, M.; Aretz, T.H.; Hajjar, R.; Picard, M.H.; Huang, P.L.
Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein
e/endothelial nitric oxide synthase double-knockout mice. Circulation 2001, 104, 448–454. [CrossRef]
[PubMed]
273
J. Cardiovasc. Dev. Dis. 2018, 5, 20
95. Moroi, M.; Zhang, L.; Yasuda, T.; Virmani, R.; Gold, H.K.; Fishman, M.C.; Huang, P.L. Interaction of
genetic deficiency of endothelial nitric oxide, gender, and pregnancy in vascular response to injury in mice.
J. Clin. Investig. 1998, 101, 1225–1232. [CrossRef] [PubMed]
96. Rudic, R.D.; Shesely, E.G.; Maeda, N.; Smithies, O.; Segal, S.S.; Sessa, W.C. Direct evidence for the importance
of endothelium-derived nitric oxide in vascular remodeling. J. Clin. Investig. 1998, 101, 731–736. [CrossRef]
[PubMed]
97. Yogo, K.; Shimokawa, H.; Funakoshi, H.; Kandabashi, T.; Miyata, K.; Okamoto, S.; Egashira, K.; Huang, P.;
Akaike, T.; Takeshita, A. Different vasculoprotective roles of NO synthase isoforms in vascular lesion
formation in mice. Arterioscler. Thromb. Vasc. Biol. 2000, 20, e96–e100. [CrossRef] [PubMed]
98. Fukumura, D.; Gohongi, T.; Kadambi, A.; Izumi, Y.; Ang, J.; Yun, C.O.; Buerk, D.G.; Huang, P.L.; Jain, R.K.
Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced
angiogenesis and vascular permeability. Proc. Natl. Acad. Sci. USA 2001, 98, 2604–2609. [CrossRef]
[PubMed]
99. Lee, P.C.; Salyapongse, A.N.; Bragdon, G.A.; Shears, L.L., 2nd; Watkins, S.C.; Edington, H.D.; Billiar, T.R.
Impaired wound healing and angiogenesis in eNOS-deficient mice. Am. J. Physiol. 1999, 277, H1600–H1608.
[CrossRef] [PubMed]
100. Murohara, T.; Asahara, T.; Silver, M.; Bauters, C.; Masuda, H.; Kalka, C.; Kearney, M.; Chen, D.; Symes, J.F.;
Fishman, M.C.; et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J. Clin. Investig.
1998, 101, 2567–2578. [CrossRef] [PubMed]
101. Kuhlencordt, P.J.; Hotten, S.; Schodel, J.; Rutzel, S.; Hu, K.; Widder, J.; Marx, A.; Huang, P.L.;
Ertl, G. Atheroprotective effects of neuronal nitric oxide synthase in apolipoprotein e knockout mice.
Arterioscler. Thromb. Vasc. Biol. 2006, 26, 1539–1544. [CrossRef] [PubMed]
102. Morishita, T.; Tsutsui, M.; Shimokawa, H.; Horiuchi, M.; Tanimoto, A.; Suda, O.; Tasaki, H.; Huang, P.L.;
Sasaguri, Y.; Yanagihara, N.; et al. Vasculoprotective roles of neuronal nitric oxide synthase. FASEB J. 2002,
16, 1994–1996. [CrossRef] [PubMed]
103. Detmers, P.A.; Hernandez, M.; Mudgett, J.; Hassing, H.; Burton, C.; Mundt, S.; Chun, S.; Fletcher, D.;
Card, D.J.; Lisnock, J.; et al. Deficiency in inducible nitric oxide synthase results in reduced atherosclerosis in
apolipoprotein e-deficient mice. J. Immunol. 2000, 165, 3430–3435. [CrossRef] [PubMed]
104. Kuhlencordt, P.J.; Chen, J.; Han, F.; Astern, J.; Huang, P.L. Genetic deficiency of inducible nitric oxide
synthase reduces atherosclerosis and lowers plasma lipid peroxides in apolipoprotein e-knockout mice.
Circulation 2001, 103, 3099–3104. [CrossRef] [PubMed]
105. Chyu, K.Y.; Dimayuga, P.; Zhu, J.; Nilsson, J.; Kaul, S.; Shah, P.K.; Cercek, B. Decreased neointimal thickening
after arterial wall injury in inducible nitric oxide synthase knockout mice. Circ. Res. 1999, 85, 1192–1198.
[CrossRef] [PubMed]
106. Sennlaub, F.; Courtois, Y.; Goureau, O. Inducible nitric oxide synthase mediates the change from retinal to
vitreal neovascularization in ischemic retinopathy. J. Clin. Investig. 2001, 107, 717–725. [CrossRef] [PubMed]
107. Vermeersch, P.; Buys, E.; Sips, P.; Pokreisz, P.; Marsboom, G.; Gillijns, H.; Pellens, M.; Dewerchin, M.;
Bloch, K.D.; Brouckaert, P.; et al. Gender-specific modulation of the response to arterial injury by soluble
guanylate cyclase alpha1. Open Cardiovasc. Med. J. 2009, 3, 98–104. [CrossRef] [PubMed]
108. Bettaga, N.; Jager, R.; Dunnes, S.; Groneberg, D.; Friebe, A. Cell-specific impact of nitric oxide-dependent
guanylyl cyclase on arteriogenesis and angiogenesis in mice. Angiogenesis 2015, 18, 245–254. [CrossRef]
[PubMed]
109. Aicher, A.; Heeschen, C.; Feil, S.; Hofmann, F.; Mendelsohn, M.E.; Feil, R.; Dimmeler, S. cGMP-dependent
protein kinase I is crucial for angiogenesis and postnatal vasculogenesis. PLoS ONE 2009, 4, e4879. [CrossRef]
[PubMed]
110. Yamahara, K.; Itoh, H.; Chun, T.H.; Ogawa, Y.; Yamashita, J.; Sawada, N.; Fukunaga, Y.; Sone, M.;
Yurugi-Kobayashi, T.; Miyashita, K.; et al. Significance and therapeutic potential of the natriuretic peptides/
cGMP/cGMP-dependent protein kinase pathway in vascular regeneration. Proc. Natl. Acad. Sci. USA 2003,
100, 3404–3409. [CrossRef] [PubMed]
111. Tsou, C.Y.; Chen, C.Y.; Zhao, J.F.; Su, K.H.; Lee, H.T.; Lin, S.J.; Shyue, S.K.; Hsiao, S.H.; Lee, T.S. Activation of
soluble guanylyl cyclase prevents foam cell formation and atherosclerosis. Acta Physiol. 2014, 210, 799–810.
[CrossRef] [PubMed]
274
J. Cardiovasc. Dev. Dis. 2018, 5, 20
112. Duda, D.G.; Fukumura, D.; Jain, R.K. Role of eNOS in neovascularization: NO for endothelial progenitor
cells. Trends Mol. Med. 2004, 10, 143–145. [CrossRef] [PubMed]
113. Sinnaeve, P.; Chiche, J.D.; Gillijns, H.; Van Pelt, N.; Wirthlin, D.; Van De Werf, F.; Collen, D.; Bloch, K.D.;
Janssens, S. Overexpression of a constitutively active protein kinase g mutant reduces neointima formation
and in-stent restenosis. Circulation 2002, 105, 2911–2916. [CrossRef] [PubMed]
114. Wu, C.H.; Chang, W.C.; Chang, G.Y.; Kuo, S.C.; Teng, C.M. The inhibitory mechanism of YC-1, a benzyl
indazole, on smooth muscle cell proliferation: An in vitro and in vivo study. J. Pharmacol. Sci. 2004, 94,
252–260. [CrossRef] [PubMed]
115. Tulis, D.A.; Durante, W.; Peyton, K.J.; Chapman, G.B.; Evans, A.J.; Schafer, A.I. YC-1, a benzyl indazole
derivative, stimulates vascular cGMP and inhibits neointima formation. Biochem. Biophys. Res. Commun.
2000, 279, 646–652. [CrossRef] [PubMed]
116. Hirschberg, K.; Tarcea, V.; Pali, S.; Barnucz, E.; Gwanmesia, P.N.; Korkmaz, S.; Radovits, T.; Loganathan, S.;
Merkely, B.; Karck, M.; et al. Cinaciguat prevents neointima formation after arterial injury by decreasing
vascular smooth muscle cell migration and proliferation. Int. J. Cardiol. 2013, 167, 470–477. [CrossRef]
[PubMed]
117. Hoenicka, M.; Schmid, C. Cardiovascular effects of modulators of soluble guanylyl cyclase activity.
Cardiovasc. Hematol. Agents Med. Chem. 2008, 6, 287–301. [CrossRef] [PubMed]
118. Ahluwalia, A.; Foster, P.; Scotland, R.S.; McLean, P.G.; Mathur, A.; Perretti, M.; Moncada, S.; Hobbs, A.J.
Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of p-selectin
expression and leukocyte recruitment. Proc. Natl. Acad. Sci. USA 2004, 101, 1386–1391. [CrossRef] [PubMed]
119. Foster, M.W.; McMahon, T.J.; Stamler, J.S. S-nitrosylation in health and disease. Trends Mol. Med. 2003, 9,
160–168. [CrossRef]
120. Namba, T.; Koike, H.; Murakami, K.; Aoki, M.; Makino, H.; Hashiya, N.; Ogihara, T.; Kaneda, Y.; Kohno, M.;
Morishita, R. Angiogenesis induced by endothelial nitric oxide synthase gene through vascular endothelial
growth factor expression in a rat hindlimb ischemia model. Circulation 2003, 108, 2250–2257. [CrossRef]
[PubMed]
121. Senthilkumar, A.; Smith, R.D.; Khitha, J.; Arora, N.; Veerareddy, S.; Langston, W.; Chidlow, J.H., Jr.;
Barlow, S.C.; Teng, X.; Patel, R.P.; et al. Sildenafil promotes ischemia-induced angiogenesis through
a PKG-dependent pathway. Arterioscler. Thromb. Vasc. Biol. 2007, 27, 1947–1954. [CrossRef] [PubMed]
122. Thunemann, M.; Fomin, N.; Krawutschke, C.; Russwurm, M.; Feil, R. Visualization of cGMP with cGi
biosensors. Methods Mol. Biol. 2013, 1020, 89–120. [PubMed]
123. Nikolaev, V.O.; Lohse, M.J. Novel techniques for real-time monitoring of cGMP in living cells. In cGMP:
Generators, Effectors and Therapeutic Implications; Schmidt, H.H.H.W., Hofmann, F., Stasch, J.-P., Eds.; Springer:
Berlin/Heidelberg, Germany, 2009; pp. 229–243.
124. Russwurm, M.; Mullershausen, F.; Friebe, A.; Jager, R.; Russwurm, C.; Koesling, D. Design of fluorescence
resonance energy transfer (FRET)-based cGMP indicators: A systematic approach. Biochem. J. 2007, 407,
69–77. [CrossRef] [PubMed]
125. Thunemann, M.; Wen, L.; Hillenbrand, M.; Vachaviolos, A.; Feil, S.; Ott, T.; Han, X.; Fukumura, D.; Jain, R.K.;
Russwurm, M.; et al. Transgenic mice for cGMP imaging. Circ. Res. 2013, 113, 365–371. [CrossRef] [PubMed]
126. Mohrle, D.; Reimann, K.; Wolter, S.; Wolters, M.; Varakina, K.; Mergia, E.; Eichert, N.; Geisler, H.S.; Sandner, P.;
Ruth, P.; et al. NO-sensitive guanylate cyclase isoforms NO-GC1 and NO-GC2 contribute to noise-induced
inner hair cell synaptopathy. Mol. Pharmacol. 2017, 92, 375–388. [CrossRef] [PubMed]
127. Shuhaibar, L.C.; Egbert, J.R.; Norris, R.P.; Lampe, P.D.; Nikolaev, V.O.; Thunemann, M.; Wen, L.; Feil, R.;
Jaffe, L.A. Intercellular signaling via cyclic GMP diffusion through gap junctions restarts meiosis in mouse
ovarian follicles. Proc. Natl. Acad. Sci. USA 2015, 112, 5527–5532. [CrossRef] [PubMed]
128. Thunemann, M.; Schmidt, K.; de Wit, C.; Han, X.; Jain, R.K.; Fukumura, D.; Feil, R. Correlative intravital
imaging of cGMP signals and vasodilation in mice. Front. Physiol. 2014, 5, 394. [CrossRef] [PubMed]
129. Schmidt, H.; Peters, S.; Frank, K.; Wen, L.; Feil, R.; Rathjen, F.G. Dorsal root ganglion axon bifurcation
tolerates increased cyclic GMP levels: The role of phosphodiesterase 2A and scavenger receptor Npr3.
Eur. J. Neurosci. 2016, 44, 2991–3000. [CrossRef] [PubMed]
130. Thunemann, M.; Schorg, B.F.; Feil, S.; Lin, Y.; Voelkl, J.; Golla, M.; Vachaviolos, A.; Kohlhofer, U.;
Quintanilla-Martinez, L.; Olbrich, M.; et al. Cre/lox-assisted non-invasive in vivo tracking of specific
cell populations by positron emission tomography. Nat. Commun. 2017, 8, 444. [CrossRef] [PubMed]
275
J. Cardiovasc. Dev. Dis. 2018, 5, 20
131. Das, A.; Smolenski, A.; Lohmann, S.M.; Kukreja, R.C. Cyclic GMP-dependent protein kinase ialpha attenuates
necrosis and apoptosis following ischemia/reoxygenation in adult cardiomyocyte. J. Biol. Chem. 2006, 281,
38644–38652. [CrossRef] [PubMed]
132. Kato, T.; Muraski, J.; Chen, Y.; Tsujita, Y.; Wall, J.; Glembotski, C.C.; Schaefer, E.; Beckerle, M.; Sussman, M.A.
Atrial natriuretic peptide promotes cardiomyocyte survival by cGMP-dependent nuclear accumulation of
zyxin and Akt. J. Clin. Investig. 2005, 115, 2716–2730. [CrossRef] [PubMed]
133. Fiedler, B.; Feil, R.; Hofmann, F.; Willenbockel, C.; Drexler, H.; Smolenski, A.; Lohmann, S.M.; Wollert, K.C.
cGMP-dependent protein kinase type I inhibits TAB1-p38 mitogen-activated protein kinase apoptosis
signaling in cardiac myocytes. J. Biol. Chem. 2006, 281, 32831–32840. [CrossRef] [PubMed]
134. Frantz, S.; Klaiber, M.; Baba, H.A.; Oberwinkler, H.; Volker, K.; Gabetaner, B.; Bayer, B.; Abebetaer, M.;
Schuh, K.; Feil, R.; et al. Stress-dependent dilated cardiomyopathy in mice with cardiomyocyte-restricted
inactivation of cyclic GMP-dependent protein kinase i. Eur. Heart J. 2013, 34, 1233–1244. [CrossRef] [PubMed]
135. Kobsar, A.; Heeg, S.; Krohne, K.; Opitz, A.; Walter, U.; Bock, M.; Gambaryan, S.; Eigenthaler, M. Cyclic
nucleotide-regulated proliferation and differentiation vary in human hematopoietic progenitor cells derived
from healthy persons, tumor patients, and chronic myelocytic leukemia patients. Stem Cells Dev. 2008, 17,
81–91. [CrossRef] [PubMed]
136. Wong, J.C.; Fiscus, R.R. Essential roles of the nitric oxide (NO)/cGMP/protein kinase G type-Iα (PKG-Iα)
signaling pathway and the atrial natriuretic peptide (ANP)/cGMP/PKG-Iα autocrine loop in promoting
proliferation and cell survival of OP9 bone marrow stromal cells. J. Cell. Biochem. 2011, 112, 829–839.
[CrossRef] [PubMed]
137. Foller, M.; Feil, S.; Ghoreschi, K.; Koka, S.; Gerling, A.; Thunemann, M.; Hofmann, F.; Schuler, B.; Vogel, J.;
Pichler, B.; et al. Anemia and splenomegaly in cGKI-deficient mice. Proc. Natl. Acad. Sci. USA 2008, 105,
6771–6776. [CrossRef] [PubMed]
138. Rukoyatkina, N.; Walter, U.; Friebe, A.; Gambaryan, S. Differentiation of cGMP-dependent and -independent
nitric oxide effects on platelet apoptosis and reactive oxygen species production using platelets lacking
soluble guanylyl cyclase. Thromb. Haemost. 2011, 106, 922–933. [CrossRef] [PubMed]
139. Rangaswami, H.; Schwappacher, R.; Marathe, N.; Zhuang, S.; Casteel, D.E.; Haas, B.; Chen, Y.; Pfeifer, A.;
Kato, H.; Shattil, S.; et al. Cyclic GMP and protein kinase G control a Src-containing mechanosome in
osteoblasts. Sci. Signal. 2010, 3, ra91. [CrossRef] [PubMed]
140. Jaumann, M.; Dettling, J.; Gubelt, M.; Zimmermann, U.; Gerling, A.; Paquet-Durand, F.; Feil, S.; Wolpert, S.;
Franz, C.; Varakina, K.; et al. cGMP-Prkg1 signaling and Pde5 inhibition shelter cochlear hair cells and
hearing function. Nat. Med. 2012, 18, 252–259. [CrossRef] [PubMed]
141. Dhayade, S.; Kaesler, S.; Sinnberg, T.; Dobrowinski, H.; Peters, S.; Naumann, U.; Liu, H.; Hunger, R.E.;
Thunemann, M.; Biedermann, T.; et al. Sildenafil potentiates a cGMP-dependent pathway to promote
melanoma growth. Cell Rep. 2016, 14, 2599–2610. [CrossRef] [PubMed]
142. Li, W.Q.; Qureshi, A.A.; Robinson, K.C.; Han, J. Sildenafil use and increased risk of incident melanoma in US
men: A prospective cohort study. JAMA Intern. Med. 2014, 174, 964–970. [CrossRef] [PubMed]
143. Loeb, S.; Folkvaljon, Y.; Lambe, M.; Robinson, D.; Garmo, H.; Ingvar, C.; Stattin, P. Use of phosphodiesterase
type 5 inhibitors for erectile dysfunction and risk of malignant melanoma. JAMA 2015, 313, 2449–2455.
[CrossRef] [PubMed]
144. Arozarena, I.; Sanchez-Laorden, B.; Packer, L.; Hidalgo-Carcedo, C.; Hayward, R.; Viros, A.; Sahai, E.;
Marais, R. Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific
phosphodiesterase PDE5a. Cancer Cell 2011, 19, 45–57. [CrossRef] [PubMed]
145. Feil, R. Viagra releases the brakes on melanoma growth. Mol. Cell. Oncol. 2017, 4, e1188874. [CrossRef]
[PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution






The Potential of a Novel Class of EPAC-Selective
Agonists to Combat Cardiovascular Inflammation
Graeme Barker 1 ID , Euan Parnell 2, Boy van Basten 3, Hanna Buist 3 ID , David R. Adams 1 and
Stephen J. Yarwood 3,* ID
1 Institute of Chemical Sciences, Heriot-Watt University, Edinburgh EH14 4AS, UK;
Graeme.Barker@hw.ac.uk (G.B.); D.R.Adams@hw.ac.uk (D.R.A.)
2 Department of Physiology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA;
euan.parnell@northwestern.edu
3 Institute of Biological Chemistry, Biophysics and Bioengineering, Heriot-Watt University,
Edinburgh EH14 4AS, UK; bv9@hw.ac.uk (B.v.B.); hkb1@hw.ac.uk (H.B.)
* Correspondence: S.Yarwood@hw.ac.uk; Tel.: +44-(0)-131-451-3148
Received: 7 November 2017; Accepted: 30 November 2017; Published: 5 December 2017
Abstract: The cyclic 3′,5′-adenosine monophosphate (cAMP) sensor enzyme, EPAC1, is a candidate
drug target in vascular endothelial cells (VECs) due to its ability to attenuate proinflammatory
cytokine signalling normally associated with cardiovascular diseases (CVDs), including atherosclerosis.
This is through the EPAC1-dependent induction of the suppressor of cytokine signalling gene, SOCS3,
which targets inflammatory signalling proteins for ubiquitinylation and destruction by the proteosome.
Given this important role for the EPAC1/SOCS3 signalling axis, we have used high throughput screening
(HTS) to identify small molecule EPAC1 regulators and have recently isolated the first known non-cyclic
nucleotide (NCN) EPAC1 agonist, I942. I942 therefore represents the first in class, isoform selective EPAC1
activator, with the potential to suppress pro-inflammatory cytokine signalling with a reduced risk of
side effects associated with general cAMP-elevating agents that activate multiple response pathways.
The development of augmented I942 analogues may therefore provide improved research tools to
validate EPAC1 as a potential therapeutic target for the treatment of chronic inflammation associated
with deadly CVDs.
Keywords: EPAC1; cyclic AMP; cyclic nucleotide binding domain; inflammation; endothelial cells;
high-throughput screening
1. Introduction
Cyclic adenosine monophosphate (cyclic AMP) is the prototypical second messenger [1,2];
its intracellular concentration is governed by the relative expression and localization of enzymes
responsible for its synthesis, adenylyl cyclases (ACs), and degradation, cyclic AMP phosphodiesterases
(PDEs) [3–8]. Cyclic AMP exerts most of its effects through the activation of a range of down-stream
sensors, including protein kinase A (PKA) [9–12], exchange protein directly activated by cyclic AMP
proteins (EPAC) [13–15], Popeye domain-containing (POPDC) proteins [16,17] and cyclic nucleotide
gated (CNG) ion channels [18]. Due to the diverse physiological responses controlled by cyclic AMP,
signalling drugs have been developed to either promote cyclic AMP production, through activation
of ACs [19], or inhibit its breakdown through inhibition of PDEs [7,20–23]. Both of these strategies
lead to elevations in intracellular cyclic AMP, with the potential to activate all PKA, EPAC, POPDC
and CNG signalling routes, depending on cell type [24]. However, such indiscriminate activation
may be problematic. For example, PDE inhibitors, such as pentoxifylline, ibudilast, drotaverine and
roflumilast, can cause undesirable physiological effects, including nausea, emesis, diarrhoea and
cardiac arrhythmia [25], limiting their therapeutic usefulness. Similarly, the use of the di-terpene,
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forskolin, to activate ACs, has also been linked to various side effects, including flush syndrome and
hypotension [26]. Therefore, the strategy of promoting the activation of all cyclic AMP signalling
routes (e.g., PKA, EPAC, POPDC and CNG) with PDE inhibitors and forskolin may be unsuitable
in therapeutic scenarios and new approaches to reduce side effects should be considered. In this
regard, it may be possible to develop compounds that selectively activate EPACs, while avoiding
many of the side effects associated with global cyclic AMP elevation. The focus of this review will
therefore concentrate on the potential benefits of selective EPAC activation for the treatment of vascular
inflammation and efforts to produce small molecule EPAC agonists to achieve this goal.
2. EPAC Proteins
EPAC proteins are cyclic AMP-regulated guanine nucleotide exchange factors (GEFs) that activate
the small GTPases, Rap1 and Rap2 [27,28]. There are two main paralogues of EPAC, EPAC1 and
EPAC2A [27,28], derived from distinct genes, in addition to two EPAC2A splice variants, EPAC2B
and EPAC2C, which arise from differential promoter usage [29]. All EPAC isoforms consist of an
N-terminal regulatory region and a C-terminal catalytic region (Figure 1) [29–32]. It is the binding of
cyclic AMP to the regulatory cyclic nucleotide-binding domain (CNBD-B; Figure 1) that promotes GEF
activity toward RAP1/2 [30–32] (Figure 2). The EPAC2A isoform contains an additional, N-terminal
CNBD (CNBD-A; Figure 1), albeit with a much lower affinity for cyclic AMP [27,28]. It is not yet clear
what the function of the second cyclic AMP binding domain is, although it has been speculated that
the subcellular localization of Epac2A is, at least partly, regulated by the presence of this CNBD [33].
Other than this difference, EPAC1 and EPAC2 share similar structural motifs throughout the regulatory
and catalytic domains. Indeed, the dishevelled-EGL-pleckstrin homology domain (DEP), Ras exchange
motif (REM), Ras association domain (RA) and CDC25 homology GEF domains are conserved between
isoforms (Figure 1) [34–36]. In the absence of cyclic AMP, EPAC is held in an inactive conformation
due to intramolecular interactions between the regulatory CNBD-B and the catalytic GEF domain
(Figure 2) [30,31]. Cyclic AMP binding to the phosphate binding cassette of the CNBD-B results in a
local tightening and closure of the “lid” region over the cyclic AMP binding pocket (Figure 2) [32].
The conformational changes induced by binding cyclic AMP evoke an open form of EPAC that allows
the GEF domain to interact with and activate Rap1 and Rap2 (Figure 2) [30,31].
Figure 1. Primary structure of the different exchange proteins activated by cyclic AMP (EPAC)
isoforms. The N-terminal regulatory region is directly connected to the C-terminal catalytic region
through the switchboard region. Cyclic AMP interacts with the cyclic nucleotide-binding domain
(CNBD-B), present in all EPAC isoforms, to trigger enzyme activation. Epac2A has an extra,
non-functional cyclic AMP binding domain (CNBD-A). The other functional EPAC domains are
indicated; DEP—Dishevelled, Egl-10, Pleckstrin domain, required for protein-protein and protein-lipid
interactions; REM—Ras exchange motif, required for the stability of the CDC25-HD catalytic domain;
RA—Ras association domain; allows interaction with members of the Ras-superfamily of small GTPases;
CDC25-HD—CDC25 homology domain, which contains catalytic GEF activity to Rap 1/2 [14,36,37].
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Figure 2. Activation of EPAC enzymes involves a conformational change triggered by the interaction
of cyclic AMP with the EPAC CNBD-B.
3. EPAC1 Signalling and Vascular Function
A number of studies have suggested that EPAC-selective ligands may be useful for the future
treatment of cardiac arrhythmia [38], obesity [39,40], diabetes [41], hypertension [42], cancer [43]
and inflammatory pain [44]. Concerning inflammation, it has been suggested that selective EPAC
regulators may be useful for the treatment of IL-8 driven lung inflammation associated with chronic
obstructive pulmonary disorder (COPD), where EPAC2 appears to be pro-inflammatory, whereas
EPAC1 suppresses lung remodelling [45–47]. Moreover, evidence is also emerging that EPAC1 is
also a candidate drug target in vascular endothelial cells (VECs) due to its ability to attenuate
pro-inflammatory cytokine signalling normally associated with atherosclerosis and neointimal
hyperplasia (NIH), which arises from mechanical injury during angioplasty with stents [14,37].
This is because the VEC layer provides an important barrier to circulating inflammatory cytokines
and leukocytes, and damage or disruption to this barrier is a key etiological precursor to various
cardiovascular diseases. In addition, NIH is characterised by localised inflammation and proliferation
of vascular smooth muscle cells (VSMCs) that underlie the VEC layer, thereby precipitating stent failure
and myocardial infarction [48]. EPAC1 has been shown to inhibit migration of VSMCs associated with
NIH [49,50], although a number of conflicting reports have been published (Table 1) and further work
needs to be done in this area. Despite this, EPAC1 has emerged as an important factor in the regulation
of the pro-inflammatory interleukin 6 (IL-6) trans-signalling pathway in VECs [51]. This makes EPAC1
an interesting candidate therapeutic target for the treatment of diseases in which IL-6 signalling is
heavily implicated, such as atherosclerosis [52–56].
3.1. IL-6 Signalling in Vascular Endothelial Cells
IL-6 signalling is mediated by a receptor complex comprising an α chain (IL-6Rα) and a
transmembrane glycoprotein (gp130) that associate on the cell surface in the presence of the cytokine
to form a 2:2:2 heteromeric complex [57]. However, the pathophysiological pro-inflammatory actions
of IL-6 in a variety of diseases, including atherosclerosis [56], are thought to be driven by aberrant
IL-6 receptor “trans-signalling” [53]. During trans-signalling, IL-6 binds to a soluble form of the
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IL-6R (sIL-6R) and this then allows IL-6 to activate gp130 on the surface of cells that are normally
unresponsive to IL-6, including VECs [53]. The new signalling complex, formed of IL-6/sIL-6R/gp130,
can now activate Janus tyrosine kinases (JAKs) in VECs, which then phosphorylate the cytosolic region
of gp130 on key residues, including Tyr767, Tyr814, Tyr905 and Tyr915 [58]. Phosphorylation of these
sites leads to the recruitment, JAK-dependent phosphorylation and activation of signal transducer
and activator of transcription 3 (STAT3), which dimerizes and translocates to the nucleus (Figure 3),
where it promotes transcription of pro-inflammatory genes [59], including VEGF and MCP-1.
Table 1. Effects of EPAC1 on experimental neointimal hyperplasia.
Experimental Model Treatments Effects
Carotid arteries and vascular smooth
muscle cells (VSMCs) from wild type
(WT) and EPAC1 −/− mice.
Ligation of carotid arteries and
pharmacological inhibition of EPAC1
Neointima formation and VSMC
proliferation were reduced in
EPAC1 −/− mice. ESI09 also reduced
neointima formation [60].
VSMCs from thoracic aorta explants from
WT and EPAC1 −/− mice. Injury of femoral artery
Reduced neointima formation and
reduced migration of VSMCs in
EPAC1 −/− mice [61].
Human saphenous vein VSMCs Effects of pharmacological EPACactivation on VSMC migration
EPAC activation reduced VSMC
migration and serum-induced vessel wall
thickening [49].
Rat VSMCs from aorta explants. Phamacological activation of EPACand PKA
A combination of EPAC and PKA
activation inhibited serum-induced
VSMC proliferation [50].
VSMCs from foetal and adult rat aorta.
Pharmacological activation of EPAC
and adenovirus-mediated
overexpression of EPAC1
EPAC activation and overexpression of
EPAC1 enhanced intimal thickening in
aorta and VSMC proliferation [62].
Primary aortic VSMCs from male rats Pharmacological activation of EPACand PKA
PKA and EPAC work cooperatively to
inhibit VSMC migration [63].
If unresolved, IL-6 trans-signalling will maintain an inflammatory condition by promoting the
recruitment and activation of inflammatory cells, endothelial dysfunction and promoting VSMC
proliferation and migration [64].
 
Figure 3. IL-6 Signalling and SOCS3 Induction. IL-6 binds to the soluble form of the IL-6 receptor
(sIL-6R) thereby promoting the dimerization of gp130 glycoprotein and activation of receptor-associated
JAKs. Activated JAKs phosphorylate STAT3, leading to its dimerization and translocation to the nucleus
where it initiates gene transcription including induction of the suppressor of cytokine signalling (SOCS)
3 gene. SOCS3 protein then serves as a negative feedback regulator of JAK-STAT signalling.
Normally, IL-6 signalling is controlled through a classical negative-feedback route involving
the induction of the gene encoding suppressor of cytokine signalling protein (SOCS) 3 by the same
JAK-STAT3 pathways that the IL-6R activates [65] (Figure 3). Once induced SOCS3 acts by binding to
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JAK-phosphorylated receptors, mediated by the SOCS3 SH2 domain, thereby inhibiting JAK activity,
STAT signalling [66] and targeting JAK for proteasomal degradation [67].
3.2. Inhibition of IL-6 Signalling by SOCS3
SOCS3 is a potent inhibitor of pro-inflammatory pathways involved in atherosclerosis [68] and
the development of NIH [69]. Indeed, SOCS3 expression is increased in atherosclerotic plaques [70,71]
and its knockdown in apoE −/− mice increases inflammatory gene expression in aorta, leading to
enhanced atherogenesis [71]. Moreover, knockdown of SOCS3 promotes pro-inflammatory actions
of IL-6 [72] and triggers angiogenesis in VECs [73]. In contrast, overexpression of SOCS3 suppresses
JAK/STAT signalling and the development of atherosclerosis and NIH, demonstrating the importance
of SOCS3 in limiting the development of cardiovascular disease [69,74,75].
3.3. Induction of SOCS3 by EPAC1 and Inhibition of IL-6 Signalling in VECs
Activation of EPAC1 in VECs leads to a down-regulation of IL-6-mediated inflammatory processes
through the JAK/STAT3 pathway [51], which occurs through C/EBP transcription factor-dependent
SOCS3 induction [76]. Moreover, EPAC1 exerts other cyclic AMP-dependent anti-inflammatory
actions in VECs, including activation of integrins, thereby promoting adhesion of VECs to the
basement membrane [77]. In addition, EPAC1 activation is able to promote endothelial barrier
function [78,79] through VE-cadherin mediated cell-cell junction stability [80], in response to
actin [81–85] and microtubule [86] cytoskeletal reorganisation. Thus, EPAC1 is involved in multiple
anti-inflammatory processes in VECs and the links between EPAC1 and SOCS3 and the development
of atherosclerosis/NIH indicate that EPAC1 regulation should be considered as a potential therapeutic
avenue for the future treatment of cardiovascular disease.
4. Development of EPAC-Selective Agonists
4.1. EPAC Agonists Based on Cyclic Nucleotides
Due to the emerging potential of EPAC isoforms as drug targets, efforts have been
made to develop small molecule EPAC agonists. The first of these, the cyclic AMP analogue,
8-(4-chlorophenylthio)-2′-O-methyladenosine-3′,5′-cyclic monophosphate (8-pCPT-2′-O-Me-cyclic
AMP; 007), and its improved cell permeable derivative (007-AM [87]; Figure 4), are able to selectively
activate both EPAC1 and EPAC2 isoforms, independently of PKA [88]. The selectivity of 007
for the EPAC isoforms over PKA is due to a single amino acid difference in the CNBD cyclic
AMP-binding pockets of PKA and EPACs, which are otherwise highly conserved in their amino
acid composition [88]. Thus, the substitution of a key glutamic acid residue in the PKA CNBD,
by a glutamine or lysine in EPAC1 or EPAC2, respectively, is responsible for the discrimination
exhibited by the 2′-O-methylated nucleotide and preference for binding to the EPACs [88]. A structural
understanding for the basis of this selectivity was assisted by the determination of the 3D structure of
EPAC2 [30,31], and now a range of cyclic AMP analogues with varying kinetic properties have been
developed that can also differentiate between EPAC1 and EPAC2 [89]. In particular, an EPAC2-selective
agonist, 8-benzylthioadenosine-3′,5′-cyclic monophosphorothioate (Sp-8-BnT-cAMPS; S-220; Figure 4),
has been developed that exerts glucose-dependent stimulatory activity in insulin-secreting human
pancreatic cells [90]. However, in vivo use of these analogues has been hampered by cardiac arrhythmia,
fibrosis and cardiac hypertrophy in animal models [91,92], limiting rigorous preclinical assessment
of their therapeutic benefit. These effects are likely linked to calcium signalling crosstalk within
cardiomyocytes [93,94] following chronic activation of EPAC2 within the heart. These observations
suggest that pharmacological exploitation of EPAC-activating compounds may need to be focused on
the development of selective EPAC1 ligands, thereby avoiding these adverse effects.
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Figure 4. Chemical structures of existing EPAC-selective agonists and antagonists together with the
cyclic analogue AMP analogue fluorescent probe molecule, 8NBD-cAMP.
4.2. The Sulfonyl Urea Family as EPAC Agonists
After 007 and its analogues, the most studied, but controversial, group of small molecule EPAC
agonists are those of the sulfonylurea (SU) family (Figure 4). SUs were originally developed as
anti-diabetic drugs capable of regulating the SUR1 receptor, leading to the opening of ATP-dependent
potassium channels in pancreatic β-cells, with consequent calcium release and increased insulin
exocytosis [95]. Recently it has been postulated that SUs also act as isoform selective activators
of EPAC2, in particular via an allosteric mechanism involving the low affinity CNBD-A of EPAC2 [96].
This idea has been challenged [97], however, and it has been shown that SUs are unable to induce GEF
activity in in vitro EPAC2 activation assays [98]. Insulin secretion is known to be impaired in EPAC2
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knockout mice, but the positive effect of SUs on EPAC2 activity in cellular assays may be indirect, as
reports indicate that these compounds induce elevations in intracellular cyclic AMP [98].
4.3. EPAC Antagonists
Further efforts to identify small molecule EPAC regulators using high throughput screening
(HTS) of compound libraries have mainly identified antagonists, both orthosteric and allosteric,
rather than agonists [1,2,99,100]. Indeed, uncompetitive (CE3F4) and non-competitive EPAC1
inhibitors (5225554 and 5376753; Figure 4) have been identified using in vitro EPAC1 GEF [2] and
EPAC-based bioluminescence resonance energy transfer-based [1] assays, respectively. Similarly,
inhibitors for EPAC2 have been identified by HTS using a displacement assay with the cyclic AMP
analogue, 8-[2-[(7-nitro-4-benzofurazanyl)aminoethyl]thio]-cyclic AMP (8-NBD-cyclic AMP; Figure 4),
which fluoresces when bound within the hydrophobic environment of the cyclic AMP binding
pocket [89]. Displacement of 8-NBD-cyclic AMP by competitor compounds leads to a reduction
in fluorescence, allowing the identification of interacting molecules. Despite this assay being equally
sensitive to agonist and antagonist molecules, so far only the EPAC2-selective competitive inhibitor,
ESI-05 (4-methylphenyl-2,4,6-trimethylphenylsulfone) [101], and a non-selective EPAC1/2 inhibitor,
ESI-09 (3-(5-tert-butylisoxazol-3-yl)-2-[(3-chlorophenyl)-hydrazonol]-3-oxopropionitrile), have been
identified [99,102,103]. Subsequently, concerns were raised over the specificity of ESI-09, which is
thought to display non-specific protein denaturing properties [104]. Despite this, several more potent
EPAC antagonistic ESI-09 and ESI-05 analogues (Figure 4) have been developed [105–107].
4.4. Identification of Non-Cyclic Nucleotide (NCN) EPAC Agonists
HTS using 8-NBD-cAMP (Figure 4) competition assays has been limited to screens involving
EPAC2, likely due to the limited fluorescence of 8-NBD-cAMP when bound to the CNBD-B of EPAC1
compared to EPAC2 [99]. This difference may be linked to structural differences between EPAC1 and
EPAC2 within the CNBD-B that selectively influence the docking of ligands to the cAMP-binding
pocket [90]. Moreover, the low stability of full length recombinant EPAC1 in vitro has limited its
study in HTS and structural assays [89]. Although full-length EPAC1 is relatively unstable in vitro,
the isolated EPAC1-CNBD-B displays superior stability and 8-NBD-cAMP has been shown to bind
and fluoresce within the CNBD-B of EPAC1 [89]. Given that the CNBDs of EPAC1 and EPAC2 display
structural differences [108–110], screening both CNBDs simultaneously may facilitate isoform-selective
compound discovery. We have used this dual-target strategy to screen 5195 compounds from the
BioAscent Compound Collection (Biocity Scotland, Newhouse, Scotland), identifying a number of
ligands with varied binding affinities to the distinct isoforms [111]. Follow up characterisation of the
top hit, I942 (Figure 4), using ligand observe nuclear magnetic resonance (NMR) confirmed direct
interaction with both EPAC1 and EPAC2 CNBD-B [111]. However, in vitro GEF assays revealed that
I942 displayed partial agonist activity toward EPAC1 (AC50 10% that of cyclic AMP [111]) and no
significant action towards EPAC2. Further study revealed that I942 had no effect in vitro on PKA
activity as measured by phosphorylation of the transcription factor CREB, a known PKA substrate.
I942 is therefore the first non-cyclic nucleotide small-molecule with selective agonist properties toward
EPAC1. As a novel, NCN scaffold, the N-acylsulfonamide chemotype of I942 might be advantageous
to nucleotide-based structures, which may require prodrug strategies for therapeutic deployment.
4.5. Putative Binding Mode of Novel EPAC Agonists
The binding mode of I942 and mechanism of EPAC1 activation remain to be experimentally
determined, although in silico modelling studies have been undertaken and a plausible binding
postulate developed to rationalise the compound’s partial activation of EPAC1 (Figure 5). As the
structure of EPAC1 has yet to be determined, homology models of EPAC1 were constructed from
crystal structures (PDB: 4MH0, 4MGY, 4MGK) of EPAC2 in the nucleotide-bound, active conformation
with and without an EPAC1-mimetic point mutation (K405Q) [90]. These models allowed us to explore
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the possible structural basis for interaction of I942 with EPAC1. Preliminary findings suggest that the
acidic N-acylsulfonamide motif (pKa ~ 4) may occupy a similar volume to the cyclic AMP phosphate
(Figure 5), engaging a key charge-pairing arginine (Arg279) within the CNBD “phosphate-binding
cassette” (PBC), defined by residues 268-FGQLALVNDAPRAAT-282 of EPAC1 [32]. The PBC is
strongly conserved in EPAC2 as residues 403-FGKLALVNDAPRAAS-417 in the murine constructs
used for crystallography, and contains a short helix that hydrogen bonds through its N-terminus to
the phosphate of cyclic AMP. The ionised N-acylsulfonamide is similarly predicted to cap this helix,
through its carbonyl oxygen, whilst additionally engaging the PBC backbone at Ala280 and Ala281 in
charge-stabilised hydrogen bonds from the nitrogen and one of the sulfonyl oxygens.
Our binding hypothesis positions the I942 m-xylyl group approximately coplanar with the bound
nucleotide’s purine in the main funnel-like opening to the binding site. However, direct overlap with
the adenine bicycle is limited in this model, and I942 does not exploit the polar interactions available
to the endogenous ligand through the adenine bicycle. Thus, co-crystal structures of EPAC2 constructs
with bound cAMP reveal that a key lysine (Lys489) on helix-α1 of the REM domain engages the purine
N-1 centre. This promotes folding of the cyclic AMP-bound CNBD onto the REM domain surface,
with the helix contributing to the EPAC “lid” region that closes over the nucleotide [30]. Lys489 is
conserved on the REM-α1 helix of EPAC1 as Lys353, but I942 lacks the necessary structural extension
and functionality to engage it. On the other hand, our model suggests that I942 may exploit additional,
hydrophobic interactions at the opposite end of the REM-α1 helix to Lys353 that are not accessible to
cyclic AMP. In particular, the model invokes threading of the oxymethylene linker through a narrow
passage (solvent filled in the absence of ligand; Figure 5) that leads to a second and smaller funnel
opening on the opposite face of the protein surface to the adenine-binding channel. It is this second
“posterior channel”, we postulate, that hosts the I942 naphthyl moiety (Figure 5) and that (based on
residue differences between EPAC2 and EPAC1) may be more restrictive in the case of EPAC2.
The posterior channel is heavily hydrophobic, with the side chains of several conserved CNBD
residues (Leu271, Asn275, Ala277, Pro278, Ala280 and Leu314) contributing much of the putative
contact surface for the ligand’s naphthyloxy group. However, three residues from the REM-α1 helix of
EPAC1 are also predicted to make a significant contribution to the posterior channel—namely Leu357,
Ala361 and Glu360 (the latter through its side chain methylenes). Of these three residues, only the
glutamic acid is conserved in EPAC2, with Leu357 and Ala361 replaced by histidine and threonine
respectively. Our model suggests that packing of the napthyloxy group against these three REM-α1
residues may stabilise the closed, active state of EPAC1, albeit less effectively than cyclic AMP through
its interactions in the anterior channel and perhaps with slightly altered seating of the CNBD against
the EPAC core. This would account for the partial agonism, whilst the selectivity of I942 for activation
of EPAC1 over EPAC2 may be explained, at least in part, by loss of the favourable surface contact
with Leu357 and steric interdiction by the threonine replacement for Ala361. An implicit corollary of
this “threaded model”, in which the ligand binds between anterior and posterior channels, is that the
mechanism of EPAC1 activation must involve stepwise binding of the ligand to the open, inactive
conformation of the protein followed by hinged closure of the ligand-bound CNBD (cf. Figure 2).
Structural studies with EPAC2 have shown that the conformation of the hinge region is sensitive
to a single point mutation in the PBC, where Lys405 of EPAC2 is replaced by a glutamine, which is
located at the cognate position of EPAC1 (Gln270) [90]. At present, we cannot rule out the possibility
that this difference between EPAC1 and EPAC2 might also contribute to the observed selectivity of
I942 by differentially modulating the seating properties of the PBC against the lid for the two EPAC
isoforms. However, the model presented in Figure 5 does not invoke a direct and EPAC1-specific
contact between I942 and the side chain of Q270.
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Figure 5. Modelling studies with EPAC1 homology models suggest that I942 may engage the cyclic
nucleotide binding domain-B (CNBD-B) with subsequent hinged closure of the domain onto the
protein core leading to a “threaded” binding mode and adoption of an active-state EPAC conformation.
In this binding mode (panel (B)) the acidic N-acylsulfonamide is predicted to occupy the position
of the endogenous ligand’s phosphate (panel (A)) and form extensive phosphomimetic hydrogen
bonds (dashed lines) with the protein’s phosphate-binding cassette (PBC, bright orange ribbon).
EPAC2 co-crystal structures show that the cyclic AMP adenine binds in a large funnel-like channel
that opens on the front face of the protein as figured in panel (A), where the adenine N1 centre
engages a lysine (conserved as K353 in EPAC1) on the REM domain’s helix-α1 (bright green ribbon).
An additional smaller opening, the posterior channel, communicates to the reverse face of the protein.
Cyclic AMP does not directly utilise this volume, which is occupied by water molecules in available
EPAC2 co-crystal structures (marked as red spheres in the panel (A) model). We postulate that this
posterior channel, which is heavily hydrophobic, hosts the naphthyloxy group of I942, as detailed in
panel (C). Occupancy of this channel may be entropically favoured by displacement of water (shown
superimposed as red spheres in panel (C)), and stabilise closure of the CNBD onto the EPAC1 core by
interaction of the naphthyl subunit with REM-α1 residues L357, E360 and A361 (h, i and j in panel (C)).
L357 and A361 are not conserved across the EPAC isoforms, which may account for the observed
selectivity of I942, as the cognate EPAC2 residues (H493, T497; magenta stick) are predicted to interdict
I942 binding. In the EPAC active conformation the REM-α1 helix folds as a lid onto the ligand binding
site due to reorganisation of the EPAC hinge sequence (dotted ribbon in panels (A,B)). Whilst the
naphthyloxy group may favourably engage the surface of REM-α1 at the C-terminal end, it fails
(in contrast to cyclic AMP) to engage K353 at the N-terminal end. This may influence equilibrium
position between CNBD-B open and closed states, with weaker overall engagement of the REM-α1 lid
by I942 (or/and ligand-specific domain seating penalties) accounting for the observed EPAC1 “partial
agonism” relative to the endogenous ligand.
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5. Conclusions
In summary, several cyclic nucleotide analogues have been developed as EPAC agonist tool
compounds in recent years, some exhibiting discrimination between the two EPAC isoforms
in addition to selectivity over PKA. To address the challenging physicochemical properties of
nucleotides and enhance cell permeability, phosphate masking strategies have been used, as with
the labile acetoxymethyl ester modification (007-AM; Figure 4) of the prototypical nucleotide agonist,
8-pCPT-2′-O-Me-cyclic AMP. Both nucleotide and non-nucleotide EPAC antagonists have also been
reported. Very recently, we have identified a unique class of selective NCN EPAC1-activating ligand,
exemplified by I942 (Figure 4). This new chemotype likely binds and stabilises the active state of
EPAC1 via a previously unobserved interaction mode. Further work is required to validate the binding
mode proposed for I942, but, if correct in its essentials, the model presented here suggests that there
should be significant scope for optimisation of the ligand’s naphthyl and m-xylyl subunits to enhance
affinity and adjust efficacy with respect to the GEF activity of EPAC1. Changes to the m-xylyl group
might additionally be harnessed, in principle, to modulate the pKa of the N-acylsulfonamide, which is
a pharmacologically well-precedented moiety [112] and which we suggest serves as a cyclophosphate
ester mimetic in the case of I942. We therefore propose that an integrated programme of chemical
synthesis of structural analogues with concurrent assessment of bioactivity may allow the generation of
a “molecular toolkit” of ligands displaying a spectrum of activity from partial to full agonism and with
prospects for tractable bioavailability. The development of such a toolkit will allow a full exploration
of the roles of EPAC1 in VECs, as well as in preclinical disease models of vascular dysfunction.
An experimental and comprehensive structure activity relationship (SAR) study of I942 alongside
confirmation of our docking models may pave the way to the development of new therapies for the
treatment of cardiovascular disease.
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